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ABSTRACT
The fluctuation test is a means of measuring bacterial mutation in a 
liquid medium. It has been modified such that it may be used in several 
different ways using different types of metabolising systems. The incorp­
oration of isolated hepatocytes instead of S9 fraction for metabolic 
activation has been developed to provide suitable culturing conditions for 
the hepatocytes and bacteria.
The test has been used to look at the mutagenicity of 2AAF with S9 
derived frcm differently pretreated animals and also isolated hepatocytes.
It was observed that there is an S9 optimum for maximal mutagenic activity 
of 2AAF, which is very much lower with aroclor-induced S9 than uninduced 
S9 in both the fluctuation test and the Ames test. The optimal S9 
concentration is greater for both aroclor-induced and uninduced S9 in the 
Ames test than in the fluctuation test indicating sane differences between 
these two tests.
As a screening test, the fluctuation test has been validated in an 
International study using carcinogen: and structurally related non-carcinogen 
pairs. Using uninduced S9 and- uninduced hepatocytes the test has a high 
predictivity of carcinogenicity. However, hepatocytes alone offer little 
advantage over S9 fraction for general screening purposes. When using
hepatocytes in comparison with S9, NM, DMBA and DMA showed increased ..
mutagenicity, while unexpectedly 2AAF showed reduced mutagenicity.
2NA and 1NA were not mutagenic with hepatocytes. In general, where a 
mutagenic response was observed with S9 fraction there was a mutagenic 
response with hepatocytes. Hepatocytes are likely to be more useful as 
\a research tool than in screening tests.
The fluctuation test has also been used to assess the mutagenicity 
of seme synthetic phenol, metabolites and their sulphate esters of BP.
1-CHBP, 3-OHBP and 12-OHBP were mutagenic without metabolic activation,
while 9-OHBP and 7-OHBP were mutagenic with aroclor-induced S9, but not
......
with 3MD-induced Ca precipitated microsames. The sulphate esters of 3-,
7- and 9-CHBP were clearly mutagenic in the presence of aroclor-induced 
S9. The mutagenicity of BP was increased fcy the presence of the synthetic 
steroid betamethasone using aroclor-induced S9, while very little effect v 
was observed with uninduced S9.
The use of the fluctuation test to assess the mutagenicity of complex 
mixtures of chemicals was exemplified by a'study on several oils.
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Chinese hamster ovary cells
CP
DAB (Butter yellow)
DEN
DES
DMA
DMOC
DMF
DMN
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Mixed function oxidase
Nicotinamide adenine dinucleotide 
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National Cancer Institute 
Polycyclic aromatic hydrocarbon
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Phosphate buffered saline 
Polychlorinated biphenyl
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UV Ultra vviolet
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Vit. C Ascorbic acid
XP Xeroderma pigmentosum
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CHAPTER 1 - INTPODUCTIQSf
1.1. GENERAL INTRODUCTiaSf - CHEMICAL CARCINOGENS AND MUTAGENS
1.1.1. Somatic mutation theory of cancer
Before the elucidation of the structure of DNA, Boveri had hypoth­
esised that cancer might be caused by heritable changes in the genetic 
apparatus of the cell (Boveri, 1914, in Wolf, 1974). Boveri's studies 
with sea urchin eggs provided evidence that the nucleus contains the 
hereditary information of the cell. He recognised that the chranoscmes 
contained the hereditary units, and that an equilibrium among these units 
was necessary for normal cellular behaviour. He also concluded that 
individual chromosomes have different characteristics. Boveri noticed that 
chromosome alterations were associated with tumour growth and that these 
alterations were transmitted to subsequent cell generations.
A mutation is any unusual change in the genetic material resulting in 
a change of phenotype which is inherited. A mutation becomes detectable 
wheij cell proliferation occurs sufficiently to give rise to an aberrant mass 
of cells, or releases detectable amounts of a specific gene product, e.g. a 
hormone.
The somatic mutation theory of cancer predicts a clonal origin of 
tumours, i.e. the tumour arises from only one cell. That tumours originate 
from a single cell was shewn by studies on cellular mosaicism in human cells 
(Gatler, 1974; Magee, 1977a). The most extensively and successfully used 
syston has been X-chromosome inactivation mosaicism with the glucose-6- 
phosphate dehydrogenase locus as the X-linked marker. An adult female is a • 
mosaic of two cell types with either an active maternal X-chromosome or an 
active paternal X-chromosome, the other X-chrcmoscme in the cell in either 
case becoming inactive early in embryogenesis. Approximately half the cells 
will shew maternal characteristics. The enzyme glucose-6-phosphate dehydro­
genase can exist in two electrophoretic variants A and B. Heterozygous 
females have both enzymes, but clones from single cell platings have only 
the A or B enzyme. Tumours arising from a single cell should also have only 
one of these enzymes and most tumours that have been investigated do have 
only one enzyme and are, therefore, clonal in origin.
Other evidence has been suggested in support of the somatic mutation 
theory. Chromosome aberrations are frequent in tumours, as observed by 
Boveri. He associated this with mutation in somatic cells. Although 
aberrations are not usually detectable during the early stages of experiment­
ally induced tumours, this does not rule out the presence of point mutations 
or chromosome changes which are too small to be observed by available
techniques (Magee, 1977^ )..
Further evidence for the sanatic mutation theory is that pyrimidine 
diners in ENA, caused by UV—light (see Section 1. 1.7) are involved in tumour- 
igenesis in the fish Poecelia formosa (Hart and Set lew, 1975). These dimers 
are removed by photoreactivation (unlike placental marrmals, fish possess 
detectable amounts of photoreactivating enzyrre). This fish reproduces 
asexually and cells may be transplanted frcm one individual to another. It 
was shown that UV-irradiation of cells prior to transplantation caused the 
appearance of tumours, and also that exposure to UV-light followed by 
visible light before transplantation, effectively removed most of the tumour- 
igenic effect (Hart and Setlcw, 1975). This data strcngly suggests a relation­
ship between the DNA damage and UV tumourigenesis.
Further evidence of the involvement of damage to DNA in carcinogenesis 
canes frcm a study showing that transformation (as indicated by growth of the 
cells in soft agar) of a baby hamster cell line by a chemical carcinogen is 
the result of a mutation in the cells (Bouck and di Mayorca., 1976) . Although 
it is likely that these cells are already partially transformed, this is 
consistent with the hypothesis that a mutational event is associated with the 
transformation of cells to those capable of malignant growth.
The case of Xeroderma Pigmentosum (XP) patients may well be the best 
evidence for the theory of somatic mutation. As discussed later in Section
1.1.8- r XP patients are defective in DNA repair mechanisms and this results in 
an increase in UV-and chemically-induced mutations in cultured skin fibro­
blasts (Maher et aL y 1976, 1977). Theoretically this increase in mutability 
of the cells should result in an increase in UV-induced skin cancer, and this 
is the principal symptom of the disorder (Arlett and Lehmann, 1978).
Finally, it is known that most chemical carcinogens are mutagenic 
and that they react with DNA (Miller & Miller, 1971; Ames et alTj 1975). This 
evidence will be discussed in more detail in the following section and forms 
the basis of research presented in this thesis.
1.1.2. The relationship between chemical carcinogens and mutagens
Boveri (1914) had suggested that scmatic mutation might be the cause 
of genetic damage, but in the early days the fact that many chemical carcin­
ogens could not be shewn to be mutagens was an argument against’ the scmatic 
mutation theory of cancer. However, Boy land (1950), postulated that epoxides 
might be formed as metabolic intermediates of polycyclic aromatic hydrocarbons 
(PAH), although epoxides had not been isolated, and that these might be 
responsible for the carcinogenicity of PAH compounds.
The work of Brookes & Lawley (1964) showed evidence that metabolic 
activation might be required before the covalent binding of a polycyclic
aromatic hydrocarbon to the DNA. of mouse skin could take place. A time course 
of the covalent binding of the chemical with the DNA showed a lag-phase which 
was attributed to metabolic activation.
Pioneering work by the Millers (Miller, 1970; Miller & Miller> 1971,
1976, 1977) showed that many carcinogens required metabolic activation in 
vivo to yield an ultimate reactive carcinogenic metabolite. Studies on the 
hepatocarcinogen aflatoxin B,/(APB) (Gamer et al, 1971, 1972) and the carcin­
ogen dime thy Ini trosamine, (DMN) (Mailing, 1971), shewed that they could be 
toxic (AEB^ , Gamer et al, 1972) or mutagenic (DMN, Mailing, 1971) in bacterial 
strains. Both chemicals were able to be metabolised when mixed function 
oxidases of the microsame fraction of animal liver (mice,, rats, hamsters 
and guineas pigs) were added. Without this fraction neither canpound caused 
any effect on the bacteria.
The liver is the most important metabolising system in mammals, there­
fore a fraction of the liver is generally used to metabolise chemicals.
Since these initial observations, considerable progress has been made 
in the recognition of chemical carcinogens as mutagens (Miller, 1970; Miller 
& Miller, 1971, 1976; Ames et:alv*,1975; McCann ^  Ames, 1977). Extensive work by. Ames
et al. ,(L973a&b,il975) on the development of a simple assay for mutagenesis in 
bacteria, incorporating a metabolic activation system, demonstrated that of 
179 known chemical carcinogens, 87.7% were mutagenic and most of these required 
metabolic activation.
Studies on the structure of various classes of chemical carcinogens, 
and their metabolic activation, indicated that most carcinogens had in common 
the ability to form an electrcphilie species. These species could be expected 
to react with nucleqphilic cellular constituents, including ENA.
Sore of the major classes of chemical carcinogens, that are also 
mutagens, are described belcw:
(1) Alkylating agents
' A number of chemicals are alkylating agents per se, and do not 
require metabolic activation, e.q. uracil mustard, 3 -propiolactone . 
methyImethanesulfonate. These are reactive with nucleophilic 
sites in vivo under physiological conditions (Miller & Miller, 1971).
A large group of chemicals are converted to alkylating agents in vivo, 
e.g. the carcinogenic hitrosamines (Miller & Miller, 1971; Magee, 
•1977b) such as'.'DMN.
(2) Aromatic amines and amides
The aromatic amine 2-acetylaminof luorene (2AAF), which has been 
widely investigated, is a chemical carcinogen. This chemical is 
first converted by N-hydroxylation to the N-hydroxy derivative,
and then conjugated with a sulphate ester to yield the probable 
carcinogenic metabolite. This chemical will be discussed in 
more detail in Chapter 3.
(3) Polycyclic aromatic hydrocarbons (PAH) ^
The study of this group of chemicals is well documented (Brookes,
1977; DePierre & Emster, 1978). Benzo (a) pyrene (BP), 3-methylchol- 
anthrene (3MC), dimethylbenzanthracene (DMBA), and many other PAHs 
are included in this class of chemicals. There are many studies 
on the metabolic profiles of the PAHs and much discussion on 
the ultimate carcinogenic metabolites (Brookes, 1977; Jerina et al., 
1977; Huberman, 1975; Nevfoold & Brookes, 1976).
Scrne other chemicals that may be metabolised to carcinogenic intermediates 
include aflatoxin (a product of Aspergillus flavus), safrole, urethane, 
pyrrolizidine alkaloids (reviewed in Miller & Miller, 1971, 1977).
1.1.3. Metabolic activation
As metabolic activation is extremely important for the activity of 
many chemical carcinogens, an outline of these metabolic pathways is essential.
Metabolic activation can be divided into phase I (biotransformation) 
followed by phase II (conjugation) (Williams, 1959).
Phase I
In phase I metabolism the chemical is modified by the addition or 
unmasking of functional groups. This is generally carried out by the mixed 
function oxidase (MFO) enzymic system, which is associated with the endoplasmic 
reticulum of the cell. This activity is found in the microscme fraction of 
the cell which contains a family of haemoproteins known as cytochrome P-450 
(cyt.P-450) which act as terminal oxidases for the oxidative reactions that 
chemicals undergo in phase I metabolism (Brodie et al., 1958; Lu, 1976).
Table 1.1 lists the oxidation, reduction and hydrolysis reactions 
that are carried out in phase I metabolism.
Reviews of metabolic activation can be found (Estabrook, 1971;
Gillette, 1976; Ullrich et al., (eds.) 1977).
Cyt. P-450 is able to bind to the substrate and after reduction is 
capable of accepting molecular oxygen and converting it to an "active oxygen" 
species, which can in turn bring about the hydroxylation of the substrate.
This requires a continuous supply of NADPH. The interaction of substrate 
with oxidised cyt.P-450 can be observed in microsomal or cell suspensions 
spectrcphotcmetrically.
By looking at microsomal fractions spectrophotcmetrically, two different 
kinds of binding spectra of the cytochromes are obtained (Gillette, 1971;
Tapj-e 1.1
Principle Phase I metabolic transformations
Type of reaction Functional group 
affected
Example
Oxidation 
Aliphatic hydroxylation
Aromatic hydroxylation 
N-Dealky lation 
O-Dealkylation 
S-Demethylation 
Oxidative deamination
N-Oxidation
S-Oxidation
Epoxidation
Reduction 
Nitro reduction
Azo reduction
Dehalogenation
Hydrolysis
De-esterification
Deamidation
FCHg-WGap 
R-0 + R-©-OH
R-NH-CH3>R-NH2+ hcho 
r-o-ch3+r-qh+ hcho 
r-s-ch3+r-sh+ hcho
9R-(^ H-CH3->-R-C-CH3+ nh2
2 OH 
Rr-NH-R1-*- R-li-R'
* l > ° 2
R ^ C"H R V C4j •
(unstable)
NO^ -O-R + NH2^ - R  
®-N=N-@ 0-NH2 + NH2- ©
rcci3+ rcci2
RDOOCH2R -^RQOOH + HOCH-R1 
4H20
RCONHR' - ROOOH+ ^ N R ”
Phenobarbital-^5-ethyl- 
5^3 -hydroxy-Lf -methyl—  
butyl) barbituric acid.. 
Acetanilid 
p- hydroxyanilid
Aminopyrine
4-aminqpyrine
Methylmorphine -*•' 
morphine
6-Methylthic^ urine-*-
6-mercaptopurine
Arrphetamine
phenylacetone
2 -Acetylaminof luorene* 
N-0H2AAF
Chlorprcmazine 
chlorpromazine sulphate
Benzo (a) pyrene 
BP epoxides
Chloranphenicol-*- 
reduced product
Prontosil**
Suphanilamide
DDT -*DDE
Procaine -*■ 
p-aminobenzoic acid+ 
dimethylamlnoethanol 
Procaine amide ** 
Hydrolysed products
Hunter & Chasseaud, 1976). Seme drugs and chemicals give type I spectra such 
as hexabarbrtone., while others yield type II spectra such as aniline (the 
converse of a type I spectra). Cyt. P-450 is present in multiple forms 
(Powis et al., 1977; Levin et al., 1977). .
A major characteristic of the MFO system is the ready inducibility by 
a wide range of chemicals, including drugs, insecticides and polycyclic 
hydrocarbons (Hidlebrant et al., 1968; Gillette, 1971; Hunter and Chasseaud,.1976)
This only occurs in vivo or with intact cells in suspension or culture. The 
most widely studied inducers are phenobarbitone (cytochrcme peak at 450 n.m.) 
and polycyclic hydrocarbons such as 3-methylfe»lanthrene (3MC) (cytochrcme 
peak at 446-448 n.m., known as cyt.R448) (Hidlebrant et al,»1968). Pheno­
barbitone induction enhances almost all of the reactions catalysed by cyt.P-450 
whereas 3M2 induces relatively few pathways and is catalysed by the P-448 
form of cyt.p-450.
Polychlorinated Biphenyls (PCB) are popular as inducers of drug 
metabolism. Aroclor 1254 possesses the ability to induce the properties of 
both the phenobarbitone and 3MC inducers. It induces both cyt.P-450and P-448 
(Alvares et al., 1973). This type of induction is less well documented
and investigated than the others described.
Induction , of cyt.P-450 species appears to be associated with de novo 
protein synthesis (Bresnick, 1978).
Phase II
These reactions are the addition of large groups to the metabolites 
formed during phase I metabolism. These reactions were originally thought 
to be detoxification reactions (Williams, 1959) and the majority of reactions- 
serve the purpose of converting lipid soluble metabolites to polar metabolites 
to facilitate their rapid removal frcm the body. These reactions are not 
associated with the endoplasmic reticulum, but with the cell cytosol. The 
exception is conjugation with gluooronic acid, which is associated with 
the endoplasmic reticulum (Dutton, 1971), although the addition of certain 
cofactors is required in these fractions. Table 1.2 shows the major conjug­
ation reactions associated with phase II metabolism. The reaction takes 
place by the addition of a group frcm a dcnor molecule, and is enzymically 
mediated by enzymes, usually known as specific transferases.
The subcellular localisation of the various metabolising enzymes is 
shown in Table 1.3. This is an important aspect of metabolism since many 
studies are performed only in microscmal fractions, and these fractions lack 
important enzymes.
Many factors can affect the metabolism of foreign chemicals, e.g. 
age, disease states, hormonal status, housing conditions, immunological 
factors, diet, sex, stress, and administration of drugs (Vessell, 1978).
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Table 1.3
Subcellular Location of some Drug Metabolising Enzymes
Enzyme .... Organelles
Endoplasmic
reticulum
Mitochondria Cytoplasm
Phase 1 
Aliphatic
hydroxylation +
Aromatic
hydroxylation +.
Dealkylation +
Demethylation +
Oxidative
deamination + +
N-oxidation +
Epoxidation
Nitro reduction + +
Azo reduction +
Dehalogenation + +
De-esterification + +
Deamination
(hydrolysis) + +
Alcohol oxidation + +
Phase 11
Glucuronidation + .
Sulphation +
Methylation + +
Mercapturic acid 
fonration 
(Glutathione 
conjugation) 
Acetylation
+
+
Glycine
conjugation +
Glutamine
conjugation +
The main site of metabolism is the liver, but other tissues also have 
metabolic activity, such as the kidney and lung (Grrenius-et al., 1973).
Metabolic activation is therefore required in the tests for detecting 
chemical carcinogens. Attempts have been made to produce metabolic^ctivation 
in several screening tests.
The most extensively used metabolising system involves 9000g super­
natant (S9) of rat liver hcmogenate (Gamer et aL-,1972; Ames et al.-, 1975).
This fraction is widely used in bacterial tests such as the Ames test (Anes 
et al., 1975). Actual microscme fractions can also be incorporated into 
bacterial tests (Frantz & Mailing, 1975) . The S9 fraction has also been 
used with mammalian mutagenicity assays (Krahn & Heidleberger, 1977), in 
DNA repair assays (Martin et al. ,1978)rt and in cell transformation assays 
(Styles, 1977, 1979).
Feeder layers of cells, which supposedly have normal xenobiotic 
metabolising ability, are used in several types of screening tests (Hubermanr 
1975). These are mammalian cells (usually embryonic,with their enzyme systems 
fully intact), cultured in vitro and inactivated by radiation or a high dose 
of a chemical (e.g. mitcmycin C). They have been used in mammalian mutagenicity 
assays (Huberman, 1978): and cell transformation assays (Pienta et-al., 1977;
Castro et al., 1977).
1.1.4. Chemical carcinogens and mutagens in the environment
The association between mutagenic activity and chemical carcinogens is' 
well established. Many chemicals in the environment have been identified 
as carcinogenic.
It is over 2(30 years ago that Percival Pott (1775) associated scrotal 
cancer in young chimney sweeps with soot. A high incidence of cancer in 
the nasal passages of men exposed to tobacco snuff was also observed at that 
period. (Redmond, 1972 on the observations of Hill in 1761).
Chemical mutagenesis was first observed ever 30.years ago using the 
fruit fly, Drosophila (Auerbach & Robson, 1944, 1946). It is new widely 
accepted that many environmental chemicals are potentially hazardous due to 
their mutaqenic and/or carcinogenic properties.
Further evidence of a relationship between the environment and cancer 
in man has been provided by epidemiological and human population migration 
studies (Doll, 1967). For example, the Japanese show a lew rate of 
breast and colon cancer and a high rate of stomach cancer, whereas in the 
population of the U.S.A. the reverse is true. In Japanese immigrants to 
the U.S.A., high colon and breast cancer incidence and lew stomach cancer
are observed within one or two generations (Hiatt et al, ,eds. 1977).
Hammond (1975) estimated that 80-85% of human cancers are probably 
caused by environmental factors. Of the hundreds of chemicals identified as 
carcinogenic in animals, only relatively few have been shown to be carcino­
genic in humans (Tcmatis, 1977) (Table 1.4).
Seme chemicals identified in the environment which are mutagenic and 
possibly also carcinogenic are as follows:
Seme hair dyes, food colourings and azo dyes (Ames et al. ,1977; Gamer & 
Nutraan,. 1977; Muzzal & Cook, 1979) are mutagenic; cigarette smoke is a 
mutagen (Kier et al, ,1974; Bridges et al.,. 1979;Sato et aL,, 1977; Hutton & 
Hackney, 1975).
The nitrofuran derivative AF2 was shown to be a mutagen and a carcino­
gen, and is no longer in use (reviewed in de Serres, 1976). Seme pesticides 
such as captan and dichlorvos are mutagenic (Bridges, 1975, 1978). Seme 
drugs, notably 8-methoxypsoralen,used in the treatment of psoriasis are 
mutagenic under certain conditions (Bridges & Mottershead, 1977; Bridges, 
1979a). In industry, several chemicals have been associated with human cancer 
and have been detected as both mutagens and carcinogens in experimental systems 
e.g. benzidine, vinyl chloride, g-prcpiolactone, ^naphthvlamine (reviewed 
de Serres, 1976). Asbestos has been associated with rare mesiothelicma of 
the lung in man (Selikoff, 1977). Perhaps one of the most significant 
chemicals to be found,in recent years,to be both mutagenic in bacteria and 
later a carcinogen in animals is Tris (2,3-dibrcmoprcpyl) phosphate .(Blum 
& Abss, 1977, Prival et al,, 1977). This chemical was a widely used flame- 
retardent for children’s nightwear in the U.S.A. which on the strength of 
results in carcinogenicity studies has since been banned.
1.1.5. Other genetic hazards of environmental mutagens
Cancer is not the only risk frcm exposure to environmental mutagens.
The most numerous types of mutations in man are recessive, and since two 
mutants alleles are required for the expression of a recessive gene, these 
are rarely expressed immediately (Suttcn, 1975). The exception is that in 
the male all mutations on the X and Y dhrcmosones are expressed as they have 
only one copy of each of these chromosomes. X-linked disorders are inter­
mediate between recessive and dominant in their effects, but can in the main 
be compared with dominant disorders.
It is estimated that 6% of live births have, or will have, serious 
inherited defects, be it recessive, dominant or X-linked, chromosomal 
mutations or aberrations. The genes may have been inherited frcm the parents, 
or in rare instances be new mutations (Sutton, 1975). One large group of
Table 1.4
Chemicals Recognized as Carcinogens in Man 
(Adapted frcm Heidelberger, 1975 and Tcmatis, 1977)
Aflatoxin
4-Aminobiphenyl
Arsenic
Asbestos
Auramine
Benzene
Benzidine
Betel nuts
Bis (chlorcmethy 1) ether
Bis (2-chloroethyl) sulphide (Mustard gas)
■Cadmium oxide
Chromium compounds
Cigarette smoke
Cutting oils
Cyclophosphamide
Diethylstiboestrol
Hematite
Malaphalan
Nickel corrpounds
2-Naj i^thylamine
Phenacetin
Progestational contraceptives 
Vinyl chloride 
Wood dust
genetic disorders are those involving chronosanal aberrations, resulting 
mainly in severe defects leading to spontaneous abortion or sterile live-born, 
e.g. Down's syndrcme (Suttcn, 1975). Cannon autosanal dominant diseases 
(2/1000 live births) include Huntingdon's chorea. Gardener's syndrome and 
cleft lip with or without a palate with lip pits. Sex linked diseases 
(0.8/1000 births) include haemophilia and muscular dystrophy. Common auto­
somal recessive diseases (2.4/1000 live births) include cystic fibrosis, acute 
spinal muscular atrophy and phenylketonuria (Bridges, 1975b).
The possible mutagenic effects of cigarette smoke in man have been 
reviewed by Bridges (1979b) and Bridges et al. (1979). Cigarette smoke has 
been shown to be mutagenic (Hutton & Hackney, 1979? Sato et al., 1977) and the 
urine of cigarette smokers has been found to contain mutagens while the urine 
of non smokers does not (Yamasaki & Ames, 1977). Other investigations hint 
towards genetic effects caused fcy smoking and therefore suggest detrimental 
effects to man.
Only one investigation to date has been published. Mau and Netter 
(1974 cited in Bridges, 1979b) estimated that perinatal morta lity and major 
congenital abnormalities based on approximately 5,200 pregnancies were related 
to the smoking habits of the father. An increase from 3.0% to 4.5% and 0.8% 
to 2.1% in perinatal mortality and major congenital abnormalities respectively 
was found in the progeny of fathers smoking more than 10 cigarettes per day 
as compared to non-smoking fathers. Bridges (1979b) suggested that 40% of 
major congenital abnormalities could perhaps be attributed to paternal smoking, 
which would amount to around 3,000 per year in the U.K. In another investigation 
(Viczian, 1969 cited in Bridges et al., 1979), a relationship between smoking- 
and occurrence of morphologically abnormal sperm was found. Although physio­
logical factors can affect sperm mutation, it is likely that a mutation may 
fesult in morphological abnormalities. This is the only investigation and 
further evidence is required to substantiate these results.
Recently damage to DNA has been suggested to contribute to heart 
disease (Benditt, 1977), ageing and cataracts (referenced in Ames, 1979).
These few examples indicate the importance of mutagens in the environ­
ment and the need for awareness of their effects both with respect to cancer 
and to other genetic effects.
1.1.6. Alternative theories of chenical carcinogenesis
The concept of scmatic mutation for the induction of cancer is not the 
only tenable theory. Alternative theories have been proposed to explain the 
induction of cancer and have been reviewed by Miller and Miller (1971, 1976) 
and Magee (1977 a).
It is difficult to distinguish between theories that are based on a
mutational event that is not immediately expressed, but requires a second 
step to allow its expression and those that suggest a completely different 
mechanism. As an illustration, viral activity has been proposed as a 
different mechanism since carcinogenic viruses are kncwn (Todaro et al., 19.72) 
and associated with uterine cervical cancer, breast cancer and Burkjtt's 
lymphcma (Magee, 1977a). Chemicals could act by activating a latent carcinogenic 
virus or cause the expression of part or all of an integrated viral gencme.
Tumour formation is thought to occur in two stages, initiation and 
promotion (Berenblum, 1954). Saccharin which is not a mutagen (Ashby et al,, 
1978a) has been shown to have promotional properties (Hicks et al. ,1975). The 
presence of a mutational event is not, in this situation, causinq cancer, but 
is induced to do so by the presence of a pranotor, saccharin. This compound 
itself only causes cancer in conjunction with a change already in the cell.
Linked to this theory is the hypothesis of immune surveillance. This 
hypothesis suggests the presence of a population of cells which have already 
undergone malignant transformation and are constantly being eliminated by 
immunological defense mechanisms. Since many chemical carcinogens are imnuno- 
suppresant, these agents may act by preventing the elimination of such 
malignant cells (Magee, 1977a). The initial malignant cells may, however, have ' 
arisen by scmatic mutation. The hypothesis of cell selection is opposed by 
evidence that nude mice which have no T- lymphocytes show no increase in 
spontaneous tumours and no increased sensitivity to chemical carcinogens.
If transformed cells are eliminated by immunological defenses, it would 
be expected that transplant patients, who are treated by immunosuppressive 
drugs, would shew an increase in cancer. Although there is an increase in 
certain types of cancer, e.g. non-Hodgkin's lymphcma and squamous carcincma 
of the skin, there is no evidence as yet of a generally increased cancer risk 
among these patients (Doll, 1979). This suggests that the concept of immune 
survei Hence may not be an adequate alternative theory for chemical carcino­
genesis.
It has been suggested that chemical carcinogenesis be defined as 
either genotypic or epigenetic (Van Abbe, 1976? Ashby et al., 1973a-). Evidence 
for an epigenetic mechanism is not extensive. The fact that not all mutagens 
are carcinogens, although many carcinogens are mutagens, has been suggested 
to support an epigenetic theory. The frequency of transformation in cell 
lines is much higher than the frequency of mutation and this was considered 
as evidence in favour of an epigenetic mechanism (Magee, 1977a) . Huberman . 
et al.,(1976), however, disagree, finding a much smaller ratio between trans­
formation and mutation. Bouck and di Mayorca (1976) also identified trans­
formed cells as resulting frcm scmatic mutation.
Although many chemical carcinogens or their active metabolites have 
been shown to react with DNA, such as N-nitroso compounds, seme compounds, 
such as arcmatic amines and polycyclic aromatic hydrocarbons, have also been 
shown to interact with t-ENA, which may affect the control of the expression 
of the cell (Weinstein et aL-, 1975). Modification of the control of the 
expression of the cell would lead to an epigenetic mechanism of cancer 
(Miller & Miller, 1976? Magee, 1977 a).
The clonal origin of seme tumours in support of the scmatic mutation 
theory of cancer has been discussed in Section 1.1.1. Evidence, however, to 
support an epigenetic approach has been accumulated in studies on mouse 
teratocarcinema. A teratoma is a bizarre neoplasm composed of a foci of 
undifferentiated malignant cells interspersed with an array of scmatic tissues, 
representing each of the three embryonic germinal layers in various stages 
of differentiation. Embryonal carcinoma cells were obtained from the 
ascitic fluid of an ascitic form of a teratoma induced in mouse testes. These 
cells, when implanted in the peritoneal cavities of mice, developed into 
ter^tocarcinomas composed of as many as fourteen well-differentiated scmatic 
tissues, in addition to embryonal carcinoma. Kleinsmith and Pierce (1964) 
concluded that the capacity of single embryonal carcinoma cells to differentiate 
into benign tissues did not support, the scmatic mutation theory of cancer. 
Studies on injecting single embryonal carcinoma cells or mouse teratocarcincma 
into blastocysts of mice prior to implantation into females, showed that the 
blastocysts could develop into tumour-free healthy mice. Cells from the 
teratoma also gave rise to sperm from which many normal progeny were obtained. • 
Illmensee and Mintz (1976) suggest that this evidence is in favour of a non- • 
mutational basis for transformation to malignancy.
It has been suggested that there may be a casual link between peroxisome 
proliferation and carcinogenesis (Peddy et al,-, 1980). This arises from 
evidence that seme hypolipidaemic drugs that cause peroxisome proliferation 
in rat liver are also carcinogenic in rats. It has been shewn that such drugs, 
including the widely used drugrClofibrate, do not cause DNA damage and are not 
mutagenic in S. it/phimurium (Warren et alr,1980). The available evidence 
supports a non-mutational mechanism of carcinogenesis. Crairpton et al.,(1977) 
have postulated that a number of hepatocarcinogens' may invoke their effect 
by causing disturbances to cellular membranes, such as proliferation of the 
smooth endoplasmic reticulum. Clofibrate,causes a large increase in endoplasmic 
reticulum (R.Hinton, personal communication).
Although an increase in peroxisomes may result in an increase in 
mutagenic metabolites that are as yet not identified, it seems likely that 
the carcinogenicity in rats of hypolipidaemic drugs, such as Clofibrate, may
resuru xxuruuyn c tii epiyerieT~LU c u iu  nut a yenetic neaicjnisiu.
The majority of the available evidence is consistent with cancer 
induction by scmatic mutation, however it is probable that no single 
mechanism is responsible for all forms of cancer induction.
1.1.7. Mutagenesis and Repair ^
Before describing the tests that have been devised to detect chemical 
carcinogens, it is necessary to understand the mechanisms causing genetic 
changes in cells. As will be discussed in Section 1.1.9, mutagenesis and 
DNA repair form the basis of the majority of screening tests and an outline 
of the mechanisms of these processes is presented belcw.
A mutation can be described as an abrupt, heritable- variation that is 
not due to segregation or recombination. This includes many types of alter­
ations within the genome. (A general review of mutation mechanisms can be 
found in Stent, 1971.) Much of the understanding of mutation and repair 
has came from studies in bacteria, most commonly Esherichia coli (E.doli).
Briefly, the various types of mutation include
(1) Base pair substitution mutations, where one base is replaced by 
another. Two types are recognised, transition when a purine 
(cytosine or thymidine) base on one of the DNA strands is replaced 
by the other purine (or a pyrimidine (adenine or guanine) by the 
other pyrimidine), and transversion when a purine is replaced
by a pyrimidine, or vice versa.
(2) Frameshift mutations, where usually a single base is added or 
deleted, causing the reading frame of the genetic code to be
_ » i
out of phase.
(3) Deletion mutations, where a substantial piece of genetic material 
is lost.
Genetic alterations may have a variety of manifestations such as 
physical (breakage of DNA), chemical factors (e.g. removal or alteration of 
ENA bases), or enzymic factors (e.g. repair or reccmbinational errors). A 
summary of the molecular mechanisms of mutagenesis can be found in the review 
by Drake and Baltz (1976).
A consequence of damage to DNA is the attempt by both bacteria and 
mammalian cells to repair damaged DNA, and it now seems probable that under 
normal conditions most DNA damage is not mutagenic, but that mutagenicity 
is the consequence of errors in one of the repair mechanisms.
There are several mechanisms identified in bacteriat cells that are 
responsible for repairing damage to DNA.
Accurate repair of DNA can be achieved by the following mechanisms:
(1) Photoreactivation in which pyrimidine dimers formed by exposure
to UV-light are reversed by the presence of 300-450 nm wavelength 
light, and the DNA is restored to its original configuration.
This repair mechanism is specific for pyrimidine dimers.
(2) Excision repair in which damage of all types can be enzymically 
excised and the gap filled enzymically by undamaged bases.
(3) Recombination repair where during ENA replication the replication 
stops at a damaged region and restarts later, possibly at the 
start of the next Okazaki fragment. These gaps are then filled 
by recombination with the sister duplex that would have been 
replicated. The resulting gap on the sister duplex can then be 
filled by using the undamaged DNA as a template.
The existence of a non-recambinational error-prone repair pathway is 
established (see Bridges, 1977), and has been implicated in mutagenesis by 
UV-light, ionzing-radiation and by many chemicals. DNA repair with respect 
to mutagenesis has been reviewed (Bridges, 1977; Green, 1978, Lehmann & 
Bridges, 1978). The process of error-prcne repair appears to consist of sore 
fomj of random polymerisation past non-coding lesions. This is a minor 
pathway, but is, in bacteria, the major route for the production of base 
pair substitution mutations. Frameshift mutations arise by a less well under­
stood mechanism. • Frameshift mutations need not arise by a covalent reaction 
of the chemical with DNA. Intercalation of a molecule in the DNA helix, thus 
shifting the reading frame, is also possible. Base repair substitution 
mutations require initial reaction with ENA.
g
There is new evidence of an association of 0 -alkylation of guanine ,
6with mutagenesis (Loveless, 1968? Green, 1978). Agents which cause 0 -alky- • 
lation of guanine are able to mutate bacteria deficient in error-prone repair
g
pathways. Misreplication of 0 -alkyl guanine with thymine or cytosine may
4lead to mutagenesis. 0 -alkyl thymine might also lead to mispairing of 
bases (Green, 1978).
1.1.8. The consequence of ENA repair in man
The relationship between DNA damage and scene cancer has been indicated. 
It is likely that repair mechanisms are as important in man as in bacteria, 
particularly as man is widely exposed to DNA damaging agents (e.g. UV-light 
frcm the sun). As discussed in Section 1.1.1, one of the most significant 
lines of evidence for the scmatic mutation theory comes frcm studies in 
repair deficient humans.
The processes of repair in mammalian cells are similar to those in 
bacteria, although they are very much more carp lex. Cultured skin cells 
frcm individuals with various genetic diseases have been shewn to be deficient 
in DNA repair. These cells also shew sensitivity to one or more DNA damaging
agents. These are recessive, rare diseases and such cases are prone to 
develop malignant disease, e.g. Xeroderma Pigmentosum (XP), Fanconi1 s 
anaemia,Ataxia Telangiectasia (reviewed by Arlett & Lehmann, 1978). It 
is significant that the parents of children with Ataxia Telangiectasia and 
Fanconi's anemia show greater risk of developing cancer than the rest of 
the population (Arlett & Lehmann, 1978).
XP is the most widely investigated of these diseases. Cleaver (1968) 
was the first to observe that cultured cells from patients with XP were 
defective in ENA repair. The syrnptans of this disease include a high 
sensitivity to sunlight, freckling, hyperpigmsntation, and eventual multiple 
skin car cinemas and melanomas which are the final cause of death usually 
before the age of 30. Seme patients also suffer neurological disorders.
Genetic studies have indicated the existence of at least 8 different complement­
ation groups. Cultured XP cells shew increased sensitivity to DNA damaging 
agents such as UV-light, which also causes a greater degree of chrcmoscme 
breaks and sister chromatid exchanges (SCE's) than in normal cells. SCE's 
invQlve the reciprocal exchange of genetic material between two chrcmatids 
of a chrcmoscme. The cells are sensitive to 2-acetylaminoflourene (2AAF) 
and 4-nitroquinoline-N-oxide (4N20) which form large adducts with DNA. 
Mutagenesis in fibroblasts frcm XP patients is induced by UV-light, 2AAF and 
benz (a)pyrene (Maher et aLr,1976, 1977). The sensitivity of XP cells to the 
lethal effects of chemicals is associated with the inability to excise damage 
to the DNA, although one class of XP cells has normal excision repair, but 
is defective in post replication repair (XP variants) (Arlett & Lehmann, 1978). * 
The defective DNA repair mechanisms result in increased levels of UV-induced ■ 
mutations probably arising during replication of unexcised damage either frcm 
more lesions being replicated (excision deficient XPs) or frcm increased 
error.-proneness of the defective post-replication repair (XP variants). As 
already discussed, this should lead to an increase in UV-induced cancer 
associated with DNA damage, which is observed and is cited as evidence for 
the scmatic mutation theory of cancer.
1.1.9. Current approaches to screening for chemical carcinogens
The presence of known chemical carcinogens has led to awareness of the 
need to be able to identify such chemicals prior to large scale human exposure. 
Long term carcinogenicity studies are both time ccnsuming and very costly. 
Currently the National Cancer Institute (NCI) of the USA requires tests , to be 
carried out in two species, usually rats and mice, and in both sexes.
Several preliminary tests are performed before a long term study is 
carried out. The maximum tolerated dose of a chemical that can be administered
to an animal, and not shorten its longevity as a result of effects other 
than carcinogenicity, during a chronic study has to be predicted on the basis 
of data collected in a 90-day subdhronic study. This is carried out in each 
sex of each strain. This 90-day study may involve several prior dose ranging 
studies using various dosing regimens, such as acute exposure (on day 1 of a 
study) or continuous exposure for up to 14 days (Sontag, 1977).
In a long term study, at least 50 animals of each sex per dose of 
chemicals are required and at least 500 animals for one long term bioassay are 
then required ( .Saffioti’, 1976? Tanatis, 1977; Arres, 1979). This type of 
experiment is by no means satisfactory. It has been calculated that at least 
455 animals per dose are needed to detect an effect in 1% of the animals with 
a probability of 0.01 (Barnes & Denz . cited in Bridges, 1976a). It is obvious 
that such tests can only be performed on a very limited number of drugs and 
chemicals either produced or in current use.
Since chemical carcinogenicity is related to mutagenicity, short-term 
tests that detect DNA damage have been widely investigated. It had been hoped, 
after the observations (McCann & Ames, 1976) that 87.7% of kncwn carcinogens 
are mutagens in various strains of S. typhimurium f that additional tests would 
enable the complete detection of carcinogens.
There are numerous short-term tests available (Bridges, 1976a and 1976b; 
Montesano et aLf(eds.), 1976; Purchase et alr ,1976 and 1978). Many tests depend 
on the detection of DNA damage in sufcmarrmalian systems. The suhmarrmalian tests 
can be broadly divided into 3 groups: tests for gene mutation, tests for
dhrcmoscme damage, and tests for DNA repair. 1
The one single test that has possibly made the biggest impact on short­
term testing is the Ames test, in which reverse mutation .is assessed in S. 
typhimurium (Ames, 1971; Ames et al-/1975; McCann et al*, 1975).
The various types of submairmalian test available are listed listed 
in Table 1.5 and are briefly summarised belcw.
Tests in bacteria
Gene mutation in bacteria can be detected by forward (frcm wild type to 
mutant) or back (reverse) mutation (frcm mutant to wild type). The Salmonella 
strains employed by Ames (Ames et aL:/1975) are mutants requiring histidine, 
and are reverted to histidine independence. E.coli can be used looking at 
reversion frcm tryptophan requirement to independence (Green & Muriel, 1976). 
Salmonella typhimurium can be used for forward mutation to 8-azaguanine resist­
ance (Skcpek et al., 1978) and other changes (Paes, 1978; Penyo, 1978). Generally, 
the bacteria are incorporated with the chemical and a metabolising system 
(if required) in an agar overlay on an agar plate. The fluctuation test, 
carried out in liquid, can be used with both Salmonella and E.Coli (Voogd et 
al.f 1974; Clarke & Wade, 1975; Green et al.r 1976, 1977a, 1977b; Venitt &
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Bushell, 1977; Gatehouse, 1978; Hubbard et al., 1980). This test will be 
discussed in much greater detail in later chapters.
Another test is the induction of prophage (inductest), which induces 
the stimulation of the lytic cycle in bacteria harbouring a latent bacterio­
phage , (Kondo, 1975; Speck et' al.y 1978;- Moreau & Devoret, 1977) . ■
The repair of damage in DNA can be used as an indication of potential mut- 
genesis. Bacterialmutants lacking different repair processes can be used 
to indicate the need for repair. The best kncwn tests are the rec-assay 
(Kada, et al., 1972, 1974) and the pol-assay (Slater et al., 1971). The 
triple mutant uvrA, recA, lexA of E.coli has recently been used and suggested 
as a prescreening test (Green & Treats, 1979). In a recent study, hcwever, 
these tests were shewn to be less efficient at detecting chemical carcinoqens 
than conventional mutation assays (see Announcement 1978; Chapter 4).
Tests in fungi
Saccharcmyces cerevisae has been used in a fluctuation test (Parry, 1977b). 
The vuse of yeast has been reviewed (Ziitmerman, 1973, 1975; Loprieno et al.,
1974). Neurospora crassa and Aspergillus have been used for both forward and 
reverse mutation (de Serres & Mailing, 1971; Rcper, 1971).
The detection of mitotic non-disjunction in S. cerevisae (Parry, .*.
1977a) and Aspergillus (Bigani et al, 1974) has been used to look for 
chemical damaging effects. The frequency of mitotic recombination or gene 
conversion has been measured in S. cerevisae (Zlirmerman, 1973, 1975;
Loprieno et al.,1974; Parry, 1977b) and in Aspergillus (de Serres & Mailing*
1971; Rcper, 1971; Kafer et al., 1976).
Tests in plants
Tradescantia can be used to detect gene mutation (Underbrink et al.,
1973; Sparrow et al.y 19y4), and chrcmoscme damage (Kihlmann, 1971) . Other 
higher plants such as, Viet cu Faba (broad bean) , (Nilan & Vig, 1976) and 
Allium Capa (carman onion) (Kihlmann, 1971) can be used to detect chrcmoscme 
aberrations.
Tests in insects
Drosophila Melanogaster is the most widely used insect and has played 
a large part in the detection of chemical mutagens. The most often used 
point mutation test has been the induction of sex-linked recessive lethals, 
which become evident in the offspring of treated individuals. The use of 
Drosophila has been extensively reviewed (Vogel & Sobels, 1976; Vogel, 1977; 
Auerbach, 1979).
Chrcmoscme damage such as non-disjunction, loss of chrcmoscmes, 
deletions, translocations and dominant lethal mutants have also been used 
(Wurgler et al., 1977; Vogel, 1977).
The wasp of the genus Habrdbracon is less widely used (Smith & Von 
Borstal, 1971; Von Borstal & Smith, 1977).
Tests in mammalian cells
The many systems for detecting gene mutation in mammalian cells are 
based on the use of phenotype markers revealing nutritional,serological, 
biochemical, temperature or antimetabolite resistance. The addition of a 
metabolising system is possible (Bimboes & Greim., 1976 ; Rogers, 1978;
Krahn & Heidleberger, 1977).
Cell nutation systems are widely used. Hamster, mouse and human 
fibroblasts are among the cell lines most often employed (Arlett, 1977a^ .
Mouse lyirphcma L5178Y cells (Cole & Arlett, 1976, 1978; Cole et al, ,1976;
Rogers, 1978) have been used in a form of fluctuation test to determine 
the induced mutation rate in these cells. Other cells used in mutation 
assays include hamster cells, including V79, ovary and lung cells (Niell et al,, 
1977; Huberman & Sachs, 1974; Krahn & Heidleberger, 1977; Dean & Senner,
1977; Kuroki et al., 1977; Arlett, 1977b); human fibroblast cells (Jacobs & De 
Mars, 1977) and lymphoblast cells (Thilly et al,, 1976; De Mars, 1974).
Chrcmoscme damage can be observed by cytological methods in mammalian 
cells in culture (Evans, 1976).
Ishidate and Odashima (1977) have used the chrcmoscme aberration test 
as a screening test in Chinese hamster cells. Human lymphocytes in culture 
have been used by Bimboes and Greim, (1976), and rat lymphocytes have been 
used by Lilley et al*, 1975). It has been suggested that sister chromatid 
exchange (SCE), involving the reciprocal exchange of genetic material' between 
two chromatids of a chrcmoscme, might be important in the estimation of chrcmo­
scme damage (Perry & Evans, 1975; Stetka & Wolff, 1976). Abe and Sasaki (1977) 
have examined the ability of various chemicals to involve both SCEs and 
chrcmoscme breaks in a pseudo diploid Chinese hamster cell line. The usefulness 
and relevance of this test is not kncwn, but it is considered as a test which 
indirectly measures DNA damage involving repair.
The repair systems in mammalian cells after damage by chemicals can 
be detected by measuring unscheduled ENA synthesis (UDS) in the cells after 
treatment. Such methods are reviewed by Stitch et al ./1977), utilising human 
cells in culture. Martin et al.r(1978) included a microscmal fraction for 
metabolism with the HeLa cells in which they measure UDS, and found a good 
correlation between induction of UDS and carcinogenicity. The use of hepato- 
cytes as metabolising systems and also for measuring UDS, has been studied 
(Williams, 1977; Lowing et al., 1979). This method seems premising as metabolism 
takes place in the same cell in which the genetic end-point is being measured.
Carcinogen invoked cell transformation in vitro has been used to
indicate a malignant change in cell lines (Marquardt; ,1976). Although this 
has been shewn to relate directly to a mutation event in the cells (Bouck & 
di Mayorca, 1976), the valid criteria for malignant transformation is the 
ability of the cell to produce a tumour when inoculated into an appropriate 
host. Nevertheless, there are several other criteria, the most widely used 
being the ability of the cell to grew in soft agar (Bouck & di Mayorca, 1976).
Most human cancers are derived frcm epithelialoells, but nearly all
fbderii
the work on cell transformation has been carried out in ^fibroblast cultures 
(DiPaolo, 1972; Pienta et al., 1977; Castro et ai , 1977; Styles, 1977). Fibro­
blast sarcomas in humans are responsible for only a minority of malignant 
disease and, therefore, the relevance of the use of fibroblasts in relation 
to carcinogenicity is not certain.
Since fibroblasts do not carry out metabolic activation they have 
been combined with metabolising systems. Feeder layers are used for metabolic 
activation in transformation assays (DiPaolo. et al, ,1972 ; Pienta et a L ,
1977). Castro et al. (1977), used a system involving the treatment of 
hamster cells frcm embryos and injecting then into the right abdominal 
quadrant, or invaginated pouch of a host, and looking for tumour production.
This could be considered as an in vitro test. The EHK cell transformation 
assay incorporating S9 fraction for metaboic activation (Styles, 1977, 1979) 
appears to be detecting chemicals with the same efficiency as the. Ames test.
Sate work has been carried out on epithelial cell lines derived frcm 
rat livers (Williams et al. r 1973a; Williams, 1976 a). They can be transformed 
by seme chemicals. The expression of transformation is very much slower 
than that in fibroblasts.
Effects on cell growth may also be considered as an indication of 
damage to ENA. Gras so and Grant (1977) have reviewed the inhibition of 
growth of kidney cells and HeLa cells in culture and related this to carcino­
genicity. Fry & Bridges (1977) and Widskin (1978) have used a mixed, 
culture system of fibroblasts and hepatocytes, to look for the cytotoxic effects 
of chemicals on the fibroblasts utilising the hepatocytes as the metabolically 
active cells.
Apart frcm the effects of DNA manifested as various types of damage, 
a number of changes have been observed during the initiation and development 
of tumours, which are not necessarily associated with modification of DNA, 
but which might be considered as possible end-points for short-term screening 
tests for carcinogenicity (Bridges & Fry, 1977). These will be listed below 
with a reference to each.
(a) Production and secretion of abnormal proteins such as foetal 
proteins (Lcwing et al., 1979 .).
(b) Changes in the endoplasmic reticulum (ER) such as loss of ribo-
sones, where degranulation of the ER has been observed with seme 
chemicals (Williams & Rabin, 1971). Other effects, e.g. the 
selective enhancement of bipheny 1-2-hydroxylase in the liver by 
chemicals (Macpherson et al, 11974) have been investigated.
(c) Other test systems which have been suggested include the Tetrazolium 
red reduction test (Iversen -r 1963) and sebaceous gland suppresion 
(reviewed in Purchase et al,, 1978) both of which are selective 
for skin carcinogens as opposed to those affecting other tissues 
and appear to have limited value.
Whole animal short-term screening tests
Although Drosophila tests may be considered an in vivo test, whole 
animal tests in mammals have been developed:
(1) Cytological studies including chrcmoscme aberrations (Lilley et al.,
1975), micronucleus test (Schmid, 1976, 1977; Heddle and Bruce,
1977), sperm abnormalities (Wyrobeck & Bruce, 1975 ; Heddle & Bruce,
1977), and sister chrcmatid exchange studies in vivo using bone 
marrow (Allen & latt, 1976).
(2) Cell transformation of culture cells in vivo has been studied
(DiPaolo& Castro, 1976; Marquardt,, 1976; Castro et aL, 1977).
(3) The in vivo coat colour spot test in mice (Fahrig, 1975).
(4) The host-mediated assay as an in vivo/in vitro test has the 
advantage that it uses the animal in vivo to metabolise chemicals 
(Legator & Mailing, 1971; Mailing, 1974; Mohn & Ellenberger, 1973; 
Legator et al„ 1977) and a number of indicator organisms have 
been employed as the response systems, e.g. bacteria, yeast and * 
fungi. However, this test relies on the release of active 
metabolites into the peritoneal cavity or blood of the animal into 
which the indicator organism is injected. If the active metabolite 
is short lived it has little chance bf reaching the indicator 
organisms.
1.1.10 Application of screening tests
Ideally a system for monitoring chemicals for mutagenic activity should:
(1) Detect the potential of the chemical to induce gene and chrcmoscme 
damage in scmatic or gem cells;
(2) Provide data for extrapolation to man;
(3) Be capable of detecting metabolic products which have ENA damaging 
potential, i.e.,a metabolising system incorporated;
(4) Be reproducible; and
(5) Be quick and economical, i.e., automatable or semi-autcmatable.
End-points include DNA-binding, chrcmoscme damage, gene mutation and
ENA-repair. Tests will only give information on a restricted spectrum of 
genetic damage. Another limitation is the failure of sane tests to provide 
a suitable range of metabolic activity. This can be remedied in principle 
by adding a metabolising system such as 9,000g fraction of liver honcgenate 
or freshly isolated hepatocytes. This will be discussed in greater detail 
in Section 1.2.5.
A battery of tests has been suggested to screen chemicals, the 
minimum requirement being one test for each type of DNA effect possible.
Bridges (1973, 1976a, 1976b) and Flamm (1974) have proposed a three- 
tier approach for the evaluation of mutagenicity and carcinogenicity tests.
Bartsch (1976) has also proposed a similar scheme. These approaches can be 
used not only to detect chemicals thought to be carcinogens, but also to 
detect those with other genetic risks.
In Tier 1, sutmarrmalian tests which are quick to perform could be 
enployed. Other metabolic and pharmacological studies may also be enplcyed.
A carbination of several short-term tests are suggested covering a variety 
of systems. The non DNA-damaging tests (biochemical tests, e.g. degranulation 
of the endoplasmic reticulum) may be included at this level.
Tier 2 tests are those in which whole animals are used. These include 
long-term carcinogenicity tests, and are usually very expensive. Other 
quicker tests include host-mediated assays, micronucleus tests and chrcmoscmal 
damage in whole animals. Drosophila may be important for the detection of 
particular types of damage, such as dominant lethal mutations and non-disjunction, 
although Drosophila can also be used in Tier 1. The use of Drosophila bears 
little relationship to whole mammalian systems, and is probably only useful- 
for the particular -types of damage noted, but may be important in testing 
occupational environments, e.g. factory atmospheres.
A chemical negative in Tier 1 would pass into Tier 2 for further 
evaluation. A chemical shewing evidence of biological activity in Tier 1 
would be treated with caution and if no-adequate substitutes is available the 
chemical would be considered for further evaluation in Tier .2.
Assessment of risk to man is the final Tier 3 in the evaluation of a 
chemical. Evaluation of risk in relation to benefit frcm the chemical and 
control measures must be considered. Further data on species differences, 
metabolic fate and toxicity may be required before a final assessment can be 
considered. The levels of exposure that would be safe for humans is very 
difficult to assess. There is no evidence that a threshold (i.e. level 
below which no effect occurs) exists for the irreversible process of carcino­
genesis (Weinhouse, 1976). Carcinogenic risks to humans have to be weighed 
against a background of an already existing environmental burden which has 
probably already exceeded any threshold which might exist (Crump et al..
1976). Bridges and Stamper*, (1975) calculated that under certain conditions 
a quasi-threshold response can be found at lew levels, i.e. a lower than 
expected, but no zero response at lew doses.
The tier system is only intended as a guideline to screening programmes 
to assess the overall effect of a chemical. There has been much investigation 
into sub-marrmalian short-term tests to limit the number of chemicals requiring 
testing in long-term tests, and to try and predict carcinogenicity.
1.1.11 Validation of submammalian tests
The most widely used screening tests are the suhmarrmalian tests.
Poirier (1976) has reviewed the correlation of mutangenicity and carcinogenicity. 
An 87.7% correlation of carcinogenic carpounds being mutagenic with the Ames 
test has been found (McCann & Ames, 1976). Non-carcinogens showed 86.3% 
correlation with negative mutagenicity. Seme false negatives can be shewn 
to be positive in other tests and may require a different metabolic system.
Others may be carcinogens by mechanisms other than scmatic mutation, e.g. 
asbestos (Selikoff, 1977). Studies in a single laboratory (Purchase at al.,
1976, 1978; Sugimura et al.,1976) have compared several tests for predicting 
carcinogenicity. The carcinogenicity or non-carcinogenicity was accurately 
predicted in 80-90% of cases, although seme tests performed better than others.
A 100% correlation between carcinogenicity and mutagenicity oannot be 
expected with the present knowledge of the ccmplexity of carcinogenesis.
Since not all carcinogens act via a scmatic mutation mechanism, the correlation 
coefficient will tend to be lowered. None-the-less, short-term mutagenicity 
tests may be used to predict the ability of chemicals to cause DNA damage 
and mutations < which in many situations may also be carcinogens. Before 
any tests can be adopted as predictive of animal and, perhaps, human, carcino­
genicity, it is necessary to find the tests that predict carcinogenicity 
with the highest degree of accuracy.
An international prograrrme for the evaluation of short-term tests for 
carcinogenicity was set up (Announcement, 1978) with the objective of system­
atically evaluating a range of mutagenic assay systems. This is discussed in 
Chapter 4. Apart frcm assessing individual assays, this study was designed 
to indicate which test systems duplicate each other, and which may detect 
specific chemical classes of carcinogens. Inter-laboratory variations were 
also investigated.
1.1.12 Potency correlation
The possibility of relating results obtained in sub-marrmalian short­
term tests to the human situation has been explored. A positive result in a 
test such as a bacterial test indicates that:
(a) the agent has the potential to react with DNA (almost invariably
covalently); and
(b) that if a liver fraction is required, it indicates that an active 
species can be formed by the enzymes present.
The tests take no account of distribution, or balance of activation or 
detoxification pathways in. vivo. It is unlikely that the present tests will 
detect hormonal or physical (e.g. asbestos) agents or pranotors.
Messelson and Russell (1977) have directly correlated the number 
of mutants obtained in an Ames test with carcinogenic potency (based on life­
time studies in rats). The carcinogenic potency (either found in an experi­
mental situation or calculated) is termed In2/D, , where D, is the daily dose
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which induces cancer in 50% of animals after two years exposure to the 
chemical. The two-year period was selected as it corresponds to the normal 
average life span of rats, mice and hamsters in the laboratory. Mutagenic 
potency is defined as the reciprocal of the number of micrograms of corpound 
giving 100 revert ant colonies in the Ames test. Messelson and Russell (1977) 
plotted the carcinogenic potency against mutagenic potency and
c
have found a good correlation over a 10 fold range of potency.
This correlation shows only that the extent of reaction of an agent 
in DNA in the bacterial test is of the same order as the possible extent of 
reaction with DNA in animal cells in a carcinogenicity study.
It is important that a simple laboratory test, which does not reflect 
the whole animal biochemistry should quantitatively predict the carcinogenic 
ability of a particular chemical. It is only the qualitative ability of a 
particular chemical to exhibit a carcinogenic characteristic under ideal 
conditions that can be predicted. It gives no account of the controls in • 
mammalian cells in vivo. In vivo diet, metabolism, hormones and many other 
factors influence cancer induction.
Ashby & Styles (1978) have argued against such correlations frcm the 
point of view of metabolic balance. Using BP and considering the balance of 
toxifying and detoxifying reactions in vitro in S9 fraction, they have 
shown that the mutagenic responses can be manipulated over a wide activity 
range by altering the enzyme balance.
Other examples can be found disproving a potency correlation in the 
enzyme balance. Coombs et al, (1976) showed that there was an overall lack 
of correlation between carcinogenic and mutagenic potency for 37 poiycyclic 
aromatic hydrocarbon carcinogens. Dimethynitrosamine requires special 
conditions to exert even a weak mutagenic effect (Ames et al. ,1975), but it is 
a potent carcinogen. A series of nitrosamines show a lack of correlation 
between mutagenicity and carcinogenicity (Nagao et al. ,1977a) in an Ames test. 
Jones and Huberman, (1980) have, however, shown a correlation with a number
of nitrosamines using a mammalian mutagenicity assay and isolated hepatocytes 
for metabolism.
McGregor (1975) showed that the S9 fraction frcm the cotton rat was 
the best of eight different liver preparations to activate 2AAFin an Aires test, 
although the cotton rat is resistant to 2AAF induced cancer. The food additive 
AF2 is a strong mutagen, but a weak -.carcinogen (Takazawa et al., 1975.).
The balance of metabolising enzymes in the S9 fraction can be altered 
by co-incubating chemicals such as butter yellow, aniline, o-toluidine and 
azobenzene with norharman (Nagao et al., 1977b? Ashby & Styles, 1978). The 
presence of norharman can dramatically increase the mutagenicity of these 
chemicals by selectively inhibiting a metabolic pathway that would normally 
detoxify them. This indicates the need to study the balance of enzymes in vivo 
and in vitro. Even the diet of an animal can alter the balance of enzymes in 
the metabolising fraction. Riboflavin dependant azo reductase enzymes can be 
controlled by riboflavin in the diet. The carcinogenicity of butter yellcw 
increases when riboflavin is reduced (reviewed by Acos and Argus, 1974). This • 
can also be reflected in the liver fraction and alter the mutagenicity of a 
chemical that relies on azo reductase enzymes for its deactivation.
With these few examples in mind it is apparent that a quantitative 
correlation is premature at this stage in our understanding of screening tests. 
When the basic flaws such as the metabolic status of such tests are further 
explored and the relative differences between species understood, then useful 
quantitative correlations'may be achieved.
In this thesis, the use of isolated hepatocytes for metabolism instead 
of the usual liver fraction in a mutagenicity assay was explored in greater' 
detail. They allow a situation in which the metabolic capacity in a short-term 
test relates more closely to the in vivo situation than the use of an S9 
fraction. Frcm this type of test a more close correlation between short-term 
screening tests and carcinogenicity might be achieved. As already mentioned, 
Jones & Huberman, (1980) have used isolated hepatocytes and mammalian cells 
for mutagenesis studies.
It is probably better at this stage in the development of screening 
tests to treat mammalian tests as a primary indication and early warning 
system of potential DNA damaging agents.
.2 . THE FLUCTUATION TEST AND THE USE OF HEPATOCYTES FOR 
METABOLIC ACTIVATION
1.2.1 Bacteria used in mutagenesis assays
The S. typhimurium strains TA98 and TAlOO have been used in this 
thesis. They form part of the series of strains developed by Ames et al. 
for mutagen screening and have been widely described (Ames, 1971; Aires et al., 
1972a, 1973a, 1973b, 1975). The five main Ames strains TA98, TAlOO, TA1538, 
TA1535 and TA1537 contain a mutation resulting in their growth requirement for" 
histidine. Mutation is detected as a reversion to histidine independance 
(his his ). They are all derived frcm Salmonella typhimurium LT^.
These strains all carry certain other mutations making them more 
susceptible to the mutagenic effect of chemicals. A deletion through the 
uvrB region of the chrcmoscme eliminates the excision repair system for
DNA. This deletion includes the gal and bio region resulting in an absolute
requirement for biotin and partial loss of the lipcpolysaccharide that coats 
the bacteria. A further mutation, rfa, results in further loss of the 
lipcpolysaccharide coat (down to the ketodeoxyoctanoate-lipid core). The 
loss of this coat makes than more permeable to large lipcphiUc molecules.
The strains TA1535 and TAlOO (which is TA1535 containing the pKMlOl 
plasmid) can be used to detect mutagens causing base pair substitutions.
TA1538 and TA98 (which is TA1538 containing pKMlOl plasmid) detect various 
kinds of frameshift mutations. Frameshift mutagens are specific for 
particular sequences they mutate and a repetitive -C-G- sequence near the 
site of the histidine mutation in TA1538 and TA98 allows then to be easily,
reverted by many carcinogens such as fluorene ccmpounds. TA1537 is specific
for intercalating agents that cause frameshift mutations and has a run of 
C's at the histidine mutation site (Ames et al., 1973a).
Summary of the properties of the bacteria
Mutation Types of mut-
Bacteria Histidine LPs Repair R. factor ation detected
TA98 his D3052 rfa uvrB pKMlOl Frameshift
TA1538 his D3052 rfa uvrB - Frameshift
TAlOO his G46 rfa uvrB pKMlOl Base pair
substitution
TA1535 his G46 rfa uvrB — Base pair
substitution
TA1537 his C3076 rfa uvrB - Intercalating 
agents (frameshii
The addition of an R-factor or plasmid pKMlOl to the S.' typhimurium 
strains TA1535 and TA1538 to give TAlOO and TA98 respectively, was found 
to make them more sensitive to mutagenesis (McCann et al., 1975). The 
plasmid pKMlOl confers ampicillin resistance on the bacteria.
The properties of the plasmid containing strains have been reviewed 
by Walker (1978) and Mortelmans and Stoker (1979). The presence of a 
plasmid has been shown to increase error-prone repair (MacPhee, 1973) and 
also mutagenesis (McCann et al., 1975). Error-prone repair is the minor 
repair pathway by which mutations arise frcm non-coding DNA lesions. The 
plasmid increases the frequency of spontaneous reversions in sane Salmonella 
strains, particularly in TAlOO (:-140 mutants/plate as ccmpared to-' 15/plate 
with TA1535). Mortelmans and Stoker (1979) suggest that the UV-protecting 
and mutagenis enhancing action of R-42 and its derivatives such as pKMlOl 
result frcm the action of a UVP (UV protecting) gene or genes causing 
repair capacity.
1.2.2 Estimation of mutation rates
The fluctuation test was devised by Luriaand Delbruck (1943) to 
establish the origin of bacteria resistant to viral attacks. Two hypotheses 
were put forward:
1. The hypothesis of acquired irrrnunity, in which all the bacteria 
interact with the virus, but seme survive the attack. Each 
bacterium has an equal chance of surviving the viral attack.
2. The hypothesis of mutation in which seme bacteria are resistant 
before addition of the virus and are not attacked by the virus at 
all. These mutations occur independently of the virus.
In this test, several cultures with a small inoculum of bacteria were 
grown to stationary phase and plated to look for bacteria resistant to viral 
infection. It was assumed that if a bacterium became resistant to virus, 
every offspring would also be resistant unless reverse mutation occurred.
The number of resistant colonies in each culture was counted, and the mean 
and variance calculated.
On the hypothesis of mutation, a resistant bacterium may arise at 
any time during the growth of the culture and give rise to a number of 
resistant offspring. The proportion of resistant bacteria will increase with 
time. In a series of cultures, a resistant bacterium may arise at different 
times in each culture, or not arise at all. It could, therefore, be 
predicted that there will be a wide distribution of resistant bacteria in a 
series of cultures. The variance will therefore be large compared to the 
mean. In the acquired irrrnunity hypothesis, a bacteria will only beccme
resistant on contact with the virus, and therefore there is a fixed small 
chance that each bacterium might become resistant on contact with the virus. 
For a series of cultures the resistant bacteria will be randomly distributed 
and according to the statistic of random sampling the variance will be 
approximately equal to the mean (Fischer, 1968).
Since in their experiments the variance was very different to the 
mean, it was concluded that the resistance to virus is due to mutations that 
can occur at any time during the growth of the culture. This theory of 
mutation can be applied to other mutations in bacteria, such as reaction 
to antibiotics, radiation or chemicals.
The Luria and Delbrfick calculations can also be used to accurately 
determine the spontaneous mutation rate of the bacteria. They define the 
mutation rate as the number of mutational events per unit time. For small 
mutation rates, the distribution of mutations in a series of similar cultures 
is distributed according to Poisson’s law. The number of cultures with no 
mutations therefore relates to the zero-term of the Poisson distribution.
This can be used to calculate the average number of mutations per culture 
frcm the fraction of cultures showing no mutations in a series of parallel 
cultures. The zero-term is given by:
where PQ = fraction of cultures showing no mutations and m = average number 
of mutations per culture. The muation rate can then be calculated frcm 
the value of m as follows:
For a tine element t the number of bacteria present will be
dNt/dt = Nt and = N efc , 2
where Nq is the number of bacteria present at time 0. The chance of a
mutation for each bacterium arising during time element dt is
adt ■ , 3
The number of mutations in a growing culture during time element dt is
dm = adtN^ , 4
m = a(N.- N ) + m  . 5t o o
In many cases Nq will be negligible as ccmpared to N^ , and for very small
mutation rates it is unlikelythat mutations occur in the first few generations,.
therefore m = 0. Fran eq.l o
InP = - m , 
o
InP = - aN. , o t '
a = - InP
 2  6
Nt
The time unit t is taken as the average division time of the bacteria
divided by In2. Frcm equations 2 and 14 (the expressions for the final 
number of bacteria in relation to both time and the number of generations), 
the relationship can be formed 
gln2 = t.
One generation therefore takes t/ln2 time to occur.
The total number of mutants r increases as m increases. The average 
number of mutants (r) in a culture can be estimated.
Let the number of mutant bacteria = p , at the end of 
time period t, then the rate of increase' in resistant bacteria is 
d p/dt = aN^ + p 7
p = taNt 8
As it is unlikely that any mutant bacteria were present at the initiation 
of the growth, a truer estimate of p which will be termed r (likely 
average) is r = (t - tQ)aNt 9
If tQis taken as the time when on average one mutation has occured in C 
cultures then fron eq.: .5
and N «  no to
Frcm eq.2
1 = aC(N, - N ) 10
to °
N. '=Re’(t“V
to t
t - t ,, = lnOb.Ca) , 11o u
and r = aNtln(NtCa) . 12
Thus frcm the average number of mutants in a culture or a series of cultures
the mutation rate may be determined. Again this expression means that the
mutation rate is time dependant.
An alternative method of calculating the spontaneous mutation rate
based on the generation period of the bacteria has been derived by Kondo (1972).
He derived an expression for the mutation rate \i per generation time in
terms of the number of mutational events m and the total number of bacteria
N : .g
m = (i(Ng - NQ) + m0  13
The final number of bacteria (N^ ) after g generations is given by
N = N 2g 14g o
Hence
m - mQ = p.(NQ2g NQ) = pNQ (2^  - 1) 15
and the mean number of mutational events in any one generation g-i is
Aiy. = Vi+l “ V i  = ^ g-i+l “ V i ’
= WNg_i = pNg2 . 16
In the final generation g each mutational event that occured in 
generation g-i has given rise to 21 mutant bacteria. The total number
it
of mutants M ( p or more accurately r as defined by Luria and Delbruck) is 
the sum of all the mutants contributed by mutational events in each 
generation:
g g
M = X 2 Am . = J 2\iN 2 1 = gpN . 17
i=l y i=l y y
A small number of parallel cultures can be used to estimate the mu-
i
tation rate and the same assumptions as those of Luria and Delbruck are 
made, i.e., when the Initial inoculum is small there is no contribution of 
mutants in the first few generations of growth. Consequently, g in eq. 17 
is smaller in reality.
When the average number of mutational events is 1 in a series of 
cultures C, then the number of generations contributing to the final 
number of mutants (M) is given by
I = 2~^1jjN C and g = ln(pN C) a 18
g g *
ln2
Hence, the mutation rate can be expressed as
II = Mln2 . 19 
Nln(jjNC)
The final number of mutants present after equal time periods as predicted
i
by both Luria and Lelbrucbs' and Hondo's expressions must be the same. 
Therefore frcm eqs. 9 and 12
jiNln (jjNC) = aNln(aNC) . 20
In2
The estimations of the final number of mutants differ by a factor of ln2.
Alternatively, frcm eqs. 14 and 2, the relationship between g and
t is
N et = N 2g , 21o o
t = g(ln2) • 22
Hence, frcm eq. 8 , if g(In2) is substituted for t, the total number of 
mutants,when all generations contribute to the final mutation number, 
is given by
M = pln2 23
ii
Since Luria and Delbruck chose t =average division time/ln2 
and implied that the occurrence probability of a mutational event in an 
individual bacterium in time dt is adt, then the mutation rate per bacterium
per division time is 
rln2
adt = aln2 24
0/
Luria and Delbruck did not allcw in their calculations for 
asynchronous growth and the fact that in any single generation period 
bacteria will be in various stages of growth. Therefore, at any instant 
in time different bacteria will have different probabilities of being 
mutated. The mutation rate therefore should be averaged over the whole 
generation period of the bacteria (Hondo, 1972). The mutation rate is 
then more accurately defined as the number of mutational events per 
generation period.
It is this failure to allow for asynchronous growth of bacteria 
which is directly responsible for the difference, by a factor of ln2 , in 
the equations for the final number of mutants, of Luria and Delbruck (1943) 
and of Hondo (1972).
The calculations of Luria end Delbruck have formed the basis for the 
calculation of the spontaneous mutation rate using a parallel series of 
cultures. Voogd et al., (1974) adopted the method of Luria and Delbrtfck 
using the fraction of cultures with no mutants present (eq. 6). Voogd 
et al., (1974) added the correction factor of ln2 to the numerator to 
allcw for asynchronous growth, the equation used be caning
a = ln2 (~lnPb) . 25
Capizzi and Jameson (1973) presented a table to .simplify the 
calculation of the spontaneous mutation rate frcm the average number of 
mutants per culture (r). Multiplication of £eq„ 12 by C gives
Cr = GaNtln(CaNt) , 26
Thus Cr is a function of the triple product CaNt and .vice, versa. They 
tabulated values of CaN^ . as a function of Cr at uniform increments of 
r.' The mutation rate can then be calculated for known values of .Cr and 
Nj_. Lea and Coulson (1949) as discussed belcw suggest that this is not 
an efficient method for the determination of the spontaneous mutation rate.
The estimation of the spontaneous mutation rate depends on an 
accurate determination of m (the average number of mutations per culture) 
frcm a series of parallel cultures. Lea and Coulson (1949) ccmpared various 
methods to calculate m.
As shown by Luria and Delbruck (1943) and Hondo (1972), the average 
number of mutants per culture may be used to calculate m ( eq. 15). Lea 
and Coulson (1949) show that the accuracy of the estimation of m does not 
increase with increasing numbers of cultures. The variance of the average 
number of mutants per culture in a series of cultures is similar to the 
variance if a smaller or larger number of cultures are taken. However, many
cultures are averaged, no improvement in the accuracy of m is obtained 
over the use of a single culture selected at randcm. It is therefore more 
accurate to use an alternative method for the estimation of m.
Lea and Coulson shewed that the use of the zero-term of the Poisson 
distribution for the estimation of m (eq.l) is less accurate for small 
or large fractions of cultures without any mutants (Pq < 0.01 and; > 0.9)
When this occurs the value of the standard error is very much increased.
The inaccuracy at small values of m is most likely due to the fact that 
there is not enough precise information about the mutation rate. At high 
levels of m there is much more information and this can be more efficiently 
used to determine m.
Lea and Coulson suggested that a more suitable method of estimation 
of m might be the use of the median, r ,• of the distribution of the mutants. 
The value m can be obtained from rQ using a table presented by Lea and 
Coulson (1949). The errors involved in the calculation of m by this method 
are much smaller when m is high, .than by the method using the fraction of 
cultures having no mutants. When the value of m is very lew there is no 
difference in the precisian of all three methods (Lea & Coulson, *1949).
Ncne of these calculations allcw for the expression time (the time 
required for ENA damage to cause a genetic change and for this change to 
be expressed (phenotypically). The expression of a mutation may take several 
generations grewth and the final number of mutants present may be influenced 
by this factor.
1.2.3 Measurement of induced mutation in a fluctuation test
In a conventional mutation assay using bacteria, the cells are 
treated with mutagen and plated on selective agar containing a grewth 
limiting amount of the required amino acid (Bridges et al., 1972); This 
supply of amino acid allcws several generations grewth during which initial 
ENA damage may either be repaired or beccme a mutation, the mutation then 
being expressed as a functional gene product. When the amino acid supply 
is exhausted, only mutants can grow. The induced mutation rate is then 
measured in the number of bacteria initially plated and once plated, unless 
sufficient mutagen is added, no more induced mutation takes place. On the 
other hand, spontaneous mutations occur throughout the grewth period on the
plate. The induced mutation rate is being measured in a smaller number of
8 9cells (e.g. 10 ) than the spontaneous mutation rate (e.g. 10 ). The
induced mutation rate must therefore be considerably larger than the
spontaneous mutation rate (of the order of 10 fold with such numbers as
used as an example) for a mutagen to be detected significantly. A mutagen
that only causes a small increase over the spontaneous mutation rate will 
not be detected.
The Ames test is the most widely used method for testing mutagens 
(Ames et al., 1975). The necessary presence of a metabolising system is 
overcome by suspending the system in a soft agar overlay on the plate, 
with the bacteria and mutagen (Mailing, 1971; Gamer et al., .1971,1972; Ames 
et al., 1975). Although in a soft agar overlay the chemical is present 
throughout the whole grewth period of the bacteria which partially over- 
ccmes the problems already stated, the chemical is likely to diffuse into the 
bottcm agar lowering the concentration and thus the induced mutation rate.
The same problems of sensitivity then again occur.
The fluctuation test is designed to directly measure the spontaneous 
mutation rate and is therefore likely to be useful to detect small induced 
increases over this rate. Voogd et al. (1974) used the classic form of 
the fluctuation test of Luria and Delbruck (1943) to measure induced 
mutations by derivatives of 5-nitroimidazole (having antiprotozoal activity) 
in Klebsiella pneumoniae, E. coli and Citrobacter freundii 425. They 
also tried to use Salmonella typhimurium TA1530, TA1531, TA1532 and TA1534, 
but found that unless the cultures were washed and diluted the spontaneous 
mutation rate was too high for application of a standard fluctuation test.
Ityan (1955) used an adaptation of the fluctuation test in liquid cultures 
using E. Coli (strain 15) in which the presence of a mutation to histidine 
independence was detected by turbidity of the-culture. The nutation rate 
was determined by using the fraction of cultures with no mutations and 
applying this to the zero-term of the Poisson distribution as in Luria and 
Delbrucks'' theory ( eq.' 6). Ryan (1955) showed that spontaneous mutations 
can occur in stationary phase (i.e. non-dividing bacteria).
The fluctuation test in the liquid form as used by Ryan (1955) has 
been shown by Green et al. (1976, 1977a) to be useful for detecting low 
levels of mutagens that were only weakly detected or undetected in 
conventional plate tests using bacteria. Preliminary studies involving 
the addition of a metabolising system were also carried out (Green et al.,
1976). The test is carried out in liquid which enables not only microscmal 
systems to be added, but whole cells such as liver cells (Green et al., 1977b) 
The possible advantages of using whole liver cells as opposed to microscmal 
fractions will be discussed in Section 1.2.5.
The fluctuation test as used by Green et al. (1976, 1977a and 
1977b)utilises the fraction of cultures with no mutations present. The 
grewth of bacteria (such as E. coli or S. typhimurium) can be detected by a
pH change in the selective medium that is present when the growth limiting 
amount of amino acid is exhausted.^ A coloured pH indicator is added which 
enables swift scoring of the test. It is unnecessary to determine the spont­
aneous mutation rate, which is inpossible unless actual bacteria numbers 
are counted, and only a caparison between a control series of cultures and 
a treated series of cultures is required. The test is not designed to 
measure the actual number of mutants present and it would become very 
tedious to do this.
A very small inoculum of bacteria is added to each replicate, such 
that no mutant is present at the start of the experiment. When all the 
replicates contain mutants/ the number of mutants per well cannot be determ­
ined. It is likely that when this happens a lower level of a mutagen can 
be used such that all the replicates do not contain mutants.
The test is remarkably simple and easy to perform and is the subject 
of present thesis. It is being used as a research tool and also as a 
screening test for the detection of chemical carcinogens and/or mutagens 
(Voogd et al., 1974; Green et al., 1975, -1977a;&b); Venitt & Bushell, 1977; 
Gatehouse, 1978; Gatehouse & Deflcw, 1979; Hubbard et al., 1980).’
1.2.4 The fluctuation test in systems other than bacteria
The principle of the fluctuation test has been used in a variety 
of different systems to estimate the spontaneous nutation -rate and origin 
-of mutants in. mammalian cells. Various cell systems and markers have 
been used including V79 Chinese hamster cells (Rouja et al., 1973; Fox & 
Radacic, 1978), human fibroblasts (De Mars, 1974), CHO Chinese hamster 
cells (Baker et al., 1974; Carver et al., 1976) and mouse lyiphcama cells 
Cole et al., 1976).
Induced mutation using a fluctuation test has been carried out with 
several capounds, including EMS, MMS, rmtulan, DEN and 2AAF for oubain 
resistance in L5178Y mouse lymphcma cellso (Cole et al., 1976; Rogers, 1978). 
Attempts have also been made to incorporate isolated hepatocytes;as a 
metabolising system, but problems arose when the presence of the hepatocytes 
reduced the plating efficiency of the mouse lymphcma cells.
The fluctuation test was shown to be sensitive to DEN and natulan 
which are negative in conventional mutation assays. EMS showed an 80-fold 
increase in sensitivity in a fluctuation test, capared to a conventional 
mutation assay. Since these chemicals are mutagenic without a metabolising 
system present, the increased sensitivity in a fluctuation test may be due 
to experimental design in which a precise definition of the spontaneous
mutation rate may be made.
In a mammalian cell fluctuation test the equations for the 
determination of the mutation rate as described in . section 1 .2*2 are of 
little use. The equations may be used to determine the induced mutation 
rate by a mutagen when the mutagen is present throughout the whole growth 
period during which mutations may occur. They assume that the mutation 
rate will be constant throughout the experiment. It is also necessary to 
correct for the fact that in early generations mutations are unlikely to 
be found in an experiment involving a small number of cultures. In these 
mammalian cell experiments, the mutagen is only present for a short period 
of time and induced mutations will only arise during this period and may 
be frequent during this period. Cell growth is necessary for a period 
before and after mutagen treatment, therefore other calculations than those 
already given have to be made. Cole et al. (1976) derived an equation 
for measuring the induced mutation rate (a1) per cell per generation in 
such a situation utilising the mean number of induced mutants per culture 
(where r' = mean in control series - mean in treated semes)
a 1 = r*log2 
Ntlog(Nt^ 0)
The principle of the fluctuation test has also been found- to be useful 
for measuring induced mutaticn in Saccharcmyces cerevisae (Parry, 1977b).
1.2.5 The use of isolated hepatocytes as a metabolising system
One of the objectives of the present study is to use isolated 
hepatocytes for metabolic activation instead of the usual microscmal 
fractions. A fluctuation test is ideal in that it is carried out in liquid 
and neither exposes the metabolising system to heat shock frcm hot agar 
nor suspends the system in agar.
The widely used S9 fraction of tissue hemogenate has several 
disadvantages, although it is relatively easy to prepare frcm a variety of 
tissues and species. Activation or inhibition of various enzymes may be 
affected by the preparation, which includes a homogenization procedure, and 
also a requirement for cold conditions. The Ziegler enzyme (an amine 
oxidase enzyme) is inactivated by temperatures above 10°C when no NADPH 
regenerating system is present (Kitchell et al., 1978; S.Moloney personnel 
communication). Hcmogenisation; can lead to destruction of membrane 
ccmponents and oof actors due to the liberation of-lysosomal enzymes. Compart­
mentalised endogenous inhibitors may be liberated by homogenisation, and 
the homogenising medium may also affect the functional state of enzymes 
(reviewed in Fry & Bridges, 1976).
S9 fractions require the addition of cofactors (NADBH • regenerating 
system) for metabolism. Optimal conditions may vary for different 
chemicals. Such differences in conditions may result in the metabolites 
being formed to different extents than in vivo (Fry & Bridges, 1976) - 
The influence of other factors such as hormones, and mitochondrial control 
is absent in microsomal fractions (reviewed Fry & Bridges, 1976).
Other differences between the two systems are that the entry of a 
chemical into the cell cannot be assessed in S9 fractions. The amount of 
the chemical metabolised in vivo might, therefore, be different to that 
observed in all fractions in vitro. The presence of extra protein available 
for binding- active metabolites in isolated cells might make considerable 
difference to the detection of active metabolites, particularly in 
mutation assays.
The absence of the conjugating mechanisms frcm S9 fractions is of 
major importance. As discussed in Section 1.1.3, the whole cell is able 
to conjugate the metabolites formed in phase 1 metabolism. This is 
generally thought to be a detoxification step (Williams, 1959). However, 
there are cases in which conjugation results in the activation of a 
chemical. Examples include 2AAF in that the sulphate conjugate is thought 
to be the carcinogenic metabolite (Clayson & Gamer, 1976), and .
1,2-dichloroethane where conjugation with glutathione is thought to be 
responsible for the activation of the chemical (Rannug 'et al., 1978; Rannug 
& Beije, 1979).
Comparisons between the metabolic profile of chemicals with S9 or 
with hepatocytes have shown differences, mainly due to the presence of 
conjugating systems. The differences are exemplified by the observation 
that the K for ethylmorphine-N-demethylase and aoetylmethadol-N-demethylase 
is lower in hepatocytes than S9 (reviewed in Jones, 1978).
The study of PAH's, many of which are potent carcinogens, has led 
to the most convincing evidence in favour of using isolated hepatocytes for 
metabolism instead of microscmal fractions. These chemicals require 
metabolic~activation before exerting their toxic effects (Sims & Grover, 
1974; Jerina& Daly, 1974). Isolated cells and organ cultures can trans­
form these chonicals to metabolites which then bind covalently to DNA 
(Burke et al., 1977; Yang et al., 1977a). Investigations of specific 
deoxyribonucleoside complexes formed in DNA by seme chemicals have led 
to interesting observations.
The most extensively studied PAH is benzo(a)pyrene (BP). BP is 
metabolised by microscmal mixed function oxidases to several oxides, phenols
and dihydrodiols (Jetfna & Daly, 1974; Sims & Grover, 1974). This is 
further discussed in Chapter 3. Studies of these metabolites led to 
observations that with microscmes large amounts of non-carcinogenic 
phenols were formed, while metabolism with intact hamster embryo cells 
favoured diol- epoxide formation (Selkirk, 1978).
The pattern of metabolism of BP with S9 or isolated nuclei 
metabolism shews different hydrocarbon-deoxyribonucleoside adduct form­
ation to those in isolated cell systems or in vivo (King et al., 1975; 
Thompson et al., 1976a; Bigger et al., 1978; Ashurst et al., 1979).
Similar studies have shewn that the same situation is true for 
7-methyIbenz (a) anthracene and 7,12-dimethyIbenz (a) anthracene.
When rat liver microscmes were used to metabolise BP, the major 
DNA-hydrocarbon adduct was derived frcm further metabolism of 
9-hydroxbenzo(a)pyrene (9-OHBP) (most likely at the 4,5 position of BP) 
rather than frcm ' ± 7 a, 8 3-dihydroxy-93,103-epoxy-7,8,9,10-tetrahydrobenzo-
(a)pyrene (7,8-diol-9,10-epoxide) (thought to be the carcinogenic metabolite) 
King et al., 1975,19.76; Thonpson et al., 1976a).:. Adducts resulting from 
metabolites in the IK-region of BP were found, and therefore, originally 
thought to be involved in carcinogenesis. This was also true of 
7-methylbenz (a) anthracene (Thcmpson et al., 1976b) and 
7,12-dimethylbenz (a) anthracene (Bigger et al., 1978). These adducts are 
different frcm those seen in isolated cell systems or in vivo (Bigger 
et al., 1978; Ashurst et al., 1979; Grover et al., 1976). The metabolites 
formed with microscmal systems (i.e. the K-region metabolites) are now 
thought not to be the ultimate active metabolites.
Binding studies of BP metabolites with DNA in Syrian hamster 
embryo cells shewed the major hydrocarbon-deoxyribonucleoside adduct was 
derived frcm the 7y8-diol-9,10-epoxide (Sims et al., 1974). This metabolite 
has been shown to be a more potent mutagen and carcinogen than BP itself 
(Wislocki et al., 1976; Kapitulnik et al., 1977a). This metabolite is 
formed in many biological systems such as ‘salivary gland epithelial cells 
(Wigely et al., 1976), mouse skin (Daudel et al., 1975; Groves et al.,
1976), mouse liver and lung (Eastman et al., 1978), isolated perfused rat 
lung (Vahakangas et al., 1979), human lung explants (Shinohara & Cerutti,
1977), human diploid fibroblasts (Baird & Diamond, 1978), cultured human 
bronchus (Jeffry et al.., 1977) and cultured human colon (Autrup et al.,
1978).
The most active site of metabolism is the liver and although PAH's 
are generally not hepatocarcinogens (IARC Monographs, 1973), a study of
: metabolism by isolated hepatocytes should relate more closely to the 
in vivo situation than metabolism by microscmes. With isolated hepatocytes 
Jernstrcm et al. (1978) shewed that the major DNA-BP adduct was derived 
frcm the 9-OHBP metabolite, which is similar to results with microscmes. 
However, further studies by Ashurst and Cohen (1980) have shown that the 
major DNA adduct with hepatocytes was that derived frcm 7,8-diol-9,10-epoxide- 
BP. In the hepatocytes-, the metabolite 9*OHBP, (that Is responsible for adducts 
when microscmes and DNA are incubated) is possibly more readily conjugated 
to its glucuronide or sulphate. Conjugating mechanisms are absent in 
microscmes, but important in vivo as the hepatocyte metabolism resembles 
BP metabolism in vivo and in other cells in culture (Ashurst & Cohen, 1980). 
Ashurst and Cohen are in good agreement with other studies using liver 
cells, e.g. mouse liver in vivo (Eastman et al., 1978) and isolated perfused 
rat and mouse liver (Kahl et al., 1979). When the metabolism of BP is 
studied in hepatocytes, most of the 3- and 9-hydroxy BP metabolites are 
further metabolised to their respective glucuronide conjugates (Jones et 
al., 1978).
9-QHBP is mutagenic in bacteria after metabolism by microscmes 
(Lubert et al., 1979; Chapter §) , and since this is not the major metabolite 
formed in intact cells or in vivo, caution is required when extrapolating 
data frcm in vitro short-term tests to expected in vivo carcinogenicity.
It may be argued that since PAHs do not induce hepatocarcinogenesis -in 
mairmals (IARC monographs, 1973) the use of hepatocytes may not be relevant 
to all chemicals. Nevertheless they are capable of forming significant 
amounts of the active metabolites thought to be responsible for the 
initiation of tumourigenesis of BP and other PAHs in animals.
It was on the basis of this type of evidence that the use of whole 
cells was introduced into screening tests. Lethally irradiated hamster 
kidney fibroblasts (BHK 21 cells) were used as feeder layers (Huberman &
Sachs, 1974; Newbold et al., 1977). Fibroblasts are of limited value as 
they can only metabolise certain classes of chemicals such as PAHs. Hepato­
cytes are widely used in drug metabolism studies and are easy to isolate 
and are therefore a potentially useful tool.
Che disadvantage of using hepatocytes is that any particular type 
of cell may be selectively isolated or beccme predominant in the cell 
population. Clearly, this, can not occur when a hemogenate of the whole 
tissue is used.
The advantage of using isolated hepatocytes is that a more realistic 
potency correlation of mutagenicity and carcinogenicity might be obtained, 
since the evidence suggests that the metabolic profile observed is more
closely related to in vivo than with cell fractions. This has been observed 
with V79 cells and hepatocytes for seme carcinogenic nitrosamines (Jones & 
Huberman, i960 ). The differences in species might also be more easily 
identified when intact cells are present rather than just cell fractions.
Isolated hepatocytes have been used in screening tests other than 
the fluctuation test. Table 1.6 lists the various tests reported to be 
using hepatocytes. In all cases, the argument for using isolated hepatocytes 
is that they provide a metabolising system that is more closely related to 
the in vivo metabolism than the other available systems such as microscmal 
fractions or feeder layers.
Long-term liver cell culture systens are also employed in mutagenesis 
assays. These lines are set up frcm adult rat hepatocytes and maintained 
over a period of time. These lines can be used for studies of mutagenesis at 
the hypoxanthine-guanine phosphorihosyl transferase (HGPRT) locus using 
resistance to 8-azaguanihg or 6-thioguanine to select mutants (Williams et 
al., 1978; Tong & Williams, 1978). This method has been used to investigate 
the mutagenicity of a variety of carcinogens and noncarcinogens such as 
methylmethanesulpbonate, and aflatoxins AFB and AFG. The advantage of 
these cultures is that they retain the ability to metabolise chemicals 
and, therefore, a separate metabolising system is not required. This 
metabolic capability is very much lcwer than that observed in primary 
cultures (Williams, 1976a; Fry & Bridges, 1977). A drop in cyt.P-450 
content and an increase in-cyt.P-MB is found in liver cell lines derived 
frcm cultures of foetal liver cells (Owens & Nebert, 1975). An 80% drcp 
in cyt.p-450 is observed over 24 hr , in adult primary,rat liver cell 
cultures (Bissell & Guzelian, 1975). Evidence that epithelial cell lines 
resemble hepatocytes ccmes frcm the observation that the histochemical 
profile of 13 enzymes in cultured liver cells was closer to that df 
hepatocytes than any other cell type in the lines (Williams et al. T 1973b).
The addition of fresh hepatocytes to adult rat liver epithelial cells 
has been used (San & Williams, 1977). In‘this instance the hepatocytes act 
as a feeder layer. Of the chemicals used in this system DMBA, DMA and 2AAF 
were all mutagenic.
The mixture of hepatocytes and V79 Chinese hamster ovary cells has 
been used to look at the nitrosamine class of chemicals (Langenbach et al., 
1978 ; Jones & Huberman, 1980) and is effective in detecting the chemicals 
as mutagenic. The data obtained by all these authors correlates well with 
data obtained in Ames bacterial tests. Although epithelial cell lines are 
useful in detecting several carcinogens, their lower metabolic capability
Table 1.6
The Incoporation of Hepatocytes in Screening Tests
Metabolising
System
Genetic Endpoint Reference
Freshly isolated Mutation in Green et al., 1977b
hepatocytes Salmonella typhimurium
Mutation in V79 
Chinese hamster cells
Mutation in adult 
rat liver epithelial 
cultures
Suppression of 
fibroblast growth
Hubbard et al., 1980
Langenbach et al., 1978 
Jones & Huberman, 1980
San & Williams, 1977 
Tong & Williams, 1978
Fry& Bridges, 1977
1.5hr cultures of 
fresh hepatocytes
Detection of UDS Williams,1976b,1978 
Lowing et al., 1979 
Brouns et al., 1980
No~exogenous Mutation in adult Williams et al., 1978
syston added rat liver epithelial 
cultures
Transformation in 
adult rat liver cell 
epithelial cultures
Williams, 1976a' 
Sanetal., 1979a,1979b
makes them less useful than the systems incorporating primary hepatocytes 
for metabolism. . Dimethylnitrosamine (DMN) which is adequately detected in 
a primary hepatocyte mediated assay is missed in the epithelial cell assay 
(Jones & Huberman., 1980). ^
Unscheduled DNA synthesis (UDS) has been investigated in hepatocytes. 
Autoradiographical methods of staining the cells after the incorporation of 
h t K a W  thymidine into the DNA has been used (Williams, 1976b; 1977; 1978) 
and also scintillation counting (lowing et al., 1979),Brauns et al., 1980).
By autoradiography a good correlation between carcinogens and the ability 
to induce UDS over a series of chemical carcinogens has been observed 
(Williams, 1976b, 1977, 1978 and perscnal ocmnunication).
In UDS investigations using scintillation counts the carcinogens 
tested (3MC, 2&AF, 3-methyl DAB) all induced UDS, whereas the non-carcinogen 
(2-methyl DAB) did not (Lcwing et al., 1979). These authors also investigated 
other changes in the hepatocytes after exposure to carcinogens such as 
a-fetcprotein production, the mitotic rate and histochsnical studies to detect 
possible early carcinogenic changes.
The suppression of fibroblast growth in a mixed incubation with
hepatocytes has been investigated (Fry & Bridges, 1977). The fibroblasts
grow up in primary hepatocyte cultures and eventually take over so that only
fibroblasts grow. This is not a mutation experiment, but sirrply a cytotoxicity 
..test.
% -
Transformation of hepatocytes in culture has been investigated as a 
means of detecting carcinogens. Since epithelial cells are the cell, type , 
that most frequently gives rise to cancerous cells, they are more valuable 
for the study of transformation than the usual fibroblasts (Williams et al., 
1973a, Williams, 1976a). The criteria for transformation of epithelial cells 
are difficult to define, but growth in agar is being considered as a reliable 
indication (San et al., 1979a; MDntesano et al., 1977). Research is being 
carried out on other criteria to determine transformation and to develop 
the transformation of adult rat hepatocyte cell cultures as a carcinogen 
screening test (San et al., 1979a, 1979b).
1.3. OBJECTIVES
This thesis is concerned with the fluctuation test using Salmonella 
typhimurium as a short-term mutagenicity test. The fluctuation test has 
been developed to a more practical form than previously described. The 
use of hepatocytes instead of liver microscmal fractions for metabolic 
activation has been developed to provide improved culturing conditions for
both hepatocytes and bacteria. By using hepatocytes it is hoped that a 
closer correlation with in vivo metabolic activation may be achieved 
than the metabolism provided by the usual liver microscmal fractions used 
in mutation assays. In this way the predictivity of the mutation assay 
might be increased.
The fluctuation test has been validated as a screening test in 
this thesis as part of an International Study (Announcement, 1978), in 
which a number of known chemical carcinogens and non-carcinogens were 
assessed for their mutagenicity. Within this study a caparison of the 
use of S9 fraction of liver with hepatocytes as metabolising systems has 
been made.
The f luctuation test has also been used in preliminary studies with 
several different compounds. The mutagenicity of 2AAF activated by a 
variety of metabolising systems has been assessed and ccrrpared with a 
plate mutation assay - the Ames test.
The potential value of mutagenicity tests in metabolic studies has 
been demonstrated in studies on the mutagenicity of a variety of BP 
metabolites, and also in preliminary investigations into the role of
betathasone as an activator of drug metabolism. As examples of chemicals 
that humans are widely exposed to, the mutagenicity of some light oils has 
been assessed.
CHAPTER 2 - MATERIALS AND METHODS
2.1. CHEMICALS, MEDIA AND EQUIPMENT
All chemicals were obtained frcm BDH Eastleigh, Hants., U.K., 
except where stated.
All solutions used were sterile. EM salts: ^HPO^, 7g; KH^PO^,
2g; (NH^ ) 2SO4 , lg; trisodium citrate, 0.25g; MgSO^^O, O.lg; distilled 
water, 1000 ml.
VB salts made up 50 x concentrated and diluted as required;
MgS04.7H20, lg; Citric Acid, lOg; K2HP04, 50g; NH4NaHP04 .4H20, 17.5g;
distilled water, 67 mis.
Solution C (Frantz & Mailing, 1975): 20 ml MgCl2 .6H20 (6.1 mg/ml);
Tris (Sigma 7-9) (30.3 mg/ml pH 7.5); 20 ml sucrose (212 mg/ml); 10 ml
distilled water. Components autoclaved separately.
KC1 solution: 33GriM. MgCl2 .7H20 solution: 8GnM. Sodium phosphate
buffer: 0.2M, pH7.4 (BDH airpoules, BDH, Eastleigh, U.K.). PBS’A 1
(Phosphate buffered saline, Dulbecco A, Qxoid, London), after autoclaving
0.5ml sterile glucose solution (20% w/v) was added to lOCml PBS'A* to give
2+a final concentration of Img/ml. Hanks Mg -free Balanced Salt Solution 
(BSS) without phenol red (Gibco-Biocult, Paisley, Scotland). CaCl2 solution: 
1M. NaHCO^ solution: 7.5% w/v (Flew Laboratories, Irvine, Scotland).
Specially prepared Basal Medium Eagle's (BME) with Earle’s salts, 2QnM Hepes 
buffer, and without NaHCO^, glutamine, phenol red, tryptcphan and histidine 
(Flow Laboratories, Irvine, Scotland). BME was supplemented with 1% Foetal 
bovine serum and 2mM L-glutamine (Flow Laboratories, Irvine, Scotland).
EGIA (Sigma, London): 0.5mM in PBS'A1. NADP (Boehringer, Lewes) G6P and ■ 
G6PDH (typeXII) (Sigma, London) were made up in sterile distilled water, 
filter sterilised and stored frozen.
Nutrient Broth: Qxoid Nutrient Broth No.2 (Qxoid, London).
Nutrient agar plates: 1.5% w/v New Zealand Agar (Davis, Leamington
Spa) in Nutrient Broth.
Minimal plates for checking cultures: 1.5% w/v New Zealand Agar in
EM Salts supplemented with 0.4% w/v glucose, histidine and biotin added as 
required.
VB plates for plate mutation assays: 1.5% w/v New Zealand Agar in
VB Salts supplemented with 2% w/v glucose.
Soft Agar: 0.6% w/v Difco-Bacto-Agar (Difco, East Molesey ) 0.5% w/v
NaCl.
L-Histidine (Sigma, London) 0.1% w/v in distilled water; Biotin 
(Sigma, London) 0.1% w/v in DM salts; Ampicillin (Sigma, London 10 mg/ml 
in 0.02N NaOH; BCP (Sigma, London) 0.1% w/v in ethanol? Crystal Violet
(Sigma, London) 0.1% w/v in 0.1M citric acid and 1 mg/ml in distilled water; 
Trypan Blue (Flow Laboratories, Irvine, Scotland) 0.5%; Collagenase 
(Boehringer, Lewes) and Hyaluronidase (Type II, Sigma, London) were made 
up in distilled water and filter sterilised. 7-ethoxycoumarin and 
7-hydroxycoumarin were a gift frcm Dr. J. Fry, University of Surrey and 
made up in DMSO. DMSO and Ethanol were An alar and Aristar grade respectively 
(BDH, Eastleigh, Hants.)
2AAF, Furacin (2-Nitro-2-furfurylidene semicarbazone) (Koch-light 
Laboratories, Colnbrook ,Bucks); BP, DMBA, betamethasone, 3MD (Sigma,
London); Aroclor 1254 was a gift frcm Monsanto Ltd., Louvaine, Belgium. 
Chemicals tested in Chapter 4 were (obtained frcm ICI Central Toxicology 
laboratories as part of a standardised batch; Benzo(a)pyrene metabolites, a 
gift frcm Dr. R. Mehta and Dr. G. Cohen, University of Surrey - the source 
as described in 5.2.1.
Chemicals to be tested were mainly dissolved as concentrated 
solutions in DMSO. , The benzo (a) pyrene metabolites were made up in aristar 
ethanol, but ethibhine and methionine (see Chapter 4) were made up in 
distilled water. Liquid samples were weighed and diluted with DMSO. All 
chemicals were then stored at -20°C.
The vessels used were Linbro white vinyl trays purchased frcm Flow 
Laboratories, repacked and gartma sterilised. Tissue culture grade trays 
were already sterile. These trays had a well capacity of 2ml . For tests 
with TA100 and hepatocytes Linbro vinyl tissue culture trays with a well 
capacity of 0.5ml were used. Microtitre polystyrene Linbro trays with flat 
bottom 0.4ml capacity wells were used under seme conditions. The trays were 
covered with either formed vinyl lids (for vinyl trays) or formed polystyrene 
lids (for polystyrene trays).
2.2. BACTERIA
2.2.1 Maintenance of bacteria stocks
The bacteria, Salmonella typhimurium TA9 8 and TA100 (obtained frcm 
B.N. Ames) were maintained, with seme modifications, as described by Ames 
et al. (1975). Stocks of the bacteria were kept In long-term storage as 
stab cultures in soft agar at roan temperature. For the duration of this 
study, master copies of the Salmonella strains were kept in a liquid N2 
refrigerator in 2ml ampoules (Sterilin) containing 0.8ml bacteria and 0.07ml 
DMSO. These stocks were set up frcm an initial investigation to obtain 
stocks of bacteria with a lew background of M s + revertants exhibiting the 
other specific properties of the bacteria as described below.
Bacteria were grown up in lCmls nutrient broth overnight with 
shaking (120 oscillations/min in a Grant shaking water bath). In the 
initial stages of the study an ampoule was quickly thawed,0 .1ml inoculated 
into lCmls of Nutrient broth and this cultured for an experiment. However, 
it was found that it was sufficient to store the strains streaked on 
nutrient agar plates (containing 25 jig/ml ampicillin). These plates were 
stored in a closed container at 4°C. Fresh cultures for experiments were ' 
inoculated frcm these plates. The plates were replaced at four weekly 
intervals, new plates being inoculated frcm frozen stocks.
Fresh liquid cultures for experiments were checked for their 
properties as described below and stored in the refrigerator for up to one 
week, when fresh cultures were grown. Cultures with a low spontaneous 
mutation rate were then used for experiments. This was particularly 
important for'TAlOO which has an excessively high spontaneous mutation rate. 
It was not so necessary to check TA98 before each use. Results obtained 
with fresh overnight cultures were not significantly different frcm those 
observed with cultures stored for up to one week.
For an Ames test, a fresh overnight culture was used.
2.2.2 Checking of bacteria strains
(a) Viability and presence of plasmid
-5The cultures were serially diluted 10 in buffer and plated on 
' nutrient agar plates. The presence of the plasmid p^KMlOl was confirmed 
by also plating for viability on nutrient agar plates supplemented with 
2^wg/ml ampicillin. When a significant difference in viability was observed 
the culture was discarded.
8The cultures of TA98 and TA100 consistently grew up to - 2x10 /ml,
9however, a consistent viability of =2x10 /ml was obtained by increasing 
the shaking of the water bath to 160 oscillations/min. Addition of extra 
histidine and biotin did not increase the viability and addition of extra 
glucose caused slight grcwth inhibition.
(b) Loss of polysaccharide coat
0 .1ml of an overnight culture was spread on a nutrient agar plate 
and a sterile filter paper disc (AA disc, Whatmans, London) with lOjil of 
1 mg/ml crystal violet placed on the surface. After 24hr incubation at 37°C 
a clear zone of growth inhibition indicated the presence of the deep rough 
character. Zones of 1.0 - 1.8 cm were observed. However, no inhibition was 
noted frequently in TA100 cultures , these' cultures were therefore discarded.
(c) Pre-existing mutants and spontaneous mutation rate
The presence of pre-existing his+ revertants was determined on minimal
agar plates supplemented with 0.4 jig/ml biotin. The number of pre-existing
7
mutants observed for TA100 was 12-50/10 bacteria plated and for TA98,
7
0-11/10 bacteria plated. Occasionally much higher numbers were observed 
(in excess of 100) for TA100 and these were discarded. Cultures with 
the lowest number of pre-existing revertants were used.
The spontaneous mutation rate was determined on minimal agar plates 
supplemented with 0.4 jig/ml biotin and 0.25 jig/ml L-histidine. The 
range of spontaneous revertants observed was 35-80/10 bacteria plated for
7
TA100 and 5-15/10 bacteria plated for TA98. Cultures for TA100 were not 
used. The age of the liquid culture (up to one week) appeared not to 
affect the spontaneous mutation rate.
2.2.3 Backgrounds observed in the fluctuation test
The number of positive wells in the controls of the fluctuation 
test using large Linbro trays is characteristic for each strain and condition, 
but, varies considerably between experiments. Levels of 4-16 and 16-32 positive 
wells out of 48 occur for TA98 and TA100 respectively, without metabolic 
activation and with hepatocytes. With S9 fraction values of 15-25 and 25-35 
respectively were usual. Experiments in which the control fell 2 standard 
deviations (based on a binonial distribution). outside the normally observed 
value were discarded. Hence experiments using TA98 both without metabolic 
activation and with hepatocytes were discarded, when the control was less 
than 4 and greater than 16 wells. TA100 experiments under the same 
conditions were discarded when the control was less than 19 and greater than 
33. With S9 fraction experiments were discarded with TA98 when the control 
was less than 12 and greater than 26 and with TA100 when the control was 
less than 22 and greater than 36 wells. However, experiments in which 
the control was not within the prescribed range were scmetimes considered 
when the reference mutagen exhibited normal response in relation to the 
control. .
The excessive spontaneous background seen occasionally for TA100 is 
due probably to an excess of pre-existing mutations arising frcm its natural 
high spontaneous mutation rate (Luria & Delbruck, 1943).
Occasionally a sample frcm a positive well was streaked onto histidine 
free agar to check the histidine independance of the revertants.
2.2.4 Measurement of pH
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Bacteria were diluted to 2x10 /ml into 10 ml DM salts supplemented 
with 0.4% w/v glucose, 0.4 pg/ml biotin, 10 jjg/ml L-histidine and 5 jjg/ml 
BCP. A series of cultures was incubated at 37°C with shaking. At time
periods of 1 hr and when the colour was changing frcm purple to yellow 
(time points of h hr ) a bottle containing 10 mis was removed, the 
viability assessed and the pH measured.
2.2.5 Number of generations growth
To measure the number of generations grown in the initial overnight
incubation of a fluctuation test, the viability of the bacteria at the
initiation of the test was determined. At completion of the experiment
after four days, the mean number of bacteria was determined frcm five wells
that had remained purple indicating the absence of revertants. Before the
sample was ramoved, the medium was agitated vigourously to remove as many
bacteria as possible that may have adhered to the wall of the well. • The
number of generations grown was determined from
g = logN - logNh 
log2
where g = number of generations grown, N final number of bacteria and 
N0 = initial number of bacteria. *
2.2.6 Toxicity tests
Toxicity tests were performed on some chemicals that were tested
blind as in Chapter 4. Only a qualitative . evaluation was carried out in
which the test compound was serially diluted in DM salts supplement with
0.4% w/v glucose, 0.4 jjg/ml biotin, 10 pg/nl histidine and 5 jjg/ml BCP
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coitaining approximately 2x10 /ml bacteria. The dilution was carried out 
using 1 ml aliquots in either plastic trays or glass tubes. Growth of 
the bacteria was indicated by a change in the pH of the medium as shown 
by the change of colour frcm purple to yellow. The growth was observed 
after both 24 hr and 48 hr .
Toxicity was, however, most often observed as a reduction in the 
number of wells positive in the fluctuation test as compared to the control 
series. Often no positive wells were observed when toxicity occurred.
2.3. TISSUE PREPARATIONS
2.3.1 Animals
Sprague-Dawley male rats (bred at University of Sussex Animal House) 
were used. The animals were given a diet of Spillers No.l animal feed 
(Spillers Ltd., Croydon) and water ad libitum. They were kept on a sawdust 
bedding ( Litalabo, France ) except while being treated with phenobarbitone, 
this is further discussed below. Animals of weight 80-100 gm. were used for 
the isolation of hepatocytes. Uninduced S9 fraction for the study in 
Chapter 4 was also obtained frcm animals of weight 80-100 gm. For all other
preparations, animals of 250 gm were used. Animals were killed by 
cervical dislocation.
Induction of drug metabolism was carried out as follows
3 methylfiUlanthrene:- a i.pinjection was administered at a» 
dose of 30 mg/Kg 3rd in com oil on three consecutive days, the last 
injection being between 20 and 24 hr s. prior to sacrifice.
Arcelor 1254:- a single i.pinjection at a dose of 500 mg/Kg 
aroelor in com oil, administered five days before sacrifice.
Phenobarbitone:-. animals were fed 0 .1% phenobarbitone-sodium in 
the drinking water for seven days prior to sacrifice. It was observed 
that the animals ate sawdust in preference to the normal feed under this 
treatment, thus increasing the toxicity of phenobarbitone and inducing 
sleep. To overcame this, they were housed on wire bottom cages with food 
provided in dishes on the bottom of the cage.
2.3.2 S9 fraction
This was prepared by the method of Ames et al_., (1975) and stored in 
2 ml aliquots in a liquid N2 refrigerator. The protein content was determined 
by the Lcwry procedure (Lowry et al., 1951) and the S9 stored at a 
protein concentration of 30 mg/ml. The S9 was stored for periods of up tb 
6 months.
2.3.3 Monitoring of S9 fraction
The fresh batches of uninduced S9 fraction were routinely checked 
throughout the study in Chapter 4 for their ability to activate 2AAFto a 
mutagen. Various S9 concentrations were used. Any S9 fraction that did 
not exhibit similar activity to previous data accumulated was discarded.
The quality control of the S9 fraction is further discussed in Chapter 6 .
As other types of S9 fraction (phenobarbitone, 3fC and aroelor) 
were not made for a large scale routine screening programme, these were 
only monitored after storage.
2.3.4 Concentration of fraction used
S9 mix was made as in Ames et al., (1975) using S9 concentration - as 
below. Unless otherwise stated the S9 mix contained in 10 mis:
1 ml,S9 (30 mg protein/ml); 1 ml MgCl2 solution; 1 ml KCl solution; 1 ml 
NADP (40 mM) and 1 ml G6P (50 mM); 5 ml sodium phosphate buffer (0.2 M) .
For sane experiments the concentration of S9 fraction was altered. When 
less protein was used the S9 was diluted in 0.15 M KCl, when more protein
was required the volume of phosphate buffer was adjusted accordingly.
2.3.5 Calcium precipitated microscmes
These were prepared as described by Frantz and Mailing (1975) 
frcm 3M2-induced animals. They were stored in a liquid N2 refrigerator 
at the protein concentration obtained.
2.3.6 Hepatocytes
Hepatocytes were prepared by the method of Fry et al. r (1976) with 
seme modifications. Initially the method was closely followed, but the
yield of viable cells was much lower than that of Fry et al.. Yields of
6 6 315^0.2x10 viable cells/g wet tissue compared to yields of 12.2± 0.7x10
viable cells/g wet tissue described by Fry et al. (1976j were obtained.
This might be attributed to the different strain of rat used since : Wistar
Albino rats were used by Fry et al. (1976). However, the yield of hepatocytes
was increased considerably by a number of changes, namely the addition of
glucose to the PBS'A' medium, increasing the shaking of the conical flasks
from 90 oscillations/imin to 120 oscillations/min , breaking up the liver
mechanically on the boulting cloth, altering the centrifugation regime by
extending centrifugation to 3 min at 100 g and finally the source of
collagenase was altered from Sigma, London to Boehringer, Lewes, which may
have been a contributing factor. Using these modifications, the yield of
6
hepatocytes was increased from 3.5± 2.3x10 viable cells/g wet tissue to
68.7± 2.4x10 viable cells/g wet tissue, with no significant effect on 
viability. The viability varied frcm 80%-90% throughout the study.
The revised procedure was as follows:-
The liver lobes were removed under sterile conditions into cold 
PBS'A', dried between sterile filter papers and sliced with a heavy duty blade 
(Swann-Morton PM40, Swann-Morton, Sheffield) so that slices 0.5-1.0 nm 
in thickness were obtained. The lcbes were held on a filter paper on a 
glass petri dish during this procedure. The slices were then incubated in 
250 ml conical flasks (3 gm liver per flask) in 10 ml PBS'A' at 37°C for 10
min in a shaking water bath (approximately 120 oscillations per min ). The
supernatant was discarded and the incubation repeated once more with 10 ml
PBS'A1 + 0.5 mM EGTA. The slices were then incubated for 60 min in a
shaking water bath with enzyme solution consisting of 10 ml Hank's BSS'with 
6 jj.g/ml phenol red, 5 mM CaCl2 (150 jil of 1 M solution), collagenase (0.05% 
w/v) and hyaluronidase (0.1% w/v). Approximately 75 jil of 7.5% sodium 
bicarbonate solution was added to make the solution just neutral as judged 
by the phenol red indicator in the Hank's BSS. Following incubation, the
mixture was filtered through a layer of boultingcloth (150 jum pore size,
Henry Simon Ltd., Cheadle Heath, Stockport) to remove undigested material 
and large cell clumps. The liver was agitated with a sterile pasteur 
pipette to aid breaking up. The filtrate was centrifuged at approximately 
lOOg for 3 min and the cell pellet resuspended and recentrifuged once in 
IQnl PBS'A1 and twice in lQnl BME. The pellet was finally resuspended in 
IQnl BME.
2.3.7 Viability index of hepatocytes
The total cell yield and viability index was determined, based on 
the ability of the cells to exclude trypan blue (Cummings, 1970). Counts 
were carried out using an improved Neubaur Counting Chamber (Gelman Hawks ley, 
Lancing).
The size of the animals was also found to affect the yield of
g
hepatocytes, the yield being lcwer frcm larger animals (3.8x10 viable 
cells/g wet tissue frcm a 150g rat as compared with 8.4x10 viable cells/ 
g wet tissue frcm a lOOg rat). Differing amounts of collagen can signif­
icantly alter the yield of hepatocytes. A larger amount of collagen can 
reduce the cell yield due to the increased requirement for collagenase.
Pretreatment of the animals with aroelor 1254 caused the liver to 
appear larger and darker than normal. On removal of the liver, it was soft : 
being easily squashed by forceps, resulting in difficulties in producing 
even slices for the isolation procedure. This was reflected in a significant 
reduction in the yield of hepatocytes, although the viability index was 
not altered (Table 2.1). A similar reduction in hepatocyte yield was 
observed by G.Williams (personal cormunication).
Table 2.1
Yield of hepatocytes after various pretreatments
Treatment No. animals Viability Index
Yield of viable hepatocytes 
xl06/g wet tissue ± SD,
Untreated ■ 7 79.8 ±1.5 8. £±1.73
Aroelor 1254 5 80.1 ±1.6 1.6 ±0.9
Com Oil alone ' 2 78.5 (80,77) 8.1 (8 .0 ,8 .2)
Preparations of hepatocytes with a cell viability of below 80% were 
not used for either metabolic studies or fluctuation tests. Hepatocytes 
were stored at 4°C until required and for not longer than 4 hr.
2.3.8 Estimation of attached hepatocytes
In an effort to determine the percentage of hepatocytes attached in 
the wells of Linbro trays after various time periods the number of hepatocytes 
in the supernatant was determined by counting in an improved Neubaur Counting
Chamber. Hcwever, it was found that a better estimate of the attached 
cells could be made by renoving the medium, vigorously washing the cell 
layer with PBS'A' and replacing with 1 ml of 0.1% crystal violet in 0.1 M 
citric acid (Absher, 1973). The resulting nuclei were counted after 
incubation for 1 hr with shaking every 10 min.
2.3.9 Metabolic capability of hepatocytes
The metabolism of 7-ethoxycou.roarin was determined in hepatocytes in
both fresh suspensions and at various tines in culture. Cells were
6distributed at a concentration of 0.2x10 viable cells/ml in 0.3 ml aliquots 
or 1 ml aliquots in Linbro tissue culture treated disposo trays as used for 
the fluctuation test. The medium was not changed,when metabolism in 
cultures was estimated,until addition of substrate, when the medium was 
replaced by fresh medium containing 7-ethaxycoumarin. For determination 
of metabolites present with 0.3 ml aliquots, the contents of 5 wells were 
pooled and metabolites extracted frcm 1 ml of supernatant. When 1 ml 
was used the metabolites were extracted frcm a single well for each deter­
mination. Estimations of metabolites were made in triplicate.
The metabolites, both free 7-hydraxycoumarin and sulphate and. 
glucuronide conjugates were determined by the liberation 7-hydroxycoumarin 
by the method described by Wiebkin (1978). The metabolites present were 
determined after either 2 hr or 4 hr incubation at 37°C.
2.4. MUTAGENESIS ASSAYS •
2.4.1 Ames test
Ames tests were performed by the method of Ames et al., (1975). 
Plates were incubated for 72 hr before revertants were counted.
2.4.2 Fluctuation tests using disposable trays
The protocols described here are those used for the majority of 
mutagenicity testing in this study, particularly for the investigation in 
Chapter 4. Development and alteration of conditions is presented in 
Chapter 3.
For a test, a bulk solution of 15 ml (see below) containing bacteria
7 6(approximately 2x10 cells TA98 or 2x10 cells TA100 total), test compound
(in not more than 1% v/v DMSO or other solvent), with or without a metabol­
ising system, was distributed in 0.3 ml aliquots into 48,2 ml capacity 
wells in Linbro white vinyl trays (tissue culture trays were used with 
hepatocytes). For experiments with TA100 and hepatocytes 50 pi was added
to Linbro tissue culture treated trays with a well capacity of 0.5 ml. The 
trays were incubated for 16-18 hr at 37°C after which iml per well of 
selective indicator was added (200 p.1 for TAlOO/hepatocytes). The indicator 
mediumconsistedof DM salts supplemented with glucose (0.4%) and 6.5ryug/ml 
BCP. The trays were incubated for a further 3 days when yellcw wells were 
scored positive and purple wells negative. When chemicals that react with 
plastic were used (e.g. safrole, Chapter 4), 12x75 cm glass tubes were 
used as an alternative, employing the. same concentrations as above.
2.4.2.1 . Without metabolic activation 
15 ml DM salts were supplemented with 0.4 pg/ml biotin, 0.4% w/v
glucose, lpg/fol L-histidine for a test with TA98 and 0.25 yUg/ml for a test 
with TA100, plus the test chemical.
2.4.2.2 With metabolic activation by S9 fraction 
The bulk test solution of 15 ml consisted of: 3 ml S9 mix? 12 ml
DM salts containing 0.4 jig/ml biotin, 0.4% w/v glucose, and 0.5 pg/ml 
L-histidine for TA98 (the S9 provides sufficient histidine for TA100); plus 
the test chemical.
2.4.2.3 With metabolic activation by freshly isolated hepatocytes
5
The hepatocytes were diluted to 2x10 viable cells/ml in BME.
Bacteria and test chemical were added to 15 ml of hepatocytes. The serum
present in the medium provided sufficient histidine for the test as ' 1
discussed in Chapter 3.
Because of the high spontaneous mutation rate of TA100, the test
had to be modified when it was used together with hepatocytes (see Chapter 3).
In this case, 2.5 ml of diluted hepatocytes, together with approximately 
6
2x10 bacteria and the test agent were dispensed in 50 pi aliquots in 
tissue culture treated trays with a well capacity of 0.5 ml. . 200 pi of 
selective indicator medium was later added and the experiment conducted as 
before.
2.4.3 Fluctuation tests using glass tubes
The fluctuation test in 12x75 cm glass tubes was used for studies 
with benzo (a) pyrene metabolites (Chapter 5 ). 5 mis of a bulk solution was
distributed in 100 pi aliquots in 50 glass tubes. After the initial over­
night incubation, 1 ml of selective indicator (DM salts with 0.4% w/v
glucose and 5 pg/ml BCP) was added and the experiment conducted in the 
normal manner. 2 mis of indicator was used in the original protocol 
by Green et al. (1977b) hcwever, in the present study 1 ml of indicator 
medium was found to be adequate. The same total number of bacteria was 
used in the bulk solution and without metabolic activation the concentration 
of histidine was adjusted to 3 pg/ml. When S9 fraction was present in the 
same proportion as when using 15 mis medium, the histidine concentration
was adjusted to 2.5 pg/ml.
2+In sane cases Ca ppt, microsanes were used. The test was conducted
as in Green et al. (1977b). The 5 mis medium consisted of 1 ml microsanes;
1 ml solution C; 4 mis DM salts and in the final 5 mis, 0.25 pg/ml NADP,
0.4 pg/ml G6P, 0.5 units G6PDH, 0.4 pg/ml biotin, 2.5 Pg/ml histidine,
7
0.4% w/v glucose. Approximately 2x10 bacteria was added to the 5 ml 
media.
2.4. 4 Fluctuation tests using microtitre trays
Small polystyrene trays (Linbro) with a well capacity of 0.4 ml were 
used as potential vessels for the fluctuation test. A bulk solution of
2.5 mis containing various histidine concentrations was divided into 50 jil 
aliquots. 200 jil of selective indicator was added to each well.
2.4. 5 Design of a fluctuation test
Chemicals were added to the test in a maximum concentration of
10 pl/ml DMSO. For unknown chemicals (as in Chapter 4) if an initial
toxicity test was not performed, a fluctuation test was carried out with 
doses of 100 pg/nl, 10 pg/ml and 1 pg/fril. Doses vary in particular studies. 
In subsequent tests doses were adjusted as necessary to find the toxic, 
mutagenic and non-mutagenic concentrations of the chemical.
Toxicity was indicated by a reduction in the number of revertants 
compared to the control and often no positive wells were found when toxicity 
occurred. When no toxicity was seen, higher.doses were used and when there 
was toxicity or significant mutagenicity doses were chosen so that the 
non-mutagenic and toxic limits of the dose range could be found. Solubility 
of the test chemical in DMSO or medium was another limiting factor. When 
a chemical exhibited insolubility in the aqueous test media this was used 
to set an upper limit on the dose range tested, although occasionally a 
higher dose was used.
The test consisted of one or two negative solvent controls, and a 
positive reference control further discussed in 2.4.6.
2.4.6 Positive controls
Controls to test the performance of the bacteria and metabolising 
system were incorporated into each experiment. Table 2.2 shows a summary 
of the positive controls generally used and sample results taken frcm three 
experiments. For the hepatocytes with TAlOO, no positive control was set 
up before commencement of the validation of fluctuation test (Chapter 4). 
However, the results frcm this study were used to find a chemical positive 
under these conditions. 2-AnriJioanthracene was found to be positive with 
hepatocytes and TA100 and was therefore used as a control in later experi­
ments. Although it is preferable to have a positive control that is 
structurally related to the chemical under test, particularly when metabolic 
activation is required, a well characterised mutagen is also of use since 
small alterations in the system may be more easily identified.
2.5. STATISTICAL EVALUATION OF RESULTS
2.5.1 Fluctuation test
The significance of an increase in the number of positive wells in a 
treatment over the corresponding control was determined by X2 with Liddell's 
correction (Liddell, 1976):
-
Wells
negative
Wells
positive Total
Control a b a+b
Treated c d c+d
Total a+c b+d a+b+c+d = n
• v2 = (ad - be - %n) ? n .
(a+b) (c+d) (a+c) (b+d)
X2 was estimated by summing together the total number of positive
and negative wells in the treated and corresponding control series in all
the experiments done. Since x2 was only determined where there was an
excess of positive wells in the treated series, this was a one-tailed
test. The mutation frequency per well may be determined by taking the
fraction of negative well and applying the zero term of the Poisson
—m
distribution (e ). Paradoxically, the smallest increase over the spontan­
eous mutation rate can be detected when 50-80% of the wells in the control 
series are positive (Fisher, 1968) , although results are satisfactory if 
20-30% of the wells are positive in the control.
Experiments were repeated on,at least two or three separate occasions. 
Normally at this stage the pooled results were clearly positive or negative
2 t
by X . If a dose response was not observed, but x for the highest non-toxic 
level after three experiments was between 2 and 3, the experiment was 
repeated (usually three times) and x2again determined. A chemical was
considered positive if the result was reproducible and the increase over the 
control was significant at p<0.05 (preferably p<0.01). When a dose response 
was seen not all levels were tested three times, since a dose response itself 
is indicative of the validity of the test. For short studies with limited 
substrate the test was most often only repeated once. However, for more 
rigorous evaluation the test was carried out three times.
In sane cases (in Chapter 4), a dose response was not observed, but 
a significant result was obtained at the highest non-toxic dose. In this 
situation the chemical was counted as positive provided at least three experiments 
showed an increase over the control. A chemical in which a dose other than the 
highest non-toxic dose exhibited a significant response (p<0.05) was considered 
questionable. Individual problems in the interpretation of results with 
certain compounds will be discussed in Chapter 4. The statistics of the 
fluctuation test are further discussed in Appendix 1.
2.5.2 Ames test
A result in an Ames test was considered positve if it was 
accompanied by a dose reponse curve and the increase over the control was 
significant at p<0.05 as judged by Student's 't'-test.
Table 2.2
Results obtained in three sample expriments using reference 
mutagens in the fluctuation test
Reference Strain INfetabolisinga Concentration Number of wells
mutagen system positive
jig/ml
Experiment No.
. . - 1 ;:2 3
Furacin TA100 -S9 0 17 19 19
0.1 30 25 34
4 -Nitro-ortho- TA98 -S9 0 7 9 6
pheny 1-diamine 0.1 39 47 .47
Aminoanthracene TA100 459 0 32 26 30
0.1 45 31 45'
2AAF TA98 +S9 0 15 22 . 9
0.1 48 48 40
Aminoanthracene TA100* tcells 0 24 26 27
1.0 47 36 37
2AAF TA98 +cells 0 7 12 14
•
1.0 25 43 31
a—  Metabolising systems -S9 - without metabolic activation
+S9 - with metabolic activation by uninduced S9 
fraction
tcells - with metabolic activation by uninduced 
isolated hepatocytes
b - 48 wells per treated series. The fluctuation test was performediinl-Llhbro 
diposable trays.
CHAPTER 3 - DEVELOPMENT AND USE OF
THE FLUCTUATION TEST
3.1 I N T R O D U C T I O N
3.1.1 General considerations - the fluctuation test
The fluctuation test has been used for the detection of mutations
in bacteria in several laboratories (Green & Muriel, 1976; Green et al.,
1977a, 1977b; Venitt, 1977; Gatehouse, 1978). '
In. the original papers by Green et al., the fluctuation test was
carried out in small test tubes. When no metabolic activation was required
a large volume of medium containing bacteria, chemical to be tested, a trace
of essential amino acid (histidine for Salmonella typhimurium) and a pH
indicator was divided into 50 equal portions (in this case 2 ml aliquots).
When the amino acid was exhausted only bacteria that had mutated (i.e. had
reverted to independence of the essential amino acid) were able to grow.
A mutant population was detected by observing the pH change resulting frcm
acid release during bacteria growth. The number of tubes containing mutated
bacteria in a control series was compared to that frcm a treated series.
Mutagenicity was observed for some ccmpaunds, e.g. methylmethanesulphanate
and mitanycin C (Green & Muriel, 1976). In the present study, fluctuation
tests without metabolic activation have been carried out in two steps as
discussed below. A single step test uses excessive volumes of medium and
chemical and a two step test is preferable.
As discussed in Chapter 1, a metabolising system is essential to
detect the mutagenicity of many chemicals, therefore a metabolising system
2+was incorporated, into the fluctuation test. In the first instance a Ca 
precipitated microscmal preparation was used, but it was also found to be 
possible to incorporate isolated hepatocytes into the test, as the test 
was performed entirely in a liquid medium (Green et al., 1977b). The 
hepatocytes quickiy became nan-viable (as judged by exclusion of the dye 
tryphan blue) when suspended in the soft agar used in the Ames test.
Benzo (a) pyrene (BP), 7,12-dimethylbenz (a) anthracene ( D M B A )  \
2-acetylaminofluorene (2AAF) were all mutagenic in a fluctuation test 
incorporating either microscmal or hepatocyte preparations (Green et al., 
1977b). In the original protocol by Green et al., the fluctuation test 
was carried out in two steps when a metabolising system was added (unlike 
their single step test with no metabolising system). There was an 
initial 16-18 hour period during which bacteria, a metabolising system,
the chemical to be tested and a trace of essential amino acid were co­
incubated in 50 , 100 fil aliquots. The second step involved the addition 
of 2 mis of selective indicator to each tube (without the essential 
amino acid). The tubes were then further incubated for three days, after 
which changes in pH were recorded.
The fluctuation test procedure as proposed by Green et al. (1977b) 
has sane disadvantages: The*main problem being that the small glass test
tubes were difficult to decontaminate and wash efficiently. They also 
used large amounts of incubator space, considerably limiting the size of 
experiments. One main objective of the present study was to develop a 
more practical test procedure. Gatehouse (1978), has also attempted to 
modify the basic method and has developed a test using microtitre plastic 
trays.
Other development work has been carried out in this study. The 
incorporation of a S9 fraction (9,000 g supernatant of rat liver hcmogenate) 
instead of microscmal preparations has been employed. S9 fraction contains 
all of the enzymes that are associated with microscmal fraction, but also 
contains a number of other enzymes associated with the cytosol fraction of 
the cell. The enzymes, such as glutathione transferases and sulphotrans- 
ferase are only active in the present of additional cofactors. However, 
seme enzymes, for example, the deacetylase enzymes found in the cytosol, 
are active in S9 fraction without addition of cofactors. Most bacterial 
mutagenicity studies are carried out in the presence of S9 fraction rather 
than a microscmal preparation (Ames et al., 1975) and it was therefore 
advantageous to be able to make comparisons with such results.
Previous work has shown that when hepatocytes are incorporated into 
the bacterial medium of the fluctuation test they became non-viable very 
quickly (Hubbard, 1976). This chapter describes development of the test 
to improve conditions for the co-incubation of the hepatocytes and bacteria. 
A protocol has been developed for the fluctuation test for routine screening 
in which microscmal preparations, S9 fraction or isolated hepatocytes may 
be used in a quick and simple procedure.
The compounds (2AAF, BP and DMBA) were used to assess the ability of 
the fluctuation test to detect chemical mutagens requiring metabolic 
activation. These particular chemicals were selected as there is evidence 
that they show different metabolic profiles with S9 fractions (or microscmal 
preparations) compared with whole cells or in vivo metabolism as discussed 
below. The effect of different inducers of drug metabolism (phenobarbitone 
(PB), 3-methylcholanthrene (3MC) and aroelor 1254) on the metabolism of
2AAF and BP to mutagenic metabolites was also investigated. The mutagenicity 
of both 2AAF and BP in the fluctuation was also conpared with the 
mutagenicity in the Ames test.
3.1.2 Metabolism of 2-acetylaminofluorene
2AAF is a widely studied chemical carcinogen that produces tumours
in many sites, including the liver and bladder (Weisburger & Weisburger,
1958; Clayson & Gamer, 1976). It was one of the first chemical carcinogens
to be shown to require metabolic activation, its metabolic profile being
elucidated mainly by the Millers (Miller & Miller, 1971, 1976). The
metabolic pathways of 2AAF are shewn in Fig. 3.1. 2AAF has been well©
documented as a mutagen in the Ames test and the fluctuation test (Ames 
et al.,1972a ;McGregor, 1975; Green et al., 1977b; Hubbard et al., 1980).
The first step in the activation of 2AAF and other aromatic amines 
is N-hydroxylation. The N-hydroxy2AAF (N-CH2AAF) is more carcinogenic than. 
2AAF itself, and unlike 2AAF, produces tumours at the site of application 
(Clayson & Gamer, 1976). Ring-hydroxylation also occurs, and is thought 
to be a deactivation step (Shaw et al., 1976).
In vitro studies with N-0H2AAF, which was originally thought to be 
the ultimate carcinogenic metabolite, indicated that it does not significantly 
bind to DNA .and that the binding seen is not consistent with in vivo data 
(reviewed in Shaw et al., 1976; Clayson & Gamer, 1976). The sulphate ester 
of N-0H2AAF, synthetically produced, was shown to be extremely reactive and 
was suggested to be the ultimate carcinogenic metabolite as it is very 
reactive with ENA, DNA and protein (DeBaun et al., 1970; Clayson & Gamer, 
1973; Weisburger & Weisburger, 1973). Guinea pigs are resistant to 2AAF 
induced cancer and have low sulphotransferase activity (Clayson & Gamer,
1976). Glucuronide conjugation is thought to be the major detoxification 
route of 2AAF.
Studies on the mutagenicity of the metabolites have been used to 
help identify the active metabolites of 2AAF. The sulphate, acetoxy and 
benzcyloxy ester of N-0H2AAF caused mutations in transforming DNA of wild 
type Bacillus subtilis (Maher et al., 1968) indicating the potential of . 
these metabolites to be carcinogenic, although, production of the sulphate 
ester (by addition of 3.'-phosphoadenosine-5-phosphate (PAPS) to'S9 
fraction). indicated that it was not mutagenic in bacteria (Mulder et al., 
1977a). The lack of mutagenicity may be due to the high reactivity of the 
metabolite, causing binding to the microscmal proteins. This is further ■ 
discussed in Section 3.3. Other metabolites may be responsible for both
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carcinogenicity and mutagenicity of 2AAF, particularly as tissues that lack 
sulphotransferase activity are susceptible to N-0H2AAF induced cancer 
(Mulder et al., 1977a). N-Acetoxy2AAF has been shown to be a mutagen in 
Salmonella typhimurium (Shaw et al., 1976), but requires further metabolism 
by postmicrosonal supernatant to exert its effect. It has been shown to 
bind extensively to proteins at non-physiological pH, and less at physiological 
pH. The acetyl group may also be transferred to the oxygen of the 
hydroxylamine. Transacetylation has been observed in tissues other than 
the liver, e.g. the kidney, stomach and small intestine (reviewed in Kriek 
& Westra, 1980). These enzymes are present in the cytosol fraction of the 
cell. Due to their extreme reactivity these metabolites have not been 
prepared. Such metabolites may have carcinogenic and mutagenic properties.
3.1.3 Metabolism of benzo(a)pyrene (BP)
BP is a chemical found widely distributed in the environment. It is. 
found in cigarette smoke, car exhaust fumes, on charcoal grilled steaks and 
in fruit and vegetables (reviewed by Brookes, 1977). It has been briefly 
discussed in Chapter 1 and its metabolism is further discussed below.
BP requires metabolic activation to exert a biological effect. It 
can be metabolised to a variety of phenols and dihydrcdiols (Jerina & Daly, 
1974; Sims & Grover, 1974). Fig. 3.2 shews the main metabolic routes of 
BP. The metabolites of the K-region were originally thought to be the \ 
ultimate carcinogens, but it is new recognised that metabolites of the bay- 
region possess carcinogenic activity. This has been substantiated by a 
quantum mechanical, approach which predicts that the bay-region should form 
the most active metabolites (Jerina et al., 1977).
As discussed in Chapter 1, the major DNA-BP adduct found in vivo 
or in a variety of cells in culture, is formed from the • 7,8-diol-9,10-epoxide 
BP metabolite which is thought to be the major carcinogenic metabolite of 
BP. However, the major DNA-adduct. formed with microsanal mediated metabolism 
is derived fran the 9-OHBP metabolite.
The epoxides from both regions of the molecule may be further 
metabolised by epoxide hydratases present in the endoplasmic reticulum 
of the cells. These epoxides may form dihydrodiols or may be conjugated with 
glutathione by glutathione s-epoxide transferase (DePierre and Emster, 1978). 
The dihydrodiols are further metabolised by mixed function oxidases to phenol 
metabolites and diol epoxides. There are four known dihydrodiol metabolites 
of BP (DePierre & Emster, 1978). The BP 2,3-dihydrodiol quickly forms
3-OHBP (Yang et al., 1977b). 3-OHEP has been identified as a metabolite in
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human, hamster and rat lung cultures (Cohen et al., 1976). The others 
.identified are BP 4,5-, BP 7,8- and BP 9,10-dihydrodiols. '
The phenols undergo further activations. 6-OHBP undergoes auto- 
oxidation to produce stable 1,6-, 3,6-, and 6,12-diol BP. It is able to 
spontaneously bind to DNA in ethanol-phosphate buffer. 3-OHBP can 
covalently bind to DNA in the presence of rat lung microsanal fractions.
The 1-, 3- and 6- positions of BP have been shown not to be involved 
in the hepatic microsane-mediated binding of BP to poly (G). The 2-OHBP is 
highly carcinogenic on mouse skin (Wislocki et al., 1977), but there is 
no evidence for its formation in vivo.
The phenols can also be further metabolised by microsanal systems and 
a second epoxide can be introduced. The epoxide can then follow the 
customary further fate of epoxides. The 3-, 6- and 9-OHEP metabolites have 
been shown to be recycled (DePierre & Emster, 1978). When liver microscmes 
are incubated with a limiting amount of BP, there is a massive recycling 
of metabolites, and substantial amounts of metabolites formed are no 
longer extractable into the organic phase.
The metabolism of BP has been studied in isolated hepatocytes (Vadi 
et al., 1975 * Jones et al., 1978). It was found that when hepatocytes were 
used,ethyL acetate-soluble metabolites (e.g. 4,5-dihydro-4,5-dihyroxyBP,
7,8-dihydro-7,8-dihydroxyBP, 9,10-dihydro-9,10-dihydrojyBP and 3-OHBP and 
its sulpate ester) were produced predominantly. Water soluble metabolites 
(such as glucuronides) were readily removed from the cells.
Mutagenicity studies have been important in the study of the 
metabolism of BP and synthesised metabolites have been used to investigate 
their relative mutagenicities. This is further discussed in Chapter 5.
In this chapter the mutagenicity of BP is investigated under conditions of 
metabolism with S9 fraction or hepatocytes, particularly in the light of 
the evidence that different metabolites and DNA-BP adducts are formed with 
microscmes compared with hepatocytes (see Ashurst & Cohen, 1980).
3.1.4 Metabolism of 7,12-dimethylbenz (a) anthracene (DMBA)
DMBA is one of the most carcinogenic PAHs, more so than 
benzo(a)anthracene, producing lung, skin and mammary tumours ^Slaga et al.,
1974). DMBA. is metabolised by the mixed function oxidase enzymes to a 
variety of epoxide metabolites (Boyland & Sims, 1965; Yang & Dcwer, 1975).
Like the BP molecule, DMBA also has a K-region and non K-region (bay- 
region). The metabolic profile of DMBA (Fig. 3.3) is not so well defined 
as that of BP.
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Various dihydrodiols of its parent structure,benz (a) anthracene, 
have been found to be mutagenic towards TA100, the 3,4-diol ^ being 
the most mutagenic using reconstructed cyt.P-448, and the 8,9-diol. '■ - 
being more active using S9 fraction (Jerina et al., 1977). The nature 
of the ultimate metabolite of benz (a) anthracene has yet to be described, 
but it appears likely that the bay-region of the molecule is involved.
A lth o u g h  b en z (a ) a n th ra c e n e  la c k s  th e  m e th y l g ro u p s  o f  DMBA, i t  i s  l i k e l y  
t o  e x h ib it  many s im i la r i t ie s  in  i t s  m e ta b o lic  r o u te .
Dipple and Nebzydoski (1978) showed that a diol-epoxide is 
responsible for the binding of DMBA to cells in culture. Huberman and 
Slaga (1979) studied fluorinated derivatives of DMBA and found that fluorin- 
ation at positions 1 and 2 (therefore blocking the bay-region), and at 
position 5 (blocking the K-region) dramatically reduces the mutagenic and 
carcinogenic activity of DMBA, suggesting the involvement of these regions 
in metablic activation. In contrast, fluorination at position 11 did not 
affect mutagenicity. The authors suggested that the involvement of the 
K-region may be due to its need to be free to interact with the appropriate 
enzyme permitting oxidation at the bay-region. Huberman et al. (1979) also 
investigated the mutagenicity in V79 Chinese hamster cells and the metabolism 
of a series of DMBA metabolites. 7-Hydroxymethyl-12- methylbenz(alanthracene, 
7-methyl-12-hydroxymethyIbenz (a) anthracene and their trans-3,4-diols are 
mutagenic in V79 cells after metabolic activation by a golden hamster cell 
feeder layer. Only the EMBA-trans-3,4-diol is more mutagenic than DMBA 
itself.
Analysis of DMBA metabolism in intact golden hamster cells showed that 
EMBA-trans-3,4-diol is one of the major metabolites along with DMBA-trans-
8,9-diol. This is further evidence in favour of the involvement of the bay- 
region in the production of active metabolites.
Since DMBA is a highly active chemical, the involvement of the 
methyl groups cannot be overlooked. They have been shown to be metabolised 
by an enzyme with similar cofactor requirements to AHH which is present in 
microsanal fractions (Yang & Dcwer, 1975; Brookes, 1977). These methyl 
groups are often the major sites of metabolism. The synthesised metabolite 
7-hydroxymethy 1- 12-methylbenz (a) anthracene caused greater adrenal necrosis 
and mammary cancer in rats than DMBA (Yang & Dower, 1975). It has been found 
to be a metabolite in golden hamster embryo cells (Huberman et al., 1979).
This metabolite is found to be most prominent when 3MC-induced microscmes 
are used for metabolic activation. The metabolite, -
7,12-dihydroxymethy lbenz (a) anthracene has been suggested to be a 
detoxification product. It has been found that when DMBA is specifically 
labelled at the 7-methyl group it becomes bound to DNA in an in vivo system 
and seme label is displaced. It has been proposed that metabolic activation 
of the 7-methyl group may precede the metabolism of the 1,2,3,4-ring 
(Ivanovic et al., 1978). Investigations into the DNA-adducts by fluoresence 
spectroscopy revealed that the adducts formed fron further netabolism of 
7-hydroxymethyl-12-methylbenz (a) anthracene and DMBA gave identical spectra. 
However, Huberman et a l t (1979) showed that the 7-hydroxy-trans-3,4-diol is 
not as mutagenic as the DMBA—trans-3,4-diol itself.
Differences have been observed in the DNA-hydrocarbon adducts 
produced in cell cultures and those produced from microsanss (Bigger et al.,
1978) as discussed in Chapter 1. The adducts arising from K-region 
metabolites are formed when microsanal metabolism is employed, whereas 
metabolites from the bay-region are responsible for the adducts in cell 
cultures. These results are considered to indicate the need for studying 
DMBA with both hepatocytes and S9.
3.2 RESULTS
3.2.1 General development of the fluctuation test
3.2.1.1 Vessels for the fluctuation test
As discussed in Section 3.1.1. the use of glass tubes posed several 
practical problems and therefore the use of disposable raultiwells plastic 
trays was investigated. One major consideration concerning the type of 
vessel used was the condition of the hepatocytes. They will not attach to 
a glass surface unless it is coated with collagen (Wiebkin, 1978), and the 
viability of the hepatocytes is reduced considerably over a short period 
under the conditions of the fluctuation test in glass tubes (Hubbard, 1976), 
although the viability may be better maintained by using a mammalian tissue 
culture medium instead of a bacterial medium (as discussed in Section 
3.2.2.1). Their metabolic capability may be increased by allowing them 
to attach to a plastic surface (Wiebkin, 1978). The choice of vessel for 
the fluctuation assay therefore probably needs to be one in which the 
viability of the hepatocyte can be maintained as long as possible 
(preferably up to 24 hr) fcy allowing them to attach to a suitable surface.
Various types of disposable vessels were available, provided the 
volume of the individual incubations was adjusted. Trays containing 2 ml 
wells in which a minimum initial volume of 300 jil (100 jj.1 or 200 j l l I  does 
not completely cover the bottom surface of the wells) and 1 ml of selective
indicator, and also microtitre trays in which 50/11 initial volume with 
150 jil or 200 jil selective indicator could be added, were selected fran a 
range of available Linbro disposable trays (Flew Laboratories, Scotland).
The means of closure of the trays was important as spread of solution across 
the lid frequently occurred if a well was overfilled, thus resulting in 
cross-contamination between wells. Preformed vinyl lids were found to be 
the most suitable.
3.2.1.2 Selection of conditions for the fluctuation test
The grewth of the bacteria, and hence the number of spontaneous 
mutations which occur is governed by the concentration of amino acid present. 
Pre-existing mutants in the bacteria culture also contribute to the number 
of wells detected as positive in a fluctuation test. An example of the 
effect of the variation of both bacterial number and histidine concentration 
cn the spontaneous mutation rate of both TA98 and TA100 is shown in 
Table 3.1. The concentration of histidine per ml had to be reduced for use 
in Linbro trays as the volume of experiment was altered (i.e. 15 mis in . 
trays, 5 mis with glass tubes). The total amount of histidine per test as 
opposed to a per ml figure is important, hence whereas 3 jig/ml is used for 
glass tubes, 1 jig/ml is used for disposable trays for TA98. A ccxtparison 
of two different initial starting volumes is shown in Table 3.2 for both 
TA98 and TA100. Care was required that a sufficient growth of bacteria 
occurred in the initial overnight period to allow an induced mutation to be 
incorporated and expressed, as a mutation requires more than one generation 
for expression. Table 3.3 shows the number of generations grown in the 
initial overnight period in TA98.
As shown in Fig. 3.4, on grewth of the bacteria in medium containing
glucose as the energy source, the pH of the medium changes frcm =pH 7.3 to
9pH 5.6. (which is obtained when the bacteria reach a density of = 1x10 /ml). 
Sufficient acid is released to alter the pH when the bacteria reach a density 
of approximately 5x10 /ml. Initially, purple wells (or tubes) are pH 7.1, 
yellow wells are pH 5.6 or below and intermediate wells (as judged by eye) 
are approximately pH 6.5. It is therefore important that the number of 
bacteria grcwn in the initial overnight incubation is sufficiently low so 
as not to affect the overall pH of the medium and thus the scoring of the 
experiment. This may be overcome by increasing the volume of selective 
medium added to "dilute" out this effect, however the volume of selective 
indicator in the disposable trays is limited due to well size. The 
concentration of histidine was therefore important in limiting the background
Table 3.1.
The effect of the concentration of histidine and bacterial
number on the background mutation rate in the fluctuation 
test in TA98 and TA.100 in a single experiment
Concentration
histidine
j-ig/fai
ciNumber of wells positive
Total number of bacteria per series
lxlO6 2x10^ lxlO7 2xl07
TA98
5.0 - - — 21+
2.5 - 16 17 17+
1.0 - 12 4 11
0.5 1 5 5 10
0.25 4 2 3 -
0 0 1 0 1
TA100
2.5 39 — - 42
1.0 28 - - 31
0.5 16 20 - 20
0.3 - 21 - ■ -
0.25 15 20 - 13
0.1 - 10 - ' 18
0 2 2 — 5
a - -48 wells per treated series. + - most wells changing colour.
The fluctuation test was carried out in Linbro trays with 2ml 
capacity wells. The testiwas carried out in two steps, the histidine • 
concentration and bacteriainurriber being in the initial 15ml incubation 
mixture.
Table 3.2
The effect of total histidine concentration in a fluctuation 
with different initial starting volumes
Total histidine 
concentration
ci; Number of tubes positive
I n i t i a l  A 7 n 1 u m p .  o f  t h o  p v n o r i T n o n f
m
15ml
.... 0.3ml/tube .
5ml ^ 
O.lml/tube
m98
30.0 16 40
22.5 11 -
15.0 7 10
7.5 8 4
3.75 11 4
0 0 0
TA100.
30.0 40 -
15.0 27 30.
7.5 30 22
3.75 24 / 11
2.5 25 12
... 0 3 .. 3
a - results from a single experiment, 48 tubes per experiment.
The test was performed in glass tubes with 2x10 bacteria/tnl TA98 
6and 2x10 bacteria/fril TA100. 1ml selective indicator was added to 
each tube.
Table 3.3
The number of generations of T&98 grown in the Initial incubation 
period of the fluctuation test in Linbro trays.
Concentration
histidine
pg/inl
Number .of wells 
positive 
(48 wells/treated 
series)
Number of generations 
grown±SD
5.0 44.. 1 1.8±G.6
2.5 16+ 11.0±0.7
1.0 12 9.8±033
0.5 5 8.9±0.3
0.25 2 7.8±0.4
0 ......... 1 0
a - mean of estimation from 5 wells not containing a revertant at the 
• conclusion of the experiment.2x10 yinl TA98 per treated series.
+ - most wells changing colour.
Table 3.4
The viability of hepatocytes in BME in glass tubes under various 
conditions of incubation
Incubation
time
Viability index±SD (%reduction in viability)
hr Conelition of incubation
4°C 37°C 37°C
(shaking)
20 71.Oil.2(6.2) 0 (100) 0 (100)
4 69.7±2.1(7.9) 32.0±3.7(57.7) 68.3±3.0(9.7)
2 73.7±6.8(2.6) 47.8±3.1(36.8) 73.3±4.2(3.1)
1 77.0±2.0(0) 57.3±1.0(24.3) 7l.7±1.6(5.2)
0 75.7 75.7 75.7
* ConVcuniMj ^
Hepatocytes were incubated in IOOjliI aliquots 1x10 viable cells. 
Viability was determined by addition of trypan blue as described in 
Chapter 2. ■ •
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3.4. The pH change :in'the culture medium when bacteria 
(TA98) are grown in minimal salts with glucose as 
substrate.
growth of bacteria. The problem of interference in the scoring of the 
experiment by wells of intermediate colour was observed, with higher levels 
of histidine (see Tables 3.1 and 3.2). This constraint on bacteria number 
and volume of experiment limits the size of experiment, hence sane 
difficulties were observed when the volume of the experiment was reduced 
to microtitre levels in which 50 pi of initial incubation with 150 pi of 
selective medium was used. However, conditions may be altered so that 
this type of test may be used (cf Gatehouse, 1978; Gatehouse & Deflow,
1979) and Section 3.2.2.3 describes experiments in which TA100 and hepatocytes 
were used under these conditions.
The levels of histidine used for the fluctuation test for both TA98 
and TA100 are given in Chapter 2 (2.4). On addition of S9 fraction to the 
fluctuation test (resulting in an increase in histidine), the histidine 
levels were reduced to allow for the histidine added. It was found that 
sufficient histidine was present in the S9 for TA100 and therefore no 
exogenous histidine was required.
3.2.2 The use of isolated hepatocytes in the fluctuation test
3.2.2.1 Modifications to the medium
The viability of hepatocytes in DM salts in glass tubes is reduced 
by 50% after 1 hr incubation at 37°C (Hubbard, 1976). By using a 
mammalian cell tissue culture medium such as Medium 199 (M199), the loss 
of viability could be improved to 12.5% reduction in 1 hr. However, 
most mammalian cell tissue culture media contain high concentrations of 
histidine and a medium with a lew concentration of histidine was evaluated 
for use in the fluctuation test.
Basal Medium Eagle (BME) with Earle's salts and Hepes buffer 
supplemented with 2 mM L-glutamine and 10% foetal calf serum was evaluated 
as a suitable medium and the viability index of the hepatocytes in glass 
tubes after various incubation periods assessed (Table 3.4). There was a 
significant difference in the viability of the hepatocytes when they were 
well oxygenated by shaking at 37°C. It has previously been observed that 
viability is maintained at 4°C (Fry et al., 1976). After 20 hr at 37°C, 
no hepatocytes were viable. Although the medium appeared adequate to 
support hepatocytes in a viable state for several hours, initial fluctuation 
tests in glass tubes were largely unsuccessful and it was found that the 
level of histidine in the medium was too high, and that the serum also 
contained an excess of histidine. As described in .Chapter 2, BME was
specially prepared for this study that"was histidine free. The presence of
histidine in a number of batches of foetal calf serum was also determined 
(Table 3.5).. Although dialysis was effective in removing the histidine, 
a reduction in the final, serum concentration was favoured as described 
in Section 3.2.2.3.
3.2.2.2 Condition of hepatocytes
As already discussed (3.2.1.1), Linbro disposable trays were chosen 
to support the hepatocytes in culture in the fluctuation test. To maintain 
the hepatocytes, tissue culture treated vinyl trays were used. To assess 
the ability of these trays to support the hepatocytes in culture, the 
attachment of the hepatocytes to the wells and the metabolic capability 
of the hepatocytes was determined. These studies were carried out in 
modified BME supplemented with 2 mM L-glutamine, 2.5 p.g/ml tryptophan and 
10% foetal calf serum, except where stated.
When hepatocytes were incubated in the wells of trays, cells could 
be seen attached to the well bottcm, and sheets of cells were observed in 
places. However, the bottcm of the wells is not completely flat, reducing 
the surface area that the hepatocytes attach to. In situ staining by 
trypan blue of the hepatocytes indicated that in any field - 90% of the 
attached cells were viable,with non-viable cells piled onto viable cells. 
Difficulties in removing attached hepatocytes were encountered. Enzymic 
detachment (with trypsin) was largely unsuccessful, while mechanical 
detachment (with a "rubber policeman") resulted in the loss of many cells, 
presumably by mechanical damage. However, by counting the numbers of 
detached pells at a 1 hr incubation, an estimate of 34.9 ± 5.6% attachment 
was obtained (three separate experiments of triplicate wells containing
g
1 x 10 cells in 1 ml medium). As shown below the unattached hepatocytes 
also retain sane viability over a period of several hours. This is important 
in the fluctuation test as the unattached cells are as important for 
metabolism as the attached cells.
Viability of: unattached hepatocytes ± SD 
Incubation time (mean of three separate estimations of triplicate
 (hr)_____  wells containing 1x 1Q6 cells in 1 ml)____
0 .80.5 ±7.2
1 78.2 ± 3.7
2 54.3 ± 13.6
4 41.0 ± 6.7
Table 3.6 shows the results obtained in a single experiment using a method
Table 3.5
Histidine concentration in some samples of foetal calf
serum
Batch no. Histidine
concentration
jjg/tnl
530 64.2
056 108.8
420 114.1
424 142.6
137 124.8
Dialysed
serum
530
(5%hr) 37.4
(24hr) 14.3
Histidine was assayed fluorimetrically by the 
method of Shore et al., (1959).
Table 3.6
Attachment of hepatocytes to wells of Linbro tissue 
culture treated vinyl trays with different cell numbers 
and serum concentrations
Number
hepatocytesyfcil
(0.3ml/taell)
%hepatocytes attached 
(meaniSD triplicate wells)
Incubation time (hr)
1 2 24
10% serum
0 .2xl06 28.3±4.5 15.3±3.6 20.3±5.3
l.OxlO6 21.6±3.7 26.2±4.1 45.0±7.2
1% serum
0 .2x10 6 7.8±2.1 7.5±1.9 10.3±3.3
1 .0x106 32.8±6.3 27.5±2.5 31.7±5.1
for the determination of the number of nuclei to indicate the number of 
hepatocytes attached(Section 2.3.8). This method may over estimate the cell 
number as many hepatocytes are multinucleate. Fran this experiment, the 
number of hepatocytes plated is important and a reduction in serum 
concentration does not appear to significantly affect the attachment when
g
1x10 cells/well are used.
Although the attachment of hepatocytes to culture vessel surface 
is a good indication of the viability of hepatocytes, the ability of 
hepatocytes to carry out metabolic conversions under the condition of the 
fluctuation is a better indication of the condition of hepatocytes. The 
metabolism of 7-ethoxycoumarin was measured, phase I metabolism being 
determined by the production of free 7-hydroxycoumarin (7-OKcoumarin) and phase II 
metabolism being determined by the production of conjugates of 7-OHcoumarin, 
(Tables 3.7a and 3.7b). These results indicate the ability of the tissue 
culture trays to support hepatocytes in a metabolising capacity for periods . 
of at least 24 hrr although there is a considerable drop in activity as 
compared to fresh suspensions.
3.2.2.3 Hepatocyte number and serum concentration in 
the fluctuation test
As shewn in Table 3.5, serum contains high levels of histidine and 
the serum concentration was therefore reduced. .Although batch no. 137 did 
not contain the lowest histidine concentration it was used for the 
fluctuation test as large stocks were available. The number of hepatocytes 
present in the test also affects the spontaneous background, possibly due 
to the release of histidine frcm non-viable cells as there is a leakage of 
cellular substances frcm such cells.
A suitable combination of hepatocyte number and serum concentration 
was therefore sought. Table 3.8 shews the results obtained when varying 
both the hepatocyte number and serum concentration. Although a combination
g
of 5x10 hepatocytes and 1% serum gives a sufficiently low average number 
of wells positive, wide variations in wells positive were observed. There­
fore, a combination of 3x10^ hepatocytes/test (0.2xi0^ /ml)--and-1% serum 
was chosen for the fluctuation test with TA98.
3.2.2.4 Modification of the protocol for TA100
When TA100 was used under similar conditions to TA98 (with reduced 
bacteria numbers), excessively high numbers of positive urells were seen
Table 3.7
Metabolism of 7-ethoxycoumarin by isolated hepatocytes 
in Linbro tissue culture treated vinyl trays
Table 7a
Metabolite
-----------------------------—5-
nmol 7-Hydroxycoumarin/4hr/0.6x10 hepatocytes
(mean of two estimations from 5 pooled wells,
0. 3ml/Well)
Time after initiation of culture (hr)
0 24
Free ■. (7^ 0Hcoumarin) / 0.45 1.3xl0~ 2
Conjugates . - . "
sulphates 2.52 0.40
glucuronides 1.42 0.21
Total conjugates 3.94 0.62
Total metabolites 4.39 0.62
Table 7b
Time after 
initiation of 
incubation 
hr
c J~
nmol 7-Hydroxycoumarin/2hr/0. 2x10 hepatocytes 
(mean of two estimations from single well§ 
1ml/Well)
: . Metabolite
Free 
(phase I)
Conjugates 
(phase II)
0 0.19 0.21
2 . 0.08 0.14
4 0.06 0.08
22 0.02 • 0.28
Table 3.8
Effect of varying serum concentration and hepatocyte number 
on the background imitation rate of T&98 in the fluctuation 
test
.
Concentrati
serum
%
Sion.. ’ Number of wells positive±SD
Number hepatocytes/15ml
ubation)(in initial inc
0 lxlO6 3X106 5x10^ 7.5xl06
0
1
2
5
10
15.018.6 
21.0±I1.7 
31.7+ . 
40.5+
3.3±1.5 
7.013.0 
I8i.0±2.5 
8 .0+ .
7.0+3.3 
12.916.5 
14.0±4.5 
5.0+ .
30.0±6.0 
15.0±0.7 • 
30.0±5,6 
18+
■' 46.0+1.5
a - mean of four separate experiments, 48 wells per treated series. 
+ - all wells in various stages of colour change.
Table 3.9
Effect of varying histidine concentration, hepatocyte number 
and size of well in Linbro trays on the background mutation 
rate of TA.100
Concentration Number of wells positive
histidine C).5ml wells - 2ml.jwells
jig/fol Number of he I 1
0a 0.07xl06b 0 .2xl06a 0.07xl06b 0 . 2x10^ 0.3xl#k
0 1 .0±0.8 5.5 15.514.3 18.- 5 27.5 37.0
1 10.7±4.6 11.5 18.314.0 27.0+ 37.0+ 38.0+
2 12.0±3.3 18.5 18.414.7 28.0+ 40.0+ 37.0+
5 15.0+ 30.0+ 48+ 35.0+ 35.0+ 40.0+
a - mean three experiments±SD, 48 wells per treated series, 
b - mean two .experiments.
+ - most wells changing colour.
(.>30) (Table 3.9). The high spontaneous mutation rate of this strain
necessitated the modification of the experiment and several measures were
considered. Firstly,the serum concentration could be lowered, but this
was already considered to be the minimum suitable concentration. Secondly,
the number of hepatocytes/ml could be reduced, but this would reduce the
number available for metabolic activation. Thirdly, lowering the bacteria
number might contribute to reducing the spontaneous background, however this
was already lower than that used for TA98. Further reduction would tend
to reduce sensitivity of the test. The final modification that could be
made and was adopted, was to reduce the volume of the experiment. Tissue
culture treated vinyl trays with a well capacity of 0.5 ml were used with
an initial inoculum of 50 pi and selective indicator volume of 200 p, 1 as
described in Chapter 2. Table 3.9 shews results obtained using TA100 in
these trays, varying the serum concentration as compared to using larger
trays (as for TA98). As presented in Chapter 2, for a test with TA100 and
6hepatocytes, the incubation mixture consisted of 1% serum and 0 .2x10 
hepatocytes/ml in a total of 2.5 mis. To further reduce histidine the 
bacteria were filtered and washed in histidine free media before use.
3.2.3 Mutagenicity in the fluctuation test
3.2.3.1 The mutagenicity of 2AAF in the fluctuation test
under different conditions of metabolic activation
The mutagenicity of 2AAF was investigated in the fluctuation test 
using the newly developed protocol. Table 3.10 shows the results obtained 
using aroclor-induced S9, phenobarbitone-induced S9, uninduced S9 and 
hepatocytes. A comparison of the mutagenicity of 2AAF under each of these 
conditions is shown in Fig. 3.5. Comparison at 10 pg/ml 2AAF under all 
conditions was not possible as 48 wells were positive and the induced 
mutants per well could not be calculated.
In view of the difference in response of 2AAF with aroclor-induced 
S9 fraction as compared to uninduced S9, the concentration of S9 was varied 
In the fluctuation* test (Table 3.11).As most of the wells were positive 
above 0.1 pg/ml with uninduced S9, it is not possible to make comparisons 
between the effects of S9 at these concentrations. Only 0.06 mg/ml S9 at 
0.1 Pg/ml 2AAF was less efficient for the metabolism of 2AAF. At lower 
concentrations of 2AAF there was no significant difference in the response 
using different concentrations of S9. However, at 0.005 p.g/ml 2AAF, 
marginally greater responses were obtained using 0.15 mg/ml S9 and 
0.06 mg/ml S9, although these results were based on one experiment only.
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Figure 3.5 The mutagenicity of 2AAF in TA98 in the fluctuation 
test with different metabolic activation systems.
Aroclor-induced S9 •---• ; FB-induced S9 a ▲ ;
uninduced S9 o o ; isolated hepatocytes □---□ .
? - induced mutants not calculated as all wells'-were 
positive.
The concentration of 2AAF is a logarithmic scale.
Table 3.11
Effect of varying the S9 concentration on the mutagenicity 
of 2AAF in TA98 in the fluctuation test
Concentration 
2AAE! jig/fril
Average number of wells positivefcSD 
(48 wells per series)
Aroclor-induced S9 Uninduced S9
' vfo.. 5Xpt Control . series ,Treatedseries No.,expt. Controlseries Treatedseries
S9 - 1.2mg/inl 
1.0 1 8 22 3 ,6.7±0.9 48
0.1 1 8 12 3 18.7±8.3 46.0±0.5
o.oi- 1 8 11 3 18.7±8.3 33.3±3.7
0.005 1 5 9 1 7 14
S9 - 0.6mg/inl
10.0 3 11.7±1.2 48 3 16.3±2.5 48
1.0 3 11.7±1.2 29.3±3.3 3 14.3±0.9 48
0.5 1 11 17 - - -
0.1 3 11.7±1.2 18.0±2.3 3 15.3±5.3 45.3±3.8
0.05 - - - 3 18.5±3.5 44.Oil.1
0.01 - - - 3 14.0±3.7 25.3±8.4
0.005 1 6 6 3 15.3±5.3 13.3±4.0
S9 - 0.3mg,4nl 
10.0 1 7 48 2 7.0 43.5
1.0 2 11.0 53.5 2 5.0 41.0
0.5 1 15 19 - - -
0.1 2 11.0 13.0 3 11.0±5.4 44.7±2.1
0.05 - - - 1 17 47
0.01 - - - 3 11.0±5.4 25.3±6.5
0.005 - - ' - 2 10.5 14.0
S9 - 0.15mg/tnl 
10.0 1 14 47
1.0 1 14 39 2 13.0 43.5
0.5 1 14 15 - . - -
0.1 1 14 12 3 1 1.7±6.2 47.7±0.47
0.05 - - - 1 10 44
0.01 - - 3 11.7±6.2 31.3±2.4
0.005 - - - 1 10 24
S9 - 0.06mg/tnl 
10.0 1 12 48
1.0 1 12 46 - . - -
0.5 1 12 32 - -
0.1 1 12 13 1 8 33
0.05 - - - 1 8 41
0.01 - - - 1 8 22
0.005 1 8 20
With aroclor-induced S9, a greater response was obtained with 0.06 mg/ml 
S9 at 0.5 jug/ml and 1 jj.g/ml 2AAF, while increasing concentrations of S9 
significantly reduced the mutagenicity of 1 jag/ml 2AAF.
A comparison between aroclor-induced S9 and uninduced S9 cannot be 
made at a single concentration of 2AAF, due to the wide difference in 
response. However, a . comparison of optimal S9 concentration. required under 
each condition is shewn in Fig. 3.6 at 1 jig/ml 2AAF with aroclor-induced 
S9 and 0.1 jig/fail with uninduced S9. Although sub-optimal concentrations 
of aroclor-induced S9 were not demonstrated, it is apparent that the 
optimal mutagenic response of 2AAF is achieved at a lower S9 concentration 
with aroclor-induced S9 than with uninduced S9.
3.2.3.2 The mutagenicity of 2AAF in the Ames test
The mutagenicity of 2AAF was also investigated in the Ames test 
with both aroclor-induced and uninduced S9 (Table 3.12). Interestingly, 
at the most coimonly used S9 concentration (0.6 mg/ml in the top agar, 
usually quoted as 50 |il/plate), the mutagenicity of 2AAF was significantly 
greater with aroclor-induced S9 than with uninduced S9« However, the 
converse is true in the fluctuation test (Table 3.11) . With aroclor- 
induced S9, at concentrations of 20 jig/ml 2AAF and higher, a large number 
of microcolanies were observed making counting of the colonies difficult.
This is due to toxicity of 2AAF towards the bacteria at these concentrations. 
As this did not occur with uninduced S9, the toxicity might be attributed 
to the metabolites of 2AAF and not 2AAF itself.
Higher concentrations of uninduced S9 fraction (1.2 mg/ml and 
0.6 mg/fril) were significantly more efficient at metabolising 2AAF to 
mutagenic metabolites, although no significant difference was observed be lew 
4 pg/inl 2AAF (Fig. 3.7). As toxicity occurred above 20 pg/plate with 
aroclor-induced S9, the effect of S9 cannot be accurately assessed. At 
4 pg/plate 2AAF, a greater mutagenic response was obtained with decreasing 
S9 concentration. (Fig. 3.8), and at 8 jig/plate 2AAF, the greatest response 
was achieved with 0.6 mg/fril S9.
As in the fluctuation test, a lewer S9 concentration for optimal 
mutagenesis of 2AAF is required for aroclor-induced S9 as coipared to 
uninduced S9 (Fig. 3.9). The mutagenic response with aroclor-induced S9 
is generally greater than with uninduced S9 at similar 2AAF concentrations. 
The extent of mutagenicity with aroclor-induced S9 was not obtained with 
uninduced S9. The optimal concentration of uninduced S9 has not been 
identified in the Ames test.
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Figure 3.6 Effect of different levels of S9 on the mutagenicity 
of 2MF in TA98 in the fluctuation test.
ljig/inl- 2AAF with aroclor-induced S9 • ----• ;
0.1|ig/tnl 2AAF with uninduced S9 O o ;
0.01jj;g/ml2AAF with uninduced S9 O o .
Table 3.12
The mutagenicity of 2AAF in TA98 in the Ames test with 
different concentrations of aroclor-induced and uninduced S9
Concentration 
2AAF in
cn-Pf-
Number mutants ±SD/j?late" (mean of two experiments 
delicate plates per experiment)
UVCJ- -LClJf —
jig/ta. Uninduced S9 Aroclor-induced S9
S9 - 1.2 mg/mL
40.0 ***335b *** 661.0±61.0 +
20.0 *** 98.8±14.5 *** 274.5±40.4
8.0 *** 57.0±7.0 *** 131.5±9.5
4.0 * 33.8±13.9 ** 56.6±15.6
0.4 24.0±3.3 ** 32.5±0.5
0 18.4+8.7 22.3±6.5
■ S9 - 0.6mgytnl
40.0 ***107.3+8.0 ***1009.0±76.0+
20.0 *** 66.0±15.2 *** 416.4±121.2
8.0 * ’39.5+11.5 *** 272.0±25.2
4.0 * 29.8±7.5 ** 63.8±24.9
0.4 19.0±4.9 ** 30.7±7.8
0 20.4±3.4 23.0±5.2
S9 - 0.3mgy4nl •
•40.0" *** 39.5+1.5 *** 572.0±24.1 +
20.0 .***. 36.6±6.7 *** 223.6±103.3+
8.0 ** 24.5±2.5 *** 185.0±24.0
4.0 ** *32.2±6.2 *** 88.0±5.7
0.4 * 23.0±Q.8 * 31.0±5.1
0 15.8±4.1- 2 0.8±6.8
S9 - O.lSmg/ML •
40.0 ***150b+ *.** 199.5±25.5+
20.0 * 25.0±6.1 *** 131.8±27.4
8.0 .2l.2±6.2 ***' 113.5±7,5
4.0 17.0±1.5 *** 75.6±25.7
0.4 21.3±1.9 28.0±8.6
0 17.0±7.7 17.8±4.7
* <
b- result frcm a single experiment.
+ many microcolonies making scoring difficult.
_ Significant increase over the control
*** p<0.001
** p<0.01
* p<0.05
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Figure 3.9 ......... Effect of different levels of S9 on the mutagenicity
of 2AAF in TA98 in the Ames test; 8)ig/nl 2AAF with
aroclor-induced S9 •---- • ; 20jig/nl 2AAF with
uninduced S9 o o
The S9 is in mg/feil in the soft agar overlay.
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A comparison of the S9 required for optimal mutagenesis of 
2AAF in the fluctuation test and the Ames test for both aroclor-induced 
and uninduced S9 is shown in Fig. 3.10 and 3.11. in each case (aroclor- 
induced S9 and uninduced S9), a lower S9 concentration is required for 
optimal mutagenesis in the fluctuation test than in the Ames test. An 
accurate comparison between the two systems is difficult because it is 
uncertain hew concentrations in the Ames test should be expressed.
Normally these are quoted as per ml of soft agar overlay. Expressing 
it in this way takes no account of the possible diffusion into the bottom 
agar.
3.2.3.3 The mutagenicity of benzo(a)pyrene in the
fluctuation test and Ames test
The mutagenicity of BP in the fluctuation test under varying
conditions of metabolic activation (aroclor-induced S9, PB-induced S9,
2+3MC-induced Ga ppt. microscmes,uninduced S9 and uninduced hepatocytes) is
shewn in Fig. 3.12. The mutagenic response with varying concentrations 
of S9 fraction was not investigated. However, at concentrations above 
1 pg/inl BP, a greater response was obtained using aroclor-induced S9 in 
contrast to the results with 2AAF. Since in the Ames test, at a single 
concentration of S9, greater 2AAF mutagenicity was demonstrated with 
aroclor-induced S9 than uninduced S9, an Ames test was performed using 
BP (Fig. 3.13). As in the fluctuation test, a greater mutagenic response 
for BP was obtained in the Ames test with aroclor-induced S9 than with 
uninduced S9. Therefore unlike 2AAF, the mutagenicity of BP is increased 
by using aroclor-induced S9 in both the Ames test and the fluctuation test.
' 3.2.3.4 The mutagenicity of 7,12-dimethylbenz(a) anthracene 
in the fluctuation test 
The mutagenicity of DMBA is shown in Table 3.13. There was only 
a weak mutagenic effect observed with uninduced S9, the response being 
much increased by the use of isolated hepatocytes. This is in contrast 
to the results obtained with 2AAF and BP where a reduction in mutagenicity 
was observed with hepatocytes as compared to uninduced S9.
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Figure 3.12 The mutagenicity of BP in TA98 in the fluctuation
test with different metabolic activation systans.
Aroclor-induced S9 •---• ; PB-induced S9 a a ;
SMC-induced S9 a a • uninduced S9 O o ;
isolated hepatocytes □---□
The concentration of BP is a logarithmic scale.
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Figure 3.13 The mutagenicity of BP in the Ames test in TA98
with aroclor-induced S9 •---• and with uninduced
S9 o O .
The concentration of BP is a logarithmic scale.
Table 3.13
The mutagenicity of 7, 12-dimethylbenz (a) anthracene in TA98 in 
the fluctuation test using uninduced S9 and uninduced hepatocytes
Concentration
DMBA
fig/hl
Number of wells positive±SD
Uninduced hepatocytes UninducedrS9 •'
control
series3
Treated
series
control ^  ^ B series
Treated,
series
100 . - • 12.3±3.1 ***29.5±3.5
50 10.0±3.3 ***36.3i7.8 12.313.1 *19.0,13.0
25 - - 12.3±3.1 **19.511.5
10 ' 7.0±3.1 ***29.3i7.4 12.3±3.1 11.5±1.5
1 7.013.1 9.3±3.4 - -  .
a - mean of three separate experiments, 48 wells per series, 
b - mean of six separate experiments.
Significant increase over the control .
*** p<0.001 . 
** p<0.01
* p<0.05
3.3 DISCUSSION
Practical aspects of the fluctuation test have been investigated. 
There are several types of vessels that can be used. Glass tubes are the 
most inert and indeed it was found that for chemicals that react with 
plastic (e.g. safrole) these are preferable. The use of disposable plastic 
trays is, however, a significant advantage in both decontamination and 
disposal,and importantly, in the utilisation of incubator space. A further 
advantage is the support of the viability of the hepatocytes in these 
trays, allowing metabolism over a longer period of time than has previously 
occurred.
It is apparent that almost any size of plastic tray may be used; 
provided the conditions of the test are adjusted accordingly. Gatehouse 
(1978) has developed a microtitre version of the fluctuation test. To 
over cane problems of background release of acid by the bacteria grown up 
overnight, in microtitre trays, Gatehouse (1978) altered the buffering 
capacity of the salts so that this excess acid release was neutralised. 
Claims that the fluctuation test performed in this manner may be more 
sensitive than by the method in glass tubes is most likely due to the 
use of a log-phase culture as opposed to a stationary phase culture in 
the microtitre method (Gatehouse, 1978; Gatehouse & Deflow, 1979). The 
use of larger trays in general was favoured in the present study, although 
for TA100 and hepatocytes, microtitre size trays had to be emplcyed. An 
advantage of the use of larger trays is that concurrent metabolite 
identification can take place, and also a greater surface area for 
hepatocyte attachment is available.
The use of hepatocytes required modification to the fluctuation test. 
The use of vinyl trays may not be the best choice since attached hepatocytes 
show abnormal morphology on this type of surface (Jones, 1978). However, 
the ideal type, i.e. polystyrene trays, in which attached hepatocytes show 
normal morphology, are not available in the appropriate size. Nevertheless, 
the hepatocytes do carry out metabolic activation when seeded in vinyl 
trays. The use of BME as a culture medium for hepatocytes appears to be 
a suitable choice as other studies have shown little difference in a 
variety of media (including BME) to support the hepatocytes in a viable 
condition (Williams et al., 1977; Jones et al., 1977). Leibovitz’s L-15 
medium has been shown to be a very suitable medium for hepatocytes (Jones, 
1978), however, this relies on the balance of amino acids to provide an 
adequate pH, and therefore histidine free medium cannot be used. Foetal 
calf serum is most caimonly used at a concentration of 10% for primary
maintenance culture of hepatocytes, however, as this contributes a large 
concentration of histidine to the system, the concentration had to be 
reduced in this study to 1%. The option of dialysing or emitting the serum 
was not followed as Williams et al. (1977) suggest that survival and 
viability of hepatocytes are much inproved by addition of as low a 
concentration as 1% and that serum is a physiological, rather than 
nutritional, requirement. The results in the present study indicate that 
with 1% serum, attachment of hepatocytes is not affected with high numbers 
of cells (1x10^ ) (Table 3.6).
Modifications of the conditions for TA100 and hepatocytes were 
essential to enable TA100 to be used. The bacteria were washed for use 
with hepatocytes to further reduce histidine that might ranain in the 
nutrient broth. The different buffering capacity of BME compared with 
EM salts may have contributed to the success in using such a small volume 
of media in fluctuation test.
Attempts to perform the test on a microtitre scale both with S9 
fraction and without metabolic activation were not always successful 
because the end point tended to be less precise, i.e. most of the wells 
were at various stages of colour change (or all yellcw). A further 
problem encountered when using the fluctuation test in microtitre plates 
was cross-contamination between wells as they were filled to near capacity 
so that exceptional care was required in handling them.
The problem of a high spontaneous mutation rate in TA100 is a 
general one and wide variations in background in the Ames test have been 
observed (McGregor, 1979). In the International Study (see Chapter 4), 
backgrounds of 20-200 were recorded by different laboratories. Although 
occasionally very lew background counts are recorded for TA100, the 
culture retains ampicillin resistance and its characteristic properties 
(McGregor, 1979). It has been suggested that this might be due to partial 
loss of the plasmid, or partial structural loss frcm the already incomplete 
R-46 derived plasmid, although this is unlikely as pKMlOl is stable.
Mbrtelmans and Stocker (1979) have constructed a plasmid pL551, a 
derivative of R6 , that confers tetracycline resistance, gives UV protecting 
properties and enhances UV-induced mutagenesis, but has no effect on 
S. typhimurium His G46 when in the co-presence of pKM115 (which is related 
to the pKMlOl plasmid). The spontaneous mutation rate is not so drastically 
increased as when pKM115: alone is present, being increased in the order of 
3x the background . wi+W , the plasmid, compared to lGx with pKM115 alone. 
Modification of TA100 in a similar manner using pL551 may be useful in
lowering the spontaneous nutation rate, while retaining other properties 
and thus may make TA100 a much more amenable strain.
The fluctuation test without metabolic activation, with metabolic 
activation by microsanes or S9 fraction and with isolated hepatocytes should 
be amenable to use with all the Ames tester strains (TA98, TA100, TA1538, 
TA1535, TA1537). Ey use of tryptophan instead of histidine the test should 
also be amenable to the use of E. ^ coli strains for mutagenicity.
2AAF is a potent mutagen and carcinogen. The identity of its 
hepato carcinogenic metabolite is not clear, although the sulphate ester 
has been implicated as one possible candidate (DeBaun et al., 1970 j 
Clayson & Gamer, 1973; Weisburger & Weisburger, 1973). On the assunption 
that a conjugated metabolite may be responsible for the carcinogenicity 
of 2AAF, the reduction in mutagenicity observed using hepatocytes (as 
catpared to uninduced S9 which is unable to synthesis sulphate 
significantly without added PAPS (see Fig. 3.5)) is surprising. This also 
suggests that the metabolite responsible for mutagenicity with S9 fraction 
may be different to the metabolite responsible for mutagenicity with 
hepatocytes and may not be a reflection of the actual ultimate carcinogenic 
metabolite.
The N-hydroxylated 2AAF metabolite is most likely responsible for 
the mutagenicity with microsomal fractions (e.g. S9) as this is mutagenic 
without further metabolic activation (Shaw, et al., 1976). However, when 
cell cytosol is present (postmicrosanal supernatant) it is activated to 
a more potent mutagen (Shaw et al. , ,1976; Felton et al., -1976). This may . 
be due to deacetylation or transacetylation by enzymes that exist in 
the cytosol of rat cells in greater quantity than in the microsomal 
fraction (Weisburger & Weisburger, 1973). It would be interesting to 
measure acetyl CoA levels in S9 to check this possibility.
The reduction in mutagenicity of 2AAF with hepatocytes might be 
attributed to several factors. Simply the conjugated metabolites formed 
may be mutagenic, but the N-hydroxy2AAF sulphate ester has been shown to 
be mutagenic to transforming DNA in Bacillus subtilis (Maher et al., 1968). 
The sulphate ester of N-OH2AAFhas been shown not to be mutagenic in 
bacteria. The addition of a PAPS generating system to postmicrosanal 
supernatant to metabolically activate N-QH2AF caused a significant reduction 
in mutagenicity , which could be prevented by the addition of P -nitrcphenol, 
a canpetitive substrate for sulphate conjugation (Mulder et al., 1977a).
The lack of mutagenicity may be due to the ionized state of the sulphate 
ester at pH 7.4, preventing transport into the bacteria. Also, the
sulphate ester is highly reactive, having a half life of 1 min in 
aqueous? solutions (Claysan et al., 1971) and may bind significantly to 
intracellular macranolecules of the hepatocytes. The binding of 2MF 
to DNA, ENA and proteins has been observed (Weisburger & Weisburger, 1973) 
and immediate binding to protein on formation has been observed in vitro 
(Mulder et al., 1977b).
As the sulphate ester is so reactive it is unlikely to be transported 
to other tissues. Clearly, an active metabolite is removed fran the 
hepatocyte, and therefore ether metabolites may be responsible for 
carcinogenicity in other tissues and the mutagenicity observed with 
hepatocytes, unless the tissue can metabolise 2AAF itself. The glucuronide 
metabolite is concentrated in the bladder and may be broken down to release 
the N-OH2AAF metabolites (Bock, 1977). The glucuronide conjugate of 
N-0H2AAF is not mutagenic but has been shown to bind slowly to intracellular 
macranolecules, although to a lesser extent than the sulphate or acetoxy 
conjugate and is also weakly carcinogenic (Claysan & Gamer, 1976). Another 
possible metabolite of 2AAF is N-acetoxyAF, which is also a mutagen (Shaw 
et al., 1976). The glucuronic acid conjugate of N-0H2AF is a potent 
mutagen for transforming DNA in Bacillus subtilis (Maher et al., 1968), 
but is less carcinogenic than the glucuronic acid conjugate of : N-0H2AAF 
The acetoxy ester of N-0H2AAFhas been shewn to be a potent mutagen with 
post-microscmal supernatant (Shaw et al., 1976) and this may also be due 
to deacetylation.
Clearly, the actual active metabolite of 2AAF is not certain, and 
a number of metabolites may actually be involved. The mutagenic effects 
with uninduced S9 fraction are likely to be due to different metabolites 
(most likely N-CH2MF orN-GH2AF since supernatant is present in S9) frcm 
those causing mutations with hepatocytes. Therefore, the use of S9 does 
not actually reflect the in vivo situation. Although the use of hepatocytes 
did not produce the expected increase in mutagenicity, they appear to have 
produced an as yet unidentified mutagenic metabolite. This metabolite may 
not be a specific hepatocarcinogen, but may be responsible for' effects 
in other tissues. Unfortunately, data is not available for the mutagenicity 
of 2AAF with PB-induced hepatocytes. Since in vivo PB induces 
glucuronyltransferases in the rat (Bock, 1977; Clayson & Gamer, 1976), the 
formation of glucuronide esters is favoured and results in a reduction in 
hepatocarcinogenicity. It might be predicted that in vitro, the 
mutagenicity with hepatocytes may be altered. Studies are required to help
identify the mutagenic metabolite of 2AAF.
'From Fig. 3.5, it appears that uninducedS9 is more efficient for 
metabolic activation of 2AAF than PB-induced S9, which in turn is better 
than aroclor-induced S9 in the fluctuation assay. Variation in the 
pattern of metabolism of 2AAF after various different induction procedures 
in different species (e.g. hamsters, rats, mice, rabbits and guinea pigs) 
is observed (Weisburger & Weisburger, 1973).
Pretreatment of mice with 3MC induces N-hydraxlation of 2AAF to a 
greater extent than ring-hydroxylation (the deactivating pathway), while 
the converse is true in PB-induced mouse liver. This results in greater 
mutagenicity with 3MC-induced S9 than with PB-induced S9 and uninduced S9 
(Felton et al., 1976; Thorgeirsson et al., 1977; Nebert et al., 1976). 
Induction in rats,, however, has a different effect on 2AAF metabolism.
PB induces the production of NrOH2AAFto a greater extent than ring-hydrcxy- . ; 
lation (Matsushima et al., 1972) which is also observed in vivo as shown 
by the increase in conjugates of NtOH2AAF in the urine of rats pretreated 
with PB. Ring-hydroxylated conjugates were increased to a lesser extent 
(Weisburger & Weisburger, 1973; Clayscn & Gamer, 1976). Pretreatment of 
rats by 3MC is thought to increase ring-hydroxylation of 2AAF to a greater 
extent than. N-hydroxylation (Weisburger & Weisburger, 1973; Lotlikar &
Zaleski, 1975). Aroclor induction of animals is thought to increase both 
3MC-type reactions and PB-type reactions and therefore is is difficult to 
predict the balance of metabolites of 2AAF that might be forrrbd by aroclor- 
induced S9 or microsanes.
The use of aroclor-induced rat S9 produced a nuch smaller response 
than PB-induced or uninduced S9, suggesting that the extent of deactivating 
enzyme activity is greater than that of the activating enzymes. The fact 
that the mutagenic response with PB-induced S9 is slightly less than with 
uninduced S9 suggests that, although induction of the activating 
(N-hydroxylating) enzymes may occur, a slightly greater induction of 
deactivating enzymes has occurred, vfoich is in contrast with the pattern 
of metabolites observed in vitro (Matsushima et al., 1972; Lotlikar &
Zaleski, 1975). However, this phenomenon may be concentration dependant 
in the system used, but concentrations above 1 jig/ml cannot be
investigated as all the wells are positive, and at high substrate 
concentrations a different pattern of induction may occur.
The finding that there is a concentration of S9 at which the 
mutagenicity of 2AAF is optimal (Fig, 3.6 and 3.9), and that the optimal 
S9 concentration varies for different induction procedures, suggests that
for each different S9 fraction, the optimal S9 concentration required 
should be determined. As observed in this study a lower concentration in 
mg/ml protein of aroclor-induced S9 is required than uninduced S9.
Therefore, care in interpreting data at a single S9 concentration is 
required. The existence of optimal S9 concentrations has been shown for 
2AAF (Nebert et al., 1976) and for BP (Rasmussen &. Wang, 1974). As stated 
earlier, the optimal S9 concentration in the fluctuation test can only be 
investigated at low concentrations of 2AAF (Ijjg/ml and. lower), but at 
these concentrations of 2AAF the optimal S9 concentration is not dose 
dependant (Table 3.11) . In the Ames test, the S9 optimum of uninduced 
S9 has not been demonstrated, but appears to require much higher 
concentrations of S9 than used in this study. The optimal concentration 
of aroclor-induced S9 occurs only above 8 }ig/ml 2AAF (in the soft agar 
overlay), the optimum being altered at lower concentrations. The require­
ment of less aroclor-induced S9 for metabolic activation of 2AAF than 
uninduced S9 has also been observed by D. Gatehouse (personnel ccmnunication)
The existence of optimal S9 concentrations may be due to a number 
of reasons. At low S9 concentrations, insufficient metabolism may occur 
to exert a significant effect. However, it is of interest as to why at 
high S9 concentrations the mutagenic activity appears to be reduced to 
near zero values, although cytotoxicity does not appear to be a significant 
contributor. The extra protein present may provide alternative binding 
sites for the mutagenic metabolites produced and thus cause an apparent 
reduction in mutagenicity. However, the enzyme to binding protein ratio 
remains constant on increasing the S9 concentration. The decrease in 
mutagenicity might be attributed to the further metabolism (producing 
inactive molecules) of the chemical on sites in the molecule other than 
those giving rise to active metabolites. This metabolism may occur when 
more enzyme is added.
The lipqphilicity of a drug,which affects its partition between 
microsomal mstibranes and the medium,may also play a part, in determining the 
optimal S9 concentration. Kuroki et al. (1979) found that there was an 
inverse relationship between the concentration of metabolising system 
necessary for optimal activity of a chemical and its lipcphilicity for a 
series .of nitrosamines. In another study, Batsch et al. (1976) found, 
that ih'-an Ame's test, for a series of nitrosamines, mutagenicity increased 
with increasing lipcphilicity, while the converse was true in a  I 
test. A feedback mechanism in which non-rnutagenic lipophilic metabolites
inhibit the formation of mutagenic metabolites may affect the S9 optima, 
particularly as Roberfroid (1980) has found that ring-hydroxylated 
metabolites of 2AAF inhibit the formation of the mutagenic N-0H2AAF.
However, addition of ring-hydroxylated metabolites of 2AAF in a fluctuation 
test and an Ames test did not affect the S9 optima for 2AAF mutagenicity 
as might be predicted on a model of feedback inhibition (M.H.L. Green, 
personal cannuni cation). It is likely that insufficient metabolite is 
formed to cause feedback inhibition. An alternative explanation has 
been suggested by Glatt and Oesch (1977), in that an association observed 
between mouse liver microsanes and bacteria indicates that at a large ratio 
of protein to bacteria, a portion of microscmes will not be in contact with 
bacteria. Competition for the mutagen between bound and unbound microsanes 
might occur resulting in a maximal effective protein concentration. However, 
an association between rat liver microscmes and bacteria could not be 
shown (Malaveille et al., 1979) and Forster et al. (1980) showed that 
varying the number of bacteria in a mutation assay did not affect the 
optimal S9 concentration.
The lcwer S9 optimum for both aroclor-induced and uninduced S9 with 
2AAF observed in the fluctuation test than in the Ames test (Figs. 3.13 and 
3.14) has also been observed’ by Forster et al. (1980) who investigated the 
phenomenon further. They were able to shew that the difference was not due 
to differing bacteria number, nor to the presence of the soft agar (although 
Malaveille et al. - (1977) s^howed that soft agar stabilises seme enzymes in 
the S9 fraction). They concluded that sane component was diffusing out of 
the soft agar overlay (a fluctuation test performed on hard agar underlay 
showed an optimal S9 concentration similar to an Ames test). This component 
was not NADP or G6P (the oof actors for monoxygenase activity) and not 
• the enzymes in the soluble portion of the S9 fraction. Forster et al. 
(1980) suggested that lipophilic non-mutagenic metabolites diffuse out of 
the agar overlay in the Ames test, preventing feedback inhibition, however 
as discussed above this is unlikely. It is also difficult to postulate 
a mechanism for the selective removal of metabolites, although 
ring-hydroxylated metabolites are more lipophilic than the parent compound.
If diffusion of sane component is the key to the differences in S9 
optima observed, a more plausible explanation may be that all metabolites 
diffuse out of the agar to sane extent, but at increased S9 concentrations 
sufficient metabolites are produced to exert an effect, although sane 
metabolites will still be lost. Since no diffusion occurs in a fluctuation 
test, less S9 is required to produce enough metabolites to exert a response.
The apparent difference in response of 2AAF between the Ames test 
and the fluctuation test with aroclor-induced and uninduced S9 appears to 
be due to the differing requirement of optimal S9 in each test. Much 
higher doses of 2AAF are required in an Ames test, although substrate 
diffusion may be responsible for this. At these doses, the design of 
the fluctuation test does not allow comparisons to be made. At present 
the reasons for S9 optima are uncertain as are the reasons for differences 
in optima between the Ames test and the fluctuation test. Clearly further 
investigations are required to find satisfactory explanations for the 
observations.
The mutagenicity of BP with aroclor-induced S9 and uninduced S9 
in both the fluctuation test and Ames test at a single S9 concentration 
was also investigated. Aroclor-induced S9 was very much more effective 
than uninduced S9 for BP mutagenicity (Figs. 3.12 and 3.13) in both assays 
in contrast to the results obtained with 2AAF. Variation of the S9 
concentration with BP was not carried out and therefore similar comparisons 
between- the Ames test and fluctuation test to those described above for 
2AAF cannot be made. The existence of an optimal S9 concentration for the 
mutagenicity of BP has been shewn. This optimum was thought to exist due 
to the trapping of mutagenic metabolites with nucleophiles or enzymic 
conjugation with glutathione at a greater rate than their formation as 
S9 concentration increases (Malaveille et al., 1979). It is not possible 
to corment on the S9 optima for BP with uninduced S9 as compared' to aroclor- 
induced S9. It is, as yet, unknown whether the results observed with 
2AAF is an effect specific for aromatic amines. From preliminary data, it 
appears that for polycyclic aromatic hydrocarbons this differing 
S9 requirement between the fluctuation test and Ames test does not occur.
As shown in Fig. 3.12, aroclor-induced S9 caused a greater mutagenic 
response for BP than the other metabolising systems tested. The use of 
3MC-induced microscmes produced a greater response than uninduced S9 or 
PB-induced S9. The induction by different chemicals produces different 
metabolites of BP (as observed for 2AAF). 3MC-lnduction (associated with 
cyt.P-448) has been shown to increase the production of predominantly 
carcinogenic metabolites (7, 8 , 9, 10 positions of BP), while PB-induction 
(associated with cyt.P-450) causes a greater production of nan-carcinogenic 
metabolites (2, 3, 4, 5 positions of BP). This results in greater
mutagenicity of BP with 3MC-induced S9 as compared to PB-induced S9 
(Nebert et al., 1976). 3MC-induced microsanes were used in this study, 
rather than 3MC-induced S9. However, a greater response was also obtained 
with aroclor-induced S9, than with 3M3-lnduced microsanes, showing that 
aroclor also induces the production of active metabolites. Aroclor is 
also expected to induce the production of non-active metabolites ( cf 
PB-induction) and therefore it might be expected to produce less BP 
mutagenicity than with 3MG-induced S9. As microsanal fraction and not 
S9 fraction was used* to investigate 3M3 induction, this may account for 
the greater response with aroclor-induced S9.
Interestingly, the use of isolated uninduced hepatocytes produced 
a mutagenic response for BP, in contrast to results obtained by Brouns 
et al., (1979) in which BP was not mutagenic with hepatocytes present.
After hepatocyte metabolism, BP was not mutagenic in V79 Chinese hamster 
cells (E. Huberman, personal caimunication). In comparison, BP mutagenicity 
with uninduced S9 was greater than hepatocytes at low BP concentrations 
(1 }ig/ml and 0 . ljig^nl), while little difference is observed at higher 
concentrations.
Jones et al. (1978) have shown that isolated hepatocytes early 
in an incubation period metabolise BP to ethylacetate-soluble metabolites 
(e.g. 4,5-dihydro-4,5-dihydraxyEP; 7,8-dihydro-7,8-dihydroxyBP; '
9, lOdihydro-9, lOdihydraxyBP and 3-OHBP and its sulphate ester) and 
appearing later in the incubation period to water-soluble metabolites, 
chiefly glucuronides. The water-soluble metabolites were readily released 
from the cells, while the ethylacetate-soluble metabolites were found 
distributed variously intra- and extracellularly, the 
9, lO-dihydro-9, 10-dihydroxyEP being found mainly extracellularly. In 
whole cells, glucuronidation of BP metabolites appears to be the main 
conjugation route (Schmetz et al., 1978>. The results in this study 
indicate that a mutagenic metabolite is released by hepatocytes. The lack 
of mutagenicity observed by Brouns et al. (1979) may be due to the fact 
that the metabolising period in that study was 1 hr. It is possible 
that insufficient metabolites are released in this time period to exert a 
mutagenic effect, as the metabolites would be removed by conjugation very 
quickly.
It is not possible with this limited data to identify the metabolite 
causing the mutagenicity observed with hepatocytes. The-water-soluble 
metabolites may possess seme mutagenicity. Other possible metabolites are 
the phenols as sane (e.g. 3-OHBP) have been shown to be released into the
extracellular medium. As shewn in Chapter 5, 3-OHBP is mutagenic without 
further metabolic activation and, therefore, this may be responsible for 
the mutagenicity observed with hepatocytes.
It is likely that different metabolites are responsible for the 
mutagenicity with S9 fraction and the hepatocytes. This is particularly 
likely as it has been shown that there is a difference between the major 
DNA adduct formed with microscmes, hepatocytes and in vivo (Ashurst &.
Cohen, 1980). This has been discussed in Chapter 1, to illustrate the 
caution required in extrapolating data obtained with microscmes to in vivo.. 
One study has investigated the DNA adduct formed in 8 . typhimurium after 
S9 activation of BP (Santella et al., 1979). It was found to be different 
when PB-induced S9 was used compared with 3MC-induced S9. The adduct 
formed with 3fC-induced S9 was derived frcm the 7,8-diol-9,10-epoxide BP 
as observed in hepatocytes and in vivo (Ashurst & Cohen, 1980), similar 
results were obtained with aroclor-induced S9. Hcwever, the adducts formed 
with PB-induced S9 was different (they were predominantly of EP-4,5-oxide-type 
DNA adducts). Since different adducts in exogenous DNA are formed by 
subcellular fractions compared to adducts in whole cells or in vivo (Ashurst 
& Cohen, 1980) these results were surprising. Hcwever, the resolution of 
the HPI£ was not good.
The results obtained with another PAH /■ DMBA ,are interesting as this 
compound is clearly more mutagenic with hepat ©cytes than with S9 fraction.
A similar result was obtained with another methylated PAH> /
9,10-dimethylanthracene (DMA) (Chapter 4). The analogous, non-methylated 
metabolite to DMA, anthracene is not mutagenic (Chapter 4). The analogous 
non-methylated chenical to DMBA, benz (a) anthracene, is hcwever both 
mutagenic (with microsanes) and carcinogenic. It is a less potent carcinogen 
than DMBA (Wood et al., 1977). The mutagenicity of benz (a) anthracene with 
hepatocytes has not been tested. The results obtained with DMA, DMBA and 
anthracene strongly suggest the involvement of the- methyl groups in the 
metabolism with hepatocytes.
As shewn in Section 3.1.4, metabolites frcm the bay-region of both 
benz (a) anthracene and DMBA have been implicated in the production of active 
metabolites, and a diol-epaxide has been shown to be responsible for the 
binding of DMBA to cells in culture (Dipple & Nebzydoski, 1978; Huberman 
& Slaga, 1979). DMBA-trans-3,4-diol-l,2-epoxide has been suggested as the 
major metabolite in golden hamster embryo cells (Huberman et al., 1979). 
Metabolism has also been shewn to proceed at the methyl groups, with
7-hydro5ymethyl-12-methylbenz (a) anthracene also being found as a 
metabolite in golden hamster embryo cells (Huberman et al., 1979).
Binding to ENA at the 7- position has been observed and DNA adducts
formed frcm the further metabolism of 7-hydroxymethyl-12-methylbenz (a) anthracene
have been observed (Ivanovic et al., 1978). There is therefore more than
one possible route of metabolic activation of DMBA (via its parent structure
benz (a) anthracene through dio 1-epoxides, or via the methyl groups).
It is unclear as to' why the methyl groups are more important when 
hepatocytes are used. In the whole cell it is expected that the majority 
of metabolites are conjugated and harmlessly removed. The possibility that 
the mutagenicity with hepatocytes results frcm a potent mutagenic conjugate
ft
is unlikely, but cannot be ignored. The "recycling", i.e. further 
metabolism of PAH metabolites occurs extensively in microscmal fractions 
(DePierre and Emster, 1978). However, in hepatocytes (whole cells) 
metabolites will be conjugated and not further metabolised, although 
quinone recycling is possible in whole cells. This conjugation may result 
in the production of a lcwer number of different metabolites. The removal 
of metabolites by conjugation may allow more methyl hydroxy lation to take 
place and the production of active metabolites not formed with microscme 
fractions. It is interesting to note that the epoxide hydrase inhibior 
1,2-epoxy- 3,3,3-trichlorcpropane (TCPO) increases the binding of DMBA 
metabolites to ENA with microscmes present, while it decreases the binding, 
of DMBA metabolites in mouse skin and cell cultures (Dipple & Nebzydoski,
1978; Bigger et al., 1978). This suggests that further activation by 
epoxide hydratase is required in mouse skin and cell'.cultures to cause 
binding r (N.B. epoxide hydratase also causes deactivation of many metabolites)
As discussed in Chapter 1, and like BP, a different major DNA-adduct 
is observed with microscmes than with cell cultures. The DNA adduct with 
microscmes arises frcm DMBA-trans-5,6-diol and in cells frcm metabolites of a 
diol-epoxide of the 1,2,3,4-ring. Therefore, the mutagenicity with 
microscmes most likely results frcm a different metabolite frcm that with 
hepatocytes. It is not known which metabolite is responsible for the 
mutagenicity with hepatocytes as metabolism by a number of different routes 
occurs.
In this chapter, an inproved fluctuation test method has been 
developed and used in preliminary studies to investigate the mutagenicity
of 2AAF, BP and DMBA with a number of metabolising systems, most importantly 
with hepatocytes. Differences in the mutagenicity with hepatocytes as 
caipared to S9 fraction most obvious with 2AAF and DMBA indicated that 
different metabolites (not necessarily ultimate carcinogens) may be 
responsible for mutagenicity with S9 as carpared to hepatocytes. However, 
in the case of 2AAF, the ultimate carcinogenic metabolites may also not 
be responsible for mutagenicity observed .with S9 or with hepatocytes.
These observations demonstrate the cate required in relating an in vitro 
systen to an in vivo situation in that different metabolic profiles may 
be observed in vitro in microsonal preparations.
CHAPTER 4 - VALIDATION OF THE FLUCTUATION TEST
4.1 INTRODUCTION
Many short-term screening tests for carcinogens have beccme 
available in the last few years and selection of the most suitable tests 
has becane of major importance. Validation studies to assess the ability 
of tests to distinguish between rodent carcinogens and non-carcinogens have 
been carried out (McCann et al., 1975; Purchase et al., 1978). The problem 
remains, hcwever, that relatively few available tests have been assessed in 
this manner. It is also important to assess whether widely used tests such 
as the Ames test produces similar results in different laboratories. For 
these reasons a multi-laboratory screening programme was set up to test blind 
a number of coded pairs of carcinogens and structurally related non-carcinogens 
(Annoucement,1978). It was initially set up by the Health and Safety 
Executive, the Medical Research Council and I.C.I.. The collaboration was 
later extended to the National Institute of Environmental Health Sciences, 
U.S.A. As shewn in Table 4.1, a wide variety of tests were involved. Among 
the advantages of the programme was that it provided a unique opportunity 
to compare results obtained in the Ames test frcm a number of different 
laboratories.
The chemicals were issued by I.e.I. as pari: of a single batch each 
having a purity of - 99% with the exception of auramine (90-92%). Details 
of each chemical may be found in Ashby and Paten (1980) in de Serres and 
Ashby (1980). They are listed in Table 4.2 with their code numbers and 
carcinogenicity assessment (discussed belcw). The chemicals were chosen 
frcm as many different chemical classes as possible, including aromatic 
amines, polycyclic hydrocarbons and alkylating agents. Chemicals were also 
included that were known to be difficult to detect as mutagenic in 
bacteria assays (e.g. urethane and safrole), so that the ability of non- 
bacterial tests to detect them could be assessed. Chemicals that may 
produce their carcinogenic effect by a nan-genetic mechanism, e.g. DES. and 
ethylenethiourea, were also chosen.
An independant assessment of the carcinogenicity data frcm long-term 
studies was carried out by an expert coimittee (Purchase et al., in de Serres 
and Ashby, 1980). Their initial assessment of the carcinogenicity is shown
in Table 4.2 and chemicals were classed as follows:(
Carcinogens. Where there was sufficient evidence of an increase in 
tumour formation, a chemical was classified as a carcinogen.
Although DMA was considered a carcinogen, the data available is
Assays used in the International programme for evaluation
of short-term screening tests for carcinogens
Prokaryotic mutation:
Reverse mutation - S. typhirnurium
E.coli
(Ames test 
Fluctuation test)
Forward mutation - S. typhirnur ium
Prokaryotic repair:
B.subtilis (rec assay)
E.coli (rec assay and Pol assay)
Dower eukaryotic systems:
Point mutation and other genetic end-points
Mammalian in vitro systems:
Point mutation: L5187Y
V79
CHO
UDS
Transformation
SCE
Cytogenetics 
Mammalian in vivo systems: 
Drosophila 
SCE
Sperm morphpology 
Micronucleus
HeLa
Fibroblasts
BHK
Lymphocytes
CHO
Other systems
Phage induction 
Tradescantia
Degranulation of the endoplasmic reticulum 
Nuclear enlargement (HeLa)
Table 4.2
Classification of chemicals as carcinogens or non-carcinogens.
(Classification taken frcm Purchase et al.in de Serres and 
Ashby, 1980).
Un­ Carcin- Non-
Code Chemical class'. ogen Carcinogen
fied I II III
8 4-Nitroquinoline-N-oxide (4NQ0) • X
15 3-Mfethyl-4-nitroquinoline-N-oxide (3M4NQ) (X) X
11 Benzidine X
2 3,31,5,5'-Tetramethylbenzidine X
1 4-Dimethylaminoazobenzene (DAB) X
10 4-Dimethylaminobenzene-4-sulphonic 
acid Na salt (Methyl orange) X
13 Benzo (a) pyrene (BP) X
5 Pyrene X (X):
29 $-Propiolactone X
21 y-ButyrOlactone (X) X
39 9,10-Dimethylanthracene* (DMA) X*
18 Anthracene X (X)
6 Chloroform X
30 1,1,1-Trichloroethane X
12 2-Acetylaminofluorene (2AAF) X
3 4-Acetylaminofluorene (4AAF) X (X) '
32 Dimethylcarbamoyl chloride (DMCC) X
24 Dimethylformamide (DMF) X
9 2-Naphthylamine (2NA) X
4 1-Naphthylamine (1NA) X
27 N-Nitroscmorpholine (NM) X
17 Diphenylnitrosamine (DPN) (X) X
19 Dinitrosopentamethylene tetramine (DNPMT) (X) X
31 Urethane x  •
28 Isopropyl N (3-chlorophenyl)carbamate X (X)
37 Methylazoxymethanol acetate (MAM-acetate) X
33 Azoxybenzene (X) X
25 DL-Ethionine X
22 Methionine X (X)
14 Hydrazine sulphate X
16 Hexamethylphosphoramide (HMPA) X
20 Ethylenethiourea X
7 Diethylstilboestrol (DES) X •
23 Safrole X
34 Cyclophosphamide (CP) X
26 Epichlorhydrin X
35 3-Aminotriazole (AT) X
36 4,4' -jyfethylenebis (2-chloroaniline) (MOCA) X
41 O-Toluidine hydrochloride X
42 Auramine (Technical grade) X
38 Sugar (Sucrose) (X) X
40 Ascorbic acid (vit.C) X (X)
*Evidence of carcinogenicity not good.
(X) reclassification on strength of data obtained after initial classification 
or on data obtained in the International study.
questionable.
Non-carcinogens. As the quality of the evidence was not good,
non-carcinogens were sub-classified as follows:
Class 1: in which there was adequate evidence in an N.C.I. 
standard bioassay.
Class 2: in which the evidence was less convincing through 
lack of numbers of animals, inadequate dosing or testing in 
a single species.
Class 3: in which there was poor evidence, when experiments were 
not of acceptable standards or results were unconvincing. 
Unclassified: For seme chemicals there was insufficient evidence 
to draw any conclusions as to their carcinogenicity, and they 
were generally considered, for the purposes of this study, as 
non-carcinogens (e.g. ascorbic acid, methionine, pyrene).
This study was used to validate the fluctuation test as a short-term 
screening test. It was used with S. typhirnur ium, TA98 and TA100 only, but 
under three different conditions
(a) without metabolic activation?
(b) with metabolic activation by uninduced S9 fraction? and
(c) with uninduced freshly-isolated hepatocytes.
Therefore the fluctuation test could be compared to other screening tests, 
and also the use of isolated hepatocytes could be assessed over a large no 
of chemicals.
The chemicals were all tested under code number using the conditions 
already mentioned. Time restrictions prevented ccxrplete testing of seme 
chemicals. Sore limited further testing with selected chemicals was 
carried out after the completion date using aroclor-induced S9 and this 
data is also included.
4.2 RESULTS
Seme toxicity tests were carried out as described in Chapter 2. 
Chemicals not tested in an initial toxicity study were tested directly in 
the fluctuation test and toxicity identified as a reduction in the number 
of wells as compared to the control series.
The data is given in Appendix 2 under the code numbers of the 
chemicals. The overall conclusion as to the mutagenicity of each chemical 
is given in Table 4.3, while the minimum detected doses of each chemical 
are given in Table 4.4. It must be stressed that sons chemicals were not 
tested completely and the minimum detected dose in seme cases is the lowest
Table 4.3
Overall assessment of each compound tested with either uninduced 
S9 fraction, uninduced hepatocytes or without metabolic activation. 
Conclusion with aroclor-induced S9 is given in parenthesis.
Code Chemical Conclusion 
f+r - or ?)
8 4-Nitroquinoline-N-oxide (4NQ0) +
15 3-Methyl-4 -nitroquinoline-N-oxide (3M4NQ) +
11 Benzidine +
2 3,3', 5,51 -Tetramethylbenzidine
1 4-Dinethylaminoazobenzene (DAB) -(+)
10 4-Dimethy laminobenzene-4-sulphonic
acid, Na salt (Methyl orange) +
13 Benzo (a) pyrene (BP) +
5 Pyrene -
29 3-Propiolactone +
21 y-ButyrOlactone —
39 9,10-Dimethylanthracene (DMA) +
18 Anthracene —
6 Chloroform 7
30 1,1,1-Trichloroethane —
12 2-Acetylaminofluorene (2AAF) +
3 4-Acetylaminofluorene (4AAF) +
32 Dime thy lcarbamoyl chloride (DMCC) +
24 Dimethylformamide (DMF) -
9 2-Naphthylamine (2NA) +
4 1-Naphthylamine (1NA) +
27 N-Nitroscmorpholine (nm) +
17 Diphenylnitrosamine (DPN) -
19 Dinitrosopentamethylene tetramine (DNPMT) 7
31 Urethane -(+)
28 Isopropyl N(3-chlorophenyl) carbamate
37 Methylazoxymethanol acetate (MAM-acetate) n.t.
33 Azoxybenzene -
25 DL-Ethionine -
22 Methionine . -
14 Hydrazine sulphate +
16 Hexamethylphosphoramide (HMPA) n.t.
20 Ethylenethiourea -
7 Diethylstilboestrol (DES) -
23 Safrole +
34 Cyclophosphamide (CP) +
26 Epichlorhydrin +
35 3-Amino triazole (AT) 7
36 4,4* -Methylenebis (2-chloroaniline) (MOCA) +
41 O-Toluidine hydrochloride 7
42 Auramine (Technical grade) 7
38 Sugar (Sucrose) —
40 Ascorbic acid (vit.C) +
Table 4.4
Summary of minimum detected doses for each compound pig/ml)
Code
No.
-S9 +S9
mi oo
tHepatocytes -S9 +S9 -fHepatocytes
8 0.00001 0.1 1.0 0.01 0.01 1.0
15 0.01 1.0 1.0 1.0 1.0 10.0
11 - 10.0 - - 1.0 -
2 — — — — — —
1 - -(100)a - - -(10) - •
10 - 500.0 - - 100.0 500.0
13 100.0 500.0 1.0 - 10.0 10.0
5 - — ■ — - — —
29 1.0 10.0 10.0 100.0 100.0 1.0
21 — - — — — —
39 100.0 100.0 - 100.0 100.0 1.0
. 18 — — — — — —
6 2 0 0.0? - - - - -
30 - - — -• - —
12 ■ - 1.0 - - 1.0 0.5
3 - 1.0 50.0 - 10.0 10.0
32 100.0 - - - - ’ —
24 - ? - — 7
9 - 1.0 - - 1.0 -
4 - 1.0 - - 1.0
27 - 500.0(100) 10.0 - - -
17 - - - - - 1 0.0?
19 - 7 - - - —
31
37 Not tested
-(1000) — — — —  •
33 - - - - — —
25 - - - - - -
22 - - — - — —
14
16 Not tested
10.0 100.0 — — —
20 — - - - - -
7 — . — — — — —
23 - • - - — ' — —
34 10.0 10.0 10.0 - - -
26 1.0 10.0 50.0 - - -
35 500.0? - - - -  •
36 - 10.0 - - - -
41 - 1 0 0.0? - ° - -
42 - - - - 50.0? 50.0
38 — — — — — —
40 - — — - - 500.0
+S9 -Minimum detected doses using uninduced S9.
figures in parenthesis indicate result using aroclor-induced S9. 
? questionable data..
dose tested and not necessarily the lowest detectable dose.
Fourteen chemicals were found to be completely negative under all 
the conditions tested during the trial. DAB,. 3,3’,5,5! -tetranethylbenzidine 
pyrene, DES, anthracene, ethylenethiourea, y-butyrolacfone, methionine, 
safrole, D,L-ethionine, O-isqprcpyl-N- (3-chlorcphenyl). carbamate, urethane 
and azoxybenzene. On further testing, urethane and DAB were mutagenic using 
aroclor-induced S9 (Table 4.5). The following chemicals were significantly 
mutagenic without metabolic activation: 4NQ0, 3M4NQO, Epichlorhydrin,
3-prcpiolactone,CP,DIV3Aand DMCC . INA, 2NA, MOCA and O-toluidine were mutagenic 
only with S9 fraction present. Several chemicals were mutagenic with both 
S9 fraction and hepatocytes: benzid ine methyl orange, BP, 2AAF, 4AAF,
NM, hydrazine sulphate and auramine. Only ascorbic acid was significantly 
mutagenic with hepatocytes although a response was obtained with DMF.
Generally the mutagenicity with S9 fraction was greater than with 
hepatocytes, however a much greater response with hepatocytes was found for 
NM and DMA.
In catparing mutagenicity in TA98 with TA100, ascorbic acid and 
auramine were the only chemicals mutagenic in TA98 alone. Hydrazine 
sulphate, MOCA, 3AT and O-toluidine were mutagenic in TA100 only, while the 
remaining mutagenic chemicals showed seme response in both strains.
Seme chemicals gave questionable responses. The data for these is 
shown in Table 4.6. O-toluidine and 3AT were retested after the completion 
date to clarify odd data, but have been included in. this section as examples 
where further testing is necessary for a final assessment of data. Seme 
statistical ideas for dealing with questionable results in which one 
experiment exhibits mutagenicity, but others do not, are discussed in 
Appendix 1.
Diphenylnitrosamine exhibited a weak response at 100 jig/ml after 
activation by hepatocytes and TA98, but only 3 out of 5 experiments showed 
a slight increase over the control. A significance of p '<0.025 was 
calculated and there was no typical dose response. As this was not observed 
in TA100 it is unlikely to be due to an artefact if toxicity of the coipound 
to the hepatocytes led to a release of histidine as discussed for DMF in 
Section 4.3.
Dlnitrosopentamethylene tetramine showed toxic, mutagenic and negative 
responses at the same dose with TA100 for a series of experiments. Non-toxic 
doses were consistently negative. It is impossible to conclude as to its 
mutagenicity without further investigations.
O-Toluidine with S9 and TA100 exhibited a significant result after
XCUJJLC ‘i.J.
Mutagenicity of DAB, urethane and NM in the fluctuation 
test using aroclor-induced S9
Concentration
|ig/ml
Number wells positive 
(48 wells per series)
Significance
Experiment no.
1 2 3
DAB - TA98
0 12 — - —
10 29 - - n.s.
100 43 - - p<0.001
200 44 . — — p<0.001
DAB - TA100
0 30 — ■ —
10 32 - - n.s.
100 35 - - n.s.
200 39 — .. — n.s.
Urethane - TA98
0 12 10 - •
100 9 - - n.s.
200 11 10 - n.s.
500 7 8 - n.s.
1000 - 8 - n.s.
Urethane - TA100
0 30 35 24
100 34 - -  • n.s.
200 34 39 32 n.s.
500 30 38 19 n.s.
1000 — 42 32 p<0.025
NM-TA100
0 35 30 24
100 39 30 35 p<0.025
200 47 37 45 p<0.001
500 47 48 47 p O .001
Results of chemicals for which questionable data was
obtained in the fluctuation test
Concen- Number of wells positivea x2 P Retest x2 P 
tration 
jig/ml
Diphenylnitrosamine - TA98 and hepatocytes
0 9 12 7 9 12 _
0 - 8 5 13 —
1 5 12 8 -■ -  . 0.07 n.s.
10 17 5 10 10 - 1.37 n.s. •
100 19 10 14 10 14 5.67 < 0.025
500 - - • - 5 - 0.03 n.s.
Dinitrosopentamethylene tetramine - TA100 and S9
0 23 29 20 29 26 _
0 • 34 37 28 32 24 -
1 33 - - 26 37 0.09- n.s.
10 37 - - 33 30 0.78 n.s.
50 - - 35 - 1 8.63 toxic
100 44 40 0 0 . - 18.43 toxic
200 - 37 0 - - 10.42 toxic
O-Toluidine - TA100 and S9
0 28 26 31 — — — 27 —
0 24 21 33 — — - - -
10 - - 29 — — 0.42 n.s. - n.s..
100 - 30 42 - . 7.79 < 0.005 35 10.64 < 0.005
■200 31 30 - - - 3.48 n.s. 33 5.75 < 0.025
500 29 20 31 - — 0.03 n.s. - — n.s.
Auramine - TA98 and S9
0 26 25 19 - ' - - .
0 - - 7 17 - - -
10 22 34 i 19 - 1.38 n.s.
20 27 34 - - - 1.93 n.s.
50 21 38 23 - - 4.22 <0.025
100 - - 2 - - 17.46 toxic
3-Aminotriazole - TA100 and S9
0 28 30 - - - - 27 -
0 24 26 - - - - - -
10 - 35 - - - 2.62 n.s. - -
100 - 24 - - - 0.74 n.s. -• -
200 32 - - - - 1.81 n.s. 27 0.97 n.s.
500 30 36 - - 3.92 <0.025 30 3.84 <0.025
Chloroform - TA100 without metabolic activation
0 25 2 18 8 — —
0 - 5 13 14 - -
10 - - - 14 - 0.51 n.s.
100 19 4 26 14 - 3.24 n.s.
200 29 5 23 - - 7.14 <0.005
500 26 8 21 — — 5.75 <0.025
Pyrene - TA100 and Hepatocytes
0 13 11 18 - ' - -
0 - 13 10 - - -
. 10 18 8 - - 0.03 n.s.
50 - - 16 - - 0.17 n.s.
100 31 6 22 . - — 7.13 <0.005
a - 48 wells per series. Each column is a separate experiment, 
b - retest after completion of International study.
two experiments at lOOjig/frtl, and a x2of 3.48 after two experiments at 
200 jig/ml, indicating that this is a mutagenic chemical. A further 
experiment confirmed this result.
Although clear positive results were obtained with TA98 and 
hepatocytes, auramine showed a weak mutagenic response in two experiments 
with TA98 and S9 at the highest non-toxic dose tested. One experiment did 
not exhibit mutagenicity. This was considered to be a weak effect and 
its mutagenicity is questionable, particularly as its colour and acidity 
may affect the scoring of a fluctuation test (see Section 4.3).
3AT was not adequately tested before the completion date, however at 
500 jig/ml with S9 in TA100, a weak response was obtained which was reproduced 
in a third experiment. Two tests with aroclor-induced S9 failed to produce 
a mutagenic response (data not shewn).
Chloroform exhibited inconsistent results with TA100 without 
metabolic activation, positive results being observed in two experiments 
and negative results in one. Further investigations are therefore required 
to clarify this response. This point is further discussed in Section 
4.3. •
Pyrene showed positive results in two separate experiments in TA100 
with hepatocytes. As there is no response in TA98 this is unlikely to 
be an artefact due to toxicity of pyrene. Further investigations into this 
are therefore required.
4.3 DISCUSSION
The large number of chemicals tested provides an opportunity to 
assess the fluctuation test as a short-term screening test for chemical 
carcinogens. It also allows a further assessment as to the use of hepatocytes 
as an alternative to S9 fraction for metabolic activation.
References for carcinogenicity data of these chemicals are not 
quoted but may be found in Purchase et al., in de Serres & Ashby (1980).
It is not intended to discuss at length the data obtained by other participants 
in the International study. References to this data may be found in the 
publication of the study (de Serres & Ashby, 1980).
8 . 4-nitroquinoline-N-oxide (4NQ0)
15. 3-methyl-4-nitroquinoline-N-oxide (3M4NQO)
NO
•CH-
3M4NQO
o
Both 4NQ0 and 3M4ISQO were direct acting mutagens in TA98 and TA100.
The results of 4NQ0 with TA100 show typical mutagenicity effects, with 
toxicity at high doses and a dose response of mutagenicity.
Both chemicals were toxic to TA98 and TA100. 4NQ0 was a more potent 
mutagen than 3M4NQO. The effect of S9 and hepatocytes was minimal, 
although a slight reduction in mutagenicity was observed with TA100.
4NQ0 is a carcinogen in rodents producing tumours at the site of 
application (e.g. skin and mouth) and also at seme distant tissue targets 
(e.g. lung). At similar concentrations 3M4NQO did not produce tumours, 
although the evidence is inadequate.
Since nitroreductase activity can convert both these chemicals 
to electrqphiles and the test bacteria contain nitroreductase enzymes, 
positive results were not unexpected. However, 3M4NQO has previously been 
found to be non-mutagenic in bacteria (Purchase et al., 1978), despite 
the presence of bacterial reductases (Tada & Tada, 1975). The less potent 
mutagenicity of 3M4NQO may be due to the presence of the 3-methyl group 
which is thought to sterically hinder the 4-nitro group interactions with 
reductases (Ashby in Purchase et al., 1978; Aroos & Argos, 1974) 1 Methylation 
at the 2-position does not sterically hinder the nitro group and 2M4NQO is 
a carcinogen (Arcos & Argus, 1974).
The active metabolite of 4NQ0 after metabolic activation is thought 
to be the N-hydroxylated 4NQ0 as this is a potent mutagen and carcinogen 
(Clayson & Gamer, 1976). However, 41SQ0 itself reacts with sulfhydryl 
ccmpounds ncn-enzymically under physiological conditions (Arcos & Argus,
1974) and can also spontaneously react with DNA in buffer (Nagao~ & Sugimura,
1976). The effect of adding S9 and hepatocytes would therefore be to provide 
an additional source of metabolism to the bacteria themselves and also more 
binding sites for active metabolites.. The observed response of minimal 
alteration or slight reduction in mutagenicity was therefore likely, . 
particularly as active metabolites formed in the S9 or hepatocytes would 
be likely to bind to the protein present. Again the 3-methyl group could 
sterically hinder metabolism of 4NQ0 by S9 fractions and hence 3M4NQO would 
be less biologically active.
Paul et al., (1971) showed that the 3-methyl group only partially 
hindered the intercalation of 4NQ0 with DNA, reducing the stability of the 
DNA complex. This suggests that 3M4NQO does have seme biological acticity.
The lack of carcinogenicity may be explained by the differences in potency 
to 4NQ0. In the International study it was generally found to be much 
less potent than 4NQ0 in laboratories using bacterial mutation assays.
The evidence for its non-carcinogenicity is not good and it may well prove 
to be a carcinogen albeit extremely weak.
11. Benzidine
3,3':,5,S -Tetramethy Ibenzidine was not mutagenic under any condition 
tested, while benzidine was mutagenic with S9 in both TA98 and TA100. The 
presence of hepatocytes abolished the mutagenicity with TA100, but did not 
affect the response with TA98. Benzidine is a bladder carcinogen in dogs 
and also causes liver tumours in mouse, rat and hamster, while 
tetramethy Ibenzidine showed no tumour response at a dose in excess of those 
carcinogenic with benzidine, although the data was less than satisfactory.
The mutagenicity therefore accurately reflected the carcinogenicity of 
these chemicals.
This pair of oorpounds is a good example of the manipulations that 
can be made by sterically hindering a potential reactive site on a molecule. 
In carman with other aranatic amines, N-hydroxylation of benzidine is thought 
to be the first step of metabolism and the mutagenicity with S9 fraction 
may be the result of the production of N-hydroxybenzidine (Arcos & Argus, 
1974; Gamer et al., 1975). A number of metabolites, including
3-hydroxybenzidine (in rat), 3,3!-dihydroxybenzidine '(in man), and their 
conjugates have been observed,(Haley, 1975) and benzidine is excreted as 
N- or O-conjugates with sulphuric or glucuronic acid. By analogy-with 
other aranatic amines, conjugates may be involved with carcinogenicity.
3,3' -dihydroxybenzidine produces hepatcma in rats and mide^  and bladder 
car cinema in rats (Haley, 1975). With hepatocytes there is a response 
with TA98 and not with TA100. This suggests that different metabolites 
may be responsible for mutagenicity, one being produced by hepatocytes 
that is mutagenic in TA98. Seme clues as to the nature of these metabolites 
can be drawn in this limited study.
likely to sterically hinder the N-hydroxylation step and any subsequent 
metabolism thus rendering it inactive. This particularly likely as the 
sterically less hindered 3,3',5,5'-tetrafluorobenzidine is a strong mutagen.
2. 3,31 .>5,51 -Tetramethylbenz idine
Benzidine
c h3 c h3
3,3 ',5,51-TetramethyIbenzidine
The presence of the methyl groups in tetramethy Ibenzidine is
Tetramethy Ibenzidine has been shown to be non-active in a number of 
screening tests (Purchase et al., 1978).
1. 4-Dimethylaminoazobenzene (butter yellow, DAB)
10. 4-Dimethylaminoazobenzene-4-sulphanic acid Na Salt
(methyl orange)
DAB was negative in the fluctuation test with uninduced S9, however 
on a retest in a single experiment using aroclor-induoed S9 in TA98, it 
was clearly positive (Table 4.5). Methyl orange, on the other hand, was 
considerably mutagenic with S9 in TA98 and only weakly mutagenic with 
hepatocytes. It was a less potent mutagen in TA100.
Although the data is not adequate, methyl orange is likely to be 
a non-carcinogen. DAB is more complicated and is a liver carcinogen only 
when the riboflavin intake is low such that the riboflavin dependant 
azo-reductase enzymes are low (Arcos & Argus, 1974). The balance of 
metabolising enzymes is therefore critical for the biological activity 
of DAB.
To illustrate the critical balance of enzymes, manipulations of 
the metabolism in vitro may be made. The intact molecule is required for 
metabolic activation (Ashby et al., 1978b).
CH CH
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Figure 4.1 ]ykjor metabolic pathways of DAB
As can be seen frcm Fig. 4.1., the presence of azoreductase enzymes 
result in deactivation of the molecule and hence a reduction in carcino­
genicity and mutagenicity. The ultimate carcinogenic metabolite is 
unclear, although it is likely to be an ester ( cf 2AAF) (Lin et al., 1975). 
Intracellular transport of an active ester of DAB has been suggested to 
occur via a binding protein (Marigi & Sorof, 1977). Frcm this metabolic 
profile it is apparent that the balance of enzymes may alter the in vitro 
responses observed, although DAB has been previously shown to be mutagenic 
(Purchase et al., 1978; Ashby et al., 1978b; Ashby & Styles, 1978;.). Ashby 
and Styles (1978) have shown it to not be mutagenic with uninduced S9.
By selectively carpeting for detoxification pathways of DAB, it can be 
made a more potent mutagen. For instance, the addition of norharman 
(Fig. 4.2) which competes for ring hydroxylating enzymes will increase the 
mutagenicity of DAB (Nagao et al., 1977b;Ashby & Styles, 1978).
Azobenzene (Fig. 4.2), a non-carcinogen and non-active in a BHK cell 
transformation assay, will compete for azo-reduction (and ring hydroxylation) 
when co-incubated with DAB and thus enhance the mutagenicity of DAB (Ashby & 
Styles, 1978). The breaking of an azo bond as a deactivation step is not 
a general rule as the action of azo-reductase enzymes on the dye, 
chrysoidin enhances its mutagenic potency (Gamer & Nutman, 1977).
and ring hydroxy lation may not be induced sufficiently to completely 
deactivate DAB, hence an enhanced mutagenicity is observed.
Methyl orange should possibly fall under the same constraints as 
DAB, however it was consistently positive in the fluctuation test, and 
a cell transformation assay (Ashby et al., 1978b), although negative in an 
Ames test (McCann et al., 1975). The non-carcinogenicity of this compound 
may be explained by the presence of the polar sulphonic group, thus reducing 
its lipid solubility and making its distribution in vivo limited (Ashby in 
Purchase et al., 1978). It is important to note that methyl orange was
Norharman Azobenzene
Figure 4.2
Variation in batches of S9 may reflect the nutrient state of the 
animal and it is very likely that variation in the level of enzymes results. 
On induction the balance of enzymes is altered, damethylation is enhanced
more soluble than DAB in aqueous solution and therefore much more methyl 
orange was available for metabolism than DAB. In vitro many of the 
membrane barriers are absent, allowing an unphysiological contact with 
both the metabolising system and DNA.. This may account for methyl 
orange being active in vitro. The fact that in this study it shows 
greater mutagenicity than DAB may be due to inhibition of ring 
hydroxy lation by the sulphonic group, thus limiting one pathway of 
deactivation and hence allowing more compound to be activated. Although 
methyl orange appears to be a false positive result, it emphasises the 
problems of extrapolation of in vitro to in vivo and indicates, the need 
for knowledge of the pharmacokinetics of the compound.
Interestingly, in the International studyscms in vivo studies 
were effective in detecting DAB as positive and methyl orange as negative.
13. Benzo (a) pyrene (BP)
BP exhibited similar mutagenicity in TA 98 to that described in 
Chapter 3. However, in TA100, testing was incomplete at all concentrations, 
and although at 10 fig/plate a greater response was observed with hepatocytes 
than S9, the response at lower concentrations is unclear. Questionable 
data was obtained for pyrene in TA 100 and hepatocytes, although it was 
negative under all other conditions tested.
The carcinogen BP has been extensively discussed in Chapter 3 and 
further in Chapter 5 and will not be further discussed here. The data 
for pyrene carcinogenicity is grossly inadequate and although considered 
a non-carcinogen for this study, it cannot be considered as adequately 
tested. Pyrene is metabolised to various epoxides in a similar manner 
to other PAHs (Arcos & Argus, 1974). It shows a lack of mutagenicity in 
other bacterial studies (McCann et al., 1975). . However, in the 
International study a large number of laboratories found pyrene to be 
mutagenic and this evidence suggests that it in fact does possess seme 
biological activity. The structure of pyrene is such that, unlike BPr it 
does not possess a "bay-region", the region from which the carcinogenic 
metabolites of PAHs are thought to arise, suggesting that pyrene should
5. Pyrene
not be a carcinogen. It can, however, form K-region metabolites and can 
intercalate without covalent binding to DNA, although this action may be 
for a specific, but unimportant,site in DNA (Arcos & Argos, 1974). This 
may result in it being mutagenic in TA1537. Sane K-region metabolites 
of BP have been shown to be mutagenic (Wood et al., 1976a).
The questionable result obtained with hepatocytes is difficult to 
explain and further investigations are required to confirm this response. 
The response with hepatocytes for PAHs in general was better than expected 
as there was no induction of drug metabolism.
29. B -Propiolactone
21. y-Butyrolactone
B-Propiolactone y-Butyrolactone
y-Butyrolactone was negative under all conditions tested’while
0-propiolactone was a direct acting mutagen, more potent in TA100 than 
TA98. The effect of S9 is not clear as it was not tested below 10 jig/ml 
in TA100. The presence of S9 with TA98 did not alter the mutagenicity.
The established carcinogen of this pair, B-prqpiolactone, is an 
example of an alkyating agent, the activity of which is dependent on the 
ring strain in the compound. y-Butyrolactone is a less strained hcmologue 
and shows less activity which is reflected in its non-carcinogenicity and 
non-mutagenic activity (Van Duren, 1965).
39. 9,10-Dimethylanthracene (DMA)
18. Anthracene
Dimethylbenz(a)anthracene Anthracene
Anthracene was not mutagenic under any condition tested. There 
is insufficient evidence to suggest that it is not a carcinogen. DMA 
on the other hand is a carcinogen causing skin papillomas and carcinomas 
after skin painting in mice. DMA was a weak direct acting mutagen and a 
weak mutagen with S9, however, with hepatocytes and TA98 the mutagenic
response was much increased.
Clearly, the metabolism with hepatocytes is very much more 
efficient than with S9 for active metabolite production. This is similar 
to the response of DMBA which has been discussed in Chapter 3. As 
discussed there, the addition of methyl groups may be responsible for 
this. On this basis, the lack of methyl groups in anthracene may be 
the cause of its inactivity. It should be noted that both DMA and 
anthracene lack a bay- or K-region, the usual sites of active metabolism 
of PAHs. However, both DMA and anthracene may be metabolised to a 
trans-diol although this does not appear to produce active metabolites 
(Jerina et al., 1977).
As DMA is anolagous to DMBA in that it exhibits a greater response 
with hepatocytes than S9, and this is discussed in Chapter 3, it will not 
be further discussed.
6 . Chloroform
30. 1,1,1-trichloroethane
chci3 ch'3 cci3
Chloroform 1,1,1-Trichloroethane
As already discussed (Section 4.2)inconsistent data in TA100 without 
metabolic activation was observed for chloroform, and it is questionable 
as to its mutagenicity. It is possible that reaction' with the plastic 
vessel caused the production of mutagenic metabolites. This requires 
further investigation. Although chloroform causes hepatocellular carcinoma 
in mice and kidney tumours in rats and has been shewn to cause hepatic 
necrosis, no response with hepatocytes was observed. It has also been 
shown to be metabolised and bind to endoplasmic protein and lipid, but 
not DNA in the liver (Uehleke et. al.,. 1977). Metabolism may give rise 
to • CC1 + Cl*, free radicals, which may cause toxicity. These are 
unlikely to getuvto the bacteria in significant concentrations as they are 
rather short-lived. It has been suggested that the carcinogenicity of 
chloroform is not a result of initial interaction with DMA but as a 
secondary reaction following chronic cellular damage (Grasso, 1976).
Although not overwhelming, the evidence is that 1,1,1-trichloroethane 
is not carcinogenic, although it causes an increased incidence of foetal 
resorptions in rats after inhalation (Fishbien, 1976). The fluctuation fesi 
correctly identified 1 ,1 ,1-trichloroethane as not active, however the 
results with chloroform are uncertain.
12. 2-Acetylaminofluorene (2AAF)
3. 4-Acetylaminofluorene (4AAF)
NHCOCH
4AAF
fHCOCH.
2AAF
Both chemicals were mutagenic after metabolic activation by both 
S9 fraction and hepatocytes. 2AAF was not tested for the dose causing 
the minimal mutagenicity, therefore the value in Table 4.4 does not 
reflect the true minimum mutagenic dose. As discussed in Chapter 3,
2AAF is a more potent mutagen with S9 than with hepatocytes. The data 
with TA100 shows a similar pattern to TA98. (As it has already been 
discussed, 2AAF will not be further discussed here.) 4AAF, however, 
has not been adequately tested for carcinogenicity and is a mutagen 
iji this study, although less potent than 2AAF. It shows a similar 
pattern of mutagenicity, being more potent with S9 than hepatocytes and 
is also more mutagenic in TA100 than TA98.
Conflicting results have been observed in bacteria with 4AAF, it 
being negative in one study (Purchase et al., 1978) and positive in • 
another (McCann et al., 1975). It is extremely likely that the metabolic 
pattern of 4AAF is similar to 2AAF (see Fig. 3.1) producing biologically 
active conjugated metabolites, after an initial N-hydroxylation step. Thp 
position of substitution in acetylaminofluorene canpounds appears to be 
of key importance in determining their biological activity. N-0H4AAF is 
only marginally carcinogenic in rats as canpared to N-0H2AAF. The
4-position is likely to be less available for reactions as it is closer 
to the electron dense central portion of the compound. A substitution at 
the 3-position also makes the molecule reactive, N-0H3AAF being a specific 
mammary carcinogen and more potent than N-0H4AAF, although it has been 
suggested that N-0H3AAF follows a different route of metabolism than 2AAF 
(Kridc & Westra, 1980).
At least three types of binding to DNA have been shown to occur in 
rat liver following N-0H2AAF administration (Kriek & Westra, 1980) , and 
the acetoxy ester of 4AAF has been shewn to be reactive towards 
nucleophiles, although less active than the 2AAF ester. This suggests 
that more than one type of damage may result in a mutagenic (or carcinogenic)
event. This may account for the responses observed in both TA98 and 
TA100, particularly as the response of 2AAF with hepatocytes and TA100 
is minimal.
The fact that 4AAF is a less potent irutagen than 2AAFr and this was 
generally observed by the laboratories in this study, suggests that 4AAF 
may be a carcinogen, although less potent than 2AAF. It deserves further 
carcinogenicity testing to confirm this. Therefore, although 4AAF was 
considered a non-carcinogen for this study and the result obtained was 
thought to be a false positive, it may well prove to be an accurate 
representation of its carcinogenicity.
.32. Dimethylcarbamoyl chloride (DMOC)
24. Dimethylformamide (DMF)
(ch3 )2n.coci hcon(ch3 ) 2
DMCC DMF
DMCC was mutagenic in TA100 without S9 fraction, but inactive in 
TA98. Inconsistent data was observed and may be due to hydrolysis of the 
two samples of DM3C received. DMF was not mutagenic with or without S9 
fraction, but showed inconsistent data with hepatocytes in both TA98 and 
TA100. DMCC produces local tumours after application in mice which 
reflects its direct alkylating activity. Limited evidence suggests that 
DMF is not a carcinogen.
The response observed with EMF may be due to its toxic effects 
on the hepatocytes causing the release of histidine and resulting in 
excess mutation. This is particularly likely as inconsistency is observed 
in both TA98 and TA100 and toxicity towards hepatocytes is kncwn to occur 
with 5% DMF (J.R. Fry, personal ccnrnunication). DMF does not cause DNA 
repair in hepatocytes (Williams, 1978).
9. 2-Naphthylamine (2NA)
4. 1-Naphthylamine (INA)
2NA INA
Both chemicals were mutagenic after metabolic activation with S9 
in both TA98 and TA100, however, the mutagenicity was abolished by using 
hepatocytes for metabolism. 2NA was slightly more mutagenic than INA
and the response in both cases was greater in TA100 than TA98. 2NA is a 
well known bladder carcinogen in rodents, dogs, and monkeys and increases 
hepatana incidence in mice, while 2NA was not carcinogenic at similar 
concentrations as 2NA, and showed no carcinogenicity in dogs after 9 yrs. 
treatment.
Both naphthylamines undergo similar metabolic conversions in the 
liver and both N-QH-INA and N-0H-2NA (the primary metabolites) are 
direct acting mutagens in bacteria, N-0H-1NA being more potent than 
N-0H-2NA (McCann et al., 1975; Miller & Miller, 1971) . There has, however, 
been difficulty in seme studies to demonstrate the mutagenicity of INA 
itself (Purchase et al., 1978). A wide spectrum of conjugated metabolites 
has been observed in the urine of dogs, rats and hamsters for both 
chemicals (Arcos & Argus, 1974). The role of the metabolites has been 
investigated by implantation studies in the bladders of animals. Although 
the actual carcinogenic metabolites of 2NA have not been identified, a 
number of carcinogenic metabolites have been found. In many cases 
analogous carcinogenic metabolites have been observed for INA. For 
instance, both N-0H-2NA and N-0H-2NA are carcinogenic and both ' 
nitrosonaphthalene metabolites have been identified and shown to be less 
potent carcinogens than the hydroxylamines. l-Amino-2-naphthol is a 
more potent carcinogen than 2-amino- 1-naphthol in bladder implantation 
studies.
The difference in carcinogenicity between 2NA and INA cannot be 
accounted for by the above metabolites. Other differences in metabolism 
may be responsible. The position of the amino group in INA would tend to 
make it less reactive than 2NA, as it is closer to the central area of 
the molecule and is. likely to be sterically hindered. Seme differences 
in metabolism have been observed. For instance, 6-hydroxy lation of 2NA 
occurs but not of INA. Also the bis (2-amino-1-naphthyl) phosphate 
metabolite is a potent bladder carcinogen, but an analogous metabolite 
has not been identified for INA. The difference in carcinogenicity may 
also be due to different rates of initial hydroxlaticn in the liver, 
particularly as pig liver microscmes have been shown to oxidise 2NA faster 
than INA. Also dog liver possesses greater "reserve" N-hydroxylating ability 
for 2NA when the substrate is limiting (e.g. at 5 mg/kg), but there is no 
difference at high concentrations (e.g. at 70 mg/kg).
The observation in this study, that the use of hepatocytes for 
metabolic activation abolishes mutagenicity suggests that the metabolites 
formed are either detoxified by conjugation mechamisms, or that the
active metabolites formed may react with intracellular macranolecules and 
never leave the hepatocytes. Patients with bladder tumours induced by 
long exposure to 2NA have unusually high levels of fc-glucuronidasein their 
urine, (Goldstein-et al. ,1972)suggesting that glucuronide metabolites 
may be broken down to active metabolites in the bladder. The bladder 
mucosa of many species contains both N-hydroxlating and 3 -glucuronidase 
activity. Therefore, if 3-glucuronidase (or bladder mucosa) is added 
to the hepatocytes in the fluctuation test, 2NA may prove to be mutagenic 
in the presence of hepatocytes. It would be interesting to observe 
whether such a modification alters the mutagenicity of INA. It is possible 
that the bladder shows substrate specificity for these ccmpounds.
Clearly, although the result for INA with S9 would suggest that 
it is a false positive result, further understanding of its metabolic 
profile can account for this. The lack of mutagenicity of 2NA with 
hepatocytes may indicate the tissue specificity obtained by using 
hepatocytes. It is apparent that the liver can metabolise 2NA to active 
metabolites, but it can also efficiently deactivate 2NA.. It is apparent 
that further studies are required to identify the reason for the lack of 
mutagenicity of both INA and 2NA with hepatocytes. Modification of 
hepatocyte metabolism may help to distinguish 2NA and INA as carcinogenic 
and nan-carcinogenic.
27. N-Nitroscroorpholine (NM~)
17. Diphenylriitrosamine (dpn)
19. Dinitrosopentamethylene tetramine(bNPMr)
NO
NM
NM produces liver, nasal, kidney, oesophagus and ovary tumours in 
rats, liver and lung tumours in mice and respiratory tract tumours in 
hamsters. There is very limited evidence to suggest that DPN is not 
carcinogenic, while insufficient data is available to draw conclusions about 
DNPMT. NM was significantly* more mutagenic in TA98 with hepatocytes than 
with S9 in which it was only marginally mutagenic, however with aroclor- 
induced S9 it was significantly mutagenic in TA100 (Table 4.5). It was
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not mutagenic in TA98. DPN has already been discussed as it exhibits a 
questionable response with TA98 and hepatocytes. More interesting is 
DNPMT which exhibits toxic and mutagenic responses at the same 
concentration, although at non-toxic doses it was inactive.
As NM is more mutagenic with hepatocytes, it suggests that an 
intermediate is formed that can be transported out of the hepatocytes. 
Further evidence for this cones frcm a host-mediated assay in which NM 
is positive (Ziegler & Legator, 1971), where a stable intermediate must 
reach the interperitoneal cavity. NM also causes liver necrosis around 
the centrilobular veins and other vascular canponents as well as the 
metabolising parenchymal cells, suggesting metabolite movements (Magee, 
1977b). This is true for all biologically active nitrosamines.
Metabolism is thought to occur via an initial breaking of the 
NM ring to yield a structure capable of following usual nitrosamine 
metabolism, a -C- >xidation, a rate limiting step, is thought to be the 
first step in nitrosamine metabolism, although slow metabolisn at the 
nitroso group may occur (Magee, 1977b). N-tencmorpholine has been 
postulated as an intermediate in NM metabolism (Ashby in Purchase et al., 
1978). The iderrHhj of the metabolite that is transported is not known, 
although Schoental (1973) has postulated that an aldehyde metabolite may 
be responsible. The acetylated a-hydroxymethylnitrossmine metabolite of
DMN has been isolated and identified as a mutagen and a carcinogen - and
)s
a similar metabolite might exist for NM. This ^particularly interesting as 
acetylation is carried out by cytosolic enzymes and would not occur in 
S9 fraction, but only in intact hepatocytes.
Hydroxlation on the aranatic rings of DPN may be responsible for 
the biological effects observed. Metabolism of the N=-0 bond is likely to 
be hindered by the presence of the aranatic rings. The response’observed 
with hepatocytes is indicative of sane possible biological activity. 
Interestingly, DPN has recently been shown to be a bladder carcinogen in 
-rodents. DNPMT has no obvious route of metabolism. The questionable 
results (see Section 4.2) obtained suggest that it may possess sate 
biological activity and deserves further investigation.
31. Urethane
28. Isopropyl N(3-chlorophenyl) carbamate
NHoC00CoH •NHCOOC^i
Urethane Isopropyl N (3-chlorophenyl)carbamate
Both chemicals were classified as not mutagenic in the study.
However, a weak response was observed for urethane in TA98 with S9 at 
500 fig/ml. As it could not be confirmed in subsequent experiments, it 
was considered negative. On further testing using aroclor-induced S9, 
urethane was mutagenic in TA100 at 1000 Jig/ml (Table 4.5). Difficulty in 
detecting the mutagenicity of urethane in bacteria has been found. It has 
been shewn to be both mutagenic (Purchase et al., 1978) and to not be 
mutagenic in other laboratories (Heddle & Bruce, 1977; McCann et al., 1975). 
Urethane is carcinogenic in rodents producing tumours at a number of sites, 
while the evidence suggests that isoprcpyl-N (3-chlorcphenyl) carbamate 'is 
not carcinogenic. Isoprcpyl-N (Bchlorqphenyl) carbamate has previously been 
shewn to not be mutagenic (Lorenzo et al., 1978). The difficulties observed 
in detecting urethane as mutagenic may lie in deficiencies in the 
metabolising system. N-hydroxyurethane is a likely metabolite, although 
it has not been detected. The metabolic profile of urethane is not at all 
clear (Weisburger & Williams, 1975).
37. Methylazoxymethanol acetate (MAM-acetate)
33. Azoxybenzene
ch2 cooch2n = n c h 3N N C H 0
MAM-acetate Azoxybenzene
The carcinogenic MAM-acetate was not tested for mutagenicity.
However, azoxybenzene was not mutagenic under any condition tested, 
which correlates with its non-carcinogenicity (based on limited data).
25. DL-Ethionine
22. Methionine
NH0 • NH0I 2 | 2
C2H 5 SCH2 CH2-CHCOOH CH3 SCH2 CH2CHCOOH
DL-Ethionine Methionine
Methionine was not mutagenic under any.condition tested. DI/-£thionine 
was extremely toxic to the bacteria, but exhibited no mutagenicity at non­
toxic doses.
Methionine has not been tested for carcinogenicity but, as it is an 
essential amino acid, serving as a methyl donor to various bicmolecules and
is the initiating amino acid in the synthesis of proteins, it is not 
expected to be carcinogenic. Ethionine, hcwever, is an antimetabolite of 
methionine , causing liver tumours in rats as a result of chronic feeding. 
Ethionine undergoes similar metabolism to methionine to form
S-adeno£ylethionine, which preferentially reacts witht ENA in vivo. 
Ethylated bases, instead of methylated bases are then observed. Large 
amounts S-aden<3S ylethionine are found in rat liver after
treatment and it is likely to be metabolised at the expense of methionine. 
Ethionine may also prevent the initiation of protein synthesis.
As ethionine interferes with biosynthetic pathways in normal cells 
it is likely to be carcinogenic by a mechanism not necessarily involving 
ENA damage, but involving its antimetabolite activity of methionine. It 
would not therefore be expected to be mutagenic in a system designed to 
detect chsnicals that cause damage to the DNA of a cell, although it has 
been shown to be mutagenic in the basiliarycete Corprinus lagopus 
(Talmud & Lewis, 1974).
14. Hydrazine sulphate
n h 2n h 2 . h 2 s o 4
Hydrazine sulphate is carcinogenic in rats and mice, but not 
hamsters. The mutagenicity observed with both S9 and hepatocytes in 
TA100 correlates with its carcinogenicity, the response with S9 being 
greater than with hepatocytes.
20. Ethylenethiourea
f V
Ethylenethiourea causes thyroid tumours and is a teratogen. It 
was not mutagenic in TA98, however, inconsistent results were observed 
with TA100 without S9. It was concluded that it was not mutagenic as 
mutagenicity was not observed at other concentrations. It has previously 
been shown to be weakly mutagenic in TA1535, although it was not active 
in cytogenetic studies (Teramoto et al., 1977). It has been found to 
accumulate in the thyroid gland but its mechanism of action is unclear.
It may act specifically on the thyroid gland through a non-mutagenic 
mechanism and would therefore not be expected to be mutagenic in bacteria.
7. Diethylstiboestrol (DES)
DES was not mutagenic under any condition tested, but was extremely 
toxic to the bacteria. It has not been shown to be mutagenic (Glatt et al., 
1979; McCann et al., 1975). DES has been shown to be carcinogenic in a 
variety of animals, but is well known in association with a rare type of 
vaginal cancer in prepubertal girls, the offspring of mothers treated with 
DES during pregnancy. Other non-necplastic changes in the female genital 
tract have been recognised as characteristic of DES-exposed females (reviewed 
in Herbstet al., 1977). Incidences of cancer (e.g. breast cancer) associated 
with estrogen therapy have lead to an Estrogen-Cancer hypothesis in which 
cancer is induced by a non-genetic mechanism (Hertz, 1977). As DES is a 
hormone analogue it is thought that it may cause cancer through a hormone- 
mediated mechanism and it is therefore not surprising that it is not mutagenic 
in bacterial mutagenicity assays.
23. Safrole
CH_CH=CH
Safrole was found to react with the plastic in the trays used for 
this study and therefore all experiments were carried out in glass. It 
was not irutagenic under any condition tested.
Safrole, an extract of sassafras oil and found widely distributed 
in foodstuffs (e.g., nutmeg, parsley), produces liver tumours following 
oral administration, and liver and lung tumours in male infant mice after ' 
subcutaneous injection. Despite its carcinogenicity and the fact that it is 
known to be metabolised to mutagenic intermediates (1 1-hydroxysafrole,
1 -acetoxysafrole) safrole is very rarely demonstrated as mutagenic (McCann 
et al., 1975; Purchase et al., 1978; Swenson et al., 1979). It has been 
shown to be mutagenic in a host-mediated assay (Green & Savage, 1978), while 
Dorange et al. (1978) have demonstrated it to be mutagenic in TA1535 after 
20 min preincubation and using 3MC-induced liver fraction.
It is therefore apparent that the metabolic conditions are extremely 
important. It is not known why in in vitro mutagenicity assays the first 
metabolic steps appear not to take place, although the rate of metabolism 
may be so low that the. enzymes become inactive before sufficient metabolites to 
exert a mutagenic effect a r e  formed.
34. Cyclophosphamide (CP)
V°^CH CH Cl
■J 2 2
^  CH2CH2C1
Cyclophosphamide was mutagenic without metabolic activation, with S9
and with hepatocytes in TA100, the response in hepatocytes being marginally 
greater. It is a cytostatic drug, and a derivative of the alkylating agent 
nor-nitrogen mustard, which is a carcinogen in rodents producing tumours at 
several sites including lung, lymph system, liver, reproductive organs and 
skin. It has been shown to degrade in vivo to produce compounds causing 
genetic damage in yeast (Mayer et al., 1976) and bacteria (Gatehouse, 1978), 
although Mohn and Ellenberger (1976) found it to be active only after 
metabolic activation.
routes of metabolism, both via the tautomeric aldehyde (aldophosphamide, by 
aldehyde dehydrogenase, a cytoplasmic enzyme) to either the non-toxic propionic . 
acid, or through £-elimination to phosphoramide mustard and acrolein, both of 
which are extremely cytotoxic (reviewed in Weibkin, 1978). Nor-nitrogen 
mustard has also been detected which possibly contributes to the toxic 
metabolites (Mohn & Ellenberger, 1976). The involvrrent' of a cofactor requir­
ing cytoplasmic enzyme (aldehyde dehydrogenase) suggests that an intact hepa- 
tocyte is useful for metabolism to active metabolites. This has been shown . 
by the suppression of fibroblast growth in a mixed hepatocyte/fibroblast 
culture (Fry & Bridges, 1977; Weibkin, 1978). The slight increase in 
mutagenicity in TA100 with hepatocytes may reflect this action. However, 
clearly the sample obtained possessed direct acting mutagenic properties 
which is probably not due to bacterial .metabolism and it is possible that 
the chemical may have degraded before testing.
Epichlorhydrin is a direct acting mutagen in TA100. The presence of 
S9 did not alter the response while hepatocytes reduced the response.
It is an initiator of skin tumours in mice. Human exposure is wide 
spread and it has been shown to be mutagenic in human lymphocytes in vitro 
and mutagenic in bacteria (reviewed in Fishbein, 1976 ). It is a monofunctional
CP is metabolised by MPO to 4-hydroxy CP, followed by two possible
26. Epichlorhydrin
35. 3-Aminotriazole (AT)
/ N\
L _
3-Aminotriazole induces thyroid and liver tumours in both rats
and mice after oral or subcutaneous administration. As already shown in 
section 4.2 (and table 4.5) it is weakly mutagenic at 500jig/ml in TA100 with 
S9 fraction. Questionable results were obtained in TA100 without metabolic 
activation. It may be carcinogenic through a mechanism not involving DNA, as 
like ethylenethoiurea is possesses goitrogenic activity. Therefore, it would 
not be expected to be mutagenic in bacteria. It has previously been reported 
as not mutagenic (McCann et al., 1975), although Braun et al., (1977) were 
able to demonstrate : its mutagenicity in a host mediated assay. It was also
shown to inhibit the growth of E. ocli and S.typhimurium at 0.5% minimal 
medium (Meretoja et al. ,1976). As AT has also been shown to interfere with 
histidine and adenine biosynthesis in S.typhimurium this may not be an ideal 
system to test it in (Hilton et al., 1965).
36. 4,4' -Methylenebis (2-chloroaniline) (MXA)
MX A  was only mutagenic with S9 fraction in TA100. It is carcino­
genic in rats and mice after oral administration, and causes bladder cancer 
in dogs. The result obtained is consistent with previous findings that it is 
an indirect acting base-pair substitution mutagen (Purchase et al., 1978; 
McCann et al., 1975). Like aromatic amines in general it would be expected 
to be metabolised via an N-hydroxy intermediate, although steric hinderance 
by the chlorine atoms may occur. In common with other aromatic amines 
(cf INA and 2NA) it exhibits no mutagenicity with hepatocytes which suggests 
that either the metabolites are deactivated, or that they cannot escape from 
the hepatocytes, or get into the bacteria.
Cl cl
41. O-Toluidine hydrochloride
O-Toluidine was not mutagenic in TA98, but was mutagenic in TA100
aroclor-induced S9 indicated that O-toluidine can be made mutagenic.
It is carcinogenic in rats and mice producing a variety of neoplasms. 
When metabolised it is likely to undergo ring-hydroxy lation, N-hydroxylation 
and demethylation, although the presence of the methyl group may hinder 
metabolism at the group. Since a variety of active and inactive metab- 
lites may be formed, the balance of enzymes in an in vitro test may be impor­
tant. It has been shown to be negative in an Ames test using aroclor-induced 
S9 (McCann et al., 1975) and also phenobarbitone-induced (Gamer & Nutman,
1977). Studies with competitive substrates similar to those described for 
DAB can be made with O-toluidine. The addition of norharman (fig. 4.2) 
to compete for ring-hydroxylation (a deactivation route), increases the 
mutagenicity if O-toluidine. emphasising the role of the amine group in 
metabolic activation. Aniline, which lacks a methyl group, shows a similar 
response with norharman present. Ihe presence of the methyl group reduces 
the activity of the aniline nucleus of O-toluidine. Addition of further 
Efethylgroups to O-toluidine inhibits ring-hydroxylation and increases mutagen-' 
icity. (Arcos & Argus, 1974).
O-Toluidine is a further example (cf DAB) of differences in the 
balance of enzymes in vitro causing differing responses in mutation assays.
42. Auramine
 __  NH
H
(CH ) N / C \ 7“N (CH ) HC1
This dye was difficult to test at high concentrations as its deep 
colour interfered with the determination of the end-point of the experiment. 
Furthermore, it was found to have a pH of 6.2 in aqueous solution which also 
affected the definition of the pH change in the fluctuation test. Although 
not mutagenic in TA100, a questionable response was obtained in TA98 with 
S9 (section 4.2) and futher investigations are required to cai-firm this data. 
Carcinogenicity studies of auramine have generally been carried out on 
impure samples, and the sample tested in this study was impure. The impure 
substance was found to produce liver tumours in rodents. Auramine has 
previously been demonstrated as non-mutagenic (McCann et al., 1975).
The weak or negligible activity of this substance may be the result of 
inadequacies in metabolism. However, the properties of the compound 
may have masked any weak mutagenic response.
Not unexpectedly this widely used substance showed no mutagenicity.
40. Acorbic acid (Vit.C)
CHo0H
■I 2
H O C H ^ O v O
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HO OH
. Ascobic acid was not mutagenic with or without S9 fraction in
either TA98 or TA100. A weak positive result was obtained at 5O0jjg/ml
with hepatocytes in TA98 and inconsistent results with TA100.
Ascorbic acid has been shown to be mutagenic in bacteria (Stich et 
al., 1976; Guttenplan, 1977) and it has been shown to inhibit bacterial mutag­
enesis induced by N-methyl-N-nitroso guanidine and D M  (Guttenplan,' 1977). It 
also prevents N-nitroso compound formation in vivo and the resultant 
carcinogenic effects. Vit. C causes an increased incidence of SCEs in 
human lyirphocytes and Chinese hamster ovary cells, the effect being reduced 
by catalase (Galloway & Painter, 1979). It is also cytotoxic towards CHO cells. 
The available evidence points to a potential damaging effect on DNA by 
vit.C, particularly as it has been shown to induce UDS and cause single­
strand breaks in DNA. However, cytotoxicity towards cells in culture.suggests
that the results with hepatocytes could be due to an artefact (i.e. release of 
histidine due to,cytotoxic effects on the hepatocytes)
. It is not possible to conclude whether the results with hepatocytes 
are due to cytotoxicity of vit.C or due to a mutation. Further investigations 
are therefore required.
In this study, a sensitivity (true positive fraction) and specificity 
(true negative fraction) value for the relationship between carcinogenesis and 
mutagenesis can be determined. For the purposes of the International 
study , in the fluctuation test with/without S9 fration, a sensitivity of
0 . 5 2 2  and. a speciricity or u./uo was uoiaiiiBa. m t ;  lxu^LUdu-ua u c & u  w x u i  
hepatocytes had a sensitivity of 0.455 and a specificity of 0.588. In 
determining these figures no account was made for chemicals that lacked 
evidence for non-carcinogenicity (e.g. ,4AAF) and may well prove to be 
carcinogenic and thus alter these figures. As a screening test, the 
sensitivity would appear to be lower than expected, however, chemicals were 
chosen that might be difficult to detect for a number of reasons, for 
example, DAB (due to differences in the metabolising systems) and DES (due to 
its mechanism df action not being mediated through DNA damage). Although 
the use of uninduced S9 (to make a comparison with uninduced hepatocytes) was 
adequate, when aroclor-induced S9 was used, both DAB and urethane were mutag- 
and hence the sensitivity of the test is increased (to 0.609). It is 
therefore apparent that care is required in choosing the metabolising 
conditions. A favourable comparison with another laboratory using the 
fluctuation test (although with induced S9) and E. coli as well as S.typhim- 
urium was obtained (sensitivity - 0.6, specificity - 0.647). Endless 
comparisons with different laboratories, all performing slighly different 
methods of the Arnes test can be made, however., in general the fluctuation 
test data also agreed favourably with their results.
Of prime importance was the use of isolated hepatocytes instead of 
S9 fraction, this being perhaps one of the most important potential advantages 
of the fluctuation test. A number of different types of response were 
expected and were indeed obtained. However, in a study such as this, further 
investigations are required in a number of cases to elucidate the reasons for 
the results obtained. Ihe types of response expected with hepatocytes cf S9:
1. Reduced mutagenicity when insufficient metabolite is produced in 
in the hepatocyte.
2. Reduced mutagenicity due to detoxification by conjugation (e.g. 
possibly the naphthylamines).
3. Reduced mutagenicity, when the active metabolites are formed, but 
are so reactive that they bind to intracellular macramolecules 
and escape to only a small extent from'.the heoatocytes. This 
would be expected with specific hepatocarcinogens.
4. Increased mutagenicity when activation by conjugation occurs 
although as observed with 2AAF, some conjugates cannot get into 
the bacteria.
5. Increased mutagenicity due to an artefact when cytotoxicity 
towards the hepatocytes causes histidine release, resulting in 
an apparent positive response due to excess bacteria growth
and the associated increase in spontaneous mutations (e.g. IMF). 
Histidine release may also occur following lipid peroxidation.
is less good than with S9 fraction, the use of hepatocytes has led to interes­
ting observations such as the absence of mutagenicity with the naphthylamines 
as compared to the response with S9. As a general metabolising system for 
screening purposes in most cases hepatocytes gave the same answer as with S9, 
although the result may have been stronger or weaker.
In summary, when considering the overall results if this study, of 
twenty three carcinogens tested,thirteen were clear positives, four (ho. 6 ,
35, 42 and 41) exhibited questionable results that could not be discarded as 
negative, three (31,23,1) may be negative due to inadequacies in the metabolism 
system and two of these (31,1) were mutagenic with aroclor-induced S9. Three 
(7,25,20) were not mutagenic and this may be due to their carcinogenicity 
being via a non-mutagenic mechanism. Of the remainder seventeen non-carcin­
ogens, five (3,15,19,4 and 40) were mutagenic and the reasons for this have 
been dicussed, while three (19,17,5) gave questionable results. The remainder . 
were not mutagenic.
CHAPTER 5 - SOME STUDIES WITH MUTAGENICITY ASSAYS
5.1. GENERAL INTRODUCTION
Mutagenicity studies in both bacteria and mammalian cells are becoming 
increasingly important in helping to identify the active metabolites of 
chemical carcinogens and mutagens. They have been widely employed for 
both aranatic amines (Chapter 3) and for poly eye lie hydrocarbons (Chapter 
3 and this chapter). In this chapter, a study of seme synthetic BP 
metabolites has been made shewing the use of the fluctuation test in such 
studies. A preliminary investigation has been made into the effects of an 
activator of drug metabolism, betamethasone, on the mutagenicity of BP.
While this work is in its preliminary stages, seme insight into the possible 
manipulations of metabolic activation can be gained.
As an example of the practical use of the fluctuation test, the 
specific problem of testing the mutagenicity of certain oils has been 
investigated. Since oils are widely used and many contain chenical carcino­
gens, particularly PAHs, this poses ari important technical problen in 
mutagenesis testing.
As three different topics are covered in this chapter to illustrate 
the various studies possible with mutagenicity assays, each topic is 
treated as a separate section.
5.2. THE MUTAGENICITY CF SOME BENZO(A)PYRENE METABOLITES
5.2.1 Introduction >
An outline of the metabolism of BP is given in Chapter 3 and 
Fig. 3.2. As was discussed in that chapter, the ultimate carcinogenic 
metabolite is thought to be the 7,8-diol-9,10-epoxide BP. However, several 
other metabolites of BP are mutagenic both without metabolic activation and 
with further metabolic activation (Wood et al., 1976a). The relative 
mutagenicity of a wide range of metabolites was reviewed by Jerina et al. 
(1976) and is shown in Table 5.1.
The easily synthesised phenol metabolites have been widely examined. 
The phenols are further metabolised by epoxidation at another site, or by 
conjugation (to glucuronide, sulphate or glutathione esters) and thereby 
eliminated. Mutagenicity studies in S.typhimurium strains without metabolic 
activation indicated that the 2-, 4-, 5-, 8-, 9-, 10- and 11-phenols were 
not mutagenic (Wislocki et al., 1976b) , although Glatt and Oesch (1976) 
showed that 4-OHBP was a weak mutagen, and 9-OHBP was a more potent mutagen. 
The phenols 6-OHBP and 12-OHBP were the most mutagenic phenols tested 
(Wislocki et al., 1976b; Glatt & Oesch, 1976) while 1-OHBP and 7-OHBP were
Table 5.1
Comparison of the inherent mutagenic activity of BP derivatives in 
Salmonella typhimurium and in Chinese hamster cells. ^
(Taken from Jerina et al. ,1976)
The data is of relative percent mutagenic activity frcm several 
separate studies.
Compound Relative % activity
TA98 V79
7,8-Diol-9,10-epoxide BP' 100 40
9,10-epoxy-7,8,9,1O-tetrahydro BP 95 40
7,8-epoxy-7,8 ,9,1O-tetrahydro BP 10 0.2
BP 4,5-oxide 20 1.0
BP 7,8-oxide 1.0 <0.1
BP 9,10-oxide 1.0 <0.1
BP''.11/12-oxide' 0.5 1.0
6-OHBP 5.0 0.3
12-CHBP 1.5 <0.1
1-OHBP 0.5 0.1
3-OHBP 0.5 <0.1
Other phenol metabolites , 
quinones, dihydrodiols 
and BP 0.1 0.1
weaker mutagens in V79 cells (Wislocki et al., 1976b) . in the sane study 
BP7,8-oxide and BP 7,8-dihydrodiol were mutagenic in both S. typhimurium
i
and V79 cells. The phenols, -4-, 6-, 7-, 8-, 9-, 10-, were not carcino­
genic in mouse skin studies (Kapitulnik et al., 1976). The 7 ,8-diol-
» ~"_l
. ■ 9,l:G-epoxide BP was an extremely potent mutagen (Wood et al., 1976a).
A few studies have been carried out in the presence of metabolic activ­
ation systems. Huberman et- al., (1976) showed that the BP trans-7,8-dihydrodiol 
is a more potent mutagen when a cell mediated metabolic activation system 
was combined with V79 cells. Wood et al.(1976a) used a highly purified hepatic 
microsomal monooxygenase system to metabolically activate sane synthetically 
produced phenol metabolites. A cyt.P-448 system was used. 1-, 2-, 3-, 6-,
9- and 12-OHBP were metabolically activated to mutagens in TA98, although 
they were less mutagenic than BP. This suggests that these metabolites are 
further activated, although the phenolic substitution of BP has been suggested 
as a deactivation route (Wood et al., 1976a).
It is of interest, therefore, to observe the mutagenicity of a variety 
of phenol metabolites and their sulphates esters to help identify their 
role in the metabolism of BP, particularly as possible deactivation products. 
The sulphate ester of 3-OHBP has been found in hamster, rat and human lung 
cultures (Cohen, et al., 1976) and it is important to evaluate the 
biological activity of this metabolite.
O.Pelkonen (personal ccmmunication) has found that the sulphate 
conjugate of 9-OHBP and 3-OHBP did not show significant mutagenicity in 
TA98 (although there was a weak response). It was suggested that toxicity 
towards the bacteria might be a problem when testing these metabolites. 
Therefore, in the present study, the fluctuation test was used as a potentially 
more sensitive mutagenicity assay.
5.2.2 Results
For this study only a limited amount of each metabolite was avail­
able, therefore it was not possible to complete the testing adequately in 
same cases.
The first metabolites received were synthesised by R. Mahta 
(University of Surrey). Although a weighed amount of the phenol metabolites 
was available, the amount of sulphate in the sulphate conjugates could not 
be determined due to the limited sample available. These samples were 
received as ethanol solutions. The sulphate conjugates were evaporated to 
dryness and the sample weighed to give an estimate of the metabolite present. 
The results of the first set of samples (1-OHBP, 3-OHBP, 12-OHBP and
1-O-SO^BP, 3-O-SO^BP, 12-O-SO^BP) have been quoted in concentrations of
jig/ml and^iM. The fluctuation tests were carried out in glass tubes.
2+Ca precipitated washed microscmes fran 200 g rats pretreated with 
3M2 were used for metabolic activation, to enable the results to be related 
to metabolic studies being carried out using 3MC-induoed microscrres at the 
University of Surrey. Aroclor-induced S9 was used in the later stages of 
the study.
Tables 5.2a and 5.2b shew results obtained with the first set of 
metabolites. The metabolites 1-QHEP, 3-OHBP and 12-OHBP were all mutagenic 
both with and without metabolic activation in TA98, while their equivalent 
sulphate esters were not mutagenic. In a single Ames test, the mutagenicity 
of 12-OHBP could not be shewn (data not presented) while 3-OHBP and 1-OHBP 
were mutagenic.
Samples of 3-OHBP, 2-0HBP, 7-0HEP, 9-0HBP and their sulphate 
conjugates were then obtained frcm NCI, Bethesda, U.S.A. Only 3-OHBP was 
significantly mutagenic without metabolic activation in TA98 (Table 5.3), 
although 7-0HBP exhibited a slight response. In a single experiment with 
TA100 without metabolic activation (Table 5.4), 3-OHBP and 7-OSO^BP were 
both significantly mutagenic. Table 5.5 shews results obtained after 
metabolic activation with 3MC-induced microscrres in TA98. 3-OHBP showed 
significant mutagenicity, while 2-0HBP exhibited a mutagenic response only 
at 10 jiM, although this was not repeated and therefore not confirmed.
When aroclor-induced S9 was used for metabolic activation and TA98 
(Table 5.6), the phenol metabolites 3-OHBP, 7-QHEP and 9-0HBP were mutagenic 
as were their respective sulphate conjugates. The conjugates were weaker 
mutagens than the parent phenols, 7-0-S0^BP exhibiting mutagenicity at the- 
highest concentration tested (10 JIM) only. In a single experiment with 
TA100 and aroclor-induced S9 (Table 5.7), at the limited concentrations 
tested, 3-OHBP was not mutagenic while 3-O-SO^BP was significantly mutagenic. 
7-O-SO^BP was also mutagenic at 20jiM only and 9-0-S0^ BP. was not mutagenic*
5.2.3 Discussion
In this study seme phenolic metabolites of BP have been shown to be 
mutagenic both without metabolic activation and with further metabolic 
activation. Without metabolic activation, 1-OHBP, 3-OHBP and 12-OHBP were 
clearly mutagenic in TA98 (Tables 5.2a and 5.3) while 7-OHBP was weakly 
mutagenic, although this result was obtained at one dose only (Table 5.3).
2-OHBP and 9-OHBP were toxic to the bacteria at the highest doses tested 
(25 jiM) as was a second sample of 3-OHBP (Table 5.3). These compounds can 
react with nitrogen bases to form Schiff bases as the covalent link to 
ENA and it has been suggested that such a mechanism may occur as certain 
phenols exist mainly or partially as keto tautcmers (references cited in
Table 5.2a
The mutagenicity of 1-OHBP, 3-OHBP and 12-OHBP In TA98 in the
fluctuation test without metabolic activation and with metabolic
2+activation by 3M>induced Ca precipitated microsones.
Concentration 
pig/tnl (pM)
No. of 
experiments
Average numbeg of tubes 
positive
Significance^
-control treated
Without metaboli 
activation
c
1-OHBP
5.0 (18.70) 1 4.0 23.0 p<0.001
1.0 (3.73) 3 5.5 12.3 p<0.01
0.5 (1.87) 1 9.0 8.0 n.s.
0.1 (0.37) 2 6.3 8.5 n.s.
3-OHBP
10.0 (37.30) 1 4.0 0 toxic
1.0 (3.73) 3 5.5 13.7 p<0.001
0.5 (1.87) 1 9.0 11.0 n.s.
0.1 (0.37) 2 6.3 6.0 n.s.
12-OHBP
10.0 (37.30) 1 4.0 12.0 jn.s.
1.0 (3.73) 3 5.5 11.3 p<0.05
0.5 (1.87) 1 . 9.0 8.0 n.s.
0.1 (0.37) 
NOPD
2 6.3 5.0 n.s.
0.1
With metabolic 
activation
1-OHBP
4 5.0 43.,5 P<0.001
1.0 (3.73) 3 8.0 22.7 p<0.001
0.1 (0.37) 3 8.0 .7.0 n.s:
3-OHBP
1.0 (3.73) 3 8.0 24.3 p<0.001
0.1 (0.37 3 6.0 9.0 n.s.
12-OHBP
p<0.011.0 (3.73) 2 8.5 18.5
0.1 (0.37) 2 ...... 8.5 10.0 n.s.
BP 1.0 (3.90) 9 6.0 19.6 p<0.001
a - 50 glass tubes per treated series, 
b - significance determined by x2*
c - result not significant in a single experiment, further experiments are 
■ required to confirm the increase over the control.
Table 5.2b
The mutagenicity of l-O-SO^BP, 3-O-SQ^BP and 12-0-S0^BP in
TAP 8 in the fluctuation test without metabolic activation and
2+with metabolic activation by 3MC-induced Ca precipitated 
microsomes.
Concentration 
pg/4nl (jjM)
No. of 
experiments
Average number of tubes 
positive
Significance^
control treated
Without metabolic 
activation
l-O-SO.BP
35.0 (101.0) . 3 5.3 8.7 n.s.
3.5 (10.1) 3 5.3 6.0 n.s.
3-0-S04BP
15.0 (43.1) 2 6.5 0 toxic
7.5 (21.6) 1 3.0 3.0 n.s.
1.5 (4.3) 
12-0-S04BP
3 5.3 6.0 n.s.
50.0 (143.7) 1 6.0 0 toxic
25.0 (71.9) 1 4.0 0 toxic
5.0 (14.0) 3 5.3 8.3 n.s.
NOPD
0.1
With metabolic
4 5.0 43.5 P<0.001
activation
i-o -so4bp
35.0 (101.0) 2 5.0 11.0 n.s.
3.5 (10.1) 3 2.6 3.3 n.s.'
3-OS04BP
15.0 (43.1) 3 7.3 9.3 n.s.
1.5 (4.3) 3 2.6 3.0 n.s.
12-O-S04BP
50.0 (143.7) 3 7.3 10.0 n.s.
5.0 (14.4) 3 2.6 3.3 n.s.
BP 1.0 (3.9) 9 6.0 19.6 p<H.001
a - 50 glass tubes per treated series, 
b - significance as determined by x2
The samples were evaporated under vacuum to dryness, weighed, and resuspended 
in DMSO.
Table 5.3
The mutagenicity of 2-OHBP, 3-OHBP, 7-OHBP, 9-OHBP and their
sulphate esters in TA98 without metabolic activation in the 
fluctuation test ^
Concentration
jllM
No. of 
experiments
Average number of tubes 
positive
Significance13
control treated
2-OHBP
25.0 1 9.0 0 toxic
10.0 2 9.0 7.0 n.s.
5.0 2 9.0 6.0 n.s.
2.5 3 4.0 11.0 n.s.
0.25 2 9.0 2.0 n.s.
0.025 1 2.0 1.0 n.s.
3-CHBP
25.0 1 9.0 0 toxic
10.0 3 4.0 9.0 n.s.
5.0 4 3.3 12.3 p<0.001
v 2.5 5 4.4 25.3 p<0.001
0.025 3 4.0 7.0 n.s.
7-OHBP
10.0 2 2.0 4.5 n.s.
5.0 2 '2.9 9.5 p<0.01
2.5 2 2.0 ' 5.0 n.s. #
9-CHBP
25.0 1 9.0 0 toxic
10.0 4 4.0 2.0 n.s.
5.0 4 3.3 3.5 n.s.' !
2.5 5 4.4 7.4 n.s.
0.25 1 9.0 11.0 n.s.
2-0-S04BP
2.5 2 1.5 1.0 n.s.
3-O-S04BP
10.0 2 2.0 5.5 n.s.
5.0 4 3.3 5.0 n.s.
2.5 5 3.0 4.8 n.s.
7-0-S04BP
10.0 2 2.0 5.0 n.s.
5.0 2 2.0 5.5 n.s.
2.5 2 2.0 5.0 n.s.
9-OS04BP
10.0 2 2.0 3.0 n.s.
5.0 4 3.3 3.3 n.s.
2.5 5 3.O.. 3.8 n.s.
NOPD
0 . lpg/ml 5 3.0 15.6 p<0.001
a - 50 glass tubes per treated series 
b - significance determined by x2
Table 5.4
The mutagenicity of 3-OHBP, 3-O-SQ^BP, 7-O-SQ^BP and 9-0-S04BP 
in TA100 without metabolic activation • in the fluctuation test
Concentration
pM
Number of glass tubes positive 
(results from a single experiment 
. . . 50 tubes per treated series)
3-OHBP
10.0 29***
5.0 23***
3-O-SO.BP4
10.0 2
5.0 3
7-0-S04BP
20.0 39***
10.0 27***
5.0 15
9-0-S04BP
20.0 2
10.0 3
5.0 2
Furacin
0.05pg/inl 35***
0 5
***. significantly mutagenic p<0.001 by x2
Table 5.5
The mutagenicity of 2-OHBP, 3-OHBP, 9-OHBP and their sulphate
2+esters in TA98 with metabolic activation by 3M3-induced Ca 
precipitated microsomes in the fluctuation test ^
Concentration
pM
No. of 
experiments
Average number of tubes 
positive3
Significance13
control treated
2-OHBP
10.0 1 9.0 21.0 p<0.01
5.0 2 9.5 11.5 n.s.
2.5 3 10.3 13.0 n.s.
0.25 3 10.3 11.0 n.s.
0.025 1 8.0 7.0 n.s.
3-OHBP
10.0 3 10.3 38.3 p<0.001
5.0 3 10.3 16.0 p<0.05
2.5 3 9.0 12.0 n.s.
0.25 3 8.0 10.0 n.s.
9-OHBP
10.0 3 10.3 10.7 n.s.
5.0 3 . 10.3 10.7 n.s.
2.5 2 8.5. 77.0 n.s..
2-0-S04BP
10.0 1 9.0 5.0 n.s.
2.5 2 11.0 10.0 n.s.
3-O-S04BP
5.0 2 9.5 11.0
*■ t
n.s.
2.5 3 10.3 10.3 n. s»
9-O-S04BP
5.0 2 9.5 7.5 • n.s.
2.5 3 10.3 13.0 n.s.
BP
4. a 4 13.0 20.7 p<0.001
a - 50 glass tubes per treated series, 
b - significance as determined by x2*
Table 5.6
The mutagenicity of 3-OHBP, 7-OHBP, 9-OHBP and their sulphate
esters in TA98 with metabolic activation by aroclor-induced 
S9 in the fluctuation test
Concentration Average number of tubes
pM .........positive
3-OHBP
10.0 40.0***
5.0 37.5***
2.5 18.0***
0.5 7.0
7-OHBP
10.0 16.0***
5.0 12.5**
2.5 10.5*
9-OHBP
10.0 36.0***
5.0 34.0***
2.5 22.5***
0.5 1 2.0**
3-O-SO .BP 4
20.0 16.0***
10.0 13.0**
5.0 6.5
2.5 3.0
7-O-SO BP
4
10.0 1 1.0*
5.0 8.5
2.5 5.5
9-0-S04BP
20.0 b33.0***
10.0 16.5***
5.0 5.0
2.5 4.0
BP
20.0 44.0***
0 .......... ........... 4.0
a - results obtained from two separate experiments, 
(50 glass tubes per treated series). 
b - result from a single experiment.
Significance determined by x2 *** p<0.001
** p<0.01
* p<0.05
Table 5.7
The mutagenicity of 3-OHBP, 3-O-SQ^BP, 7-0-S0^BP and 9-0-S0^BP 
in T&iOO with metabolic activation by aroclor-induced S9 
in the fluctuation test ^
Concentration
pM
Number of glass tubes .positive., 
(results from a single experiment 
.... 50 tubes per treated series)
3-OHBP
10.0 32.0
5.0 26.0
3-0-S04BP
10.0 50.0**
5.0 50.0**
7-0-SO4BP
20.0 49.0**
10.0 23.0
9-0-S04BP
20.0 14.0
10.0 18.0
BP
40.0 • 44.0**
0 28.0
significance determined by x2 ***p<0.001
** p<0.01
* p<0.05
Wislocki et al., 1976b). In addition,6-OHBP has been shown to spontaneously 
bind to ENA. in ethanol-phosphate buffer as it undergoes autooxidation to 
produce stable 1,6-, . 3,6- and 6,12-diol BP metabolites.
When 3M3-induced microscmes were added for metabolic activation, 
1-OHBP, 3-OHBP, 12-OHBP were equally potent mutagens as ljig/ml BP 
(Table 5.2a), while 2-OHBP was mutagenic at only a single dose in one 
experiment and 9-OHBP was not mutagenic (Table 5.5). The data of Wood et al. 
(1976a) suggested that 12-OHBP was a more potent mutagen than either 3-OHBP 
and 1-QHEP, however the data presented here does not substantiate this.
Wood et al. (1976a) used purified cyt.P-448 for metabolic activation whereas 
the data obtained here was with the unpurified microscmal fraction which 
may account for the differences observed. The use of aroclor-induced S9 
fraction as an alternative for metabolic activation with TA98, showed 
that 9-OHBP was clearly mutagenic, as was 7-OHBP and 3-OHBP (Table 5.6). 
Interestingly, with TA100 (Table 5.7), 3-OHBP was not mutagenic at doses 
significantly mutagenic with TA98.
v The production of 7-OHBP in vivo is thought to be frcm the spontaneous 
non-enzymic isanerization of BP 7,8-oxide, and is thought to be a deacti­
vation route. The mutagenicity observed after metabolic activation indicates 
scms potential biological activity, however in vivo these further metabolites 
may be conjugated and therefore removed. 7-OHBP was a less potent mutagen 
than 9-OHBP and 3-OHBP.
9-OHBP has been shown to be a more potent mutagen than BP (Lubert et al
1979) and to be the major precursor of the BP-deoxyribonucleoside adduct ■ 
after metabolic activation by 3M0-induced microscmes (Jernstrcm et al., 1978) 
It has been suggested that BP 9-OH-4,5-oxide is the actual metabolite 
responsible for the DNA product (Thompson et al., 1976a> King et al., 1976), 
although this adduct is different to that observed in all cultures or 
in vivo. The lack of mutagenicity of 9-OHBP with 3MC-induced microscmes is 
therefore surprising, however, it is possible that the optimal concentration 
of microscmes was not used. Alternatively, the supposed DNA-adduct 
formed in metabolic studies may not occur in the S.typhimurium. BP 4,5-oxide 
has been shown to be a potent mutagen in both S. typhimurium and V79 
(Wislocki et al., 1976a), and it is thought that arene oxides can be 
spontaneously or enzymically converted to dihydrodiols. However, when 
epoxide hydratase is added to BP 4,5-oxide and purified cyt..P-448, the 
mutagenicity is significantly reduced suggesting that if 9-OHBP is further 
metabolised to BP 9-OH-4,5-oxide, the presence of epoxide hydratase may 
further metabolise it to inactive products (Wood et al., 1976 a)..
The mutagenicity of 9-OHBP with aroclor-induced S9 suggests that 
a different metabolic product is produced. The obvious difference in 
induction procedures, therefore producing different metabolites (Nebert 
et al., 1976) may not be the only reason for the differences observed in 
mutagenicity. The metabolism was not by a washed microsomal fraction with 
3M2 Induction, but by a crude S9 fraction with aroclor induction. The 
presence of seme supernatant of the cell may help contribute to different 
patterns of mutagenicity.
It is established that phenols undergo further microsomal metabolism 
although it is uncertain how many epoxides may be introduced into a single 
polycyclic hydrocarbon. The 3-, 6- and 9-OHBP metabolites have been shown 
to be recycled (DePierre & Emster, 1978) and further unspecified metabolism 
take:- place.
The presence of 3-GHBP sulphate conjugates of BP intracellularly in 
rat hepatocytes and human lung cultures has been demonstrated (Cohen et al., 
1976; Jones et al., 1978). There was concern that the physiological 
properties of the 3-O-SO^BP may cause it to persist in humans as its 
molecular weight is lower than the human bile threshold. However, the 
sulphate is also not well cleared in rats, although its molecular weight 
is higher than the rat bile threshold. The sulphates of 1-, 2-, 3-, .7- 9- 
and 12-OHBP exhibited no mutagenicity in TA98 without metabolic activation 
although 7-O-SO^BP was mutagenic in TA100 without metabolic activation 
(Table 5.4). The data suggests chat with the exception of 7-O-SO^BP the • 
addition of the sulphate group has prevented the mutagenic action of the 
phenol metabolites. Neither 2-, 3- or 9-O-SO^BP were mutagenic with 3M3- 
induced microscmes indicating that they are not further metabolised by 
cyt.P-448 dependant reactions. However, when aroclor-induced S9 was used,
3-, 9- and 7-O-SO^BP were clearly mutagenic in TA98. 3-O-SO^BP and 
7-OSO^BP were also mutagenic in TA100. It is likely that these metabolites 
are further metabolised to mutagenic products. 0. Pelkenen (personal 
communication) also observed weak mutagenic responses for both 9-O-SO^BP 
and 3-O-SO^BP in an Ames test with metabolic activation by S9 fraction.
The addition of the sulphate group does not, therefore, completely 
inhibit the further metabolism of the phenol metabolites. The metabolism 
of the sulphate esters may therefore occur at similar sites to the phenol 
compounds resulting in potentially active metabolites. The sulphate group 
may inhibit either the formation or binding of these further metabolites.
It cannot be ruled out that cleavage of the sulphate group may occur using 
aroclor-induced S9 although there is no reason to assume that sulphatases 
are induced by either 3MC or aroclor. However, sulphatases may be associated 
with the cytosolic fraction of the cell and, therefore,not present in 
microsomal fractions, but present in S9 fractions.
The role of sulphate esters is unclear. Their biological activity 
may be important particularly as the presence of 3-O-SO^BP intracellularly 
in hepatocytes has been demonstrated (Jones et al., 1978) and it is likely 
to be formed in a number of other tissues. Glutathione and glucuronide 
conjugation occur to a greater extent than sulphate conjugation (DePierre 
& Emster, 1978) and the formation of sulphate esters may not be a major 
metabolic pathway. The further metabolism of these esters, however, may 
be a step in a possible deactivation pathway allowing easier elimination 
from the cell. The sulphate esters,therefore, are not final deactivation 
products. The biological activity of these esters (as indicated by their 
mutagenicity without metabolic activation) may be of no consequence, although 
it is of interest that they do shew sane biological activity.
It can be concluded from this study that sane phenolic metabolites 
of BP may be further metabolised. Only 1-, 3-, 5-, 6-, 7- and 9-OHBP have 
been demonstrated as actual microsomal metabolites (DePierre & Emster 
1978). The mutagenicity of the 1-, 7-, 9- and 12-OHBP metabolites does not 
correlate with their non-carcinogenicity in mouse skin. However, 2-OHBP, 
which was only weakly mutagenic, has been shewn to be approximately as 
potent a carcinogen as BP in mice (Wislocki et al., 1977) . It has not 
been identified as a microsomal metabolite and is therefore unlikely to 
have any biological significance. The existence of metabolic pathways for 
sulphate conjugates is not unlikely particularly if they are not quickly 
eliminated. The observations of their mutagenicity suggests that they may 
be biologically active, or that they are not final deactivation products 
and require further metabolism before elimination.
One of the limitations of using liver fraction and not whole cell 
systems is demonstrated in this study. It is likely that in a whole cell 
system, metabolites may be conjugated and removed and therefore be unavail­
able for further metabolism, thus sane mutagenic metabolites (such as those 
formed from the phenols) might not be formed.
5.3. MUTAGENICITY OF BENZO(A)PYRENE IN THE PRESENCE BETAMETHASONE
5.3.1 Introduction
• Betamethasone is a fluorine-substituted synthetic steroid which 
has been shown to enhance drug metabolising enzymes in vitro. Enhancement 
is by a mechanism that does not involve de novo protein synthesis 
(unlike induction by such chemicals as phenobarbitone (PB), 3-methylckolanthrene 
(3MC) or aroclor 1254). Acetone, ethylisocyanide and metyrapone have 
been shown to activate the hydroxy lation of certain aromatic amines 
(references cited in Benford & Bridges, 1980). The glucuronyl transferases 
can be activated by a number of chemical or physical means, e.g. detergents 
(Dutton & Burche11, 1977). The mechanism of activation of drug metabolising 
enzymes is as yet unclear. The activation of cyt.P-450 dependant enzymes has 
been suggested to be due to either a change in equilibrium between two 
forms of cyt.P-450 or a direct effect on the rate limiting step in the 
cyt.P-450 sequence (Cinti, 1978). The increase in glucuronyl transferase 
activity may be due to changes (such as on the phospholipid and protein 
of the endoplasmic reticulum membrane) increasing the access Ibility of the 
active site of the enzyme (Illing & Benford, 1976).
Steroids, such as betamethasone, have been shown to selectively 
activate biphenyl 2-hydroxy lation in vitro (Tredger et al., 1976; Benford 
et al., 1980). This activation was also caused by certain carcinogens and 
originally suggested as a screening test for chanical carcinogens 
(McPherson et al., 1974). Benford and Bridges (1980) showed that 
benzo (a) pyrene (BP) hydroxylase activity was also selectively activated by 
the presence of betamethasone. Activation of BP hydroxylase by 
a -naphthof lavone has been reported in rat and human liver and the existence 
of two different forms of the enzyme suggested (Kapitulnik et al., 1977b).
In the light of these observations it was of interest to see if 
betamethasone would affect the microsome-mediated mutagenicity of BP.
5.3.2 Results
The mutagenicity of BP in TA98 in the presence of varying concentrations 
of betamethasone was investigated in the fluctuation test and also in the 
Ames test. Betamethasone itself was not mutagenic to TA98 in either assay 
(Table 5.8).
The mutagenicity of BP with aroclor-induced S9 was apparently 
unaffected by the presence of 0.4 and 0.2 pmol/ml betamethasone in the 
fluctuation test (Table 5.9). However, at concentrations of BP of 1 p.g/ml 
and above, the number of positive tubes exceeded 80% of the total treated.
This allowed only a small margin to detect increases in mutagenicity at
Table 5.8 .
The inutagenicity of betamethasone in TZV98;:in the fluctuation 
test with aroclor-induced S9, and in the Aires test with both 
aroclor-induced S9 and uninduced S9
Fluctuation test
Concentration *. 
betamethasone 
p, mol/tnl
Average number of wells positive 
Aroclor-induced S9
0.4 14.6 (15,18,11)
0.2 10.3 »»
UDrHs.
00
0 10.7 (10,1 1,10)
Ames test
Concentration
betamethasone
•rjjmol/plate
Revertants +SD/plate
Uninduced S9 Aroclor-induced S9
2.0 1 2.0±2.0 21.0±5.1
i:o 9.3±4.4 20.5±6.4
0.2 9.0±4.2 17.3±7.9
0.02 - 15.0±0.5
0 11.0±2.7 14.0±4.4
a - average of three separate experiments, 48 wells per treated series 
in each experiment. Actual data in parenthesis, 
b - average of three separate experiments, duplicate plates at each 
concentration in each experiment.
Table 5.9
The mutagenicity of BP in the presence of betamethasone and 
aroclor-induced S9 in the fluctuation test using T&98
Concentration 
BP jig/tnl
Number of wells positive
Concentration 
betamethasone jjmol/nl
0 ' .0.2 , .0.4
10.0 43.0 (46,40) 47.0 (46,48) 42.0 (43,411
5.0 47.0 (48,46) 47.0 (48,46) 43.0 (42,44)
1.0 43.5 (39,48) 35.5 (41,30) 40.5 (46,35)
0.5 18.5 (16,21) 26.5 (18f23) 21.0 (2 1,21)
0.1 11.0 (1 0,12) 8.5 (12,7) 10.0 (1 0,10)
0.01 6.0 (1 0,2) 7.0 (8 ,6) 11.0 (14,8)
0 10.5 (11,10) 14.5 (1 8,11) 11.5 (16,7)
a - mean of two separate experiments, actual data in parenthesis. 
48 wells per treated series.
these doses. The enhancement of mutagenicity would need to be 
sufficiently high so as to significantly decrease the minimum mutagenic 
concentration of BP. Marginal increases in mutagenicity might, therefore, 
be missed. Decreases in mutagenicity cn the other hand would be detected.
Modifications to overcome this problem would have involved increasing 
the amcunt of betamethasone and BP and the number of tubes used in the 
fluctuation test. Hence, the Ames test was used instead of the fluctuation 
test. Actual colonies of revertants were counted, which allowed changes in 
mutagenicity to be observed at concentrations that could not be investigated 
in the fluctuation test.
The use of both aroclor-induced S9 and uninduced S9 was investigated. 
Fig. 5.2 and 5.3 (and Tables 5.10a and 5.10b) show the dose responses with 
BP in the presence of betamethasone. BP formed a precipitate when added to 
the agar at concentrations above 20 jl g/plate. This prcblem also occurred 
in the fluctuation test above 10 pg/ml. When precipitation occurs it is 
not possible to define the exact concentration of BP in solution. However, 
concentrations at which precipitation occurred were used.
The results with aroclor-induced S9 indicated a clear effect of 
betamethasone on the mutagenicity of BP. There was no significant effect 
on the mutagenicity of BP at a BP concentration of 100p.g/plate or lp, g/plate. 
At 20 p.g/plate BP, the mutagenicity was enhanced by the presence of various 
concentrations of betamethasone, the lowest concentration of betamethasone 
(0.02pmol/plate) ■ causing the largest increase in mutagenicity. The 
increase in mutagenicity, however, declined with increasing concentration 
of BP, there being a significant decrease in mutagenicity at 50 pg/plate 
BP.
The effects on the mutagenicity of BP by betamethasone with uninduced 
S9 was less clear (Fig. 5.2). The presence of betamethasone generally caused
a reduction in the mutagenicity of BP. At a concentration of 2 pmol/plate
betamethasone a signification reduction in mutagenicity occurred with 
10 p, g/plate BP and 100 jig/plate BP (Table B.lOa). Although a reduction at
50 jig/plate BP was observed, this was not statistically significant. At
1 pmol/plate betamethasone, a wide variation in results was observed and 
hence it is not possible to draw any conclusions as to whether significant 
inhibition had occurred. At a lower concentration of betamethasone 
(0.2 pmol/plate) significant inhibition occurred with 20 jig/plate and 
50 p.g/plate BP, and an increase in mutagenicity was observed at 100 p.g/plate.
5.3.3 Discussion
Drug metabolism may be manipulated in several ways. .Pretreatment of .: 
animals with chemicals such as PB, 3MC or safrole can induce drug
Table 5.10
The effect of betamethasone on the mutagenicity of BP in the 
Ames test in TA98 in the presence of uninduced S9 (Table 5.11a) 
and in the presence of aroclor-induced S9 (Table 5.11b)
Table 5 JQa Uninduced S9.
clNumber of revertants±SD/plate
Concentration Concentration
BP betamethasone
pg/plate pmol/plate
-
0 0.02 0.2 1.0 2.0
0 11.0±2.7 — 9.0±4.2 9.3±4.4 1 2.0±2.0
1 23.3±8.1 - 21.3±4.9 21.2±1.3 19.5±3.5
10 41.7+2.4 - 36.3±7.2 34.7±11.0 28.5±4.5*
20 49.5±6.5 - 33.3±6.4 30.0±16.0* --
50 53.3±9.1 - 38.3±4.6* 38.8±14.4 42.0±6.0
100 55.5±2.5 56.6±0.5 35.5±1.5 * 34.5±5.5*
Table 5.10b Arolcor-induced S9
ciNumber of revertants±SD/plate
Concentration Concentration *
BP
pg/plate
betamethasone
pmol/plate
0 0 .02b 0.2 1.0 2.0
0 14.0±4.4 15.5 17.3±7.9 20.5±6.4 21.0±5.1
1 29.3±6.8 33.5 32.5±7.8 44.3 ±13.9 45.0±5.0*
10 47.8+24.4 126.5 112.8±14.6** 143.0±20.3** 128.0±9.0**
20 82.8±20.6 176.0 155.8±19.4** 154.0±2.8** 155 .-5 ±18.5**
50 180.3±19.4 108.5* 120.3±26.6 * 147.0±15.5 1 2 1.0 ±1 0.0**
100 160.5±7.5 169.0 143.7±7.8* 169.0±12.8 174.0±3.0
a - mean, of two separate experiments, duplicate plates in each experiment, 
b -mean of duplicate plates in a single experiment.
Result significantly different from BP without betamethasone ** p<0.01
* p<0.05
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Figure 5.3 The effect of betamethasone on the mutagenicity of
benzo(a)pyrene in TA98 in an Ames test with aroclor-induced S9. 
The concentration of BP is a logarithmic scale.
metabolising enzymes. The addition of substrates (e.g. norharman) in 
vitro that canpete for metabolising enzymes may be used to enhance or 
decrease the activity of a chemical (Ashby & Styles, 1978). The selective 
activation of biphenyl 2-hydroxylase in vitro by various carcinogens and 
steroids is another example of modification of drug metabolism (Benford et 
al., 1980). As betamethasone could activate BP hydroxylase in addition 
to biphenyl 2-hydroxylase, it was considered likely that betamethasone 
would enhance the mutagenicity of BP, as hydroxy lation is an important 
step in the metabolic. activation of BP.
The inhibition of BP mutagenicity by betamethasone with uninduced 
S9 is in contrast to that observed with aroclor-induced S9. This inhibition 
observed with uninduced S9 may be due to activation by betamethasone of 
enzymes that cause the production of more non-mutagenic or cytotoxic 
metabolites, than of mutagenic metabolites. The dose of betamethasone 
was unimportant at lcwer concentrations of BP (50 jj, g/plate and lower), 
however , at 100 jig/plate BP normal mutagenicity occurred with 0.2 jjmol/?late 
• betamethasone while higher concentrations of betamethasone caused 
significant decrease in mutagenicity (Fig. 5.2).
The effect cn the mutagenicity of BP with aroclor-induced S9 
(Fig. 5.3), however, was more marked, there being a different pattern of 
mutagenicity in the presence of betamethasone. An enhancement of 
mutagenicity was observed at low concentrations of BP followed by a .decrease 
in mutagenicity at a concentration where the mutagenicity of BP without 
betamethasone was maximal.
Analysis of the metabolites of BP frcm uninduced microscmes in the . 
presence of betamethasone showed a selective increase in 3-OHBP (Benford & 
Bridges, 1980). As already indicated in this chapter, 3-OHBP is a mutagen 
without metabolic activation and a more potent mutagen with 3MC-induced 
microscmes and aroclor-induced S9. The enhancement of the mutagenicity of 
BP may therefore be due to an increase in the production of 3-OHBP and its 
subsequent metabolism. The decrease in mutagenicity observed may be due 
to cytotoxicity of 3-OHBP. However, since the mutagenicity with uninduced 
S9 was not increased, the production of 3-OHBP might not be the only 
explanation. It is not kncwnwhether betamethasone enhances 3-OHBP production 
to a greater extent with induced microscmes.
The pattern of mutagenicity of BP in the presence of betamethasone 
with aroclor-induced S9 suggests that at low concentrations of BP, 
betamethasone causes the activation of the first enzyme responsible for 
BP mutagenicity (possibly through the production of 3-OHBP). At higher
concentrations of BP the normal enzymes for metabolic activation came 
in to operation. The lower concentrations of betamethasone appear to be 
more effective in modifying the mutagenicity of BP, although all 
concentrations caused seme effect.
The effect of betamethasone with aroclor-induced S9 at low 
concentrations of BP is similar to the effect observed when the concentration 
of S9 is lowered in experiments involving a liquid rpre-incubation 
(Malaveille et al., 1979). An increase in BP mutagenicity occurs by lowering 
the S9 concentration. With S9 concentrations higher than those required for 
optimal BP mutagenicity, the cjwxn.fi hj of metabolites being deactivated (either 
by further oxidation, conjugation with glutathione or reaction with 
nucleqphilic sites in the S9) is greater than their rate of formation. 
Betamethasone,therefore,causes activation of enzymes such that the rate of 
formation of active metabolites increases. The observed decrease in mutagen­
icity may therefore be duef sinply,to the rate of deactivation becoming 
greater than the rate of activation.
The mechanism of action of betamethasone has been suggested to 
involve either two enzymes, or a single allosteric enzyme (Benford & Bridges, 
1980). It is unlikely to involve cyt.P-448 since 3MC induces a greater 
increase in 5,6-diol BP and 9,10-diol BP formation as compared with 9-CHBP 
and 3-OHBP formation, whereas betamethasone induces mainly 3-OHBP production. 
Betamethasone appears to be very selective in its activating effects on 
cyt.P-450 dependant enzymes. The nature of the activation is not clear and 
further investigations are required.
The study on the mutagenicity of BP in the presence of betamethasone 
is in its preliminary stages. Chemicals that activate drug metabolism and 
therefore modify the metabolism of certain chemicals provide useful tools in 
the investigation of both the nature of drug metabolising enzymes 'and the 
metabolic pathways of chemicals such as BP. The effects of betamethasone on 
cyt.P-450 may be valuable in studying both the properties of cyt.P-450 and 
its role in the activation and deactivation of chemicals such as BP.
This study is a clear indication of one limitation of the fluctuation 
test. By using the fluctuation test, it is only possible to assess changes 
in mutagenicity at concentrations which do not cause all the tubes (or wells) 
to be positive. This is a disadvantage, particularly if a dose dependant 
effect is being investigated.
5.4. MUTAGENICITY TESTING CF OILS
5.4.1 Introduction
The development of the petroleum industry has led to the exposure 
of a large number of people to industrial oils resulting in concern as to 
the biological activity of such products (Epler et al., 1977). There 
have been reports of skin cancer among workers in a coal-liquefaction 
plant, and that fractions of hydrogenated coal oils might be carcinogenic 
(Epler et al., 1978a).
Industrial oils such as synthetic fuels are a mixture of ccmpouhds, 
and it has been suggested that the best approach in assessing the mutagenicity 
of such mixtures is to fractionate them and then test the separated fractions. 
This would lead to greater ease in identifying the chonicals involved.
Epler et al. (1977, 1978b) suggested a scheme for the fractionation of 
crude oils prior to mutagenicity tests. They detected mutagenic activity 
in various fractions of seme synthetic oils. It was found that the crude 
sample was toxic to the bacteria and, therefore, difficult to test.
The studies of Epler1 s group have clearly indicated the success of 
fractionation of sample prior to testing for mutagenicity. However, there 
is still a need to assess the complete oil sarrple for its mutagenic activity. 
The mixture of chemicals may have a different biological activity than the 
separate fractions and exposure is usually to the crude sample.
Six oil samples were obtained, which consisted of a sample of unused 
oil, two samples of oils after various time periods of use, and three samples 
that had undergone various stages of a recycling process. The process has 
been shown to produce PAHs in the oils. It was also known that the used oils 
contained significant quantities of PAHs.
5.4.2 Results
The physical properties of each oil were as follows:
Oil 1 - Clear yellow oil
2 - Clear yellow/orange oil
3 - Clear yellow/orange oil
4 - Black oil
5 - Thick black oil
6 - Clear yellow oil
Oil 6 was a sample of unused oil. Oils 4 and 5 are samples of oils after 
extensive use, while oils 1 - 3  were frcm various stages of a reclaiming 
process, oil 1 being the most refined.
Samples of each oil were suspended in a number of solvents, ethanol,
acetone, DMSO, IMF and 1,4-Dioxan. The samples were shaken at 37°C for 
30 mins. After this time significantly greater amounts of the samples 
were dissolved by 1,4-Dioxan as judged by the eye.
The intention was to test the whole sample, and not fraction si 
However, only 1,4-Dioxan soluble components could be tested. Oils 1, 2 and 
6 were completely dissolved at 50 mg/nl while oil 3 formed an enulsion 
and oils 4 and 5 did not completely dissolve.
The mutagenicity of 1,4-Dioxan was assessed (Table 5.11) and found to 
have no significant mutagenic or toxic effect when tested at concentrations 
of up to 10 jj. 1/ml.
The sarrples were dissolved at concentrations of 50 mg/ml, and the 
highest concentration of 1,4-Dioxan used was 4 p. 1/ml. At concentrations 
of 200 jig/ml and 100 jig/kil in the aqueous test media, oily droplets were 
observed on the surface. The mutagenicity was assessed in a fluctuation 
test without metabolic activation and with metabolic activation by aroclor- 
induced S9 in TA98 only (Table 5.12) .BP was used as a positive control as 
it was known that PAHs were present in these oil samples. At the con­
centrations tested • oils 1, 2, 3, 5 and 6 were not mutagenic. Only oil 
4 exhibited an extremely weak mutagenic effect that was reproducible 
over three experiments. This mutagenicity was not confirmed by testing at 
higher concentrations. It is therefore questionable as to whether this 
response is significant.
5.4.3 Discussion
Oils are a complex mixture of chemicals, comprising of fractions 
soluble in a variety of solvents. There was a particular problem in 
getting the oils into solution so that the whole sample might be tested.
The use of detergents was considered inappropriate since these were toxic 
to the bacteria and were difficult to sterilise (A. Pegnier, personal 
communication). Solvents such as acetone, DMSO and ethanol did not 
dissolve the samples very effectively. Therefore, the data only reflects 
the 1,4-Dioxan soluble portion of the oils.
The absence of any significant mutagenicity, with the exception of 
oil 4, is interesting as Epler et al.', (1977, 1978a, 1978b); found that a large 
variety of oils were mutagenic when fractionated. It was shewn that 
metabolic activation was also necessary (Rao et al., 1978). The mutagenicity 
was mainly associated with the basic fraction (in which aromatic amines, 
alkylpyridines and quinolines may be responsible for mutagenicity) and the
Table 5.11
The mutagenicity of 1,4-dioxan in T&98 in the fluctuation 
test, without metabolic activation and with metabolic 
activation by aroclor-induced S9
Concentration 
1,4-dioxan
ciNumber of tubes positive
-S9 +S9
10.0 12.0 17.0
7.5 13.0 18.0
5.0 16.0 20.0
2.0 17.5 18.0
1.0 19.5 14.0
0 13.0 14.0
a - 50 glass tubes per treated series. Average of twc 
experiments without S9 (-S9) ,and results from 
a single experiment with S9 (459).
Table 5.12
The mutagenicity of six oil .samples in TA98 in the fluctuation 
test with metabolic activation by aroclor-induced S9
Concentration 
of oil
jjg/ml
No. of 
experiment
Average number of wells 
positive
Significance13
control treated
Oil 1
200 1 19.0 15.0 n.s.
100 4 18.5 18.8 n.s.
10 3 16.7 17.6 n.s.
1 2 15.0 15.5 n.s.
Oil 2
200 1 20.0 20.0 n.s.
100 4 18.8 20.8 n.s.
10 3 16.0 14.6 n.s.
1 2 15.0 13.5 n.s.
Oil 3
200 3 21.0 22.3 n.s.
100 3 19.3 23.3 n.s.
10 2 22.0 19.5 n.s.
1 2 22.0 25.5 n.s.
Oil 4
200 3 21.0 28.3 p<0.05
100 2 20.0 2 0 .0 ' ■n.s.
10 2 22.0 22.0 n.s.
1 2 22.0 22.5 n.s.
Oil 5
200 2 22.0 24.0 n.s.
100 2 22.0 20.5 n.s.
10 2 22.0 22.0 n.s.
1 2 22.0 22.5 n.s.
Oil 6
200 2 22.0 22.5 n.,s.
100 2 22s0 24.5 n.s.
10 2 2 2 .0 * 23.0 n.s.
1 2 22.0 25.5 n.s.
BP
1 4 15.5 26.0 p<0.001
a - 48 wells per treated series, 
b - significance determined by x2*
neutral fraction (in which PAHs such as benzanthracene and benzo (a) pyrene 
may be responsible for mutagenicity). Interestingly, synthetic fuels 
showed greater mutagenic activity than crude natural oils.
Fractionation of these particular oils may have led to greater 
mutagenicity particularly as they are kncwn to contain PAHs. It is, 
however, possible that artefacts might arise during the fractionation 
procedure resulting in modification of potential mutagens. In the whole 
sample, chemicals may act either synergistically or antagonistically with 
respect to both metabolism and mutation. Such interactions would be lost 
on fractionation. Therefore, there is a need to be able to examine the 
complete sample.
It was noticed; that, although most of the oil was soluble in 
1,4-Dioxan, on addition to the aqueous test medium oily droplets formed.
It is possible that lipid soluble mutagens (or prcmutagens) may partition 
into the oil making them less available to exert a mutagenic effect and 
also unavailable for metabolic activation. Both BP and 2AAF showed reduced 
mutagenicity when they were tested as solutions in com oil, presumably 
due to selective partitioning in the com oil (M.H.L. Green, personal 
coimunication). This would favour the fractionation of oil samples such 
that such partitioning cannot occur.
Although these samples were not fractionated, a weak mutagenic 
response in a sample of oil after extensive use was observed. The oils 
that had been reclaimed did not show any mutagenicity.
The problems of testing chemicals such as oils has only been dealt 
with in a preliminary manner. It is evident that testing such complex 
corpounds needs further investigation. The treatment of oil samples by 
fractionation is currently being reviewed and further developed to remove 
the possible artefacts (Epler et al., 1979).
CHAPTER 6 - GENERAL DISCUSSION
The fluctuation test is an alternative means of measuring bacterial 
mutation +o ..the Ames test which is widely used as a screening test for 
chsnical carcinogens and mutagens.
In the present study it has been modified to be used in a more 
convenient form than previously described (Green & Mariel, 1976; Green 
et al., 1977a, 1977b) . However,several problems in performing the fluctuation 
test have been observed during this study and must be taken into account 
when carrying out the assay. When the fluctuation test is carried out in 
different volumes of incubation mixture (such as when using different vessels 
for the experiments) ,an alteration of the required amino acid (in this case 
histidine) is necessary, the ratio of total amino acid to bacteria present 
being important. Excess histidine causes a greater growth of bacteria in 
the initial incubation period, and a large volume of selective indicator 
is then required to dilute the effect of the acid released by the bacteria 
present. There is also,therefore, a minimum volume of selective indicator 
which may be used, below which there is very little visible distinction 
between wells containing revertants and those not containing revertants.
By altering the buffering capacity of the selective medium and changing 
the pH indicator (as in Gatehouse, 1978), the problen of the acid release 
by his (non-revertant) bacteria may be overcame. Another problem- 
encountered was that if deionised water was used in the selective medium, 
no pH change was detectable unless bromo-thymol blue was used as the pH 
indicator.
The high spontaneous mutation rate of TA100 caused the need to 
modify the conditions of the fluctuation test. The number of bacteria 
used is ten times less than for TA98 and other bacteria strains. ' Even with 
this modification and also reducing the histidine present, the number of 
spontaneous revertants is still considerably higher than other strains.
It is likely that the number of spontaneous revertants m y  be reduced by 
using less bacteria, however, sensitivity m y  be lost. In the presence 
of hepatocytes, but not S9, extensive modifications were required to allow 
TA100 to be used. On occasion all the wells in the spontaneous control 
contained revertants, and the experiment was invalid. As dicussed in 
Chapter 3, the addition of a second plasmid (pKMll$) to TA100 m y  help to 
reduce the spontaneous mutation rate.
In studying modifications of drug metabolism by betamethasone (Chapter 
5), a further limitation of the fluctuation test was encountered. Dose
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(at non-toxic doses), frequently all wells contain revertants. It is 
therefore not possible to make ccraparitive studies at these concentrations.
A similar situation was observed at high concentrations when comparing the 
metabolism of 2AAF under different conditions of metabolism (uninduced S9, 
PB-induced S9, aroclor-induced S9 and isolated hepatocytes). At concen­
trations of lOjig/ml 2AAF and above^no comparison of mutagenicity was 
possible.
Despite problems encountered in the fluctuation test, it has a number 
of advantages over conventional plate mutation assays. The test is easily 
automated, although it is more time consuming than plate assays. The 
fluctuation test allows bacteria to grow and mutate in the presence of a 
constant low concentration of test chemical. In a conventional Ames test, 
diffusion from the agar overlay may make it necessary to use a higher 
initial concentration.of chemical. Normally this will not matter, but in 
the case of toxic, weakly mutagenic agents it may be critical. Another 
advantage of the fluctuation test is that when testing water samples for 
traces of mutagenic activity, up to 90% of the water in the treated sample 
can be replaced with the water sample under test.
The test can be used with a variety of organisms and can be employed 
to measure avariety of genetic end-points in addition to reversion to 
amino acid indepedence. Provided that during the first 16-18hr incubation 
period,growth is limited in a non-selective way, in the second stage a 
suitable selective medium can be added and genetic end-points such as 
mutation to bacteriophage or antibiotic resistence can be scored.
Another important advantage of the fluctuation test is that the 
metabolising system can be varied while avoiding the problems of adverse 
affects of soft agar which is used in the Ames test. The importance of 
metabolising systems is clear as many chemicals require metabolic activation 
to exert a mutagenic (or carcinogenic) reponse. As discussed below,- as 
the test is performed in liquid, isolated cells such as hepatocytes as well 
as cell fractions may be used for metabolic activation.
In short-term screening tests, the most commonly used metabolising 
system is the S9 fraction of the liver, most often frcm aroclor-pretreated 
animals. Little attention has been paid, in general, to the quality of the 
enzyme preparations and seme variation of results seen in the literature 
(as for chemicals such as DAB and urethane) may be due to variations in the 
in the quality of the metabolising systems. It is important that care is 
taken when preparing a metabolising system that over homogenisation does 
not occur as this may impair the quality of the fraction. Differential
loss of enzymes may result if the preparation is allowd to warm above 4'C 
without NADP present (the amine oxidase enzymes are particularly vunerable 
(Kitchell et al.,1976)), or if inappropriate storage and thawing is carried 
out. It is also important that the S9 fraction be standardised. In this 
study fresh batches of uninduced S9 were monitored for their ability to 
convert 2AAF to mutagenic intermediates. However, for general screening 
purposes, routine determination of particular enzymes is a better indication 
of the quality of the fraction. Routine monitoring of amine oxidase (as 
indicated by the N-oxidation of dimethylaniline), is probably a good 
indication of adequate preparation procedures, whilst determination of 
ethoxycoumarin-O-deethylase, acetanilide and BP-3-hydroxylation are 
indicators of cyt.P-450, cyt.P-448 and cyt.P^-450 type enzymes activities 
respectively.
The use of a single S9 concentration and a single type of S9 fraction 
(i.e. aroclor-induced S9) may give erroneous results. As shown in the 
present study,and -as observed by other workers (Malaveille et al., 1979), 
there is an optimal S9 concentration for maximum mutagenic response of a 
chemical. Although the reasons are not certain for this S9 optimum, 
it is clear that the use of a single S9 concentration may be inadequate 
as the mutagenicity may be severly reduced or missed altogether. This is 
exemplified by the observations in chapter 3 that uninduced S9 appears to 
be very much more efficient than aroclor induced S9,at a single S9 con­
centration, in metabolising 2AAF to mutagenic intermediates in the fluctation 
test , while the converse is true in the Ames test. It is apparent, however, 
that this difference is only due to the .different S9 optimum for each 
type of S9, the optimum for aroclor-induced S9 being very much lower 
than for uninduced S9 in both the Ames test and the fluctuation test.
The use of a single type of S9 is also, in seme cases, inadequate, as 
shown by the results obtained with DAB and urethane which were not mutagenic 
with uninduced S9, but were mutagenic with aroclor-induced S9. It is 
possible that by varying the uninduced S9 concentration both chemicals may 
have been mutagenic. Although aroclor is a good inducer of drug metabolism, 
it has a detrimental effect on the liver in vivo, making the liver fragile, 
and making it very difficult to prepare hepatocytes. Also^ large amount 
of polychlorinated biphenyls is present in the liver which may cause 
competitive inhibition of cyt.P-450 dependent activity. As an alternative 
to the use of aroclor, induction by PB and cmaphthoflavone has been 
suggested (Matsushima et al. , 1976)
It is in the study of S9 optima that seme of the differences between 
the fluctuation test and the Ames test were observed. The reason for the 
differences in the optima in each test is~ not certain. Other differences
between tests performed in liquid and agar have been observed for 
nitrosamines (Bartsh et al., 1976). It is difficult to ascertain which
test gives a truer reflection of the performance of S9, however, it is 
possibly advantageous to use a fluctuation test as most in vitro metabolic 
studies have been carried out in the liquid phase.
With respect to metabolic activation, a significant advantage of the 
fluctuation test is that isolated cells such as hepatocytes can be readily 
incorporated. However, the co-incubation of hepatocytes and bacteria under 
the condition of the fluctuation test poses limitation on the choice of 
medium. As dscussed in Chapter 3, hepatocytes became nan-viable in bacterial 
medium, modified mammalian tissue culture medium isr.therefore required, which 
also reduces the histidine content in the test. By using isolated 
hepatocytes, a closer profile to that observed in vivo should be obtained. 
Many metabolites that in vivo would be conjugated and rendered harmless, 
but in vitro are mutagenic with S9, are likely to be negative with 
hepatocytes. From the diverse results obtained in this study it is 
apparent that a number of different responses between S9 and hepatocytes are 
possible, but frcm single mutagenicity studies it is not possible to 
identify unambiguously the reason for the different responses. Particularly ' 
of note is that toxicity towards the hepatocytes might cause a mutagenic 
response that is in fact an artefact of this toxicity (causing excess 
release of histidine frcm the hepatocytes) as in the case of DMF.-Sane 
metabolites may not be formed in sufficient quantity in hepatocytes to cause 
a mutagenic response (e.g. O-toluidine and MOCA), or same metabolites may be 
short-lived and not escape frcm the hepatocytes (such as for specific 
hepatocarcinogens). In the present study only a few chemicals were more 
mutagenic with hepatocytes than with S9 (NM, DMA and DMBA), however, 
surprisingly,the aromatic amines which are thought to have conjugated 
carcinogenic metabolites showed reduced mutagenicity (e.g. 2AAF)',or no muta­
genicity (e.g. 2NA). It is only possible to speculate ,based on the 
metabolic profiles, as to why these results occur, however, modification of 
the metabolism in vitro may give further insight. It is likely that con­
current metabolic studies will be required to identify the mutagenic 
metabolites.
Inhibition of conjugation reactions by various chemicals such as 
galactosamine ('inhibitsglucuronic acid conjugation), diethylmaleate (inhibits 
glutathione conjugation) and salicylamide (inhibits sulphate and glucuronic 
acid conjugation), may help to elucidate the metabolites further. Most 
particularly, suppresion of glucuronidation may help explain why 2NA and
1NA are not mutagenic with hepatocytes. Other selective effects on 
metabolism such as inhibition of deacetylation by paraoxon (which may alter 
the mutagenicity of 2AAF) and addition of non-mutagenic chemicals (such as 
norharraan or'azobenzen# that are selectively metabolised by a pathway that 
may activate another chemical, may also aid in identifying mutagenic 
metabolites (as discussed for DAB in Chapter4) . with respect to DMA and 
DMBA, studies involving fluorinated derivatives of these chemicals and 
hepatocytes may confirm the involvement of the methyl groups in the metabolic 
activation of these chemicals.
The fluctuation test serves two roles. It is extremely important as 
a screening test for chemical carcinogens, as by design it accurately mea­
sures the spontaneous mutation rate and small increases over the rate 
may be detected. The test also serves as a research tool.
In the study to validate the fluctuation test (Chapter 4), the assay 
was able to predict the carcinogenicity of the chemicals with a high degree 
of accuracy. The predictivity obtained was of the same order as that of the 
Arres test in several other laboratories (see de Serres & Ashby,. 1980), and 
also a fluctuation test carried out by Gatehouse (in de Serres and Ashby,
1980). Like other tests looking at genetic end-points, the fluctuation test 
is unlikely to find chemicals mutagenic that are carcinogens via epigentic 
mechanisms. In this present study same chemicals that are thought to be 
carcinogenic through non-genetic mechanisms were tested (e.g. DES, 
ethylenethiourea, 3-aminotriazole). For each chemical that was either a 
false positive or a false negative there was a plausible explanation that 
most often came from knowledge of the structure and metabolic profile 
of the chemical. However, some chemicals (DAB, safrole and urethane) appear 
to require more clearly defined metabolic activation systems to exert a 
response. A greater knowledge of the enzymes present and variation of S9 
concentration and induction procedure is likely to be appropriate as in 
the case of urethane and DAB which were found to be mutagenic with aroclor- 
induced S9.
Although in this study there was seme questionable data, the majority 
of this may be clarified by carrying out further experiments to confirm 
the results obtained, particularly when there is one aberrant observation.
If the data in the validation study (Chapter 4) in which a questionable 
result was obtained is not considered (as further clarification is needed), 
then of the 23 carcinogens and 10 non-carcinogens tested adequately (using 
either uninduced S9, aroclor-induced S9 or isolated hepatocytes), a 
sensitvity of 0.74 abd a specificity of 0.6 is obtained. The predictivity 
of all this combined data is therefore rather good. "It is necessary to
clarify the questionable results obtained before making a final assesment 
of this data in the International trial for the fluctuation test. It must 
also be stressed that due to inadequate animal data, sane chemicals 
considered to be non-carcinogenic in this study may prove to be carcinogens 
in future animal studies (e.g., 4AAF and 3M4NQO).
The predictivity o.f the fluctuation test with hepatocytes alone was 
poorer than with S9. Hepatocytes are unlikely to replace S9 as a metabolising 
system in the fluctuation test, and are more likely to serve as a adjunct 
to S9. They may be more useful in confirming results obtained with S9 
particularly with doubtful results. The hepatocytes may be more useful 
when used in studies in relation to in vivo studies to restore species, 
tissue and strain differences which are largely lost in subcellular fractions.
The use of hepatocytes in screening tests is also hampered by the 
membrane barrier between the metabolising system and the response system.
The use of hepatocytes as both the metabolising and response system
may prove to be more suitable for a screening test. However., since primary
hepatocytes do not divide significantly, then mutation and cell transformation
are inappropriate. At present, the most relevant end-point would
appear to be the measurement of DNA repair in primary hepatocytes (see Table ,
1 .6), although other parameters may be used, e.g., production of foetal
proteins, changes in mitotic index and nuclear volume.
The use of hepatocytes may have a more significant place in the second 
role of the fluctuation test. The fluctuation test is a valuable research 
tool particularly in investigating the metabolic profiles of chemicals.
This is exemplified by the study of the mutagenicity of BP metabolites.
The use of mutagenicity assays to help elucidate the metabolic pathways of 
other chemicals such as 2AAF and DMBA has been reported. Because the test 
is used in liquid, parallel metabolic studies under largely similar 
conditions may be carried out to help identify mutagenic metabolites 1 As 
already discussed, modification of the netabolism by many different factors 
may also be used with both subcellular fractions and isolated hepatocytes.
In future studies, the fluctuation test may be useful for helping to 
identify metabolic pathways as already discussed both with hepatocytes and 
S9. The test is easily adaptable for use with cell fractions or isolated 
cell preparations frcm any tissue. Further work is required to help identify 
particular tissue specificity of chemicals . By using the fluctuation test 
with a number of different tissue preparations insight into this aspect 
may be gained.
The fluctuation test clearly has a part to play as a screening test 
for chemical carcinogens and mutagens. Hepatocytes may be useful as an 
adjunct to S9, but are unlikely to be an advantage Wien used alone for 
screening purposes. As a research tool, the fluctuation test has an 
important role particularly in conjunction with hepatocytes.
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APPENDIX 1
Statistical Evaluation of the Fluctuation Test.
In this study the stategy for the evaluation of data is outlined in 
Chapter 2. Simply, a ,2x2 homogeneity x2 is estimated after up to three 
experiments:
2x2 Contingency Table
Wells
negative
Wells
positive Total
Control a b a-fb
Treated c d c+d
Total a+c b+d a-tb+c4d = n
X2 = (ad - be ± in)2 n ' •
(a*4b) (c-fd) (a+c) (b4d)
i
This equation for x2 has been adpated by Green et al., (1976) to be 
used when there is an equal number of wells used in the control and treated 
series. This equation is given belcw without any continuity correction.
X 2 = 2N(t - c)2 (2)
(t+c) (2N - (t + c))
Where N = total number of wells in either the control or treated series, 
t = the number of wells positive in the treated series, 
c = the number of wells positive in the control series.
The use of x2 has been argued against for two reasons (Collings et al., 1980 ; 
Gilbert, 1980). Firstly, that it is not homogeneity that is being tested, 
but the difference between proportions. Secondly, the "critical values"
i.e., the values for x2 with which a significant result is obtained (x2>3.84, 
p <0.05 & x2>6 .6 8,p<0 .01) are for a two tailed test, when in fact a one 
tailed test is more appropiate. This is due to the fact that the test is to 
see if the treated series contains more positive wells than the control series, 
and not whether it is different frcm the control. However, it has to be 
noted that many chemicals are toxic at some doses and cause a reduction in 
the number of positive treated wells as opposed to the number in the control. 
Therefore, the test might be considered as a two-tailed test and not a 
one-tailed test.
As an alternative to x2/these authors propose the use of the z test. 
Gilbert (1980) presents an equation for z2 which is distributed as x2 with 
1° freedom.
z2 = (n21 - nu ) 2 (n- 1) (3)
n .l n .2
This is taken from the following table:
Wells Wells
negative positive
Control n12 n11
Total
n1.
Treated n22 n21 n,2.
Total n.1 n.2 n
If the symbols used by Gilbert are inserted into the equation of 
Green et al.- (eq. 2), then the following equation is obtained:
X 2 =  n ( n 21 -  n n )2
n .ln .2
(4)
Clearly the only difference between this and equation 3 is the use of 
n and not(n - 1) . Since invariably n is greater than 100, it appears that 
the use of z2 offers no advantage over the use of x2*
Aberrant Observations
In Chapter 4, some questionable data was obtained, and, as shown below for 
auramine, this is sometimes based on one dose showing a j. large response in 
one-experiment, but cannot be reproduced in other experiments.
Auramine, TA98 and uninduced S9
Concentration
jig/nl
Number of wells positive 
Experiment number
X2 Significance
1 2 3
0 26 25 19
0 - - 17
10 22 34 19 1.38 n.s.
20 27 34 - 1.93 n.s.
50 21 38* 23 4.22 p< 0.025
100 mmm 2 17.46 toxic
* result much higher than in other experiments. Is this an aberrant 
observation?
±11 c u iy  Jbfcil. u ±  u a u a  t-xxtu-t; xiiciy c u i v a t_lljxx i_j.xo.l- x &  v c u j u l ^  u x x x u l o i l
frcm the other observations. A mistake may have been made and when this is 
known the observation can be rejected. Alternatively, an unknown error may 
have occured. When experiments such as those involved in this study are 
considered, variations in pipetting or diluting might occur. Other"factors 
such as bacterial contamination, or errors in recording the experiment 
may also occur. In dealing with bacteria in which very occasionally the 
spontaneous mutation rate will be excessively high (such as with TA100), 
it will not be unexpected to have a very high observation,be it in the 
control or treated series. Usually when an experiment has a high control 
value, higher than that expected (as discussed in Chapter 2), the entire 
experiment is rejected. When all the parameters of the experiment are normal 
(e.g., negative and positive controls), a unusual observation cannot be 
rejectedunless by a defined criterion. Statistical calculations are 
necessary to reject an observation in seme cases, as limited sample may restrict 
the number of experiments that can be carried out.
Several methods of statistical analysis that may be used to reject or 
accept such observations are presented here. Other methods may also be 
applicable.
Collings et al., (1980) suggested a method for rejecting aberrant 
observations based on studentized analogues of the observations. However, 
they do not present a working hypothesis and other approaches are necessary.
A simplistic way of dealing with an aberrant observation is to calculate 
the standard deviation of the mean and it is usual to reject observations
' I
that are more than two standard deviations frqn the mean. The meaniSD in the 
case of the data for auramine at 500jjg/fril is 27.3±7.6. Observations 
greater than 42 should therefore be rejected. However, in this particular 
set of data the so called "aberrant" observation is 38, and should not 
be rejected. This is an inefficient method as the mean is affected by all 
the observations. It is mare efficient when there are ten or more observations, 
although again all observations affect the mean.
Chauvenet's Criterion (Pugh & Winslow, 1966), in which the limiting 
probability of occurance of acceptable observations depends on the number of 
observations, is a possible method of dealing with aberrant observations.
In this method only one observation at a time may be rejected and then X 
(a value set as as the distribution limit of acceptable observations) must be 
recalculated. In a set of n readings, the distribution from the mean is 
calculated. 2nP is the area under the distribution curve for-X < v <:+X.X
. 2nP is the number of distributions less than X and therefore the number
X
of distributions greater than X is (n - 2nP ). If P is large enough suchX X
that (n - 2nP ) is less than 0.5, it is likely that a result different from 
the mean by more than X does not belong to the same distribution.
The limit if rejection is given by
I = n(l - 2Px)
or P = 2n - 1 (5)x --------  .
4n
For the data of auramine at 500jig/inl P = 0.417. Frcm a table for theX
integral of the normal distribution function, P reaches 0.417 when
X/er = 1.39, where a = the standard deviation which for the data at 500jig/fril
auramine is 7.6 and X = 10.6. Therefore, observations differing by more than
10.6 from the mean should be rejected. The observation of 38 wells
positive differs by 10.7 frcm the and is therefore considered to possibly
be an aberrant observation, although it is only just outside the limit of
rejection.
v An alternative approach is to consider each well as an indepedent 
observation and calculate the sampling error (ap) based on a binomial 
distribution:
o = Vpq/tt (6)
P . ■
where p = proportion of wells negative
g = proportion of wells ’positive (1 - p)
N = total number of wells. ' '
For values N ^ 30 the binomial distribution approximates the normal distribu­
tion. A comparison of the sampling errors for each experiment (performed at 
different times) may be made by calculating standardised variables:
where P^ and 1?2 are the proportion of wells without a mutation in each 
experiment. A value for z can be calculated for pairs of observations 
For the auramine data, the sampling error of the fraction of wells 
negative in each separate experiment is 0.051 (27+) , 0.043 (38+) and 
0.052' (23+). The value for z for pairs of observations is as follows:
23 cf 38, z = 5.31; 21 cf 38, z = 10.81. On the basis of a one-tailed
test at a level of significance of p<0.01, the value of z = 2.33.
Therefore, as the value of z for each pair of observations is greater than 
2.33,it is likely that the observation of 38 wells positive is aberrant.
Although this would appear a satisfactory way of dealing with observations, 
there are other factors that might be considered. For example multiple 
comparisons are made and therefore a correction may be necessary. However, 
a method of making multiple comparisons (Duncan, 1955), relies on a single 
value for the standard error. It may also be necessary to allow for the 
value of the control wells positive as this may affect the result.
Clearly the statisical basis for eliminating an observation in the 
fluctuation test requires further investigations. Several possible ways 
of dealing with such observations have been dealt with and each method 
gives a different result. There is obviously no substitute for the 
repetition of experiments, .an aberrant observation being eliminated when 
several other, experiments do not confirm it.
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APPENDIX 2
Mutagenicity data of chemicals tested in the International Study.
The data presented in this appendix is discussed in Chapter 4. It is- 
in numerical order of code numbers as listed below.
Code Chemical
1 4-Dimethylaminoazobenzene (DAB)
2 3,3',5,5'-Tetramethylbenzidine
3 4 -Acetylaminofluorene (4AAF)
4 1-Naphthylamine (1NA)
5 Pyrene
6 Chloroform
7 Diethylstilboestrol (DES)
8 4-Nitroquinoline-N-oxide (4NQ0)
9 2-Naphthylamine (2NA)
10 4-Dimethylaminoazobenzene~4-sulphonic acid Na salt (methyl orange) 
.11 Benzidine
12 2-Acetylaminofluorene (2AAF)
13 Benzo (a) pyrene (BP)
14 Hydrazine sulphate
15 3-Methyl-4-nitroquinoline-N-oxide (3M4NQO)
16 Not tested
17 Diphenylnitrosamine (DPN)
18 Anthracene
19 Dinitrosopentamethylene tetramine (DNPMT)
20 Ethylenethiourea
21 y-Butyrolactone
22 Methionine
23 Safrole * '
24 Dimethylformamide (DMF)
25 DL-Ethionine
26 Epichlorhydrin
27 N-Nitrosanorpholine (NM)
28 Isopropyl N(3-chlorophenyl)carbamate
29 B-Propiolactone
30 1 /1 > 1 -Tr ichloroethane
31 Urethane
32 Dimethylcarbamoylchloride (D4CC)
33 Azoxybenzene
34 Cyclophosphamide (CP)
35 . 3-Aminotriazole (3AT)
36 4,4' -Methylenebis (2-chloroaniline) (MOCA)
37 Not tested
38 Sugar (sucrose)
39 9,10-Dimethylanthracene (DMA)
40 Ascorbic acid (Vit. C)
41 O-Toluidine hydrochloride
42 Auramine (Technical grade)
strain TA100
NO ACTIVATION
concentration experiment number
CROGRAMS/ML 7 13 17 20 24 28
WELLS POSITIVE
0 , 0 0 0 0 0 0 26 19 20 23 17 18
0 . 0 0 0 0 0 0 .... - - - - -- 16
1 . oooooo 32 21 17 -- - - - -
5.000000 . __ -- 24
1 o.oooooo 31 26 2 A 29 23 22
2 0 . 0 0 0 0 0 0 - - - - - - 14 - -
1 0 0 . 0 0 0 0 0 0 35 14 9 -- — --
concentration number average NUMBER 2 PROBAB
MICROGRAMS /ML OF OF WELLS X I LI T Y
EXPTS. positive
CONTROL TREATED
i , onoooo 3 21.7 23.3 0.28 N.S. 0.0654
5,000000 1 23.0 2470 0 . 0 1 N.S. 0.0408
1 o.oooooo 6 19,9 25:8 9.40 < 0.005 0,2387
2 0 . 0 0 0 0 0 0 1 23.0 14;0 3.13 N.S.
100. OOOOOO 3 21.7 19.3 0.60 n. s;
compou.no 1 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML ' 9 18 19
WELLS POSITIVE
0 . 0 0 0 0 0 0 20 21 23
0 , 0 0 0 0 0 0 - - 17
1 , oooooo 17 21 25
1 0 . 0 0 0 0 0 0 13 18 2.0
ino.000000 15 22 24
induced 
mutants 
PER WELL
CONCENTRATION
micrograms/ ml
1 . 0 0 0 0 0 0  
1 0 .000000 
1 0 0 . 0 0 0 0 0 0
NUMBER AVERAGE NUMBER
of of wells
expts. positive
control treated
compound 1
STRAIN TA100
INTACT hepatocyte ACTIVATION
PROBAB
ILITY
3 2 0 . 2 21-.0 0.05 n. s;
3 2 0 . 2 1 7*. 0 1 ,44 N.s.
3 2 0 . 2 20*. 3 0 . 0 0 N.s,
INDUCED
MUTANTS
per well
0.0274
0.OO30
CONCENTRATION experiment NUMBER
MICROGRAMS/ML 91 88 101
WELLS POSITIVE
0.OOOOOO 12 11 11
0 . 0 0 0 0 0 0 20 13 10
1.OOOOOO 24 - -
10.OQOoOO -- 8 12
50.OOOoOO 13 9
1 0 0 . OOOnOO 8 a 9
concentration
micrograms/ ml
number AVERAGE NUMBER
of of wells
EXPTS. POSITIVE
probab
UITY
INDUCED 
MUTANTS 
PER WELL
control TREATED
1.000000 1 16. 0 24. 0 3. 40 N.S. 0,28 77
10.000000 " '
50.000000
1 0 0 . 0 0 0 0 0 0
1 16. . .4
2 1 1 . 2 1 0 . 0 0.18 N.S.*■> 13.2 1 1 . 0 0.61 N.S.
3 1 2 . 8 8:3 4.42 TOXIC
u u u p u u n d I 
STRAIN TA98 
NO activation
CONCENTRATION
M I crograms/ ml
0 . oooooo
0.OOOoOO 
1,OOQnOO
4 0 . oooooo 
1 * 0 , oooooo
EXPERIMENT number 
3 12 21 .22 25
WElLS 
8 4
POSITIVE 
6, 6 a
■* — -- g 5
a 6 6 6 --
9 11 4 — --
5 4 3 7 12
29
CONCENTRATION number AVERAGE NUMBER 2 probab • INDUCED
micrograms/ ml Of of wells X ILITY mutants
. EXPTS. positive PER WELL
CONTROL TREATED
1 . OOOOOO 4 6.4 6 '. 5 0 . 0 0 N.S. 0.0024
1 0 . 0 0 0 0 0 0 j 6.5 8 . 0 0.52 N.S. 0.0368
1 0 0 . oooooo 6 6.5 6 . 8 0.04 N.S. 0.0081
COMPOUND 1 
STRAIN TA98 
S9 ACt IVATIOU
concentration
MICROGRAMS/ML
EXPERIMENT NUMBER 
1 A 8 33
WELLS POSITIVE
0 . oooooo 15 21 11 15
0 , 1 OOoOO - ~ 16 -- --
1 .‘ OOOoOO 21 18 6
1 0 . OQQd OO 1-6 15 11 m m
10 0 . OQOoOO 13 .... 9 18
concentration
MICROGRAMS/Ml
number average-number 
of of wells
EXPTS, POSITIVE
probab
ility
INDUCED' 
MUTANTS 
PER WELL
CONTROL TREATED
0 . 1oooon 1 2 1 . 0 1 6 . 0 ' 0 . 8 9 N.S
1 . oooooo 3 1 5 . 7 • 1 5 : 0 0 . 0 4 N.S
1 o . oooooo 3 1 5 . 7 1 4 . 0 0 . 3 3 N.S
1 0 0 . ooooon 3 1 3 . 7 13*. 3 0 . 0 0 N.S
compound 1
STRAIN TA98
intact hepatocyte activation
concentration
micrograms/ ml
EXPERIMENT NUMBER 
45 46 47
WELLS POSITIVE
0.OOOOOO 12 15 5
0 . oooooo *•- 17 7
1 .oooooo 19 16 7
1 0 . ooonoo 13 16 15
1 *>0 . oooooo 12 15 10
concentration
Ml CROC,RAMS /ML
n'Mb.er average number 
of of wells
EXPTS. POSITIVE
probab
ILITY
INDUCED 
MUTANTS 
PER WELL
1.00000n 
1 o.ooooon
10D.0OU00O
control treated
1 .2
‘<1.2
11 .2
1410 
1 4.7 
<2.3
1 . 46
2.25
0.21
N.S.
N.S.
N.S.
0.0701 
0.0089 
0.0313
NO ACTIVATION
concentration experiment number 
HICR0C,R4MS/ML 418 401 404 406 411 413  
WELLS POSITIVE
o.oooooo 21 26 17 16 23 9
o.oooooo 14 25 29 20 16 11
i o . o o o n o o - - 27 14 17 -- 10
1 0 0 . oooooo -- 17 10 27 --
2no.OOOnOO - - 16 22 22 -- - -
4 0 0 . OOOOOO - - *f m -- - - 18 - -
5 00 .  0 00 00 0 17 —  —  - -  —  7
CONCENTRATION •NUMBER AVERAGE number 2 probab induced
MICROGRAMS/ML OF of wells X il ity MUTANTS
EXPTS. positive PER WELL
control treated
10.OOOOOO 4 19.1 17.0 0.97 N.S.
1 0 0 . 0 0 0 0 0 0 3 2 2 . 2 ' 18.0 2.77 N.S.
200.OOOOOn 3 2 2 . 2 2 0 . 0 0.70 N.S.
400.OOOOOn i 19.5 18-.0 0.07 N.S.
500.OOOOOn 2 13.7 1 2 . 0 0.34 N.S.
COMPOUND 2. 
STRAIN TA100 
SO ACTIVATION
CONCENTRATION EXPERIMENT NUMBER 
MICROGRAMs/ML 419 424 407 409 415 
WELLS POSITIVE
o.oooooo 32 19 24 24 23
o. oooooo 33 21 24 22 25
1 . ooonoo 35 21 -- .... 14
1 0 . ooonoo 30 16 27 31 27
1 0 0 . ooonoo 26 -- 25 37 18
2 0 0 . 0 0 0 0 0 0 — -- 25 37 13
500.ooonoo 39 22 - - -- - -
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X ILITY MUTANTS
EXPTS. POSITIVE PER WELL
CONTROL treated
1 . ooooon 3 2 5 . 5 2 3 , 3 0 . 7 0 N.S.
1 o.oooooo 5 2 4 . 7 26T2 0 . 5 7 N.S. 0 . 0 6 6 5
1 0 0 . 0 0 0 0 0 0 4 2 5 . 9 2 6 . 5 0 . 0 6 N.S. 0 . 0 2 8 7
2 0 0 . ooooon J 2 3 . 7 2 5 . 0 0 . 2 4 N.S. 0 . 0 5 6 4
5 0 0 . ooooon 2 2 6 . 2 3 0 . 5 1-.88 N.S. 0 . 2 1 7 4
compound. 2
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 91 88 101 107
WELLS POSITIVE
0 . ooonoo 12 11 11 12
0 . 0 0 0 0 0 0 20 13 10 14
5 0 ; ooonoo 20 - - 8
1 0 0 . OOOnOO 25 13 14 6
5 0 0 . 0 0 0 0 0 0 12 8 8 " -
CONCENTRATION
micrograms/ ml
5 0 . OOOOOn 
1 0 0 . OOOOOn 
5 0 0 . OOOOOn
number average number 
of of wells
EXPTS. POSITIVE
CONTROL treated
13.2
1 2 . 9
12.8
14,0
14.5
9.3
0 . 0 4
0 . 6 5
2 . 5 8
PROBAB
ILITY
N.S.
N.S,
N.S.
INDUCED
MUTANTS
per well
0.0218 
0.0474
CONCENTRATION experiment number 
MICROGRAMS/ML 422 433 403 405 412 417 
WELLS POSITIVE
0 . OOOoOO 7 10 3 13 6 15
o. ooonoo 9 14 6 18 9 11
1.  00.0nOO - ~ - - - - - - - - 8
1 0 . 000D00 6 2 8 4 13
1 0 0 , OOOnOO 5 - - 5 12 ", 10
2D0.OOOnOO 1 - -  . 5 8 * - -
5 0 0 , ooonoo 0 15 8
CONCENTRATION number average number 2 PROBAE
MICROGRAMS/ML OF OF WELLS X il ity
EXPTS. POSITIVE
CONTROL treated
1 . ooooon 1 1 3 . 0 8 . 0 1 . 6 5 N.S.
1 o.oooooo 5 9 . 7 6 . 6 4 . 2 9 TOXIC
1 0 0 . ooooon 5 9 . 7 6 . 6 4 . 2 9 TOXIC
2 0 0 . oooooo 4 8 . 9 3 . 7 11 . 0 7 TOXIC
5 0 0 , 0 0 0 0 0 0 3 1 1 . 0 1 0 . 7 0 .0 1 N.S.
COMPOUND 2 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION
MICROGRAMS/ML
EXPERIMENT NUMBER 
420 425 430 416 
WELLS POSITIVE
o.ooonoo 17 16 27 9
0 . ooonoo 23 5 15
1 . 0 0 0 0 0 0 - » m 33
i o . o o o n o o 21 7 - - • 5
1 0 0 . ooonoo 15 4 - - 5
2 0 0 . ooonoo 17 4 - - 6
5 0 0 . ooonoo 23 2 33 - -
concentration number average NUMBER 2 probab
MICROGRAMS/ML OF OF WeLLS X ILITY
EXPTS, POSITIVE
CONTROL- TREATED
1.OOOOOn 1 27.0 33,0 1 .34 N.S.
1 o.ooooon 3 14,2 1 1 , 0 1 .94 N.S.
1 oo.ooooon 3 14.2 8 . 0 8.06 TOXIC
2 0 0 . ooooon 3 14.2 910 5.51 TOXIC
500.ooooon 3 17.6 19.3 0.42 N.S.
COMPOUND 2 
STRAIN TA93
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
■MICROGRAMS/ML 49 57 59 61
WELLS POSITIVE
0 . ooonoo 12 4 7 7
o;oooooo 14 3 8 9
' 0 . ooonoo 10 2 --
1 no. ooonoo 9 7 ' 9 - -
2 0 0 . OOOOOO a 6 0 --
5 n o . 000000 - - - - 8 9
concentration
MICROGRAMS/ML
number AVERAGE number 
of of wells
EXPTS. POSITIVF
probab
ility
1 0 . ooooon 2
CONTROL
9.5
treated
6 . 0 2 . 1 2 N.S
1 0 0 , ooooon 3 8.3 8 . 3 0 . 0 4 N.S
2 0 0 . ooooon j 8 . 8 8 , 0 0 . 1 4 N.S
5 0 0 . OOOQOn 2 7.7 8.5 0 . 0 6 N.S
induced 
mutants 
per well
INDUCED 
MUTANTS 
PER WELL
0,3365
0.0587
INDUCED 
MUTANTS * 
PER WELL
0,0188
COMPOUND 3 
STRAIN TA100 
NO ACT I VAT I 0!j
CONCENTRATION EXPERIMENT NUMBER
.MI CROC,RAMS/ML 523 528 S3?
WELLS POSITIVE
0 . ooonoo 11 10 2
o.ooonoo 20 13 5
1^0 . 0 0 0 0 0 0 r. 17 5
500.ooonoo 8 o 7
concentration 
MICROC,RAMS/ML
number average number 
of of wells
EXPTS, POSITIVE
PROBAB 
I LITY
induced
MUTANTS 
PER WELL
1oo.ooooon 
500.000000 3
COMPOUND 3 
STRAIN TA100 
SO ACTIVATION
control treated
1 0 . 2
10.2
10.3
7\7
0.00 
1 .50
n. s;
N. S T
0.0044
CONCENTRATION
MICROGRAMS/ML
experiment number 
524 529 537 
WELLS POSITIVE
o,ooonoo 30 28 36
o. ooonoo 26 24 --
0 . 1 0 0 0 0 0 ■*«, 34 34
1 . 0 0 0 0 0 0 48 42 44
1 0 , 0 0 0 0 0 0 48 48 47
1 0 0 . 0 0 0 0 0 0 48 -- --
CONCENTRATION NUMBER AVERAGE number 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X ILITY MUTANTS
EXPTS, POSITIVE PER WELL
control treated
0 . 1 0 0 0 0 0 2 29.3 34;o 2,13 n. s; 0.2877
1 .oooooo 3 28.8 44 V 7 48.39 < 0,0005 1.7509
1 0 . OOOOOO 3 28.8 4 7.7 72.61 < 0.0005 4.0535
1 0 0 . oooooo 1 28.0 48.0 26.66 < 0,0005 ???????
compound 3
STRAIN TA100
intact hepatocyte activation
CONCENTRATION EXPERIMENT NUMBER
MICPOGRAMs/ML 87 92 96 106 107
WELLS POSITIVE
0.OOOOOO 7 20 10 18 12
0.OOOOOO 14 12 12 10 14
50.000000 20 23 33
1 0 0 , 0 0 0 0 0 0 23 18 20 16
2 0 0 . ooonoo -- -- - - 17 21
500.000000 14 22 13
CONCENTRATION 
MI CROf.RAMS/ML
number average number 
of of wells
EXPTS. POSITIVE
PROBAB
ILITY
induced
MUTANTS 
PER WELL
50.000000
1 0 0 . ooonoo 
2 0 0 . ooooon 
5 0 0 . ooooon
CONTROL TREATED
j 12.7 25.3 28.74 < 0,0005 0.4439
/* 12.9 19.2 1 0 . 2 0 < 0.005 0.2003
O 13.5 19.0 3.61 n. s; 0.1737
3 12.5 16; 3 2.80 n. s; 0.1143
COMPOUND 3 
STRAIm TA98
NO activation
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML- 520 527 533
WELLS POSITIVE
0.OOOOOO 7 4 16
0 . OOOOOO 4 3 11
1 0. 000000 4 — --
100.000000 7 7 •
290;000n00 - -  - -  8
500.000000 22 6 2
CONCENTRATION NUMBER AVERAGE number 2 PROBAi
MICROGRAMS/ML OF OF WELIS X ILITY
EXPTS, POSITIVE
CONTROL treated
1 o.oooooo 1 5.5 4 ; o 0.19 N. s ;
1 0 0 . oooooo L 5.7 7.0 0.28 N.S.
2 0 0 . 0 0 0 0 0 0 1 13,5 8 . 0 1 .98 n. s;
500.OOOOOO 3 8.3 1 O', o 0,66 n. s;
COMPOUND 3 
STRAIN ' TAP8 
S9 ACTIVATION
CONCENTRATION 
MI CROGRAMs/ML
experiment number
522 531 542 
WELLS POSITIVE
0,000900 13 30 18
0,000000 17 28 19
1.OOOOOO 15 27 17
10.OOOoOO 37 38 21
190,000000 . 48 37 29
CONCENTRATION number AVERAGE number 2 probab
MICROGRAMS/ML of of wells X il ity
EXPTS. POSITIVE
CONTROL treated
1.oooooo 3 21.7 19,7 0.60 n. s;
1 0.oooooo 3 21.7 32.0 17.41 < 0,0005
1 0 0 . ooooon 3 21.7 38’. 0 44,53 < 0,0005
COMPOUND 3 
STRAIN TA93
INTACT HEPATOCYTE ACTIVATION
concentration
MICROGRAMS/ML
EXPERIMENT MUHreR 
7S 33 34 94 104
WELLS POSITIVE
0 . 0 0 0 0 0 0 3 20 8 4 13
0.OOOOOO 11 11 6 12
1 . 0 0 0 0 0 0 7 10 12 f* m - -
1 0 . 0 0 0 0 0 0 32 17 11 - -
50,OOOOOO -- »“ - ~ 4 --
1n0 .oooooo 25 -- 19 — 26
:onccntratton number AVERAGE number 2 PROBAB
!ICROGRAMS/ML of of wells X ILITY
EXPTS. positive
CONTROL TREATED
1.OOOOOO 3 10.7 9.7 0.10 n . s;
10.000000 .1 10.7 20.0 17.26 < 0,0005
50.ooooon 1 4.0 4.0 0,00 N.S.
1 0 0 . oooooo 3 9.7 23.3 36.63 < 0,0005
induced
MUTANTS' 
PER WELL
0.0300
0.0429
INDUCED 
MUTANTS 
PER WELL
0.49R2
0.9683
I nduced
MUTANTS 
PER WELL
0,2377 
0.4409
NO ACTIVATION
CONCENTRATION 
Ml CrOGRAMS/ML
EXPERIMENT NUMBER 
418 402 406 411 413 
WELLS POSITIVE
0.000000 
0 . oooooo 
1 . oooooo 
1 o.oooooo  
1 0 0 . 0 0 0 0 0 0  
2n 0.OOOOOO 
5 0 0 . OOOOOO
21 22 16 23 9
14 24 20 16 11
—  29 25 16 —
—  20 23 16 —
—  16 18 17 - -
1 4 ....................................
4 - -  - -  - -  0
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
micrograms/ ml of of wells x rlitv
expts. positive
CONTROL TREATED
1 . oooooo 3 2 0 . 2 2 3'. 3 1 .56 n. s;
1 o . oooooo 3 2 0 . 2 1 9‘. 7 0 . 0 2 n. s;
10 0 . oooooo 3 2 0 . 2 1 7 VO 1 .61 N.S.
2 0 0 . oooooo 1 17.5 1 4; 0 0.60 N.S.
sou. oooooo 2 13.7 2 T0 22.80 TOXIC
COMPOUND 4 
STRAIN T A100 
S9 activation
concentration experiment number
MICP.OGRAMS/ML 419 424 407 409 415 
WELLS POSITIVE
o. oooooo 52 19 24 24 23
o.oooooo 33 21 24 22 25
0 . 0 1 0 0 0 0 32 23 - - - - - -
0 . 1 0 0 0 0 0 34 23 -- - - 28
1 . oooooo - - - - 21 38 37
1 o,oooooo - - - - - 42 46 42
1 0 0 . 0 0 0 0 0 0 — -- 48 48 48
CONCENTRATION NUMBER AVERAGE number 2 probab
MICROGRAMS/ML OF OF W-eLLS .X ILIT Y
EXPTS. POSITIVE
control treated
0 . 0 1 0 0 0 0 ->t. 2 6 . 2 2 7 . 5 0 . 1 3 N.S.
0 . 1 ooooo 3 2 5 . 5 2 8 ‘, 3 1 . 2 4 n. s;
1 . oooooo 3 2 3 . 7 3 2 s. 0 1 1 . 3 5 < 0 . 0 0 0 5
1 o.oooooo 3 2 3 . 7 4 3 . 3 6 8 . 2 3 < 0 . 0 0 0 5
1 oo. ooooon 3 2 3 . 7 48T0 1 0 9 . 1 4 < 0 . 0 0 0 5
COMPOUND 4
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 91 88 101 108
WELLS POSITIVE
o.ooonoo 12 11 1 1 12
o.oooooo 20 13 10 14
1 O.OOOnOO c 5 - - - -
5 0 . ooonoo 16 - - 14 14
1oo.ooonoo 10 9 1 0
concentration
MICROGRAMS/ML
number average number
OF OF WELLS
EXPTS. POSITIVE
CONTROL TREATED
probab
ility
1 0 . 0 0 0 0 0 0  
5 0 . 0 0 0 0 0 0  
1 0 0 . ooooon
1 4 . 0
13.2
12.8
7.0
14.7
9.7
7. 01
0.39
2.08
TOXIC
N.S.
N.S.
INDUCED 
MUTANTS 
PER WELL
0.1208
INDUCED
MUTANTS
per well
0.0592 
0.1346 
0.4193 
1 .6514 
???????
INDUCED 
MUTANTS 
PER WELL
0.0440
S T R A I N  TA93 
NO a c t i v a t i o n
concentration EXPERIMENT NUMBER
MI CROGRAMS/ML 422 433 403 405 412 417
WELLS POSITIVE
o.ooonoo 7 10 3 13 6 15
0 . oooooo 0 14 6 13 0 11
1 . ooonoo -- -- 5 1 0 5
1 0 . ooonoo -- 12 19 ? --
1 0 0 , ooonoo «- 4 11 3
2 0 0 . ooonoo 1 5 7 9
500.OOOOOO 5 n
CONCENTRATION number AVERAGE number 2 pkobae
MICROGrAMS/ML of OF WELLS X ility
EXPTS, POSITIVE
CONTROL treated
1 . oooooo 3 1 1 . 0 6 7 4 . 6 3 TOXIC
1 a . oooooo 3 9.2 1 1 . 0 0 . 7 5 N.S.
1 oo.oooooo 3 9.2 7 . 7 0 . 5 3 N.S.
2 0 0 . ooooon 3 1 1 . 0 1 0 ‘. 3 0 , 0 7 N.S.
5 0 0 . 0 0 0 0 0 0 2 1 0 . 5 2 . 5 1 2 . 4 2 TOXIC
COMpOtlND 4 
STRAIN TA98 
S9 ACTIVATION
INDUCED 
MUTANTS 
PER WEIL
0 , 0 4 8 4
CONCENTRATION EXPERIMENT NUMBER
Ml CROCiR AMS/ML 420 425 430 431 410 416 
WELLS POSITIVE
0 . 0 0 0 0 0 0 17 16 27 27 1 9
0 . ooonoo 23 5 - - -- 17 15
. o ; i o o o o o 28 9 - - 11
1 . ooonoo 27 5 31 33 40 8
1 0 . OOOnOO 31 9 30 23 48 5
m o .  ooonoo 37 - - - - -- 48 23
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X UITY MUTANTS
EXPTS, POSITIVE PER WELL
CONTROL TREATED
0 . 1 0 0 0 0 0 3 1 4 . 2 1 6 . 0 0 . 5 7 N.S. 0 . 0 5 5 7
1 . ooooon 6 1 5 . 7 24'. 0 2 2 . 2 2 < 0 . 0 0 0 5 0 . 2 9 7 0
1 o.ooooon 6 1 5 . 7 2 4 . 3 2 4 . 0 0 < 0 . 0 0 0 5 0 . 3 1 1 0
1 0 0 . ooooon 3 1 3 . 7 36'. 0 8 3 . 4 1 < Q. 0 0 0 5 1 . 0 5 1 2
compound 4 
STRAIN TA98
intact hepatocyte activation
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 57 59 60
WELLS POSITIVE
O.OOOnO0 4 7 10
o . o o o n o o 8 8 - -
: o,oooooo 3 7 Q
1 no.'OOOnOO 6 3 11
2 * 0 ,  OOOnOO 9 6 7
CONCENTRATION number average number
MICROGRAMS/ML OF OF WgLLS
EXPTS. POSITIVE
CONTROL treated
PROBAB
ility
induced
mutants
PER WELL
1 0 . o o o o o n  
1 0 0 . ooooon
200.OOOOun
7.4
7.4
7.4
a:o
8.3
7.3
0.06
0.13
0.00
N.S.
N.S.
N.S.
0.0149 
0.0233
1-WilHUllNO 3
STRAIv TA100
NO activation
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 426 43B 449 454 472 444 65
WELLS POSITIVE
0 . ooonoo 10 8 7 21 16 9
o.ooonoo 16 6 - - 15 16 10
1 . oooooo 5 .... 12 17
1 o.ooonoo 4 10 13 15 22 m m
1 0 0 , OOOoOO 21 - - 12 21 20 9
500.OOOoOO 3 5 -- 29 10
9
12
13
12
12
concentration
MICROGRAMS/ML
number average number 
OF OF Wells
EXPTS. POSITIVE
CONTROL TREATED
1 . 0 0 0 0 0 0  
10.000000
100.000000
500.000000
COMPOUND 5 
STRAIN TA100 
S9 ACTIVATION
PR08AB
I L I T Y
3 1 3 . 8 1 1 . 3 1 . 0 8 N.S
6 1 2 . 4 1 2 . 8 0 . 0 7 N.S
6 1 2 . 8 1 5 . 8 3 . 4 3 • N.S5 1 1 . 2 11 ‘. 8 0 . 1 1 N.S
concentration
MICROGRAMS/ML
EXPERIMENT NUMBER 
462 468 534 
WELLS POSITIVE
o.ooonoo 28 20 26
o. ooonoo 35 18 28
1 . 0 0 0 0 0 0 26 24 -•*
1 0 . ooonoo 31 21 - •
1 no. ooonoo 28 25 30
2 0 0 . ooonoo - - 26
5no. ooonoo 30 19 27
CONCENTRATION
MICROGRAMS/ML
number average number 
of of wells
EXPTS. POSITIVE
INTACT HEPATOCYTE ACTIVATION
PROBAB
I L I T Y
CONTROL treated
1 . ooooon 2 2 5 . 3 2510 0 . 0 0 N.S
1 0 . ooooon 2 2 5 . 3 2 6 . 0 0 . 0 4 N.S
1 0 0 . oooooo 3 2 5 . 8 2 7 . 7 0 . 4 9 N, S
2 0 0 . ooooon 1 2 7 . 0 2 6 , 0 0 . 0 2 N. S
5 0 0 . ooooon 3 2 5 . 8 2 5 . 3 0 . 0 2 N , S
COMPOUND 5
-STRAIN TA100
CONCENTRATION 
MI CROGRAMs/ML
experiment number 
73 88 106
WELLS POSITIVE
o.obonoo 13 11 18
0 . 0 0 0 0 0 0 - - 13 10
10.OOOoOO 18 8 - ~
50.OOOnOO -- m " 16
m o . OOOnOO 31 6 22
CONCENTRATION
MICROGRAMS/ML
10.000000
50. OOOOOO
100.000000
NUMBER AVERAGE number 
of of wells
expts. POSITIVE
CONTROL TREATED
12.3
14.0
13.0
i3;o
16.0
19.7
PROBAB
ILITY
0 . 0 3  N . s .
0 . 1 7  N . s .
7 . 6 3  < 0 . 0 0 5
induced
MUTANTS 
PER WELL
0.0133 
0.0896 
0,0164
INDUCED 
MUTANTS 
PER WELL
0 . 0 3 3 5
0 . 0 8 6 3
induced 
mutants 
per well
0 . 0 1 8 9  
0 . 0 6 0 6  
0 . 2 1 1 3
LUriKUUND J
STRAIN TA98
NO ACTIVATION
c o n c e n t r a t i o n ' EXPERIMENT n u m b e r  
MICROGRAMS/ML 4 3 3  4'37 4 4 3  44 8  
WELLS P O S I T I V E
o . o o o o o o 10 9 7 7
o , o o o n o o 14 12 - - *F
1 . ooonoo 7 9 - - 11
1 0 . oooooo 10 2 4 --
1 0 0 . ooonoo 10 3 7
5no.OOOOOO 6 4 6 "• -
CONCENTRATION NUMBER AVe RAGE NUMBER 2 PROBAB
m i c r o g r a m s / ml  of  of  w e l l s  x i l i t y
EXPTS.  P O S I T I V E
c o n t r o l  t r e a t e d
1 . 0 0 0 0 0 0 3 9 . 2 9 , 0 0 , 0 0 N . S .
1 0 . ooooon 3 1 0 . 4 5 . 3 6 . 5 2 TOXIC
1 0 0 , 0 0 0 0 0 0 3 1 0 . 4 6 . 7 3 . 3 2 N . S .
5 0 0 . OOOOOo 3 1 0 . 4 5 ‘. 3 6 . 5 2 TOXIC
COMPOUND 5 
STRAIN TA98  
S9 ACTI VATI ON
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 461 4 6 7  532
WELLS P O S I T I V E
0 . o oonoo 9 19 26
0 , QQOoOO -- 12 --
1 . oooooo 17 16 , —
1 0 , ooo no o 13 15 m-
m o .  ooonoo 12 7 27
5 0 0 . ooo no o 13 11 25
c o n c e n t r a t i o n
MICROGRAMS/ML
n u m b e r  a v e r a g e  n u m b e r  
of  of  w e l l s
EXPTS,  P O S I T I V E
PROBAB
i l i t y
CONTROL TREATED
1 . ooooon 2 1 3 . 3 .1675 1 .03 N. S
1 0 . ooooon 2 13.3 14.0 0.n3 N.S
1 0 0 . ooooon 3 16.5 15.3 0 . 1 7 N. S
500.ooooon 3 16.5 16.3 0.00 N. S
compound 5
s t r a i n TA98
I NTACT HEPATOCYTE A CTIVATION
CONCENTRATION
m i c r o g r a m s / ml
EXPERIMENT NUMBER 
59.  60  61 62
WELLS P O S I T I V E
0 . ooonoo 
o . o o o n o o
10.OOOoOO 
100.OOOnOO 
500.OOOnOO
10
7
14
12
7 8 
9 - -
5
2
5 - -
CONCENTRATION 
Ml CROGRAMS/ML
NUMBER AVERAGE NUMBER
of  of  w e l l s
EXPTS.  P O S I T I V E
PROBAB
I L I T Y
10.OOOOOn 
100,000000 
500 .OOOOOn
CONTROL TREATED
3.2
3.2
8.2
6.7
o;o
7.0
0.56 
1 .23 
0.33
N.S.
N.S.
N.S.
INDUCED 
MUTANTS 
PER WELL
INDUCED 
MUTANTS 
PER WELL
0 . 0 9 5 8
0 . 0 1 9 4
INDUCED 
MUTANTS 
PER WELL
i, U'imuNO o
STRAIN TA100 
NO ACTIVATION
CONCENTRATION EXPERIMENT number
MICROGRAMS/ML 536 53<> 5*1 77
UELLS POSITIVE
0 . 0 0 0 0 0 0 25 2 18 8
0 . 0 0 0 0 0 0 5 13 1 4
- 0 . oooooo -- -- 1 4
mo.oooooo 19 4 26 1 4
2 0 0 . oooooo 29 5 23 --
mo. oooooo 26 8 21 --
CONCENTRATION NUMBER AVERAGE NUMBER 
MICROGRAMS/ML OF OF wells
EXPTS. POSITIVE
CONTROL TREATED
1 0 . 0 0 0 0 0 0 1 11 . 0 1 4 ; 0 0,51 n. s; 0.0846
1 oo.oooooo 4 1 2 . 1 157 7 3,24 N.S. 0.1060
2 0 0 . OOOOOO 3 1 2 . 6 197 0 7.14 < 0.005 0.1994
500.OOOOOO 3 1 2 . 6 18V 3 5.75 < 0.025 0.1767
COMPOUND 6
STRAIN tA10u 
S9 ACTIVATION
2 PROBAB INDUCED
X ILITY mutants
PER WELL
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 534 535 537
WELLS POSITIVE
0 . 0 0 0 0 0 0 26 37 36
0 , 0 0 0 0 0 0 28 29 --
2 0 , 0 0 0 0 0 0 23 34 - -
1 0 0 . 0 0 0 0 0 0 - - - - 36
2 0 0 . 0 0 0 0 0 0 33 29 34
500.000000 25 31 27
CONCENTRATION
MICROGRAMS/ML
2 0 . 0 0 0 0 0 0
100.000000
200.000000
500.000000
number
OF
EXPTS.
AVERAGE NUMBER
of wells 
positive-
CONTROL TREATED
30, 
36,
31. 
31,
28; 5 
36.0 
3270 
2777
COMPOUND 6
STRAIN TA100
intact hepatocyte ACTIVATION
0,20
0.00
0.08
1.92
PROBAB
ILITY
N.S,
N.S.
N.S.
N.S.
INDUCED
MUTANTS
PER well
0,0488
CONCENTRATION
micrograms/ ml
EXPERIMENT number 
87 95
WELLS POSITIVE
0 . 0 0 0 0 0 0 7 11
o.ooonoo 14 10
50.000000 - - 10
1 0 0 . ooonoo 12 12
500.OOOnOO 9 9
CONCENTRATION
MICROGRAMS/ML
50.ooooon 
1oo.ooooon
500.ooooon
NUMBER AVERAGE number
of of wells
expts. POSITIVE.
control treated
10.5
10.5
10.5
10.0
12.0
9.0
0.00
0.27
0.29
PROBAB
ILITY
N.S.
N.S.
N.S.
INDUCED
MUTANTS
per well
0.0408
COMPOUND ' o
STRAIN TA98
NO ACTIVATION
CONCENTRATION 
MICROGRAMS/ml
EXPERT flENT NUMBER 
546 74
WELLS POSITIVE
o . o o o n o o  
0 . OOOOOO 
1 0 . ooonoo  
i n o ; o o o o o o  
2°0,000rt00 
5 0 0 , ooonoo
11
n
12
o
18
CONCENTRATION number AVERAGE number 2 PROBAB
MICROGRAMS/ML OF of wells X ility
EXPTS. POSITIVE
CONTROL TREATED
1 o.ooooon 1 5.0 2.0 1 .25 N.S.
1oo .ooooon 2 7.5 7.5 0.00 N.S.
200.000000 10.0 8.0 0.23 N.S.
500.OOOOOn 2 7.5 9.5 0.65 N.S.
COMPOUND 6 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION
MICROGRAMS/ML
experiment number 
540 542 543 
WELLS POSITIVE
0 . OOOOOO 12 13 25
o .ooonoo 12 19 --
1 0 . OOOoOO 10 20 --
1 0 0 . 0 0 0 0 0 0 11 20 24
2D0.OOOnOO -- - - 34
5 0 0 . 0 0 0 0 0 0 6 24 26
CONCENTRATION
MICROGRAMS/ML
number average number 
of of wells
EXPTS. POSITIVE
CONTROL treated
probab
ility
1 0 . ooooon 2 ~ 15.2 1570 0.00 N.S
1 0 0 . ooooon 3 17.2 18.3 0.17 N.S
200 .ooooon 1 25.0 34 7 0 3.18 N.S
500.000000 3 17.2 18.7 0.30 N.S
COMPOUND 6 
STRAIN TA93
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION 
MI CROGRAMs/ML
o;  ooonoo
5 0 ,  OOOOOO 
m o . o o o n o o  
5 0 0 . OOOOOO
EXPERIMENT NUMBER 
94 98
WELLS POSITIVE
4 11
-- 12 
— 14
5 6
CONCENTRATION
micrograms/ ml
50.000000 
1 0 0 . OOOOOO 
5 0 J . o o o o o n
number average number
of OF WELLS
EXPTS. POSITIVE
CONTROL TREATED
11.0
11.0
7.5
12.0
1 4 . 0
5 . 5
0. 01 
0 . 3 4  
0 , 5 4
probab
ility
N.S.
N.S.
N.S.
INDUCED 
MUTANTS 
PER WELL
0 . 0 5 0 6
induced 
mutants 
PER WELL
0.0375
0,4964
0.0488
INDUCED 
MUTANTS 
PER WELL
0.0274 
0.0346
CONCENTRATION experiment NUMBER 
MICROGRA.MS/ML 426 438 449 457 472 444 65
WELLS POSITIVE
0.000000 10 S 7 30 16 o 9
0,000000 16 6 - -  - -  16 10 12
0.100000 5 18 - -  - -  22 - -  —
1.000000 1 13 3 - -  19 12 —
10.000000 5 20 9 21 19 13
50. 000000 1 2 10 - -  - -  — - -  10
lOO.'OOOOOO - -  - -  — 22 15 10 7
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
MICRnGRAHS/ML OF OF WELLS X UITV
EXPTS. POSITIVE
control treated
0. 1 00000 3 12.0 15.0 1 .74 N.S.
1 . oooooo 5 10.9 9*. 6 0.58 N.S,
10 .000000 6 10.8 14V 5 5.61 < 0.025
50.000000 3 10.2 10.7 0.03 n. s;
1 0 0 . oooooo 4 14.6 13; 5 0.24 N.s.
COMPOUND 7 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 534 462 468
WELLS POSITIVE
0,000000 26 28 20
0 . 0 0 0 0 0 0 28 35 18
1 . 0 0 0 0 0 0 - - 13 25
1 0 . oooooo - - 14 22
50.000000 25 25 23
100.000000 18 - - 23
2^0.000000 19 - -
500.OOOOOO 20 — --
concentration number average NUMBER 2 probab
MICROGRAMS/ML OF OF UELLS X IlITY
EXPTS. POSITIVE.
CONTROL TREATED
1 , oooooo nc. 25,3 19; 0 4.09 . TOXIC
1 0 . 0 0 0 0 0 0 z 25.3 18*,0 5.56 TOXIC
50.OOOOOO 5 25.8 24 V 3 0.32 N.S,
1 0 0 . 0 0 0 0 0 0 2 23.0 20.5 0.60 N.S.
200,OOOOOO 1 27.0 19 VO 3.23 N.S,
500,OOOOOO 1 27.0 20-. 0 2.44 N.S,
COMPOUND * 7
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 73 88 102 108
WELLS POSITIVE
0 . oooooo 13 11 11 1?
0 . ooonoo - - 13 10 14
1. OOOnOO 12 -- ....
10.OOOoOO 16 10 -- - -
50.OOOnOO - - — 9 4
1n0,OOOoOO 11 1 -- 11
CONCENTRATION 
Mi CROGRAMS/ML
NUMBER AVERAGE number
of of wells
EXPTS. POSITIVE.
probab
ility
1 . oooooo
10.OOOOOo 
50.OOOOOn 
1 0 0 , 0 0 0 0 0 0
CONTROL treated
.13.0
12.3
12.2
12.8
1 2 : 0
1 3 . 0
6.5
7.7
0. 01
0.03
5.29
5.95
N.S.
N.S.
TOXIC
TOXIC
INDUCED 
MUTANTS 
PER WELL
0.0870
0.1043
0,0133
induced
MUTANTS 
PER WELL
INDUCED 
MUTANTS 
PER WELL
0,0189
concentration experiment number
MICROGRAM^ /Ml 433 436 43? 453 443 445 
UEtlS POSITIVE
o.ooonoo 10 3 9 0 7 12
o,oooooo 14 2 12 — -- 6
0 , 1 0 0 ft 0 c 1 2 2 11 — -- ~-
1 . 0 0 0 ft o o 12 4 7 -- 4
10,000000 11 6 -- 6 5
50,000000 5 7 3 — 1
100, 000.000 -- ft - - 0
CON.CnUTRAT I ON HUMBER AVERAGE NUMBER. 2 P«OBaB INDUCED
micrograms/ ml of of wells x ility mutants
EXPTS, POSITIVE PER WELL
CONTROL TREATED
0.10000ft 3 8.3 8'. 3 0.00 N.S.
1 . oooooo 4 8.5 6:7 1.11 N.S.
10.oooooo 4 7.7 7.0 0.15 N.S.
50.000000 8.5 4.0 8.66 TOXIC
100.00000ft 9.0 0.0 19.35 TOXIC
COMPOUND 7 
STRAIv TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/Ml 461 467 532 543 
WELLS POSITIVE
O.'OOOOOO 0 19 26 25
0 . OOOOOO -» 12
1 . OOOftOO 2 7 _ - „ _
1 0 . OOOnOO 4 10 __ m m
5 0 , OOOftOO 8 9 14
10 0 . oooooo - - 9 20 12
2oo;oooftOo -- 21 12
5 0 0 . OOOftOO — . . 12
concentration
micrograms/ ml
1 . oooooo
I 0 . 00000ft 
50.00000ft 
1 00. 00000ft
200 .OOOOOo 
500.00000ft
NUMBER AVERAGE NUMBER
of of wells
EXPTS. POSITIVE
CONTROL TREATED
PROBAB
ILITY
INDUCED 
MUTANTS 
PER WELL
2 13.3 4T5 11.45 TOXIC2 13.3 7.0 5,38 TOXIC3 16.5 10.3 6.30 TOXIC3 20.5 13.7 6.88 TOXIC2 25.5 16’. 5 6.48 TOXIC1 26.0 12,0 7.94 TOXIC
COMpOijND 7 
STRAIN TA93
INTACt hepatocyte activation
CONCENTRATION
MICROGRAMS/ML
experiment number 
50 62 63
WELLS POSITIVE
ft,OOOftOO 7 8 9
O.'OOOftOO ao --
1 .OOOftOO 12 --
10.OOOftOO 11 10 10
100.OOOftOO 5 6 10
200.OOOftOO -- 5 3
CONCENTRATION
MICROGRAMS/ML
number average number 
of of wells
EXPTS, POSITIVE
control treated
pkobab
ILITY
INDUCED 
MUTANTS 
PER 'JELL
1 . 0 0 0 0 ■ j ft 
10.00000ft 
1 00. 00000ft 
200.00000ft
7. 5
a.  o 
a . o
8. 5
12.0
10.3
7.0
4.0
1 . 55 
1 . 1 2  
0 . 2 0  
3.32
N.S.
N.S.
N.S.
N.S.
0.1178 
0,0601
compound 8
STRAIN TA100 
NO activ a t i o n
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 7 13 17 20 24 23 30 39 43
WELLS POSITIVE
o.oooooo 26 19 20 23 17 18 21 32 16
0 . 0 0 0 0 0 0 -- -- -- 16 -- -- -- -i-
0 . 0 0 0 0 0 1 — — -- -- -- 17 31 15
0 . 0 0 0 0 1 0 27 39 -- --
0 . 0 0 0 1 0 0 -- — -- *■- 39 35 -- --
0 . 0 0 1 0 0 0 -- .. -- 46 40 -- -- --
0 . 0 1 0 0 0 0 -- 47 46 41 — — -- -- --
0 , 1 0 0 0 0 0  
1.000000 
10,000000 
m o . o oo oo o
22
0
CONCENTRATION NUMBER AVeRAGe NUMBER 2 PR O BAS
micrograms/ ml of of wells x ility
EXPTS. POSITIVE
CONTROL TREATED
0.000001 3 23.0 21 ;0 0.42 N. S.
0.000010 -»u 19.5 33'. 0 14.76 < 0.0005
0.000100 2 17.0 37T0 39.24 < 0.0005
0.001000 2 18.7 43*. 0 60,23 < 0.0005
0.010000 3 20.7 44.7 81 .65 < 0.0005
0.100000 3 20.7 7;3 26.22 TOXIC
1 . oooooo 3 21 .7 O'.O 32.66 TOXIC
1 o.oooooo 1 26.0 0',0 34.30 TOXIC
100.000000 1 26.0 0 . 0 34.-30 TOXIC
COMPOUND 8 
STRAIN ■ TA100
S9 ACTIVATION
CONCENTRATION 
Ml CPOGRAMS/ML
EXPERIMENT NUMBER 
9 18 19 26 32 AO 44
WELLS POSITIVE
0.000000 
0.000000 
0.000100 
0.001000 
0.010000 
0,100000 
1 . 0 0 0 0 0 0  
’I), oooooo 
1 no. 000000
20 21 23 23 21 21 25
17 27
25 31
-- -- -- -- 25 30 20
-- -- -- -- 23 20 31
-- -- 42 37 -- - - - -
41 48 48 -- - - - - --
43 26
CONCENTRATION HUMBER AVERAGE NUMBER 2 PRQBAB
micrograms/ ml of of wells x ility
EXPTS. POSITIVE
CONTROL TREATED
0 . 0 0 0100 4. 21 .0 28. 0 3.80 N. S.
0 . 0 01 0 00 3 22,3 25.0 0.70 N.S,
J.0 1ooon 3 22.3 24'.7 0. 59 N.S.
J. 100000 <. 24.3 39.5 24.09 < 0.0005
1 , oooooo -» 20.2 45'. 7 100.10 < 0.0005
1J.oooooo 3 20.2 25:0 3.04 N.S.
1 0 0 . oooooo 1D.3 O'.O 49.<50 TOXIC
INDUCED 
MUTANTS 
PER WELL
0,6419 
1.0361 
1.7693 
2,1041
INDUCED 
MUTANTS 
PER WELL
0.3001 
0,1007 
0.09 53 
1.0240 
2.4759 
0,1 <377
compound a
STRAIN TA10U
INTACT HfcPATOCYTE ACTIVATION
concentration
III cpograms/ ml
0 .000*00 
0. 000*00 
0 . 10 0*0 0 
1 .00 0*0 0  
s . o o o * o o  
« 0. 000*00
EXPERIMENT NUMBER
8 a 101 108
UElLS POSITIVE
11
13
18
14
11
10
35
39
0
12
14
16
26
16'
CONCENTRATION NUMBER AVERAGf. NUMBER
micrograms/ ml of of uells
EXPTS. POSITIVE
CONTROL TREATED
o . i o on on . 1 1 3 . 3 1 6 . 0 0. 41 N.S. 0 , 0 8 0 0
1 .onooon 3 12. 1 2 6 . 3 38. 51 < 0 . 0 0 0 5 0 . 5 0 3 8
5 . oooooo 3 12. 1 2 3 . 0 2 3 . 1 5 < 0 . 0 0 0 5 0 . 3 6 0 7
1 o.oooooo 1 1 0 . 5 0.0 11 . 43 TOXIC
2 PROBAB INDUCED
X ility MUTANTS
PER UF LI
CONrEUTRATlOri 
MICPOORAMS/ML
EXPERIMENT 
3 12 21
NUMBER 
27 25 2° 31 37 41
0 . JOUOOO
WELLS 
3 4
POSITIVE 
6 6 8 _ 12 5 3
0 , OOOOOO — -- 3 -- 5 -- -- - - --
0.000010 0 0 5
0.000100 17 15 10 3
0.001000 19 5 10 7 5
0.010*00 - - 36 -- 31 24 -- 23 - - - -
0.1 00*00 - - 0 0 0 o 0 - - -- - -
1 . oooooo 0 0 0 0 — — -- - -
* <). 000*00 0 — 0
1 DO,OOOoOO 0
concentration number AVERAGE number 2 PK!
MICROGRAMS/ML OP OF UELLS
EXPTS. POSITIVE
CONTROL TREATED
ILITY
induced 
MUTANTS 
PER WELL
'0.00001* 3 6.7 7.7 0.1? N.S. 0.0245
0.00010* 4 6.7 10.0 2.82 N.S. 0.0821
0.001000 5 6.7 9.2 2.43 N.S. 0.0632
0.010000 4 7.0 28.5 93.73 < 0.0005 0.7432
o.ioooon 5 6.3 0.0 33,11 TUXIC
1 . ooooo* 4 6.4 0.0 26.63 TUXIC
1d.00000O 2 • 7.3 o:o 15.24 TOXIC
100.000000
compound
strain
1
a
TA98
a.o 0.0 7.67 TOXIC
SO ACTIVATION
CONCENTRATION 
MI CPOGRAMs/ML
0.OOOnOO 
0.001*00 
0,010*00 
0.100*00 
1 . 0 00 *0 0  
10,000*00 
ioo;ooo*oo
EXPERIMENT NUMBER 
1 4 8 33 38
WElLS POSITIVE
15 21 11 15 17
U  7 
8. 16 
19 13
48 47 - -  46 
1 -- --
— 10 
42*12
CONCENTRATION
MICROGRAMS/ML
number average number 
of of wells
EXPTS. POSITIVE
PROBAB
ility
INDUCED
mutants 
PER WELL
control TREATED
0. 00100* 2 16.0 10.5 2.87 N.S.
9.01000O 3 14.3 1 1:3 1 .23 N.S.
0. 10000* 4 ' 16.0 21.5 5.06 < 0.025
1.oooooo 3 16.3 4710 129.50 < 0.00*05
10.000000 2 18.0 0:5 39.85 TOXIC
100.OOOOO* 1 15,0 0 . 0 16.61 TOXIC
COMPOUND 3
STRAIN TA98
intact hepatocyte activation
0,1886
3.4553
CO'N^ ENTratION
MICROGRAMs/ML
EXPERIMENT NUMBER 
<♦6 <*7 48
WELLS POSITIVE
0 . 000 *0 0  . 15 5 12
0 . OOOnOO 17 7 10
0.010*0* 15 4 9
0 . 1 0 0*0* 21 5 18
1 . OOOnOO 23 23 21
conc- ntrat row
MICROGRAMS/ML
0.01000* 
0 .1 0 0 o 0 o
i*. ooooo*
N-IM3ER AVERAGE NUMBER
of of wells
EXPTS,  P O S I T I V E
CONTROL TREATED
11 . o 
1 1 . 0  
11.0
9.3
14.7
24.0
0.58 
2.73 
31 .77
PKOBa S
ility
N.S.
N.S.
0.0005
induced
MUTANTS 
PER WELL
0 . 1044 
0.4329
CONCENTRATION EXPERIMENT NUMBER
Ml CROT,RaMS/Ml 401 404 406 411 
WELLS POSITIVE
0, 000(100 26 17 16 23
o.oooooo 25 29 20 16
0.1ooooo -- -- -- 19
1.oooooo 21 13 21
10.OOOOOO 13 27 17 --
100.000000 15 7 1 4 --
CONCENTRATION NUMBER AVERAGE number 2 PROBAE
MICROGRAMS/ML OF OF Wt LLS X ILITY
EXPTS. POSITIVE
CONTROL TREATED
0.100000 1 19.5 19; 0 0.00 n. s;
1 . oooooo 3 22.2 20’. 0 0.70 N.S.
10.OOOOOO 3 22.2 19.0 1 .56 N.S.
100.000000 3 22.2 1 2*. 0 17.64 TOXIC
COMPOUND 9 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION 
Ml CP.OORAMS/ML
EXPERIMENT NUMBER 
419 424 432 407 409 415 
WELLS POSITIVE
0.000000 32 19 17 24 24 23
0.000000 33 21 8 24 22 25
0.000100 — -- 9 -- -- --
0.001000 -- -- 12 -- - - --
0.010000 -- 30 13
0.100000 42 28 -- - - 21
1.oooooo -- -- -- 43 47 33
10.000000 25 43 48
i *o \  oooooo 48 48 48
CONCENTRATION NUMBER AVERAGE NIJmBER 2 PROBAB
MICROGRAMS/ML OF OF WELLS X UlTY
EXPTS. POSITIVE
CONTROL TREATED
0.000100 1 12.5 9; 0 0.75 n. s;
0.001000 12.5 12.0 0.00 N.S.
0.01oooo L. 16.2 21 -.5 3.04 N.S.
0.100000 3 25.5 30'. 3 3.76 N.S,
1 . oooooo 3 23.7 42 -.7 63.34 < 0.0005
1 o.oooooo 3 23.7 40'. 3 47.87 < 0.0005
1 0 0 . oooooo 3 23.7 48.0 109,14 . < 0.0005
COMPOUND 9
STRAIN TA100
INTACT HKPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 91 38 101
WELLS POSITIVE
0. 000*00 12 11 11
o;oooooo 20 13 10
1 ,• 0 0 0 n 0 O' 21 - -- 13
1 0 . OOOnOO 23 11 --
100,000*00 13 9 8
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
MI CROGRAMS/ML OF of wells X ILITY
EXPTS. positive
CONTROL TREATED
1 . ooooo* n 13 .2 17.0 1 . 67 N.S.
1 J . ooooo* 2 14 ,0 17'. 0 1 .02 N.S.
1 0 0 . ooooo* 3 12 .8 10 .0 1 .64 N.S.
INDUCED
MUTANTS
per well
induced
MUTANTS
per well
0.1807 
0.2418 
1.5179 
1 .1550 
???????
INDUCED 
MUTANTS 
PER WELL
0.1142
0.0O24
NO ACTIVATION
CONCENTRATION EXPERIItFMT NUI-UjEK
MICROGRAMs/ML 422 403 405 412 417 
WELLS POSITIVE
o.oooooo 7 3 13 6 15
0.000*00 0 6 13 9 11
1,000*00 -- 6 13 •t —
* 0.OOOOOO -- 10 15 2 --
1*0.0*0*00 -- 3 13 1 --
2*0.000*00 2? -- -- -- 4
5*0,00 0*00 4 *
CONCENTRATION NUMBER AVERAGE NUMBER 2 PK0BA3 INDUCED
(11CROGRAMS/M.L OF OF WELLS X ILJTY MUTANTS
EXPTS. POSITIVE PER WELL
1.0000OO 3
CONTROL
9.2
TREATED
10,3 0.23 N.S. 0.0305
13.00000* 3 9.2 9.0 0.00 N.S.
1 0 0 .oooooo 3 9.2 7.3 0.33 N.S.
200.0*000* •>u 10.5 13.0 0.32 N.S. 0.0690
500.000000 2 10.5 2.0 14.30 TOXIC
COMPOUND ‘9 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT number 
MICROGRAMs/Mi 420 425 410 416 
WELLS POSITIVE
0. 000*00 17 16 1 9
0.000*00 23 5 17 15
0.100*00 14 4 -- 3
1.000*00 25 30 -- 7
10.000*00 42 -- 47 31
100,000*00 48 -- 48 47
CONCENTRATION
MICROGRAMS/Ml
NUMBER average number 
of of wells
EXPTS, POSITIVE
PROBAB
I L I T Y
INDUCED 
MUTANTS 
PER WELL
CONTROL TREATED
0,10000* 3 13.4 7'. 0 9.56 TOXIC
1.ooooo* 3 13.4 2 0 : 7 10.11 < 0.005 0.2349
10.00000* 3 13.0 40.0 128.33 < 0.0005 1.4759
1 0 0 .ooooo* J 13.0 4 7.7 209.00 < 0.0005 4.6540
COMPOUND 9 
STRAIN TA93
intact hepatocyte activation
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ ml 49 57 59 61 6? 63
WELLS POSITIVE
0,OOUOO* 12 4 7 7 3 9
0.000*00 14 3 3 9 -- --
0.100000 12 -- -- --
1.0*0*00 a 1* 7 — --
' o'. 000*00 11 6 12 — -- --
1*0.000*00 13 3 17 10 3 3
2*0.000*0* — -- —  — 3 --
CONCENTRATION 
MICROGRAMS/ML
number . AVERAGE NUMBER 
of of wells
expts. positive
P R O B a B
ILITY
INDUCED 
MUTANTS 
PER WELL
control treated
0.100*0* •5 13.0 12.0 0. *3 N.S.
1.00000* 3 8.8 8.3 0.04 N.S.
10.ooooo* 3 3.8 9.7 0.14 N.S. 0.0215
100.00000* 6 3.6 1 o.7 1 .99 N.S. 0.0 539
203 .OOOOvj* 1 3.0 3.0 2.03 N.S.
COMPOUND 10
STRAIv TA100
NO ACTIVATION
c o n c e n t r a t i o n  EXPERIMENT number  
MICrOGRAMs/ML 418 413  438 7 13 17 20
WELLS POSITIVE
0 . 0 0 0 n O O  21 '  9 ’ 8 26 19 20 23
C . 0  0 0 0 0 0 14 11 6 - -  —  - -  —
1.  OOOOOO —  —  —  21 30 21 —
1 0 . 0 0 0 0 0 0  - -  —  —  30 27 21 16
1 * 0 . 0 0 0 0 0 0  - -  —  10 45 22 26 - -
5 * 0 , 0 0 0  0 00 24 8 9 —  —  —  —
CONCENTRATION NUMBER average NUMBER 2 PROBAB
micrograms/ ml OF of wells X ILITY
EXPTS, positive
CONTROL treated
1 . ooooo* 3 2 1 . 7 2 4 , 0 0 . 5 9 N.S.
1 0.00000(1 4 2 2 . 0 2 3 . 5 0 . 3 2 N.S.
1 0 0 . oooooo 4 1 5 . 8 2 5 . 7 1 8 . 3 8 < 0 . 0 0 0 5
5 0 0 . OOOOOO 3 1 1 . 5 1 3 . 7 0 . 9 2 N.S.
COMPOUND 10 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION experiment number 
MICROGRAMs/ML 419 415 9 18 19 26 40 44
WELLS POSITIVE
0., oooooo 32 23 20 21 23 23 2.1 25
o,, 0 0 0* 0 0 33 25 - - 17 - - 27 — --
1 ,, OOOdOO - - •»- 17 25 .25 - - - -
10,, 000000 - - - - 20 26 23 - - » - - -
1*0, , 000000 - - mrn 25 27 28 13 34 28
500,, 000000 41 33 — - - — - - — 35
concentration number AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML OF OF WELLS X ILITY
EXPTS. POSITIVE
CONTROL TREATED
1.00000* 3 20.2 22.3 0.54 N.S.
10.OOOOOn 3 20.2 23.0 0.98 N.S.
100.000000 6 22.1 25.'8 3.78 N.S.
500.00000(1 3 27.6 36.3 12.59 < 0.0005
COMPOUND 10
STRAIN TA100
INTACt wepatocyte ACTIVATION
CONCENTRATION experiment NUMBER
MICROGRAMS/ML 91 88 101 108
WELLS POSITIVE
0,000(100 12 11 11 12
0.000*00 20 13 10 14
10.000*00 18 — 14 8 •
100.000*00 12 8 -7 --
2*0,000000 -- 8 »-
5*0.000000 8 9 6 --
:oncentration number average number 2 PROBA
UCROGRAMS/ML OF , of wells X ILITY
EXPTS. positive
CONTROL treated
1o.ooooo* 3 13.2 13.3 0,00 N.S,
100.00000* 2 1 4.0 10.0 2.08 N.S.
200.00000* 1 10.5 8.0 0.39 N.S.
500.00000* 3 12.8 7.7 5.95 TOXIC
induced
mutants
PER WELL
0.0928
0.0594
0,3696
0.0612
INDUCED 
MUTANTS 
PER WELL
0.0780
0.1044
0,1547
0.5588
INDUCED
MUTANTS
per well
0.0048
COMPOUND 10
STRAIN TA98
NO ACt IVa TION
CONCENTRATION EXPERIMENT.NUM8ER
MICROGRAMs/ML 422 433 4-|7 3 12 21
WELLS POSITIVE
0 . 0 0 0 * 0 0 7 10 15 8 4' 6
0 . oooooo 9 14 11 8
1 . 0 0 0 * 0 0 -- - - 6 11 7
10.OOOnOO -- -- - - 9 4 7
1 * 0 . 0 0 0 0 0 0 -- mmrn - - 10 15 6
5 * 0 . 0 0 0 * 0 0 7 14 12
CONCENTRATION
HICROGRAMS/Ml
number average number 
of of wells
EXPTS. POSITIVE
PR08A8
ility
1 . 000000 
10. OOOOOo 
100,OOOOOn 
500.oooooo
3
CONTROL
6 . 5
TREATED
s;  o 0 . 5 2 N.S
3 6 . 5 6.7 0 . 0 0 N.S
3 6 . 5 1 0 . 3 3 . 4 5 N.S
3 1 1 . 0 1 1 . 0 0..00 N.S
COMPOUND 10 
•STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 420 416 1 4 8 42
WELLS POSITIVE
0 . oooooo 17 9 15 21 11 8
0 . OOOOOO 23 15 - - -- - - --
1 .OOOnOO — 11 16 12
1 0 . OOOnOO — «,*• 13 24 16 --
1 0 0 . oooooo - - 29 45 48 --
5 0 0 .0 0 00 0 0 47 44. ... -- 48
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
micrograms/ ml of of wells x ility
EXPTS. POSITIVE
CONTROL TREATED
1 . oooooo 3 1 5 . 7 1 3 , 0 0 . 9 3 N.S.
1 0 . OOOOOC 3 1 5 . 7 1 7 , 7 0 . 4 6 N.S.
1 0 0 . OOOOOn 3 1 5 . 7 4 0 . 7 7 9 , 4 8 < 0 . 0 0 0 5
5 00 .0 0 0 0 0 0 3 1 4 . 4 4 6 . 3 1 5 9 . 5 7 < 0 . 0 0 0 5
COMPOUND 10 
STRAIN TA98
intact hepatocyte ACTIVATION
CONCENTRATION EXPERIMENT NUM3ER
MICROGRAMS/ML 46 47 48 49
WELLS POSITIVE
0 . 00 0*0 0 15 5 12 12
0 .00 0*0 0 i 7 7 10 1 4
1 0 .'0 00*00 17 7 12 --
1* 0 . 000*00 19 15 10 --
5*0.000000 22 10 -- 24
C 0 fl C C. fl T R A T I 0 H 
MICROGRAMS/ML
13,OOOOOn 
100.OOOOO* 
500.OOOOOO
NUMBER
OF
EXPTS.
AVERAGE NUMBER 
OF WELLS
positive
CONTROL TREATED
11.0
11 .0
11.7
12.0
14.7
18.7
PROBAB 
I LITY
0.< 8 N.S.
2.75 N.S.
9.53 < 0.005
INDUCED 
MUTANTS 
PER WELL
0.0368
0.0040
0.0969
INDUCED 
MUTANTS 
PER WELL
0.0639 
1.4837 
3.0037
INDUCED 
MUTANTS ,
per well
0,0274 
0.1044 
0. «*1 40
STRAIN T A10 0 
NO ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MlCROGRAMr/ML 402 406 411 413 
WELLS POSITIVE
0,OOOnOO 2? 16 23 9
0.000000 24 20 16 11
0,100000 -- -- 1
1.OOOoOO 10 -- 16 13
10,000000 12 15 9 --
1*0.000000 14 0 10 --
concentration
MICROGRAMS/ML
number average NUMBER 
of of wells
EXPTS. POSITIVE
CONTROL TREATED
PROBAB
ILITY
0 . 1 0 0 0 0 0  
1.000000 
10,OOOOOO
1 0 0 , ooooon
COMPOUND 11 
STRAIN TA100 
SO activation
1 10.0 1.0 8,29 TOXIC
3 17.5 16.0 0.34 n. s;
3 20.2 12.0 11 .65 TOXIC
3 20.2 11.0 14,85 TOXIC
concentration experiment number
MICROGRAMs/ML 410 424 407 409 415 
WELLS POSITIVE
o.oooooo 32 19 24 24 23
o,oooooo 33 21 24 22 25
0.100000 - m - - - - 19
1.OOOnOO - - 24 28 19
1 0 . oooooo 42 26 24 23 36
100.000000 - - m m 32 24 37
2*0 . ooonoo 45 38
5*0,000000 44 *- m  m - - - -
CONCENTRATION
micrograms/ ml
number average number 
of of wells
EXPTS, POSITIVE
PROBAB
ILITY
CONTROL treated
0.100000 1 24.0 19,0 1.191.000000 3 23.7 23.7 0,0010.000000 5 24.7 31 .2 11.63 <100,000000 3 23.7 31 .0 8,73 <200,000000 2 26.2 41.5 27,80 <
500.000000 1 32.5 44,0 9,34 <
n. s;
n. s;
0,0005
0,005
0,0005
0,005
COMPOUND 11
STRAIN TA100
INTACT HF.PATOCYTE ACTIVATION
concentration experiment number
MICROGRAMS/ML 91 38 106 101 107
WELLS POSITIVE
0.ooonoo 12 11 18 11 12
o.ooonoo 20 13 10 10 14
i o. ooo no o -- «•- 22 -- ...
50.000*00 20 .... -- --
1*0.000000 13 9 -- 6
200.000*00 a 6 -- -- 9
CONCENTRATION
MICROGRAMS/ML
number
OF
FXPTS,
AVERAGE number 
of wells
POSITIVE
PR0BA8
ility
10.000000
50.000000 
100.OOOOOO
2 0 0 . ooooon
CONTROL TREATED
14.0
16.0 
12.3 
13.7
2 2 ;o
20.0
9.3
7.7
3. 56 
0.79 
2.58 
7,82
N.S.
N.S,
N.S.
TOXIC
INDUCED
MUTANTS
per well
induced 
MUTANTS 
PER WELL
0.5271 
0.5586 
1.2078 
1.5545
INDUCED 
MUTANTS 
PER WELL
0.2683
0,1335
5 T KAI M TAVM
NO ACTl VATt Oi J
CONCENTRATION EXPERIMENT NUMBER
MICPOGRAMs/ ml 422 403 405 41 2 41 7 
WELLS POSITIVE
0.OOOOOO 7 3 13 6 15
O.OOOftOO 0 6 13 9 11
1.OOOflOO 4 12 4
10,OOOnOO 3 0 10
100,OOOftOft . — 0 — 7 5
200,000000 6 -- — -- —
son. o o o n o o  6  —  - -  —  0
CONCENTRATION N'JMBER. AVERAGE number 2 PROBAS INDUCED
micrograms/ ml of of wells x ility mutants .
EXPTS, POSITIVE PER WELL
CONTROL TREATED
1.OOOOOO 3 9.2 6.7 1,64 n. s;
1 0.00000ft 3 3.3 7.3 0,23 N.S.'
100.00000ft 3 8.3 4.0 6,00 TOXIC
200.000000 1 8,0 6,0 0,23 n. s:
500.000000 2 10,5 3.0 10,69 TOXIC
COMPOUND 11 
STRAIN- TA93 
S9 ACTIVATION
CONCENTRATION experiment number 
MICROGRAMS/ML 420 425 430 410 416 
WELLS POSITIVE
O.OOOftOO 17 16 27 1 9
o.ooonoo 23 5 17 15
0,010000 7 33 — —
o . i o on oo 25 11 — — 13
1 .oooooo 4 — — 29 31
1 0 . oooooo 43 — 31 46
100.000000 43 — — 33 47
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X ILITY MUTANTS
EXPTS, POSITIVE PER WELL
CONTROL TREATED
0.01000ft <• 16.0 20.0 1.55 n. s; 0,1335
0.10000ft 3 U.2 16.3 0.81 n. s; 0,0662
1 .oooooo 3 13.7 21.3 10.59 < 0.005 0,2527
10.000000 3 13.7 41.7 129,73 < 0.0005 1,6903
100.00000ft 3 13.7 42.7 139,07 < 0,0005 1.8621
compound 11
STRAIN TA98
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 5? 5° 60 61
WELLS POSITIVE
0.OOOOOO 4 7 10 7
O.OOOftOO 8 8 — 0
0.100000 • f a 12 7
1,OOOftOft 34 47 46 —
10, OOOftOft 44 47 47 —
1ftft.OOOOOO 24 39 — —
OUCENTRATlOu 
I C R n ft R A V S / M L
NUMBER average NUMBER 
of of wells
FXPTS, positive
CONTROL TREATED
PROBAB
ILITY
INDUCED 
MUTANTS 
PER WELL
0 . 1 0 0 0 0 0  
i . oo on oo  
1o.ooonoo 
1 0 0 . 0 0 0 0 0 0
3.2
7.4
7.4 
6.7
9, 0 
42.3 
46.0 
31 .5
0,12
193.34
233,03
78,00
N.S,
0.0005 
0.0005 
0,0005
0,0203 
1,9602 
3.01ft6 
0.9163
NU ACTIVATI'HI
concentration EXPERIMENT huhbek 
MI CROGR AMS/ML 523 636 541
WELLS P O S I T I V E
o.ooonoo 11 a 18
o.oooooo 20 •• 13
1 o. ooonoo 1? ... - -
1 0 0 . ooonoo 12 a - -
2 5 0 . ooonoo mm - - 21
5 0 0 . ooonoo 19 6 28
CONCENTRATION
MICROGRAMS/ML
NUMBER AVERAGE NUMBER
of  of  w e l l s
EXPTS. POSITIVE
c o n t r o l  t r e a t e d
PROBAB
ILITY
INDUCED
m u t a n t s  
PER WELL
1 o . o o o o o o 1 1 5 . 5 12 .0 0 .6 5 N.S
100 .0000 00 p 1 3 . 0 10 .0 1 ,05 N.S
200 .0 000 00 1 1 5 . 5 21 .0 1 . 53 N.S
500 .000000 3 1 4 . 0 1 7 .7 2 ,2 4 N.S
compound 12
strain TA100
SO ACTI VATI ON
0.1854
0.1141
concentration
MI CROGRAMs/ML
EXPERIMENT NUMBER 
525 534 538 
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 31 26 26
o . o o o n o o 33 28 21
1.OOOnOC “ r 47 48
10.000000 43 48 48
50.OOOoOC 43 * -
100.000000 48 48 48
500.000000 48 v m - -
CONCFNTRATtON NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X ILITY MUTANTS
EXPTS, POSITIVE PER WELL
CONTROL TREATED
1 . ooooon 2 2 5 . 3 4 7 . 5 6 2 , 1 9 < 0 , 0 0 0 5 3 . 8 1 7 7
1 o . o o o o o o 3 2 7 . 5 48 . 0 8 4 . 9 4 < 0 . 0 0 0 5 ???????
5 0 , OOOOOO 1 2 7 . 0 4 8 . 0 2 8 . 6 0 < 0 , 0 0 0 5 ???????
1 0 0 , oooooo 3 2 7 . 5 4 8 . 0 8 4 , 9 4 < 0 , 0 0 0 5 ???????
5 0 0 . o oooon 1 3 2 . 0 4 8 . 0 1 9 . 6 2 < 0 , 0 0 0 5 ???????
COMPOUND 12
STRAIN TA100
INTACt hepatocyte ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 87 92 96 106
WELLS POSITIVE
o . o o o n o o 7 20 10 18
Q.OOOOOO 14 12 12 10
5 o ; o o o n o o •* m 22 16
1 0 0 , ooonoo 11 22 15
200.ooonoo -- 12 10
500.ooonoo 11 13 8
CONCFNTRATtON NUMBER AVERAGE NUMBER
MICROGRAMS/ML OF
EXPTS.
OF WELLS 
POSITIVE
PROBAB
ility
induced
MUTANTS 
PER WELL
control TREATED
50.OOOOOn 2 12.5 19.0 5.22 < 0.025 0.2022
100.000000 3 13.5 16.0 1.12 N.S. 00752
2 0 0 . 0 0 0 0 0 0  ‘
5 0 0 . oooo o n
2 12.5 . . < 0.025
3 13.5 . . N.S.
2 12.5 1 1 ; o 0.26 N.S.
3 12.5 i o ; 7 0.65 N.S.
CONCENTRATION EXPERIMENT NUMb EK
MI CCnr,RAM<?/f'|. 520 533 81
WELLS POSITIVE
o . o o o n o o 7 16 a
o . o o o n o o 4 11 5
1 o , o o o o o o 5 -- --
1 n o . o o o n o o 5 11
2 0 0 . 0 0 0 0 0 0 ”» 16
5 O.OOOnOO 10 1 3 12
concentrati on
MICROGrAMS/Mi,
NUMBER average NUMBER 
of of wells
expts, positive
CONTROL TREATED
PROBAB
■ILITY
INDUCED 
MUTANTS 
PER WELL
10.OOOOOO 
1 0 0 . 0 0 0 0 0 0  
200.000000 
500. 000000’
5.5 5;0 0,00 n. s;
9.5 3.0 0,31 n. s;
6.5 16 -. 0 7.19 < 0.005
3.5 11.7 2.42 n. s;
0.2*00
0,0836
COMPOUND 12 
STRAIv TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT number 
MICROGRAMS/ML 522 526 532 543 
WELLS POSITIVE
0.000000 13 19 26 25
o.ooonoo 17 17 - - «■ m
1.oooooo “  n - - 48 48
1 o.oooooo 48 48 48
100,000000 m 48 43 48
500,QOOnOO 48 - - - -
CONCENTRATION
MICROGRAMS/ML
1.OOOOOO 
1 0-. OOOOOO 
1 0 0 . 0 0 0 0 0 0  
500.000000
number
OF
EXPTS,
AVERAGE NUMBER 
o f  w e l l s  
POSITIVE
CONTROL TREATED
25.5 
21 . 7  
21.7
17.5
48.0
48.0
48.0
48.0
compound 12
STRAIN TA93
intact hepatocyte activation
57,48
113.28
113.28 
51 .62
PROBA8
ILITY
0,0005
0.0005
0,0005
0,0005
INDUCED 
MUTANTS 
PER WELL
???????
???????
???????
???????
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 81 73 84 104
WELLS POSITIVE
0 . oooooo 28 a 8 13
o.oooooo - - 11 6 12
o . i o o o o o - - mtm 10
0,500000 - - 22 37
1 . oooooo -- r 25 43
5, 0001)00 43 48
o.ooonoo 48 -~ --
100.OOOoOO 43 «■ M
500,ooonoo m m 46 r> •»
"ONCrNTRATjON number AVERAGE NUMBER 2 PROBAB I HDUr.ED
'ICROGRAms/ML of of wells X I LITY MUTANTS
EXPTS, POSITIVE PER WELL
CONTROL treated
0,100000 1 12,5 19.0 2.46 N.S. 0.20?2
o.ooonoo T ° . 7 29 . 5 47.35 < 0.0005 0.7264
1. ooooon -> 9.7 3 A. 0 t>8.8 r, < 0.0005 1,0051
5 . 0 0 0 f! o n 2 14.0 45.5 00 .08 < 0,0005 2.6101
1 3 . 0 0 n o 0 0 1 9.5 48. f 81 .14 < 0.0005 ???????
10 0/000000 1 9.5 48. 0 31 ,1 4 < 0.0005 ???????
500. 0000 On 1 o.5 46.0 73.1* < 0.0005 2.9575
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 426 449 454 477 444 65
WELLS POSITIVE
0 . 0 0 0 0 0 0 10 7 21 16 9 0
0.  000000 16 - - 15 16 10 12
1 . oooooo 5 3 - - 23 - - - -
1 0 , 0 0 0 0 0 0 14 4 12 - - - - 23
1 0 0 . oooooo 23 15 26 - - 18
5 0 0 . oooooo 22 4 22 15 22 0
concentration NUMBER AVERAGE number 2 PROBAB INDUCED
M I CRDGRAMS/ML OF of wells . X ILITY MUTANTS
EXPTS. positive PER WELL
CONTROL treated
1 . oooooo 3 1 3 . 0 1 0 . 3 1 . 3 4 N.S.
1 o.oooooo 4 1 2 . 7 1 3 / 2 0 . 0 5 N.S, 0 . 0 1 4 3
1 0 0 , 0 0 0 0 0 0 4 1 4 .1 20-: 5 1 0 . 2 8  < 0 . 0 0 5 0 . 2 0 8 9
5 0 0 . OOOOOO o 1 2 . 7 1 5 . 7 3 . 3 3 N.S. 0 , 0 8 6 4
compound 13
STRAIN . TA100 
S9 ACTIVATION
concentration experiment number
MICROGRAMS/ML 535 548 462 468 
WELLS POSITIVE
0 . oooooo 37 20 23 20
o.oooooo 29 28 35 13
1 .oooooo -- - - - - 23
1 o.oooooo - - 27 28 33
2 0 , 0 0 0 0 0 0 35 - - - -
m o . o o o o o o - - 30 26 33
2 0 0 . 0 0 0 0 0 0 33 *■- - - - -
500.OOOOOO 36 -- 29 36
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X ILITY MUTANTS
EXPTS. POSITIVE PER WELL
CONTROL TREATED
1.oooooo 1 19.0 23.0 0.75 fi. s; 0.1484
1o.oooooo j 24.8 29,3 3.22 N.S. 0.2160
20,000000 1 33.0 35.0 0.18 N.s. 0,1431
100.oooooo 3 24.8 29.7 3.73 N.S. 0,2340
20J.OOOOOO 1 33.0 33.0 0.00 n. s;
500,OOOOOO 3 27.8 33.7 5.76 < 0.025 0.3414
COMPOUND 13
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 73 88 102 107
WELLS POSITIVE
0. ooonoo 13 11 11 1?
0.000000 -p. 13 10 14
1.OOOOOO 32 mm -~ - -
10.OOOOOO 26 mm 19 25
50.OOOOOO •* m 18 19 10
m o .  ooonoo 2 13 17 - -
CONCENTRATION number AVERAGE NUMBER 2 PROBAB induced
MICROGRAMS/ML OF of wells X ILITY mutants
'EXPTS, positive per well
CONTROL TREATED
1 . ooooon A 1 3 . 0 3 2 ;  o 1 4 . 3 2 < 0 . 0 0 0 5 0 . 7 8 2 8
1 0 . oooooo 3 1 2 . 0 23' .  3 21 . 8 8 < 0 . 0 0 0 5 0 . 3 7 8 1
5 0 . OOOOOn 3 1 1 . 8 1 5 , 7 2 .  89 N.S. 0 , 1 1 2 0
1 0 0 .  OOOOOn 3 11 .6 1 o ; 7 0 . 1 4 N.S.
NO A C T I V A T I O N
CONCENTRATI ON EXPERI MENT HUMBER
MI CROGRAMS/ ML 4 3 3  4 3 7  4 4 3  4 4 8  
WEI LS P O S I T I V E
0, 0 0 0 n 0 0 10 9 7 •>
0,OOOnOO 4 12 — 3
1.OOOnOO •* - - 11 7
'0.OOOOOO 12 - - 1 6
1 '>0, OOOnOO 1 9 8 5 --
5-no. OOOnOO 11 6 1 --
CONCENTRATION number average number 2 PKQBAB INDUCED
MICROGRAMS/ML OF uf wells X ILITY mutants
EXPTS. positive PER WELL
CONTROL treated
1 . OOOOOn 3 a . 2 ' 8 . 3 0 . 0 0 N . s . 0 . 0 0 3 4
1 0 . oooooo j 8 . 2 6 . 3 0 . 8 9 N.S.
1 0 0 . ooooon 3 1 0 . 4 1 0 . 7 0 . 0 0 N.S. 0 . 0 0 7 1
5 0 0 , OOOOOO 3 1 0 . 4 6 : o 4 . 7 7 TUXIC
COMPOUND 13 
STRAIv TA98 
S9 ACTIVATION •
CONCENTRATION EXPERIMENT NUMBER
MI CnOGRAM«!/ML 461 467 532
WELLS POSITIVE
0. OOOOOO 9 19 26
0.OQOnOO -- 12
1.OOOnOO -- 16 . -*•
10.ooonoo 25 23 34
100.000000 33 17 43
50a.oooooo 21 18 29
CONCENTRATION
MICROGRAMS/ML
NUMBER
OF
EXPTS.
AVERAGE NUMBER
of wells
. POSITIVE
PROBAB
ility
INDUCED 
MUTANTS 
PER WELL
CONTROL TREATED
1iOOQOOn 1 15.5 16.0 0.00 N.S. 0.0155
10.OOOOOO 3 18.4 27.3 12.21 < 0.0005 0.3593
100.OOOoon 3 18.4 31 :o 24.32 < 0.0005 0.5546
500.OOOOOO 5 13.4 22.7 2.75 N.S. 0.1557
COMPOUND 13 
STRAIN TA98
INTACt hepatocyte activation
CONCENTRATION EXPERIMENT NUMBER
Mi cr or ,RAMS/ML 59 61 62 63
WELLS POSITIVE
o. oo o no o 7 7 8 9
0 . ooonoo 3 9 - - - -
0 . 1  0 0 n 0 0 - - — 3 - -
1 . ooonoo -- 14 7 '11
‘' 0 .  0 0 00 00 24 14 14 - -
5 0 . OOQnOO - - -- - - 18
1 no,OOOnOO 17 6 13 18
5 0 0 , OOunOO 17 -- -- —
C 0 N C C N T R A TI 0 N NUMBER AVERAGE number 2 PROBAB INDUCED
MlCRnr,ra s^/ ml OF of w^ lls X ILITY MUTANTS
EXPTS. positive PER WEL
control treated
o. m o o o n i 5.0 3.0 2.03 N.S.
1 . ooooon 5 3.2 10.7 1 .13 N.S. 0.0627
1 o . ooooon 3 7.3 17,3 19.09 < 0.0005 0.2707
50.ooooon ■\ 9.0 18.0 3.72 N.S. 0.26?4
1 00 .ooooon 4 3 . 0 13.5 8.70 < 0.005 0 , 1 479
500.oooooo 1 7.5 1 7 . 0 6.69 < 0.005 0.2673
COMPOUND 14
STRAIN TA100
NO a c t i v a t i o n
concentration EXPERIMENT NUMBER
MICROGRAMS/ML 13 15 17 20 24 30 39 43
WELLS POSITIVE
0 . 0 0 0 0 0 0 10 17 20 23 1 7 21 32 16
o.oooooo - - - - - - - - 16 - - - -
0 . 1 0 0 0 0 0 28 -- 20 24 36 38 8
1 . oooooo 25 18 24 - - - - 28 12
1 o.oooooo 19 24 26 10
m o . o o o o o o 0 - - 9
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML OF OF WeLLS X ILITY
EXPTS. POSITIVE
CONTROL TREATED
0.100000 6 20.3 25'. 7 7.59 < 0.005
1 . oooooo 5 20,8 21 .4 0.05 n. s;
1 o.oooooo 4 18.0 1 9/7 0.46 n. s;
1 0 0 . oooooo ou 19.5 4.5 • 24.17 TOXIC
COMPOUND 14 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 11 18 19
WELLS POSITIVE
o. oooooo 22 21 23
o. oooooo - - 17 - -
r .  oooooo 27 23 24
lO.OO'O'OOO ■ 25 27 28
mo . o o o o o o 35 32 42
CONCENTRATION NUMBER AVERAGE number 2 PROBAB
MICROGRAMS/ML OF OF WgLLS X ILITY
EXPTS. POSITIVE
CONTROL TREATED
1 , oooooo 3 2 0 . 7 2 4 . 7 2 . 0 4 N.S.
1 o. oooooo 3 2 0 . 7 2617 4 . 7 6 < 0 . 0 2 5
1 0 0 . 0 0 0 0 0 0 3 2 0 . 7 3 6 ; 3 3 4 . 7 5 < 0 . 0 0 0 5
COMPOUND 14
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
concentration experiment number
HICROGRAMS/ML 91 88 101
WELLS POSITIVE
0 . ooonoo 12 11 11
o;ooonoo 20 13 10
1 . OOOoOO 14 - - 15
1 0 . 0 0 0 0 0 0 20 19 - -
5 0 , ooonoo - - m ™ 11
m o . o o o n o o 22 27 39
CONCCNTRATtON NUMBER AVERAGE NUMBER
MICROGRAMS/ML OF
EXPTS.
of wells
POSITIVE
PROBAB
ILITY
control treated.
1 . OOOOOO 2 1 3 . 2 1 4 , 5 0 . 1 5 N.S.
1 3 . ooooon 2 1 4 . 0 19". 5 3 . 5 5 N.S.
5 0 . ooooon 1 1 0 . 5 1 1 . 0 0 . 0 0 N.S.
1 0 0 . 0 0 0 0 0 0 3 1 2 . 8 2 9 . 3 4 7 . 3 3 < 0 . 0 0 0 5
INDUCED
mutants 
per WELL
0.2159
0.0223
0.0601
INDUCED 
MUTANTS 
PER WELL
0.1552
0.2448
0.8483
induced
MUTANTS 
PER WELL
0.0366 
0.1765 
0.0134 
0.6334
COMPOUND 1 4
STRAIN TAPS
NO ACTIVATION
CONCENTRATION experiment NUHrER
MICROGRAMS/ML 3 14 21 27. 25
WELLS POSITIVE
o;ooonoo 3 16 6 6 3
0.000000 — -- 8 - - 5
0.1OOnOO -- 16 — 4 (
1.000000 8 12 5 -- —
' 0 . OQOnOO 4 1? 3 - -
1 no.OOOOOO n 0 - - —
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
micrograms/ ml of of wells x il ity
EXPTS. POSITIVE
CONTROL TREATED
0.1OOOOn 3 8.7 9.0 0.00 N.S,
1.000000 3 9.5 813 0.24 N.S.
10. OOOOOO 3 9,5 8.7 0.11 N.S.
100.000000 2 7.3 0.0 1 5.24 TUXIC
COMPOUND 14 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 2 4 10 33 42
WELLS POSITIVE
0 . OOOOOO 22 21 24 15 a
0 , 1 ooooo -- 20 -- 11 7
1 .OOOoOO 23 16 15 - - ...
i o ; o o o o o o 16 11 14 - -
100.OOOnOO 11 - - 5 -- - -
CONCENTRATION NUMBER AVERAGE NUMBER 2 PRQBAB
MICROGRAMS/ML OF OF WELLS X ILITY
EXPTS. POSITIVE
CONTROL TREATED
0.10Q00O 3 1 4 . 7 12T7 0 . 5 2 N.S.
1 , ooooon 3 2 2 . 3 1 a : o 2 . 2 3 N.S.
1 0.OOOOOn 3 2 2 . 3 1 3 . 7 9.63 TUXIC
i o o . o o o o o n 2 2 3 . 0 8.0 2 0 . 7 3 TOXIC
COMPOUND 14 
STRAIN TA98
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 45 46 47
WELLS POSITIVE
0 , oooooo 12 15 5
0 . ooonoo - - 17 7
0 . 1 0 0 0 0 0 13 12 4
1 . ooonoo 12 17 11
1O.OOOnOO 9 12 5
CONCENTRATION NUllBtR average number 2 pkqbas
MICROGRAMS/ML OF OF WELLS X ILITY
FXPTS. POSITIVE
CONTROL TREATFD
0.1OOOOn 3 11.2 9.7 0. 44 N.S.
1.OOOOOn 3 11.2 13.3 0.33 N.S.
1 0 . ooooon 3 11.2 8.7 1 .34 N.S.
INDUCED 
MUTANTS 
PER WELL
0,0064
INDUCED 
MUTANTS 
PER WELL
induced
MUTANTS 
per WELL
0.U597
concemtration
MICROGRAMS/Ml
experiment number 
7 15 17 20 24 28
WELLS POSITIVE
o . o o o n o o 26 17 20 23 17 18
o . o o o n o o -- -- -- -- 16 - -
o . o o m o o 14 27 15
0 . 0 1 0 9 0 0 - - -- 46 16 27 --
0 . 1o o noo - - 30 39 -- 35 --
.1 . oo o n o o 4? -- 48 -- -- --
1-0. OOOnOO 47 48 36
1n 0,QCOnOO G -- -- -- --
CONCENTRATION NUMBER 
MICrmGrAMS/ML OF
EXPTS.
0, OOlOOn 3
0 . 01 0000 3
0 . 1 00 0 00 3
1 .ooooon 2
1 0.ooooon 3
i oo . oo oo on 1
COMPOUND 15
STRAIN TA100
S9 ACTIVATION
average number 2
OF WELLS X
POSITIVE
CONTROL TREATED
18.5 • 18.7 0 . 0 0
19.0 29.7 • 15.82
17.5 37.7 57.72
23.0 47.3 62.81
2 0 . 0 43. t 77.26
26.0 0 . 0 34.30
PROBAB INDUCED
ILITY MUTANTS
PER WELL
N.S. 0.0057
< 0.0005 0.4586
< 0.0005 1.0824
< 0.0005 3.9120
< 0.0005 1.8659
TOXIC
concentration experiment number
MICROGRAMS/ML 11 18 19 26
WELLS POSITIVE
o.ooonoo 22 21 23 23
O.OOOnOO - - 17 27
0 . 0 10 0 0 0 — - - 25 - -
o . l o o n o o ' 18 27 2o
1 .ooonoo 48 44 48 m m
1o,oooooo 0 0 - - mm
1 0 0 .OOOnOO 0 .... - - - -
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
micrograms/ml of of wells x ility hutants
expts. POSITIVE PER well
CONTROL TREATED
0 . 0 10 0 00 1 23.0 25.0 0.09 N.S. 0.0334
0 . 1 ooooo 3 2 2 . 2 24.7 0.85 N.S. 0.1005
i . oo oo on 3 20.7 46:7 106.27 < 0.0005 3.0174
1 0 . 00 0 00 0 2 2 0 . 0 0 , 0 52.23 TUXIC
1 0 0 . 00 0 00 0 1 2 2 . 0 o;o 27.26 TUXIC
compound 15
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION
HICROGRAMs/ML
experiment number 
91 88 101 108
WELLS POSITIVE
0 . 0 0 0 0 0 0 12 11 11 12
o.ooonoo 20 13 10 1 4
0 . loonoo mm 1?
1 . ooonoo 17 18 43
5 . OOOnOO 46 39 48
i o , ooo oo n 41 46 mm
CONCENTRATION NUMBER 
MICROGRAMS/ML OF
EXPTS.
0.1OOOOn 1
1.0OOOOn 3
5.000000 3
10.OOOQOn 2
average NUMBER 2
of wells x
POSITIVE
CONTROL Treated
13.0 1 2 . 0 0.03
1 2 . 8 2 6 . 0 30,80
13.2 44.3 160.65
14.0 43,5 95.47
PROBAB INDUCED
ILITY MUTANTS
PER WELL
N.S.
< 0.0005 0.4601
< 0.0005 2.2513
< 0,0005 2.0223
COMPOUND 15
STRAJv TA98
NO ACt IVATIO?)
CONCENTRATION EXPERIMENT number 
MICROGRAMs/ml 3 14 21 22 25 20
WELLS POSITIVE
o . o o o o o o fl 16 6 6 3 7
o . o o o o o o - - - - 8 5 —
0 . 0 1 onoo - - m m 11 11 p
0 . 1 oo ooo - - 2° - - 6 4
1 . OOOOOO 41 46 - - . . . _ _
* 0 . 000O00 46 31 22 30 __ . .
1 0 0 . o o on oo 0 - - 0 - -
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
micrograms/ml op of wells x ility
EXPTS. POSITIVE
CONTROL TREATED
0 . 0 10 0 00 3 6.5 10.3 3.45 N.S. 0.0969
0 . 1 00 0 00 3 8.7 13.0 3.50 N.S. 0.1146
1 . oooooo 2 1 2 . 0 43.5 83.42 -< 0.0005 2.0704
1 0 . 0 0 0 0 0 0 4 8.7 32.2 117.35 < 0.0005 0.9152
1 0 0.oooooo Oim 7.3 o;o 15.24 TOXIC
COMPOUND 15 
STRAIN TA98 
59 ACTIVATION
induced
mutants
PER WELL
concentration
micrograms/ml
0.OOOoOO 
0.100*00 
1 . ooonoo
10.000O00
1O0 .oooooo
EXPERIMENT number 
2 4 10 33
WELLS POSITIVE
22 21 24 15
—  19 T3 17
10 40 42 —
5 1. 0 "»
0 —  —  --
CONCENTRATION
MiCROGrAMS/ML
number AVERAGE number 
OF OF WELLS
EXPTS, POSITIVE
CONTROL TREATED
0.1 0 0 00O 3 2 0 . 0 16.3 1 .63
1.OOOOOO 3 22.3 33.7 16.03
1 0.oooooo 3 22.3 2 : 0 67.16
100.OOOOOO n 2 2 . 0 o;o 27.26
COMPOUND 15 •
STRAIN TA9fl
PROBAB
ility
N.S.
0.0005
TOXIC
TOXIC
induced 
mutants 
PER well
0.5326
INTACT hepatocyte activation
concentration
MICROGRAMS/ML
EXPERIMENT NUMBER 
46 47 43
WELLS POSITIVE
o.oooooo 15 5 12
o,oooooo 17 7 10
o; i ooooo 16 8 10
1 . oooooo 13 15 17
1 0 , OOQnOO 43 46 42
CONCENTRATION
micrograms/ml
NUMBER AVERAGE NUMBER
of of wells
expts. POSITIVE
PROBAB
ILITY
INDUCED
mutants 
per WELL
control treated
0 . 1 OOOOn 
1 . OOOOOo 
1 3 . OOUOoO
11.0
11.0
11.0
11.3
15.0
43.7
0 . 0 1
3.23
177.87
N.S.
N.S.
< 0.0005
0,uOOp 
0.1144 
2,1446
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 451 459 472 547 65
WELLS POSITIVE
0 . 0 0 0 0 0 0 26 .27 16 26 9
0.OOOOOO 19 23 16 34 12
1 . ooonoo p 20 -- -- - -
< 0 . ooonoo 12 25
1 0 0 . ooonoo 10 20 22 --
500.OOOnOO — 12 0 19
concentration
MICROGRAMS/ML
number average number 
of of wells
EXPTS. POSITIVE
CONTROL TREATED
PROBAB
ILITY
induced
mutants
PER WELL
1 . ooooon 2 2 3 . 7 1 4 . 5 9 . 3 0 TUXIC
1 0 . oooooo 2 2 3 . 7 1 3 . 5 2 . 8 7 N.S.
1 0 0 . oooooo 3 21 . 2 1 7 . 3 2 . 3 6 N.S.
500.00000(1 3 1 8 . 8 i o ; 3 1 3 . 1 5 TOXIC
COMPOUND 17 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION 
HI CROGRAMs/ML
experiment number
471 535 548 60 71
WELLS POSITIVE
0 . oooooo 32 37 20 29 26
o. ooonoo 34 29 28 32 34
1 . OOOOOO 36 . - ~ 29 - -
1 0 . oooooo 38 28 — 33 31 37
2 0 . OOOnOO -m 35 — - -
1 0 0 . 0 0 0 n.00 0 33 36
2 0 0 . 0 0 0 0 0 0 - - 37 0 - - . «
40-Q, ooonoo - - 33 —
5 0 0 . oooooo —  31
CONCENTRATION NUMBER AVERAGE number 2 PROBAB INDUCED
micrograms/ ml OF of wells X ILITY MUTANTS
EXPTS. positive PER WELL
CONTROL treated
1 . ooooon 2 31 . 7 3 2 . 5 0 . 0 4 N.S. 0 . 0 4 7 3
1 0 . ooooon 5 30 .  1 3 3 J. 4 3 . 1 7 N.S. 0 . 2 0 3 8
2 0 , ooooon 1 3 3 . 0 3 5 . 0 0 . 1 8 N.S. 0 , 1 4 3 1
1 0 0 . ooooon 3 2 8 . 2 2 3 . 0 4 . 2 8 TOXIC
2 0 0 , oooooo 2 2 8 . 5 1 8 . 5 1 0 , 7 2 TOXIC
4 0 0 . OOOOOn 1 3 3 . 0 33 . 0 0.00 N.S.
5 0 0 . OOOOOO 1 3 0 . 0 31 . 0 0 , 0 2 N.S. 0 . 0 5 7 2
COMPOUND 17 --
STRAIN TA100
INTACt HEPATOCYTE ACTIVATION
CONCENTRATION
MICROGRAMS/ML
experiment number 
73 95 89 102
WELLS POSITIVE
0 . 0 0 0 0 0 0 13 11 6 11
O.'OOOoOO m m 10 13 10
1 0.; OOOoOO 15 9 - - »-
1 0 0 . oooooo 16 -- 11 7
500,OOOoOO 14 7 5 - -
Concentration NUMBER AVERAGE number 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X ILITY MUTANTS
EXPTS. POSITIVE PER WELL
CONTROL treated
1 0 . oooooo 2 1 1 . 3 1 2 , 0 0 . 0 3 N.S. 0 . 0 1 8 3
100  .ooooon 3 1 0 . 6 11 '.3 0.08 N.S. 0 . 0 1 9 8
500.000000 3 1 0 . 6 8.7 0.77 N.S.
CONCENTRATION EXPERIMENT NUMBER
MI CpOGRAMs/Ml 450 456 546 82
WELLS POSITIVE
o.ooonoo 7 12 11 21
0 . ooonoo 7 - - 9 11
1. ooonoo o 13
 ^o .oooooo 1 5 8 11 1 5
m o .  oooooo 14 10 7 31
500.  OOOOOO — 0 32
CONCENTRATION
MICROGRAMS/ML
number average NUMBER 
of of wells
EXPTS. POSITIVE
CONTROL TREATED
PROBAB
ility
INDUCED
mutants
PER WELL
1 . oooooo 2 8.7 i r . o 0 . 71 N.S.
1 o.ooooon 4 11 .1 1 2 : 2 0 . 3 0 N.S.
1 0 0 . 0 0 0 0 0 0 4 1 1. 1 1 5 ; 5 4.94 < 0 . 0 2 5
500 . 0 0 0 0 0 0 2 1 3 . 0 u : o 1 .06 N.S.
COMPOUND 1 ? "
STRAIN TA98
0.0612
0.0305
0.1258
0.0896
S9 ACTIVATION
concentration
MICrOGRAMs/ML
EXPERIMENT NUMBER 
532 543 68 70
WELLS POSITIVE
0 .OOOOOO 
0.OOOOOO 
0.100000 
1 . oooooo 
10.000000  
50.OOOoOO
100.000000
200.000000
500.000000
26 25 21
9
—  14
—  20 
—  22
19
16
22
17
18 18 — — 
— 12 — 14
17 8
CONCENTRATION
microgrAhs/ ml
number AVERAGE NUMBER 
OF OF WELLS
EXPTS, POSITIVE
CONTROL TREATED
PROBAB
ILITY
INDUCED
MUTANTS
PER well
0.10000O 1 15.0 14.0 0.03 N.S.
1 . ooooon A 15.0 20.0 1 .31 N.S.
1 0 . 0 0 0 0 0 0 4 15.0 22.0 2.64 N.S.
50.000000 1 26.0 22.0 0*. 51 N.S.
1 0 0 . oooooo 3 18.2 14.0 2.85 N.S.
2 0 0 . ooooon 2 25.5 i s ; o 4.42 TOXIC
500.000000 2 20.0 13.0 5.02 TOXIC
C O M P O U N D 17 •
strain TA98
0.1643
0.2384
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION
micrograms/ ml
EXPERIMENT NUMBER 
63 66 67 72 104
WELLS POSITIVE
o.oooooo 9 12 7 5 13
o.ooonoo - - 8 — 9 12
1. OOOnOO 5 12 a - -
' 0 . 0 0 0 0 0 0 17 5 1 10 - -
1 no.ooonoo 19 10 14 10 14
5no.OOOnOO - - — -- 5 —
CONCENTRATION
micrograms/ ml
number average number
OF OF WELLS
EXPTS. POSITIVE
PROBAB
ILITY
INDUCED 
MUTANTS 
PER WELL
1 . ooooon 3
CONTROL
9.0
treated
8.3 0.07 N.S.
1 0 . ooooon 4 8.3 8:2 o.oc " N.S.
1 0 0 . ooooon 5 9.4 13,4 5.67 < 0.025
500.000000 i 7.0 5.0 .0.32 N.S.
0.1100
STRAIN T A10 o 
NO ACTIVATION
concentration
HICROGRAMr/Ml
o . o o o n o o  
o . ooo no o
1.OOOnOO
i o . o o o n o o
25.OOOoOO 
1 0 0 . ooonoo
200,000O00
EXPERIMENT NUMBER
528 539 541 77
WELLS POSITIVE
10 
1 3
14
14
P
18
13
17
15
8
14
10
11
concentration
micrograms/ml
NUMBER average NUMBER 
of of wells
expts. positive
PROBAB I NDUCED
I L I T Y  MUTANTS
PER WELL
control TREATED
1.OOOOOn 1 1 1 , 0 1 0 . 0 0 . 0 3 N . S .
10 .OOOOGo \ 1 1 . 0 1 1 . 0 0 . 0 0 N . S .
2 5 . OOOOOn 1 1 1 . 5 1 4 v 0 0 . 3 3 N . S . 0 , 0 7 1 0
1 0 0 . OOOOOn 4 1 0 . 4 1 U 7 0 . 5 2 N . S . 0 . 0 3 7 2
2 0 0 . ooooon 3 1 0 . 2 9 . 7 0 . 0 4 N . S .
COMp Oi jND 18  
STRAI N TA100  
S9 ACTI VATI ON
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r  
MI CROGRAMs / ML 5 2 4  52 5  529  5 3 7  75
WELLS P O S I T I V E
0 . oooooo 30 31 28 36 11
o . o o o n o o 26 33 24 - - 13
1 . ooonoo - - - - - - - - . 9
1 0 , 0 0 0 0 0 0 41 33 27 39 4
1 0 0 . ooonoo 26 30 40 14
2 0 0 . o oonoo 24 - - 28 28 —
c o n c e n t r a t i o n n u m b e r a v e r a g e n u m b e r 2 PROBAB INDUCED
MI CROGRAMS/ ML OF of  w e l l s X I L I T Y m u t a n t s
EXPTS. p o s i t i v e PER WELL
CONTROL t r e a t e d
1 . ooooon 1 1 2 . 0 9 . 0 0 . 5 4 N . S .
1 o . o o o o o n 5 2 5 , 8 2 8 : a 2 . 3 6 N . S . 0 . 1 4 6 2
1 o o . o o o o o n 4 2 4 . 0 2 7 . 5 2 . 4 6 N . S . 0 . 1 5 7 6
2 0 0 . ooooon 3 2 8 . 8 2 6 . 7 0 , 6 4 N . S .
compound 18
STRAIN TA100
I NTACT h e p a t o c y t e  ACT I VATI ON
c o n c e n t r a t i o n  e x p e r i m e n t  NUMBER
MICROGRAMs / ML 87  95  89 105
WELLS P O S I T I V E
0 . ooonoo 7 11 6 17
o . o o o n o o 14 10 13 16
s o . o o o n o o *■ m 4 -- 1 5
i o o ; o o o n o o 13 ... 9 8
2C0.OOOOOO 20 6 7 m 9*
c o n c e n t r a t i o n
MICROGRAMS/ML
5 0 . ooooon 
1 0 0 . oooooo 
2 0 0 . ooooon
n u m b e r AVERAGE n u m b e r 2 PROBAB INDUCED
OF of  w e l l s X i l i t y m u t a n t s
EXPTS, p o s i t i v e p e r  WELL
c o n t r o l t r e a t e d
2 1 3 . 5 9". 5 2 . 1 3 N . S .
3 1 2 . 2 1 0 : 0 0 . 9 6 N . S .
3 1 0 . 2 1 1 . 0 0 . 1 2 N . S . 0 . 0 2 2 3
COMPOUND 18
STRAIN TA98
NO ACTIVATION
concentration experiment number
MICPOGRAMs/Ml 527 533 74 82
WELLS POSITIVE
o. ooonoo 4 16 4 21
o, ooonoo a 11 6 11
1 ,'OOOnOO - - - - 6 - -
i o . o oo n o o 7 - - 8 5
5 0 , OOOnOO - - 7 - - - -
1 no,OOOOOO 8 - - 4 8
2C0. OOOoOO 11 11 - - 12
CONCENTRATION NUMBER AVeRAGE NUMBER 2 PROBAB INDUCED
micrograms/ ml of of wells x il ity  mutants
EXPTS, POSITIVE PER WELL
CONTROL TREATED
1 . ooooon 1 5 . 0 6 * 0 0 . 0 5 N. S
1 0 . ooooon 3 9 . 0 6 . 7 1 . 4 3 N. S
5 0 , ooooon 1 1 3 . 5 7 . 0 2 . 8 9 N. S
1 0 0 . ooooon 3 9 . 0 6 . 7 1 . 4 3 N. S
2 0 0 . OOOOOn 3 1 1 . 8 1 1 . 3 0 , 0 3 N. S
COMPOUND i8 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER 
MICROGRAMS/ML 521 531 540
WELLS POSITIVE
o. ooonoo 25 30 12
o. oooooo 11 28 12
1 0 . 0 0 0 0 0 0 13 28 12
1 0 0 . ooonoo 20 - - 11
2 0 0 . 0 0 0 0 0 0 16 22 11
CONCENTRATION
MICROGRAMS/ML
number AVERAGE number 
of OF WELLS
EXPTS. POSITIVE
CONTROL TREATED
PROBAB
ILITY
INDUCED 
MUTANTS 
PER WELL
1 0 . OOOOOn 3 1 9 . 7 1 7 : 7 0. 61 N. S
1 0 0 . oooooo 2 1 5 . 0 1 5 . 5 0. 01 N. S
2 0 0 . 0 0 0 0 0 0 3 1 9 . 7 1 6 . 3 1 .81 N. S
COMPOUND 18 
STRAIN TA98
INTACT HEPATOCYTE ACTIVATION
0 , 0 1 5 3
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 78 83 93 98
WELLS POSITIVE
o, oooooo 8 20 13 11
0.000000 11 11 7 - -
5o; oooooo - - 16 16
1 AO.oooooo 12 16 - - m m
2AQ;ooonoo 12 17 13 7
CONCENTRATION NUMBER AVERAGE number pkubab INDUCED'
MICrOGrAMS/ML OF of wells X ility MUTANTS
EXPTS, positive PER WELL
CONTROL treated
5 0 . ooooon 2 1 0 . 3 16;  o 3 . 3 5 < 0 . 0 2 5 0 . 1 6 3 0
1 0 0 , 0 0 0 0 0 0 Tlm 1 2 . 5 1 4 . 0 0 . 2 4 N.S. 0.  0432
2 0 0 . OOOOOO 4 1 1 .6 1 3 . 5 0 , 9 3 N.S. 0 . 0 5 4 4
concentration 
MI CROGRAM^ /Ml
e x p e r i m e n t  n u m b e r  
451 455 459 4?2 65
wel LS P O S I T I V E
0 . ooonoo 26 29 27 16 9
o. ooonoo 19 - - 23 16 12
0 . 1 oonoo - - - - - - 7
1 .OOOnOO 11 30 - - 24 - -
5 . OOOOOO - - - - - - 12
i o . o o o n o o 10 25 - - 16
5 0 . OOOOOO - - - - 4 - -
1 0 0 . 0 0 0 0 0 0 0 0
JONCENTRATION n u m b e r AVERAGE n u m b e r 2 PROBAB
11 CrOGr AMS/ML OF of wel l s X ILITY
EXPTS. p-o s i t i v e
c o n t r o l t r e a t e d
0,1OOOOn 1 10.5 7.0 0.87 N.S.
1.OOOOOO 3 21.2 21 .7 0.02 N.S.
5.ooooon 1 10.5 1 2 ; 0 0.10 N.S.
10,ooooon 3 21 .2 17,0 2.67 N.S.
50.000000 1 25.0 4.0 25.21 TOXIC
100.ooooon 2 24.7 0.0 70.13 TOXIC
COMPOUND 19
STRAIN TA1 00
S9 ACTIVATION
CONCENTRATION EXPERIMENT n u m b e r
MICROGRAMS/ML 471 535 548 69 71
WELLS POSITIVE
o.ooonoo 32 37 20 29 26
o.ooonoo 34 29 28 32 34
1.ooonoo 33 -- 26 37
10.ooonoo 37 — 33 30
20.000n00 -- 35 — - -
5 o, o o o n o o - - —  . 35 1
100.ooonoo 44 40 0 0 --
200,000O00 37 0
CONCENTRATION n u m b e r a v e r a g e n u m b e r 2 PROBAI
MICROGrAMS/ML OF OF WELLS X ILITY
EXPTS. POSITIVE
c o n t r o l t r e a t e d
1.ooooon 3 31 .2 32.0 0.09 N.S.
10.ooooon 3 31.2 33.3 0.73 N.S.
20.OOOOOO 1 33.0 35.0 0.18 N.S.
50.ooooon 2 27.0 18.0 8.63 TOXIC
ioo.ooooon 4 30.1 21 v 0 18.43 TOXIC
200.ooooon 2 28.5 18; 5 10.72 TOXIC
COMPOUND 19 
STRAIN TA100
intact hepatocyte ACTIVATION
CONCENTRATION
MICROGRAMs/ML 73 95 89 105
WEL LS POSIT IVE
0.  OOOnOO 13 11 6 17
o.ooonoo - - 10 13 16
1 . ooonoo 11 p» m 21
1 0 . ooonoo - - 9 17 12
i o o . oo on on 14 14 20
INDUCED 
MUTANTS 
PER WELL
0.0176
0.0408
induced
mutants
PER WELL
0.0508
0.1378
0.1431
concentration
MICrOGrAMS/ML
1 . ooooon 
10,OOOOOn
i oo . o o o o o n
NUMBER average number
OF OF WELLS
expts, POSITIVE
CONTROL treated
PROBAB
ility
2 15.5 16,0 0.01 N.S
3 12.7 12.7 0.00 N.S
3 12.7 16.0 2.15 N.S
INDUCED 
MUTANTS 
PER WELL
0.0155 
0 097
Nn a c t i v a t i o n
CONCENTRATION EXPERIMENT NUMBER
HICROGRAMs/ML 45 0  4 5 6  54 6  8? -
WELLS P O S I T I V E
o . o o o n o o 7 12 11 21
o . o o o n o o 7 9 11
1 . ooonoo 6 3 - - - -
1 o . o o o o o o 4 3 16 8
r»o . o o o n o o — -- 15 - -
i o n . o o o n o o 0 0 - - 3
CONCENTRATION NUMBER AVERAGE n u m b e r 2 ‘ PROBAB INDUCED
MICROGr AMS/ML OF of  w e l l s X I L I T Y m u t a n t s
EXPTS. p o s i t i v e PER WELL
c o n t r o l t r e a t e d
1 .oooooo 2 8 . 7 4 . 5 3 . 1 4 N . S .
1 0 , OOOOOn 4 1 1 . 1 7.7 3 . 5 1 N . S .
5 0 . 0 0 0 0 0 0 ' 1 0 . 0 1 S'.O 1 .61 N . S .  • 0 , 1 4 1 1
1 0 0 , ooooon 3 1 1 . 6 1 . 0 3 2 . 0 3 TOXIC
COMPOUND 19 
STRAIN TA98 
S9 A CT IV A TI ON
c o n c e n t r a t i o n
m i c r o g r a m s / m l
0,000000 
0 . oooooo 
0 . 1 0 0 0 0 0  
1 .ooonoo  
1 0 . ooonoo 
5 0 . ooonoo 
1 0 0 . ooonoo 
2 0 0 . ooonoo
EXPERIMENT n u m b e r  
53 2  54 3  68  70
WELLS P O S I T I V E
25 38
2 7  32
19
16
26  25 21
—  —  9
—  —  2 2 —
—  —  18 16
•12 16 
—  17
0 —  
0 .......
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WE LL$ X I L I T Y  MUTANTS
EXPTS.  P O S I T I V E  PER WELL
c o n t r o l  TREATED
0 . 1 OOOOn 1 1 5 . 0 2 2 . 0 2 . 6 4 N . S . 0 . 2 3 8 4
1 . ooooon 2 1 6 . 2 1 7 , 0 0 . 0 4 N . S . 0 . 0 2 3 9
1 0 . ooooon 2 1 6 . 2 1 4 . 0 0 . 5 4 N . S .
5 0 , OOOOOO 3 2 1 . 5 2 6 . 7 3 . 6 0 N . S . 0 . 2 1 6 9
1 0 0 , OOOOOn 3 2 0 . 2 1 9 . 7 0 . 0 3 N . S .
2 0 0 . OOOOOO 1 2 6 . 0 0 * 0 3 4 . 3 0 TOXIC
COMPOUND 19 
STRAIN TA93
INTACT HEPATOCYTE A C TI V A TI O N
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 63 64  66
WELLS P O S I T I V E
o.ooonoo □ 6 12
0 . OOOOOO -- 6 8
1 . ooonoo 8 6 11
' o .oooooo 8 6 10
1 9 0 . oooooo 8 6 10
CONCENTRATION NUMBER AVERAGE n u m b e r 2 . PROBAB INDUCED
MICROGRAMS/ML OF of  w e l l s X i l i t y MUTANTS
EXPTS. P O S I T I V E PER WELL
CONTROL TREATED
1 . OOOOOO J 3 . 2  8 . 3 0 .  00 n . s . 0 . 0 0 3 4
1 0 . OOOOOn 3 8 . 2  8 . 0 0 . 0 0 N . s ,
m o . o o o o o n 3 8 . 2  8 . 0 0 . 0 0 N . S .
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/Mu 42 6  4 4 °  4 5 4  472 4 4 4  65
WELLS P O S I T I V E
0.000000 10
0 . 0 0 0 0 0 0  16
1.OOOOOO 10
10.000000 10
1 0 0 . 0 0 0 0 0 0  15 
2^ 0.000000
5 0 0 . 0 0 0 0 0 0  3
7 21 16 9 9
- - 15 16 10 12
12 - - 12 - -
15 - - 14 13
7 - - 13 11
- - 21 19 - -
3 34 23 i 2
c o n c e n t r a t i o n NUMBER AVERAGE n u m b e r 2 p r o b a j
MICROGRAMS/ML OF of  w e l l s X I L I T Y
EXPTS. p o s i t i v e
c o n t r o l t r e a t e d
. 1 . 0 0 0 0 0 0 3 1 0 . 4 1 1 . 3 0 , 1 4 n . s ;
1 o . o o o o o o 4 1 0 . 6 1 3 . 0 1 . 5 9 N . S ,
1 0 0 . oooooo 4 1 0 . 6 1 1 ; 5 0 . 1 9 N . S .
2 0 0 . 0 0 0 0 0 0 2 1 7 . 0 2 o :  o 0 . 9 4 N . S .
5 0 0 . OOOOOO 5 1 1 . 7 1 5'. 0 3 . 6 9 N.S, '
COMPOUND 20 
STRAIN TA10U 
S9 A CT IV A TI ON
CONCENTRATION e x p e r i m e n t  n u m b e r  
MICROGRAMS/ML 53 5  4 6 2  468
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 37 23 20
0 . oooooo 29 35 18
1 . oooooo - - - - 17
1 o . o o o o o o - - 22 36
2 0 , OOOOOO 35 - - - -
1 0 0 . 0 0 0 0 0 0 - - 19 22
2 0 0 . 0 0 0 0 0 0 34 .... * _ •
5 0 0 . 0 0 0 0 0 0 28 17 21
CONCENTRATION n u m b e r  a v e r a g e  NUMBER 2 PROBAB
MICROGRAMS/ML OF OF We LLS X I L I T Y
EXPTS,  P O S I T I V E
c o n t r o l  t r e a t e d
1 . oooooo 1 1 9 . 3 17- .0 0 . 2 6 n . s ;
1 o . o o o o o o 2 2 4 . 2 2 9 . 0 2 . 5 6 N . s ,
2 0 . oooooo 1 3 3 . 0 35 L 0 0 . 1 8 n . s ;
1 0 0 . OOOOOO 2 2 4 . 2 2 o ; 5 1 . 4 8 n . s ;
20.0.  OOOOOO 1 3 3 . 0 34*  0 0 . 0 3 N . s ,
5 0 0 . OOOOOO 3 2 6 . 7 2 2 s. 0 3 . 7 1 n . s ;
COMPOUND 20
STRAIN TA10 0
INTACT HEPATOCYTE A C TI V A TI O N
c o n c e n t r a t i o n  e x p e r i m e n t  NUMBER
MICROGRAMS/ML 73 88 10 2  10 7
WELLS P O S I T I V E
o . o o o n o o 13 11 11 12
0 . oooooo - - 13 10 14
1 o . o o o n o o 13 - - 9 m
1 0 0 . ooonoo 22 9 17
2 0 0 . OOOnOO - - 9 12
5 0 0 , OOOoOO 16 7 10 •* m
c o n c e n t r a t i o n
MICROGRAMS/ML
NUMBER AVe RAGe NUMBER 
OF OF U e L L s
EXPTS.  P O S I T I V E
PROBAB
I L I T Y
CONTROL TREATED
1 0 . ooooon  
1 0 0 . 0 0 0 0 0 0  
2 0 0 . ooooon
5 0 0 . OOOOOn
1 1 . 3
1 2 . 6
1 1 , 7
1 1 . 6
11.0
i6;o
10^ 5
1 1 . 0
0.00
2 . 0 3
0 . 1 7
0 . 0 5
N . S .
N . S .
N . S .
N . S .
INDUCED
m u t a n t s  
p e r  w e l l
0 . 0 2 5 1
0 . 0 6 5 7
0 . 0 2 3 7
0 . 1 0 1 8
0 . 0 9 5 3
i n d u c e d
MUTANTS 
PER WELL
0 , 2 2 5 2
0 , 1 4 3 1
0 , 0 6 0 0
i n d u c e d  
MUTANTS 
PER WELL
0 . 1 0 1 0
STRAIN T A9 8
NO ACTIVATION
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r
MICROGRAMS/ML 433 436 A43 445
WELLS POSITIVE
0 . OOOOOO ■i o 3 7 1 2
0 . 0 0 0 0 0 0 14 -Jc 6
1 . oooooo 10 3 7 4
 ^ 0 . 0 0 0 0 0 0 o 1 12 7
1 ^ 0 . 0 0 0 0 0 0 14 4 6 7
50 0 , OOOOOO 13 2 6 3
c o n c e n t r a t i o n
m i c r o g r a m s / ml
I . oooooo 
1 o. oooooo
1 0 0 . 000000
5 0 0 . 0 0 0 0 0 0
NUMBER AVERAGE NUMBER 
o f  o f  w e l l s
EXPTS.  P O S I T I V E
COMPOUND 20 
STRAIN T A9 8 
S9 A C TI VA TI ON
PROBAB
i l i t y
CONTROL TREATED
4 7 . 7 6- .0 1 . 1 0 N. S
4 7 . 7 7'. 2 0 . 0 5 N. S
4 7 . 7 7 . 7 0 . 0 0 N. S
4 7 . 7 6 : o 1 . 1 0 N. S
CONCENTRATION e x p e r i m e n t  NUMBER
MI CROGRAMS/ML 461 46 7 532
WELLS P O S I T I V E
0 . OOOOOO 9 19 26
0 . 0 0 0 0 0 0 -- 12
1 . oooooo -- 15 20
1 o, oooooo 10 11 23
1 0 0 . 0 0 0 0 0 0 6 6 28
5 0 0 . OOOOOO 5 7 28
c o n c e n t r a t i o n n u m b e r AVERAGE n u m b e r
MICROGRAMS/ML OF OF WELLS
EXPTS. P O S I T I V E
c o n t r o l  t r e a t e d
1 . 000000 2 19.0 17;5
1o. oooooo 3 16.5 1417
100.000000 3 16.5 13V3
500.OOOOOO 3 16.5 13;3
COMPOUND 20
s t r a i n TA98
i n t a c t  h e p a t o c y t e  A C TI V A TI O N
CONCENTRATION EXPERIMENT NUhre'r
MICROGRAMS/ML 61 62 63
WELLS P O S I T I V E
0:000000 -> 8 9
0.000000 0
10.000000 0 5
1no. oooooo 4 10 6
5 ^ 0 , ooonoo 5 11 8
CONCENTRATION NUMBER AVERAGE NUMBER
MICROGRAMS/ML OF of  w e l l s
EXPTS. P O S I T I V E
CONTROL TREATED
10.oooooo 2 3.3 7.0
100.OOOOOn 3 8 . 2  6.7
500.OOOOOO 3 3.2 a ’ 0
0 , 1 8
0 . 4 6
1 . 5 1
1 . 5 1
PROBAB
ility
n . s ;
n . s ;
n . s ;
n . s ;
0.23
0.56
0.00
PROBAB
ILITy
N.S.
N.S.
N.S.
INDUCED 
MUTANTS 
PER WELL
0 , 0 0 0 9
INDUCED 
MUTANTS 
PER WELL
i n d u c e d
MUTANTS 
PER WELL
COMPOUND 21
STRAIN TA100
NO ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MJCr OGr AMr /ML 528 53? 77
WELLS POSITIVE
0 . 0 0 0 0 0 0 10 2 3
o . o o o o o o 13 5 14
1 0 . o o o o o o - - - - 7
1 OO.'OOOCOO 16 5 3
2 0 0 . OOOOOO 21 2 - -
5 9 0 . 0 0 0 * 0 0 11 5 7
CONCENTRATION n u m b e r AVERAGE n u m b e r 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X I l I T Y MUTANTS
EXPTS.. P O S I T I V E PER WELL
c o n t r o l TREATED
1 o . o o o o o o 1 11. -0 7 . 0 1 . 1 3 N . S .
1 0 0 . 0 0 0 0 0 0 3 8 . 7 9 . 7 0 . 2 1 N . S . 0 . 0 2 5 8
2 0 0 . 0 0 0 0 0 0 ->t. 7 . 5 1 1 ; 5 2 . 6 9 N . S . 0 . 1 0 4 0
5 0 0 . OOOOOO 3 8 . 7 7 . 7 0 . 2 2 N . S .
COMPOUND 21 
STRAIN TA 10 0  
S9 A C TI V A T I O N
CONCENTRATION EXPERIMENT NUM8 ER
MICROGRAMs/ML 5 2 4  52?  53 4  53 7  
WELLS P O S I T I V E
0 . OOOOOO 30 28 26 36
0 . OOOOOO 26 24 28
1 0 . OOOoOO 33 - - mm m m
1 0 0 , o o o o o o 30 35 22 35
2 0 0 , 0 0 0 0 0 0 - - 28 31 31
5 0 0 , OOOOOO 27 29 28 32
CONCENTRATION n u m b e r a v e r a g e n u m b e r 2 PROBAB i n d u c e d
MICROGRAMS/ML OF OF WELLS X I L I T Y MUTANTS
EXPTS. P O S I T I V E PER WELL
CONTROL t r e a t e d
1 0 . OOOOOO 1 2 8 . 0 3 3 1 0 1 . 2 6 N . S . 0 . 2 8 7 7
1 0 0 . OOOOOo 4 2 8 . 3 3 0 : 5 0 . 9 9 N . S . 0 , 1 1 9 1
2 0 0 . OOOOOO j 2 8 . 4 3 0 : 0 0 . 3 5 N . S . 0 . 0 8 5 2
5 0 0 . 0 0 0 0 0 0 4 2 8 . 3 27.7 0 . 0 4 N . S .
COMpOuND 21 
STRAIN TA100
INTACT h e p a t o c y t e  a c t i v a t i o n
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 8 7  96  89 105 1 0 6  1 0 7
WELLS P O S I T I V E  *
0 . o o o o o o 7 10 6 17 18 12
0 . OOOoOG 14 12 13 16 10 14
1 0 0 . OOOoOO 44 5 7 10 — 12
2 0 0 . 0 0 0 0 0 0 -- 19 -~ ** M 15 12
5 0 0 . OOOOOO 11 13 11 - - --
c o n c e n t r a t i o n n u m b e r a v e r a g p NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML of of  we l l s X i l j t y MUTANTS
EXPTS. p o s i t i v e PER WELL
CONTROL t r e a t e d
1 0 0 . 00000O 5 1 2 . 1 1 5 . 6 4 . 0 7 < 0 . 0 2 5 0 , 1 0 2 6
2 0 0 . OOOOOO m) 1 2 . 7 1 5 . 3 1 . 3 3 N . S . 0 . 0 7 8 5
5 0 0 . 0 0 0 0 0 0 3 1 0 , 3 1 1 . 7 0 . 3 5 N . S . 0 . 0 3 6 0
COMPOUND 21
STRAIN TA98
NO ACt IVATIOM
CONCENTRATION EXPERIMENT NUMBER
'HICROGRAMS/HL 527 533 81 74
WELLS POSITIVE
0,, o o o o o o 4 16 8 4
0. , 0 0 0 0 0 0 a 11 5 6
10 , , OOOOOO .. 4
10 0 , , 0 0 0 0 0 0 10 -- 8 5
200 , 0 0 0 0 0 0 4 7 8
51 0 | , o o o o o o 13 6 15 1
CONCENTRATI ON NUMBER AVERAGE NUMBER 2 PROBAB I NDUCED
m i c r o g r a m s / m l  of  of  w e l l s  x i l i t y  m u t a n t s
EXPTS,  P O S I T I V E  PER WELL
CONTROL TREATED
1 0 , OOOOOn 1 5 . 0 4 . 0 0 . 0 6 N . S .
1 0 0 . OOOOOo 3 5 . 8 7 . 7 1 . 0 5 N . S . 0 . 0 4 4 5
2 0 0 .  OOOOOo 3 8 . 7 6 1 3 1 . 4 8 N . S .
5 0 0 . OOOOOO 4 7 . 7 8 , 7 0 . 3 3 N . S . 0 . 0 2 5 2
COMPOUND 21 
STRAi u  TA98  
S9.  a c t i v a t i o n
CONCENTRATION EXPERIMENT NUMBER
: crog r a m <?/ml 521 531 54 2
WE LLS POST'
0.o o o o o o 25 30 18
0.o o o o o o 11 28 19
1 0 . o o o o o o 15 ... .«
1 0 0 . o o o o o o 15 22 25
2 6 0 . o o o o o o  • - -- 23 21
5 0 0 . o o o o o o 16 23 29
CONCENTRATION
MICROGRAMS/ML
n u m b e r  a v e r a g e  n u m b e r  
of  of  w e l l s
e x p t s , P OS I T I V E
PROBAB
ILITY
INDUCED 
MUTANTS 
PER WELL
c o n t r o l t r e a t e d
1 o . o o o o o o 1 1 8 , 0 1 5 . 0 0 . 4 2 N.S
1 0 0 . 0 0 0 0 0 0 3 21 . 8 2 0 . 7 0 . 1 8 N.S
2 0 0 . OOOOOO 2 2 3 . 7 2 2 . 0 0 . 2 7 N.S
5 0 0 . 00 000O 3 21 . 8 2 2 . 7 0 . 0 8 N.S
COMPOUND 21
s t r a i n TA98
i n t a c t  h e p a t o c y t e  a c t i v a t i o n
0 . 0 3 2 4
CONCENTRATION
MICROGRAMs/ML
EXPERI MENT NUMBER 
78 83 9 3  98
WELLS P O S I T I V F
0 . 0 0 0 0 0 0 • 8 20 13 11
0 . 0 0 0 0 0 0 11 11 7 . . .
5 0 . OOOOOO - - m «■ 19 9
1 0 0 . OOOoOO 9 15 ..
5 0 0 ; o o o o o o 12 13 1 5 ..
Co n c e n t r a t i o n
MICROGRAMS/ML
50.00000O
1 00.000000
500.00000O
NUMBER a v e r a g e NUMBER 2 PROBAB i n d u c e d
OF of  w e l l s X I L I T Y MUTANTS
EXPTS. p o s i t i v e PER WELL
CONTROL TREATED
2 1 0 . 3 1 4 . 0 1 . 61 N . S . 0 . 1 0 2 4
2 1 2 . 5 1 2 : 0 0 . 0 1 N . S .
3 11 . 7 1 3 : 3 0 . 5 2 N . S . 0 . 0 4 7 0
COMPOUND 22 
s t r a i n  t a 1 o o 
NO ACtJVATIOM
CONCENTRATION EXPERIMENT NUMBER 
MICROGRAMs/ML 451 *55 472
w e l l s  p o s i t i v e
o.OOOOOO 26 29 16
o.oooooo 19 -- 16
1 o.oooooo 16 31 --
100,OOOOOO 15 19 21
500.000000 17 2 23
c o n c e n t r a t i o n
m i c r o g r a m s / ml
10.000000
100.000000
5 0 0 . 0 0 0 0 0 0
number average NUMBER 2 PR OB A1
OF of wells X ILITY
EXPTS. positive
CONTROL treated
2 24.7 23.5 0.09 N.S.
3 2 1 . 2 18.3 1 . 2 0 N.S.
3 2 1 . 2 14.'0 8.24 TOXIC
COMpOuND 22 
strain TA100 
S9 activation
CONCENTRATION experiment number 
MICROGRAMs/ML 471 535 548 69 71
WELLS POSITIVE
o.oooooo 32 37 20 29 26
o.oooooo 34 29 28 32 34
1 0 . 0 0 0 0 0 0 28 -- -- 19 37
100 , oooooo 36 -- 21 33 29
2 0 0 . OOOOOO -- 36 23 mmm --
5 0 0 . OOOOOO 32 — 20 22 31
CONCENTRATION NUMBER AVERAGE number 2 PROBAB
MICROGrAMS/ML OF of wells X il ity
EXPTS. positive
CONTROL TREATED
1 0 . oooooo 3 31.2 28.0 1 .65 N.S,
1 0 0 . oooooo 4 29.4 29.8 0 , 0 2 N.S.
2 0 0 . oooooo 2 28.5 2915 0.08 N.S.
500.oooooo 4 29.4 26:2 2 .1 1 N.S,
COMPOUND 22
strain TA100
intact hepatocyte activation
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 73 89 108
WELLS POSITIVE
o;oooooo 13 6 12
0 . oooooo -- 13 14
1o. oooooo 9 — 12
100.OOOoOO 12 11 —
500.000000 6 9 11
CONCENTRATION NUMBER average number 2 PROBAB
MICROGRAMS/ML OF of wells X ility
• ■ EXPTS. POSITIVE
CONTROL treated
10.OOOOOo 2 13.0 10.5 0.70 N.S.
100.OOOOOO 2 11. 2  1 r .  5 0 . 0 0 N.S.
500 . OOOOOf) 3 11.8 8.7 2 .2 1 N.S.
INDUCED 
MUTANTS 
PER WELL
INDUr.ED 
MUTANTS 
PER WELL
0 . 0 2 0 3
0 . 0 5 2 6
induced 
MUTANTS 
PER WELL
0,0068
COMPOUND 22
STRAIN TA98
NO a c t i v a t i o n
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs /ML 450 456 546 8?
WELLS POSITIVE
o. ooonoo 7 12 11 21
o. oooooo 7 9 11
10.000000 9 15 - - - -
1O0.Q00O00 7 - - 12 .13
500.000000 1 6
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAE
MICROGRAMS/ML OF of wells X ility
EXPTS. positive
CONTROL TREATED
1 0 . oooooo 2 8 . 7  1 2 , 0 1.48 N.S.
1 0 0 . 0 0 0 0 0 0 3 1 1 . 0  1 0 . 7 0. 01 N.S.
5 0 0 . 0 0 0 0 0 0 2* 11.5 3;s 11 .29 TOXIC
COMPOUND 22
strain tA98
S9 ACTIVATION
CONCENTRATION experiment number 
MICROGRAMs/ML 532 540 68 70
WELLS POSITIVE
0.000000 26 12 21 19
0. OOOoOO ~m 12 9 16
10.000000 - - 9 10
100,OOOOOO 16 -- 5 1 3‘
500.OOOoOO 24 9 11 17
CONCENTRATION NUMBER AVERAGE NUMBER 2 . PROBAB
MICROGRAMS/ML Of OF wells X ILITY
EXPTS. POSITIVE
CONTROL TREATED
10.OOOOOO 2 16.2 9;5 5.79 TOXIC
100.OOOOOO 3 18.2 11.3 8.07 TUXIC
500.000000 4 16.4 15.2 0.28 N.S.
COMPOUND 22
strain TA98
intact hepatocyte activation
CONCENTRATION EXPERIMENT NUMBER*"
MICROGRAMs/ML 64 66 67 72
WELLS POSITIVE
0.OOOOOO 6 12 7 5
0.OOOoOO 6 8 9
10,OOOoOO 5 5. 8 0
100.OOOoOO 4 8 7 rn m
5oo;oooooo 3 7 6 ^ m
CONCENTRATION 
MlCROGRAHS/Ml
1 0 . oooooo
100.000000
500.000000
NUMBER AVERAGE number 2 PROBAB
of of w e l l s X ilityEXPTS, POSITIVE
CONTROL treated
4 7.6 6.7 0.22 N.S.3 7.8 6.3 0.54 N.S.
3 7.8 5.3 1 .73 N.S.
INDUCED
MUTANTS
per well
0.0886
induced
mutants
PER WELL
induced 
mutants 
per well
CONTENT RATION EXPERIMENT NUMr ER
MICPOGRAMS/ML 435 453 457 46f) 472 442 447 56
DELLS POSITIVT
o.  oooooo 7 21 30 26 16 5 13 20
0 . 0 0 0 0 0 0 5 15 -- -- 16 --
2 . 0 0 0 0 0 0  • 15
5 .  OOOOOO 12
1 0 . 0 0 0 0 0 0  ' o 7 11 16
2 0 . 0 0 0 0 0 0 14 19 - - 24 -- 5 12 18
50 . OOOOOO 13 -- -- 27 26 - - -- --
100 . oooooo 8 3 23 -- 11 14 --
2 ^ 0 . 0 0 0 0 0 0 - - - - 0 0
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML OF OF UgLLS X I L I T Y
EXPTS.  P O S I T I V E
c o n t r o l  TREATED
2.  0 0 0 0 0 0 1 2 0 . 0 1 5 , 0 0 . 9 1 n . s ;
5 . OOOOOO 1 2 0 . 0 1 2'. 0 2 . 6 4 n . s ;
1 0 . 0 0 0 0 0 0 4 1 0 . 0 10V 7 0 , 1 1 N . S .
2 0 . OOOOOO 6 1 4 . 0 15V3 0 , 5 4 n . s ;
5 0 . OOOOOO 3 14 .  0 22V 0 1 0 , 5 7  < 0 . 0 0 5
1 0 0 . 0 0 0 0 0 0 5 1 4 , 3 " 11 V 8 1 . 7 0 N . S ,
2 0 0 . 0 0 0 0 0 0 2 9 . 0 OVO 1 8 . 7 7 TOXIC
COMPOUND 23 
STRAIN TA'100 
S9 A C TI V A TI O N
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r
MICROGRAMS/ML 46 3  46 8
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 33 20
0 . oooooo 18
2 0 . 0 0 * 0 0 0 0 34 26
5 0 . OOOOOO 37 19
1 0 0 , 0 0 0 0 0 0 37 21
2 0 0 , OOOOOO 32 25
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML Of OF WgLLS X I L I T Y
EXPTS.  P O S I T I V E
CONTROL TREATED
2 0 . 0 0 0 0 0 0 2 2 3 . 7 3 0 . 0 3 . 7 8 N.S
5 0 , OOOOOO 2 2 3 . 7 2 8 . 0 1 . 7 1 N.S
1 0 0 . 0 0 0 0 0 0 c 2 3 . 7 29 VO 2 . 6 4 N.S
2 0 0 . 0 0 0 0 0 0 2 2 3 . 7 2 8 , 5 2 . 1 5 N.S
c o m p o u n d  23
STRAIN TA100
INTACT HEPATOCYTE A CT IV A TI ON
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r
MICP.OGRAMr /ML  9 7  90  10 7
WELLS P O S I T I V E
0 . oooooo 12 10 12
0 . OOOoOO - - - - 14
1o . o o o o o o - - - - 10
2 0 . OOOoOO 12 13 14
1 0 0 . 0 0 0 0 0 0 11 6 - -
2 0 0 . OOOOOO 6 1 - -
CONCp n TR A T i ON NUMBER AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML OF OF We LLS X H I T Y
EXPTS.  P O S I T I V E
c o n t r o l t r e a t e d
1 0 . OOOOOO 1 1 3 ;  0 1 0 . 0 . 6 . 51 N . S .
2 0 . OOOOOO 3 1 2 . 0 1 3 . 0 0 . 1 4 N . S .
1 0 0 . 00000O 2 11 . 0 8 . 5 0 , 6 5 N . S .
2 0 0 . 0 0 0 0 0 0 2 1 1 . 0 3V5 8 . 5 4 TOXIC
i n d u c e d
m u t a n t s
PER WELL
0 . 0 1 9 9
0 . 0 4 0 0
0 , 2 6 8 3
INDUCED 
MUTANTS 
PER WELL
0 . 3 0 1 5
0 . 1 9 6 1
0 . 2 4 7 4
0 . 2 2 1 4
i n d u c e d  
MUTANTS 
PER WELL
0.0282
CONCENTRATION EXPERIMENT n u m b e r
HICROGRAHS/ML 45 2  4 5 8  441 4 46 
WELLS P O S I T I V E
0.000000 •3 0 6 9
2.000000 -- 6 — --
1 o.oooooo 6 9 1?
30.OOOOOO -- 6 4 7
ICO.OOOOOO 4 1 7
200,OOOOOO 0 -- 0 0
CONCENTRATION'  NUMBER AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML OF OF WELLS X I L I  TY
EXPTS,  p o s i t i v e
. c o n t r o l t r e a t e d
2 . OOOOOO 1 9 . 0 6 ; o 0 . 4 9 N . S .
1 0 . 0 0 0 0 0 0 3 8 . 0 9 : 0 0 . 1 5 N . S .
2 J.OOOOOO 3 8 . 0 5V7 1 . 2 0 N . S ,
1 0 0 . OOOOOO 0 8 . 0 4 . 0 4 . 2 0 TOXIC
2 0 0 . OOOOOO 3 6 . 0 0 : 0 1 8 . 1 5 TOXIC
COMPOUND 23 
STRAIN TA98 
S9 A C TI V A TI O N
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r
M I C r OGRAMS/ML 43 4  46 4
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 18 11
0, OOOOOO 14 ...
2.OOOOOO 18
5.000000 13 --
1 0 . 0 0 0 0 0 0 17
20.OOOOOO 19 16
50.OOOOOO ... 14
1 0 0 . 0 0 0 0 0 0 mrm 14
200.000000 13
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
MICROGRAMS/Mi  OF OF We LLS X U I T Y
EXPTS.  P O S I T I V E
c o n t r o l  t r e a t e d
2 . OOOOOO 1 1 6 . 0 18' .  0 0 . 1 6 n . s ;
5 . OOOOOO 1 1 6 , 0 1 3 ;  0 0 . 4 5 n . s ;
1 0 . OOOOOO 1 1 6 . 0 17V0 0 . 0 2 N . s ,
2 0 . OOOOOO 2 1 4 . 3 17V 5 1 . 0 0 n . s ;
5 0 . OOOOOO 1 1 1 . 0 14*. 0 0 . 3 4 n . s ;
1 0 J . o o o o o o 1 1 1 . 0 1 4T0 0 . 3 4 n . s ;
2 0 0 . oooooo 1 1 1 . 0 1 3 7 0 0 . 1 3 n . s ;
COMPOUND 23 
s t r a i n  t A98
i n t a c t  h e p a t o c y t e  A CT IV A TI ON
c o n c e n t r a t i o n  EXPERIMENT NUMBER
MICROGRAMs/ML 80 82  100
WELLS P O S I T I V E
0.OOOOOO 12 9 7
10.000000 m  r* - - a
20.000000 16 10 --
ICO.’OOOoOO 6 13 1
2^0.000000 11 12 9
CONCENTRATION
MICROGRAMS/ML
n u m b e r  a v e r a g e  n u m b e r  
of  of  w e l l s
EXPTS.  P O S I T I V E
PROBAB
i l i t y
CONTROL TREATED
1 0 . o o o o o o
20. 00000O 
1 0 0 . 0 0 0 0 0 0  
200.00000O
7 . 0
1 0 . 5
9 . 3
9 . 3
8.0
1 3 . 0
6 . 7
10V7
0.02 
0 . 5 7  
1 .41 
0 . 2 6
N . S .
N . S .
N . S .
N . S .
INDUCED
MUTANTS
p e r  w e l l
0 , 0 2 5 3
INDUCED 
MUTANTS 
PER WELL
0 , 0 6 4 5
0 , 0 3 1 7  
0,0988 
0 , 0 8 4 6  
0 , 0 8 4 6  
0 . 0 5 5 6
INDUCED 
MUTANTS 
PER WELL
0 . 0 2 4 7
0 . 0 6 9 0
0.0351
COMPOUND 24
STRAIN TA100
NO ACTIVATION
CONCENTRATION experiment NUMBER 
MICROGRAMs/ML 451 455 459 472 65
WEL LS POSIT IVE
o,, oooooo 26 29 27 16 9
0., OOOOOO 19 -- 23 16 12
10.,oooooo 16 26 • - 18
1 00.,OOOoOO 24 -- 17 1 3
500.,000000 32 — 18 - - 5
concentration
MICROGrAMS/ML
10.OOOOOn
1 0 0 . 000000
500.000000 
COMPOUND
strain
NUMBER average number 2 PROBAB INDUCED
OF OF WELLS X il ity mutants
EXPTS. POSITIVE PER WELL
CONTROL treated
3 21 .2 20.0 0.18 N.S.
3 16.3 18:0 0.43 N.S. 0.0541
3 19.3 18.3 0.13 N.S.
24
T A1 00
S9 ACTIVATION
concentration EXPERIMENT number 
MICROGRAMS/ML 471 535 69 71
WELLS POSITIVE
0 .oooooo 32 37 29 26
O.OOOoOO 34 29 32 34
10.OOOoOO 28 36 33
i o o ; o o o o o o 32 - - 30 39
200.OOOOOO - - 33 -- --
500.000000 31 32 36 «r»
CONCENTRATION NUMBER AVERAGE number 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X ILITY MUTANTS
EXPTS. positive per well
CONTROL treated
10.oooooo 3 31.2 32:3 0.20 ’n. s. 0.0718
100.000000 3 31.2 33.7 1 .06 n. s. 0.1608
200.000000 1 33.0 33 ; 0 0.00 n. s.
500.OOOOOO 3 32.2 33.0 0.10 N.s. 0.0541
COMPOUND 24
STRAIN TA100
INTACT HEPATOCYTE activation
CONCENTRATION experiment number
MICrOGRAMs/ML 73 89 105 108
WELLS POSITIVE
0 .oooooo 13 6 17 12
o.oooooo 13 16 14
10.000000 11 —  16 7
100.oooooo 11 13 44 - -
500.oooooo 5 17 37 12
CONCENTRATION number AVERAGE number 2 PROBAB INDUCED
UICROGRAMS/Ml OF OF WELLS X ILITY MUTANTS
EXPTS, POSITIVE per well
control TREATED
10.OOOOOO 3 14.7 11.3 2.12 N.S.
100.000000 3 13.5 22.7 15.08 < 0.0005 0.3088
500.ooooon 4 13.4 17.7 4.77 < 0.025 0.1351
CONCENTRATION e x p e r i m e n t  n u m b e r  
MICPOGRAMs / ML  4 ^ 0  45 6  82
WELLS POSITIVE
0 . oooooo 
0.OOOOOO 
10.OOOoOO 
100,OOOOOO
soo. oooooo
7 12 Zm>
7 — 11
6
7 21 21 
6 4 18
CONCENTRATION number AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML OF OF Wells X ILITY
EXPTS. POSITIVE
control treated
10.OOOOOO 1 7.0 6 . 0 0,05 N.S.
1 0 0 . 0 0 0 0 0 0 3 11 . 6 16I3 4.11 < 0.025
500.000000 3 1 1 . 6 9.3 1 , 02 N.S.
COMPOUND 24 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT
MICROGRAMs/ML 540 68 70
WELLS POSI'
0. OOOOOO 12 21 19
o;oooooo 12 9 16
1 . 0 0 0 0 0 0 ■» m 18 --
1 0 . 0 0 0 0 0 0 “ m 12 13
190.000000 7 17 16
500.oooooo 13 15 15
CONCENTRATION
MICROGrAMS/ML
1 . oooooo 
1 0 . oooooo 
1 0 0 . 0 0 0 0 0 0  
500.OOOOOO
NUMBER
QP
EXPTS.
AVERAGE NUMBER
of wells 
positive
control treated
15.0
16.2
14.8
14.8
i8;o
12:5
13.3
14:3
COMPOUND 24 
strain tA9s
INTACT HEPATOCYTE ACTIVATION
0,43 
1 .64 
0.38 
0.03
PROBAB
ILITY
n. s.
N.S,
N.S.
N.S.
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 64 66 67 72 104
WELLS POSITIVE
0 . oooooo 6 12 7 5 13
0 . oooooo 6 8 9 ' 1 2
1 . oooooo - - 7 - - - -
10.OOOoOO 10 10 8 -- - -
1 0 0 . 0 0 0 0 0 0 4 12 10 18 —
2 0 0 . OOOnQO -- - - 15 15
5 0 0 . OOOoOO 2 4 -- —
CONCENTRATION NUMBER AVeRAGf NUMBER 2 PROBAB
MICROGRAMS/ML OF OF WF|.LS X ILITY
EXPTS, ’POSITIVE
1 . oooooo 1
CONTROL
7 . 0
treated
7 . 0 0 . 0 0 N.S.
. 1 0 . oooooo 3 7 . 8 9 ; 3 0 . 5 3 N.S.
1 0 0 . 0 0 0 0 0 0 4 7 . 6 1 1 . 0 3 . 9 2 < 0 . 0 2 5
2 0 0 . 00000O 2 9 . 7 1 5 . 0 3 .9 1 < 0 . 0 2 5
5 0 0 . ooooon 2 8 . 0 3 . 0 5 . 6 2 TOXIC
INDUCED 
MUTANTS 
PER WELL
0.1393
INDUCED 
MUTANTS 
PER WELL
0,0953
induced
MUTANTS
per well
0.0389
0.0886
0.1476
COMPOUND 25
STR4IM T A 1 rt<_j
NO ACT I V AT I Oil
CONCENTRATION experiment NUMBER
I I I  CPOGRAMS/ML 523 536 541 547 77
WEUS P OSI T I VE
0,000000 11 25 18 26 3
0 . oconoo 20 -- 13 34 14
0.010000 -- -- -- -- 14
■ 0.1ooooo -- »•- -- -- 15
0.500000 1 --
1, OOOOOO -- 18 10 0. 10
2 . OOOOOO - - 3 7 - - - -
5.000000 ' -- 5 1 .. --
TO.OOOOOO 0
i no,oooooo 
5^ 0.OOOftOO
CONCENTRATION 
hi croc,rams/ml
NUMRER AVERAGE NUMBER
of. of wells
EXPTS. POSITIVE
' CONTROL treated
0.010000 1 11.0 V4;0 0.51
0 . 1ooooo 1 11.0 1 s; o 0,96
0.500000 1 30.0 1.0 46«61-
1 . oooooo 4 19.7 9 : 5 24.42
2 . OOOOOO 2 18.7 7'. 5 14.41
5 ; OOOOOO *)r. 13.7 3 : 0 • 31.18
10.OOOOOO i 15.5 ovo 18.81'
100.OOOOOO * 15.5 o.o 18.81
500.OOOOOO 1 15.5 0.0 .18,81
COMPOUND 25
STRAIN t AIOO
so a c t i v a t i o n
CONCENTRATION e x p e r i m e n t NUMBER
m i c r o g r a m s / ml 525 534 538 69 71 75
WELLS P OSIT IVE
0 , oooooo 31 26 26 26 26 11
0,000000 33 23 21 32 34 13
0.010000 - - - - 39 —
0,100000 28 - - 30 33 10
1' ,o o o oo o 27 21 1 32 29 8
2.000000 9 0 -- ~ -
5.000000 -- 1 0
10.000000 10 3
c o n c e n t r a t i o n NUMBER AVERAGE n u m b e r 2
MICROGRAMs /ML OF of w e l l s X
e x p t s . p o s i t i v e
c o n t r o l TREATED
0.010000 • 1 30.5 . 39.0 4.32
0 , 1 oo ooo 4 26.1 26.5 0.02
1. o o o o o o 6 25.8 19.7 12.42
2 . ooooon r. 25.3 4.5 49.75
5 . OOOOOO n 25.3 0.5 73.27
10 . OOOOOO 3 24.7 7.3 51 .70
PROBAB
ility
N.S.
N.s.
TOXIC
TOXIC
TOXIC
TOXIC
TOXIC
TOXIC
TOXIC
PROBAB
ility
0.025
N.S,
TOXI C 
TOXIC 
TOXIC 
TOXIC
INDUCED 
MUTANTS 
PE« WELL
0,0846 
0.1U4
INDUCED
MUTANTS
per well
0.6650
0,0173
c o m p o u n d  25
STRAI»l TA100
INTACT HEPATOCYTE a c t i v a t i o n
c o n c e n t r a t i o n  EXPERIMENT n u m b e r
MICROGRAMs /ML 89 105 108
WELLS POSI T I VE
0 ,  OOOnOO 6 17 12
0 . OOOoOO 13 16 14
0 . 500O00 - - 13 13
1 . ooonoo 1 4 20 --
5.  OOOfiOO 7 15 - -
c o n c e n t r a t i o n n u m b e r a v e r a g e n u m b e r 2 PROBAB INDUCED
MICROGRAMS/ML o f ' of  w e l l s X i l i t y MUTANTS
EXPTS. p o s i t i v e p e r  w e l l
CONTROL t r e a t e d
0 . 5 0 0 0 0 0 2 1 4 . 6 1 3 . 0 0 . 2 9 N . S .
1 . oooooo 2 • 1 3 . 0 1 7 : 0 1 . 9 3 N . S . 0 . 1 2 1 4
5 . ooooon 2 1 3 . 0 1 1 . 0 0 . 4 8 N-.S.
CONCENTRATION EXPERIMENT NUMBER
MI CROGRAMS/Hl r>33 546 51 74
UELLS POSITIVE
0 . oooooo 1 6 .11 8 4
o. oooooo 11 0 5 6
0.1OOOOO . . - - -- 3
0. 500000 - - 15 - - - -
1. 0 0 0 0 0 0 10 0 13 1
2 . ooonoo 3 7 - -
5,OOOOOO 4 - - 4 - -
10.000000 -- — -- 0
c o n c e n t r a t i o n
MICRAGRAMS/ML
NUMBER AVERAGE NUMBER 
OF OF WELLS
e x p t s '. POSIT IVE
PROBAB
ILITY
i n d u c e d
MUTANTS
p e r  w e l l
0 , 1 0 0 0 0 0 1
CONTROL
5 . 0
TREATED
3 . 0 • 0 .4 5 N . S .
U . 5 0 00 00 1 1 0 . 0 1 5 . 0 1 .61 N . S .
i .ooonoo 4 8.7 8'. 2 0 . 0 6 N . S .
2 . 0 0 0 0 0 0 3 1 0 . 0 7.7 1 . 31 N . S ,
5 . 0 0 0 0 0 0 2 1 0 . 0 4.0 6 . 7 6 TOXIC
1 0.oooooo 1 5 . 0 0 . 0 4 . 6 0 TOXIC
0 , 1 4 1 1
COMPOUND 25 
STRAIN TA93 
S9 ACTIVATION
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r
MICROGRAMS/ML 526 532 543 68 70
WELLS POSI T I VE
0,000000 10 26 25 21 19
0 . oooooo 17 -- -« 9 16
0,010000 -- -- 13 --
0.1 ooo'oo 13 »- •-*» 12 8
1 .oooooo 19 23 29 14 14
2.000000 -- 21 21 m wm --
5. OOOOOO -- 17 3 -- --
10.000000 2 — -- -- 0
ONCENTRATION n u m b e r AVERAGE n u m b e r 2 PROBAB i n d u c e d
i c r o g r a h s / ml OF of w e l l s X I L I T Y MUTANTS
EXPTS. p o s i t i v e PER WELL
CONTROL t r e a t e d
0 . 0 1 oooo 1 1 5 . 0 1310 0 , 1 8 N . S .
0 . 1 0 0 0 0 0 3 1 6 . 8 1 1 0 6 , 3 5 TOXIC
1 . oooooo 5 1 9 . 0 1 9 ; 8 0.1.4 N . S , 0 . 0 2 8 0
2 . OOOOOO 2 2 5 . 5 2 1 : 0 1 . 5 1 N . S ,
5 . OOOOOO 2 2 5 . 5 1 0 . 0 2 0 . 7 9 TOXIC
1 0 . oooooo 2 1 7 . 7 1-.0 4 0 . 2 7 TOXIC
COMPOUND 25 
STRAIN TA9 8
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION
MICROGRAMs /ML
0 . OOOnOO 
0 . OOOa OO 
0. 10 0n0 0
1.000000
5 . 0 0 0000
EXPERIMENT NUMBER 
81 78 93  99 104 
WELLS POSI T I VE
23 * 3  13 15 13
17
23
11 7
7 —
17 15
—  17
—  12
21 —  
14 13
c o n c e n t r a t i o n  
m i  CROGRAHS/ML
0 . 1 OOOOo
1.ooooon
5 . OOOOOO
number
OF
EXPTS.
AVERAGE NUMBER 
OF WELLS 
P OSIT IVE
CONTROL TREATED
9.5
13.7
14.3
7.0
17.5
16.7
0.42
3.21
1 .37
PROBAB
i l i t y
N.S.
N.S.
N.S.
i n d u c e d  
m u t a n t s  
p e r  WELL
0.1134
0.07.59
•n c e n t r a t i o n EXPERIMENT n u m b e r
CPOGRAMS/ML 451 455 459 547 65
WELLS POS I Tivn
0 . oooooo 26 29 27 26 p
0.000000 19 - - 23 34 1?
0.500000 - - - - .*» 33 --
1 . ooonoo 20 43 28 rtm 35
”o.oooooo 35 45 -- - - h7
i no.oooooo 34 48 -- ~ - 48
concentration number AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF of wells X ILITY MUTANTS
EXPTS. POSITIVE per well
CONTROL TREATED
0,500000 1 30.0 337 0 0.42 N.S,. 0,1823
i . o o o o o n 4 20.7 31 V 5 24.25 < 0.0005 0,5030
10.000000 3 19.0 42; 3 86.20 < 0.0005 1 .6327
1 0 0 . o o o o o o 3 19,0 43*. 3 94.29 < 0.0005 1.8269
COMPOUND 26 
STRAIN TA10U 
S9 ACTIVATION
concentration experiment number
MI crograms/ ml 535 548 69 71 471
wells posit IVE
0,000000 37 20 29 26 32
0,000000 29 28 32 34 34
1 ; o o o o o o ... -- 35 37 34
10.000000 — f 36 37 40 31
20.000000 47 •» •• -- --
100,000000 48 48 48 48
200,000000 48 48
:oncentration number average number 2 PROBAB INDUCED
IICROGRAMS/ML of OF wells X ility MUTANTS
EXPTS. positive PER WELL
control TREATED
1 . o o o o o o 3 31 . 2 35‘.3 3,12 N.S. 0.2844
10.000000 4 29. 4 36 : o 10,53 < 0.005 0.4396
20.000000 1 33. 0 4770 15.26 < 0.0005 2.7081
100.OOOOOO 4 29. 4 48'. 0 99,49 < e.0005 ???????
200,000000 2 28. 5 4870 52,46 < 0,0005 ???????
compound 26
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER ,
MICROGRAMs/ML 73 39 105 108
WELLS POSITIVE
0 . OOOnOO 13 6 17 12
0. o o o o o o - - 13 16 1 4
1. o o o n o o 48 •  _ _ -
10. o o o o o o 38 - - 10 8
- 50. o o o n o o pm m 18 241 00. o o o n o o 42 21 29
CONCENTRATION
MICROGRAMS/ML
1 . o o o o o n
10.OOOOOO 
50.o o o o o n
100.OOOOOn
NUMBER
of
expts.
average NUMBER 
of Wells 
POSITIVE
CONTROL treated
13.0 
14.7
15.0 
1 1 . 6
48.0 
18:7 
21 . 0  
3 0 : 7
PROBAB
ILITY
INDUCED 
MUTANTS 
PER WELL
53,52 < 0.0005 ???????
2.82 N.S, 0.1278
A.45 < 0.025 0.2007
58.83 < 0.0005 0.7419
CONCENTRATION EXPERIMENT NUMBER
MICr OGRAMS/ML 450 456 546 82
WELLS POSITIVE
0.000000 7 12 1 1 21
0.000000 7 -- o 11
1 . oooooo 1 --
10.000000 5 5 12 10
50.000000 -- — 20 —
i no.oooooo 12 -- 14 10
CONCENTRATION number average number 2 probab induced
MICROGRAMS/ML OF of wells X . ILITY mutants
EXPTS. positive PER WELL
CONTROL treated
1 . oooooo 1 7.0 1.0 4.71 TOXIC
1 0 . oooooo 4 11.1 81 0 2.98 N.S.
50,000000 1 10.0 20*. 0 6.41 < 0.025 0.3054
100,000000 3 11.0 1270 0.13 N.S. 0.0274
COMPOUND 26 
STRAIN TA98 
S9 ACTIVATION
concentration experiment number 
MICROGRAMS/ML 540 68 70
WELLS POSITIVE
0 . oooooo 12 21 19
0.000000 12 a 16
0.100000 ... 16 --
1 .oooooo -- 15 18
1o,oooooo 13 11 14
100.000000 11 14 10
500.000000 20 --
CONCENTRATION
MICROGRAMS/ML
number average number 
of of wells
EXPTS. POSITIVE
PROBAB
il ity
induced
MUTANTS 
. PER WELL
control treated
0 . 1 ooooo 1 15.0 16.0 0.02 n. s: 0,0308
1 . oooooo 2 16.8 16.5 0.00 n. s;
10.000000 3 15.4 1277 1 .44 n. s;
1 0 0 , oooooo 3 15.4 1177 2.78 n. s;
500,000000 1 12.0 20'. 0 3.81 n. s. 0.2513
COMPOUND 26 
STRAIN TAOS
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 64 66 67 72 78 104
WELLS POSITIVE
0.000000 6 12 7 5 3 13
0,OOOnOO 6 8 -- 9 11 12
1. o o o o o o - - 8 9
1o . o o o n o o 5 9 10
1 9 0 . o o o n o o 3 7 1 2 8 11 --
500,OOOoOO 14 -- -- 13 32 31
CONCENTRATION 
MI CROGRAMS/Ml
NUMBER AVERAGE NUMBER
of of wells
EXPTS. POSITIVE
1 . oooooo 2
CONTROL
9.0
treated
8:5 0. 01
1 0. 00000O 3 7.8 8.0 0.00
1 0 0 . oooooo 5 8.0 8.2 0.01
500.OOOOOO 4 8.7 22.5 51 .64
PROBAB
ILITY
N.S.
N.S.
N.S.
< 0.0005
induced
MUTANTS 
PER WELL
O.OO.SO
0.0050
0.4313
CONCENTRATION EXPERIMENT number 
MICROGRAMs/ML 451 *55 459 65
WELLS POSITIVE
0,, o o o n o o 2 6 29 2 7 1 6 9
o. , o o o n o o 19 ... 23 1 6 1 2
' 0,, OOOnOO 1 7 29 2 6 1 2
1 0 0 , ,000000 2 6 21 - - 13 - •
500,,000000 1 7 25 21 —
concentration
MICROGRAMS/ML
number AVERAGE number 
of of wells
EXPTS, POSITIVE
CONTROL TREATED
PROBAB
ility
COMPOUND 27 
STRAIN TA100 
S9 ACTIVATION
INDUCED 
mutants 
PER well
10.000000 4 18.5 2 1 : o 1 ,34 N.S. 0.0886
100.000000 3 21 ,2 2070 0.18 N.S.
500.000000 3 24.8 21 .0 2.10 N.S.
concentration EXPERIMENT NUMBER
:crograms/ ml 471 535 548 69 71
WELLS- POSITIVE
0.ooonoo 32 37 20 29 26
0 .ooonoo 34 29 28 32 34
1 . oooooo - - m .*> 29 43
10. o o o o o o 36 - - 28 - -
20. o o o o o o - - 38 - - - - - -
100. ooonoo 30 - - 18 34 35
200. o o o o o o -«■ 33 24 - - . .
500. o o o o o o - - 39 47 —
IONCENTRATi ON number average number 2 PROBAB INDUCED
IICROGRAMS/ML OF OF WELLS X ILITy MUTANTS
expts. POSITIVE PER WELL
control treated
1.oooooo 2 30.2 36.0 3.89 < 0.025 0.3915
10.oooooo 2 31.7 32:0 '0,00 N.S. 0.0155
20.OOOOOO 1 33.0 38:o 1 .48 N.S. 0.4055
100.000000 4 29,4 29.2 0.00 N.S.
200.000000 2 28.5 28.5 0.00 N.S.
500.ooooon 2 28.5 43.0 26.82 < 0.0005 1 .3610
COMPOUND 27
—
STRAIN TA1 00
intact hepatocyte activation
CONCENTRATION
micrograms/ ml
EXPERIMENT NUMBER 
73 88 102 108
WELLS POSITIVE
o . o o o n o o 13 11 11 12
o , o o o o o o 13 . 10 1 4
1 . o o o n o o -- -- 14
5.000000 -- -- -- 15
10.OOOOOO 32 10 20
190.000000 44 27 30
500.000000 48 — 36 --
CONCENTRATION
MICROGRAMS/ML
number average number 
of of wells
EXPTS, POSITIVE
CONTROL TREATED
probab
ility
INDUCED 
MUTANTS 
PER WELL
1.OOOOOo 1 13.0 14. 0 0.03 N.S. 0.02905.OOOOOo 1 13.0 15.0 0.18 N.S. 0.058810.000000 3 11.6 20.7 14.51 < 0.0005 0.28651 0 0 , ooooon 3 11.6 3377 77.46 < 0.0005 0,9320500.OOOPOo 2 11.3 42.0 92.80 < 0.0005 1.8101
concentratiOn
MICROGRAMs/ML
EXPERIMENT NUMBER
450 456 82
WELLS POSITIVE
0. 000O00 
0.OOOOOO 
1 0 . 0 0 0 0 0 0  
100,OOOOOO 
5oo;oooooo
7 12 21
7 -- 11
4 5 --
8 6 6
4 5 11
concentration number average number*
MICROGRAMS/ML OP OF WELLS 
EXPTS. POSITIVE
2
X
PROBAB
ILITY
control treated
1 0, 00000(1 
100.000000 
500.000000
2 8.7 4.5
3 11.6 6.7 
3 11.6 6.7
3,14
5.56
5.56
N.S.
TOXIC K 
TOXIC *
COMPOUND 27 
STRAIN TA93 
S9 ACTIVATION
concentration
MICROGRAMs/ML
EXPERIMENT NUMBER 
545 68 70 
WELLS POSITIVE
O.OOOoOO 
0.000000 
0.100000 
1 . ooonoo
10.OOOoOO
100.000000
200.000000
500.000000
28 21 19 
25 9 16
— 17 - -
8 18
— 11 18 
- -  10 13 
25 —
21 - -  —
CONCENTRATION
MICROGRAMS/ML
number average number 
op of wells
EXPTS. POSITIVE
control treated
2
X
PROBAB
ILITY
0.100000 
1 . oooooo 
10.000000 
100.000000 
200,000000 
500,OOOOOo
1 15.0 1 7 : 0
2 16.2 13.0 
2 16.2 14:5 
2 16.2 H i  5 
1 26.5 25.0 
1 26.5 2170
0,17 
1.21 
0.31 
2.73 
0,07 
1 .46
N.S.
N.S.
N.S.
N.S.
N.S.
N.S.
COMPOUND 
STRAIN 
INTACt HE
27
TA98
PATOCYTE ACTIVATION
CONCENTRATION
MICROGRAMS/ML
experiment number 
64 66 72 104 
WELLS POSITIVE
o.oooooo 
0.000000 
1 .000(100 
1 0, 000(100 
100,oooooo
500. 000(100
6 12 5 13 
6 8 9 12
............................
5 9 9 — 
4 6 9 - -  
- -  8 14
CONCENTRATION
MICROGRAMS/ML
number average NUMBER 
* of of uells
expts. POSITIVE
control treated
2
X
PROBAB
ility
1 . oooooo 
1 0 . oooooo 
100.ooooon 
500.ooooon
1 6 . 0  5 . 0
3 7.7 7.7 
3 7.7 6.3
2 9.7 11,0
0,05
0.00
0.48
0.19
N.S,
N.S.
N.S.
N.S.
IN D U C E 0 
MUTANTS 
PER WELL
INDUCED 
MUTANTS 
PER WELL
0.0625
i n d u c e d
MUTANTS 
PER WELL
0.03.12
CONCENTRATION EXPERIMENT NUMBER
Ml CPOGRAMS/ML 451 455 459 472 o5
WELLS POSITIVE
0 . oooooo 26 29 27 16 o
0 . OOOOOO 19 -- 23 16 12
1 , 0 0 0 0 0 0 15 21 -- 1 5 7
5 . 0 0 0 0 0 0 -~ -- 28 10 --
' 0 . 0 0 0 0 0 0 13 18 21 14
1^ 0 .ooonoo 1 2 5 -- -- 27
CONCENTRATION NUMBER a v e r a g e NUMBER 2 PROBAB i n d u c e d
MICROGRAMS/ML OF of  w e l l s X I L I T Y MUTANTS
EXPTS. p o s i t i v e p e r  w e l l
CONTROL T r e a t e d
1 . o o o o o o 4 1 8 . 1 1 4'. 5 2 . 9 3 M . S .
5 . 0 0 0 0 0 0 4- 2 0 . 5 2 3 . 5 0 , 8 9 N . S . 0 , 1 1 5 5
1 o . o o o o o o 4 1 3 . 1 16V 5 0 . 5 5 N . S .
l o o . o o o o o n 3 1 9 . 0 1 4 V 7 2 . 9 3 N . S .
COMPOUND 23 
STRAIN TA100  
S9 ACT I VAT I Oil
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 5 3 5  5 4 8  69 71 471 •
WELLS P O S I T I V E
0.000000 37 20 29 26 32
0.OOOOOO 29 28 32 34 34
1 . o o o o o o -- - - - - — 27
1o . o o o o o o -- 18 29 34 24
2 0 . OOOOOO 33 -- - - — - -
m o r o o o o o o -- 16 24 27 20
200,OOOOOO 0 0 20 - -
50 0. OOOOOO 0 - - 4 — - -
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF We LLS X I L I T Y  MUTANTS
EXPTS.  P O S I T I V E  PER WELL
CONTROL TREATED
1 .OOOOOO 1 33.0 27:0 1 .92 n .s ;
1 o.oooooo 4 29.4 26:2 2.11 n .s ;
2 0 , OOOOOO 1 33.0 33:0 0.00 n .s ;
100.000000 4 29.4 21.7 12.78 TOXIC
200.000000 3 29,0 6:7 83.06 TOXIC
500.OOOOOO 2 31.7 2V0 97.90 TOXIC
COMPOUND 28
STRAIN TA100
INTACT HEPATOCYTE A C TI V A TI O N
CONCENTRATION
m i c r o g r a m s / ml
e x p e r i m e n t  n u m b e r  
73 39 102 10 8
WELLS P O S I T I V E
0.ooonoo
0 . OOOOOO
1 .oooooo
1 0 . OOOoOO
100.000000 
200. ooonoo’
5 0 0 . 0 0 0 0 0 0
13 6 11 12
— 13 10 14
16 —  —  —
16 •*" 
12  17 a —
—  —  *7 20
n 6 —
CONCENTRATrON n u m b e r  AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WE LLS X I L I T Y  MUTANTS
EXPTS,  P O S I T I V E  PER WELL
CONTROL t r e a t e d
1 .ooooon 1 13.0 16; o 0.31 N . S . 0.0806
10 .ooooo* 1 13.0 16: o 0.31 N . S . 0.0806
1oo.ooooon 3 10.6 12.3 0.56 N . S , 0.0475
200.ooooon 2 1 1 . 7 137 5 0.36 N . S . 0.0495
sob.ooooon 2 10.0 3.0 9.61 TOXIC
runpuUND ?.**>
STRAIN TA98
NO a c t i v a t i o n
CONCENTRATION EXPERIMENT n u m b e r
MI Cp OGRAMS/ml 456 546 82
WELLS POSITIVE
0.000000 12 11 21
o.oooooo -- 9 11
1 . oooooo 30 -- 9
10.000000 — o --
50.000000 -- 7 --
100.000000 c 0 4
CONCENTRATION
MICROGRAMS/Ml
number average NUMBER 
OF of wells
EXPTS. POSITIVE
probab
ILITY
CONTROL TREATED
1 . oooooo nu 16.2 1 9 V 5 1.13 N.S.
10.000000 1 10.0 9 VO 0.03 n. s;
50.000000 1 10.0 7.0 0.63 n. s;
100.000000 3 14.2 4.3 22,39 TOXIC
COMPOUND 23 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 540 68 70
WELLS POSITIVE
0,000000 12 21 19
0,000000 12 o 16
10,000000 -- 15 13
1 0 0 , oooooo 3 8 12
200,000000 8 -- 8
500,000000 2 0 --
concentration number average NUMBER 2 PROBAB
micrograms/ ml of of wells x ility
EXPTS. POSITIVE
CONTROL TREATED
1 o.oooooo f. 16,8 14:0 0,92 n. s;
1oo.oooooo 3 15.4 7r.7 12.88 TOXIC
200.oooooo 2 15.6 8:0 8.14 TOXIC
500.000000 2 13.5 1 :o 26.88 TOXIC
COMPOUND 28 
STRAIN TA98
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 64 66 67
WELLS POSITIVE
0.000000 6 12 7
0, 0 0 0 0 0 0 6 8
1.OOOoOO 3 13 12
10.OOOoOO 7 7 11
mo.ooonoo 2 4 7
CONCENTRATION number average number 2 probab
MI CRC>GRAMS/ML OF of Wells X il ity
EXPTS. POSITIVE
CONTROL TREATED
1.ooooon 3 7.8 9,3 0.53 n. s.
10.OOOOOn 3 7.8 8.3 0.05 N.S,
100.OOOOOn 3 7.8 413 3.71 N.S.
induced
MUTANTS
per well
0,1080
INDUCED
mutants 
PER WELL
INDUCED 
MUTANTS 
PER WELL
0.0389
0.0134
CONCENTRATION EXPERIMENT n u m b e r
Ml CPOGRAMS/ML 523 528 77
WELLS P O S I T I V E
o. oooooo 11 10 8
0 . OOOOOO 20 13 14
1 . oooooo - - 20
1 0 , oooooo 14 31
5 0 . OOOOOO 38
1 0 0 . 0 0 0 0 0 0 43 45 48
5 ^ 0 . OOOOOO — 48
CONCENTRATION number AVERAGE NUMBER 2
MICROGRAMS/ML OF of wells X
EXPTS. POSITIVE
CONTROL TREATED
1.OOOOOO 1 11.5 20:0 4,33
10.OOOOOO u 11.2 22.5 15.82
50.OOOOOO 1 15.5 3 8 V 0 27,24
100.000000 5 12.7 45:3 176,55
500.OOOOOO 1 11.0 48:0 74,53
compound 29
STRAIN TA100
S9 activation
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 524 529 537
WELLS POSITIVE
0,OOOOOO 30 28 36
0.000000 26 24 —
1o , o o o o o o 31 35 42
100.000000 48 48 42
200.000000 48
CONCENTRATION NUMBER average number 2
micrograms/ ml OF of wells X
EXPTS, POSITIVE
CONTROL TREATED
1 o . o o o o o o 3 28.8 36'. 0 8.65
1 o o . o o o o o o 3 ' 28.8 46',0 • 58.33
200.000000 1 28.0 48i'0 26,66
compound 29
strain TA100
INTACT hepatocyte ACTIVATION
concentration experiment number
MICROGRAMs/ML 87 92 96 106 107
WELLS POSITIVE
0.OOOOOO 7 20 10 18 12
0,OOOoOO 14 12 12 10 14
10 . o o o o o o -- — — 20 18
2 0 . OOOoQO -- 19
50.000O00 • *- - -  27
100.000000 21 40 34 35 — ’
2 0 0 ; oooooo — 44 - -  - -
500.OOOOOO 24 12 33 - -  19
CONCENTRATION NUMBER average number 2
MICROGRAMS/ML OF OF WELLS X
PROBAB
i l i t y
0.025
0.0005
0.0005
0.0005
0.0005
p r o b a b
U I T Y
< 0.005
< 0.0005
< G.0005
EXPTS. POSITIVE
PROBAB
i l i t y
CONTROL treated
1o.OOOOOo *>u 13.2 19.0 4, 41 <20.OOOOOO 1 12.7 19.0 2.69
50.000000 1 14.0 27.0 9 .38 <
100 . oooooo 4 12.9 32.5 37.98 <200 .000000 1 11.0 44.0 59.55 <500.OOOOOo 4 12.6 22,0 23.12 <
0,025
N.S.
0.005
0.0005
0.0005
0,0005
INDUCED 
mutants 
per well
0.2651 
0.3655 
1.1787 
2,5840 
???????
INDUCED 
MUTANTS 
PER WELL
0.4700
2.2618
???????
induced
MUTANTS 
PER WELL
0.1873
0.1975
0.4818
0.8181
2.2246
0.3099
COMPOUND
STRAIN TA98
NO ACTIVATION
concentration experiment NU|1BeR 
MICROGRAMS/ml 527 546 81 1L.
WELLS POSITIVE
0.000000 4 11 8 4
o,oooooo 8 o 5 6
'0.000000 -- - - 2
100,000000 13 18 1? 2
£n0 .OOOOOO 5 17 1 5
500,000000 -- - - - - 0
CONCENTRATION number AVERAGE number 2 probar INDUCED
micrograms/ ml of of wells x il ity  mutants
EXPTS. POSITIVE PER WELL
CONTROL TREATED
1 0 . oooooo 1 5.0 2.0 1.25 N.S.
100.000000 4 6.9 11;2 7.10 < 0.005 0,1125
2 0 0 . ooonoo 3 7.5 12.3 6,01 < 0.025 0.1271
500.oooooo 1 5.0 0.0 4.60 TOXIC
COMPOUND 29 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAHS/ML 521 531 540
WELLS POSITIVE
o.oooooo 25 30 12
0.000000 11 28 12
1.oooooo g - -
10.000000 0 - -
1 0 0 . oooooo 15 19 7
200.000000 - - 26 4
CONCENTRATION
MICROGRAMS/ML
NUMBER AVERAGE NUMBER
of of wells
EXPTS, POSITIVE
CONTROL TREATED
probab
U I T Y
INDUCED 
MUTANTS 
PER WELL
1 . oooooo
10.OOOOOO 
1 0 0 . 0 0 0 0 0 0  
200.000000
18,0
18.0
19.7
20.5
9;o 
9 tO 
13'. 7 
15t 0
COMPOUND 29 
STRAIN TA98
INTACT HEPATOCYTE ACTIVATION
4.81
4.81 
6.18 
3.30
TOXIC
TOXIC
TOXIC
N.S,'
CONCENTRATION
MICROGRAMS/ML
EXPERIMENT NUMBER 
78 83 84 98 104
WELLS POSITIVE
O.'OOODOO 8 20 8 11 13
0. OOOoOO 11 11 6 12
1.OOOoOO *“ r* 18 -- 1 3 ...
10.OOODOO 17 14 13 . .
100,OOOoOO 33 21 1 18 16
CONCENTRATION number AVERAGE number 2 probab INDUCED
MI CROGRAMS/ML of OF WELLS X ility MUTANTS
EXPTS. POSITIVE PER WELL
control treated
1.OOOOOo 2 .  14.0 15.5 0. 20 N.S. 0.045110.OOOOOO 3 12.2 14.7 1 . 07 N.S. 0.0714100,OOOOOO 5 11.3 1718 14.20 < 0.0005 0.1949
COMPOUND 30
STRAIN TA100
NO ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 636 539 541 77
UELLS POSITIVE
o . o o o n o o 8 2 18 a
0 . o o o o o o - - 5 13 1 4
1o . o o o o o o - - - - -~ 11
100 , o o o o o o a 5 29 1 5
2 0 0 . OOOOOO c 2 32 - -
50-0,  OOOOOO 1 a 5 — --
concentration NUMBER AVERAGE NUMBER 2 probab
MICROGRAMS/ML OF of wells X ility
EXPTS, positive
CONTROL treated
1 0 . 0 0 0 0 0 0 1 1 1 . 0 11' , 0 0 . 0 0 n. s;
100. oooooo 4 9.7 14' .  2 5.78 < 0 . 0 2 5
2 0 0 . 0 0 0 0 0 0 3 9.2 14; 3 5 , 4 0 < 0 . 0 2 5
500.OOOOOO 2 . 5 . 0 1 1 ’.5 7.43 < 0 . 0 0 5
COMPOUND 30 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER 
MICROGRAMS/ML 534 535 537
WELLS POSITIVE
0.000000 26 37 36
0.000000 28 29 --
20,000000 33 35
1 0 0 , oooooo m m 32
-200,OOOOOO 29 35 32
500,000000 18 36 29
CONCENTRATION
MICROGRAMS/ML
NUMBER AVERAGE NUMBER
of of wells
EXPTS, POSITIVE
probab
ILITY
CONTROL TREATED
20.000000 2 30.0 34; 0 1 .78 n. s;
100.000000 1 36.0 32.0 0,62 n. s;
200.OOOOOO 3 31.2 3 2; 0 0.03 n. s.
500.OOOOOO 3 31.2 27.7 1 ,92 N.s,
COMPOUND 30
strain TA100
intact hepatocyte ACTIVATION ' ^
CONCENTRATION experiment number
:crograms/ ml 92 95 105
WELL3 POS I
o . o o o n o o 20 11 17
0,OOOoOO 1? 10 16
100.OOOnOO 17 13 14
200,OOOOOO - - 9 17
500.0 Q 0 0 0 0 a 10 16
CON CENTR AT j ON number average number 2 PROBAB
MICROGrAMS/ML OF OF WELLS X ILITY
EXPTS. POSITIVE
control treated
100.OOOOOn 3 14.3 14.7 0.01 N.S.
200.OOOOOn 2 13.5 13.0 0.01 N.S.
500.OOOOOn 3 14.3 11.3 1 .72 N.S.
induced 
mutants 
per WELL
0 . 1 2 6 1
0,1419
0,1639
induced 
MUTANTS 
PER WELL
0.2513 
0.0488
INDUCED 
MUTANTS 
PER WELL
0 , 0 1 0 0
COMPOUND 30
STRAIN TA9 3
NO ACTIVATION
C O N C E N T R A T I O N  
MI C R O C , R A M S / M L
e x p e r i m e n t  n u m b e r
546 74
WELLS POSITIVE
0 . O O O O O O  
0.OOOOOO 
I 0,OOOOOO 
1 0 0 , O O O O O O  
2 0 0 ,  O O O O O O
P O O , o o o o o o
8
8
15
C O N C E N T R A T I O N
micrograms/ml
1 0 , 0 0 0 0 0 0
1 0 0 . 0 0 0 0 0 0
2 0 0 . 0 0 0 0 0 0
5 0 0 . 0 0 0 0 0 0
n u m b e r  a v e r a g e  n u m b e r  
o f  o f  w e l l s
e x p t s . P O S I T I V E
C O N T R O L  T R E A T E D
p r o b a b
I L I T Y
1 ' 5 . 0 2'.0 1 . 2 5 N . S
7 . 5 6*.0 0 . 3 3 N . S
1 1 0 . 0 8 1 0 0 . 2 3 N . S
c. 7 . 5 a c o 0 . 0 2 N . S
I N D U C E D
m u t a n t s  
p e r  w e l l
0 . 0 1 2 4
C O M P O U N D  s o  
S T R A I N  T A 9 8  
S ?  A C T I V A T I O N
C O N C E N T R A T I O N  E X P E R I M E N T  N U M B E R
M I C R O G R A M S / M L  5 4 0  5 4 2  5 4 3
W E L L S  P O S I T I V E
0 . o o o o o o 12 1 8 2 5
0.000000 1 2 19
1o . o o o o o o 10 21 - -
100 . o o o o o o 8 2 0 3 2
2 0 0 , O O O O O O - - - - 3 3
5 0 0 . 0 0 0 0 0 0 8 2 3 3 4
C O N C E N T R A T I O N N U M B E R A V E R A G E n u m b e r 2 p r o b a b i n d u c e d
M I C R O G R A M s / M L O F o f  w e l l s X I L I T Y M U T A N T S
E X P T S . p o s i t i v e P E R  W E L L
C O N T R O L t r e a t e d
10 , o o o o o o 2 14.6 1 5 : 5 0 . 0 7 N . S , 0 . 0 2 7 3
100.000000 3 1 6 . 3 2 0 ;  0 2 . 2 5 N . S . 0 , 1 2 3 1
2 0 0 . O O O O O O 1 2 5 . 0 3 3  s. 0 2 , 4 5 N . S . 0 , 4 2 7 4
5 0 0 . 0 0 0 0 0 0 3 1 6 . 3 2 1 . 7 4 , 8 1  < 0 . 0 2 5 0 . 1 8 4 4
C O M P O U N D  3 0  
S T R A I N  T A 9 8  •
I N T A C T  H E P A T O C Y T E  a c t i v a t i o n
C O N C E N T R A T I O N
M I C R O G R A M s / M l
e x p e r i m e n t  n u m b e r  
9 3  9 4  9 9  1 0 4
W E L L S  P O S I T I V E
0 . o o o n o o 1 3 4 15
0 . O O O n O O 7
5 0 . O O O n O O 1 4 - - 1 6
1 * 0 . O O O n O O 1 4 4
5 0 0 . o n o n O O 0 1 20
- 12
—  1 5
CONCENTRATION
M I C R O G R A M S / M L
50.ooooon
100.000000
500.ooooon
n u m b e r A V E R A G E n u m b e r 2 p k o b a b
O F O F  W E L L S X i l i t y
E X P T S . P O S I T I V E
C O N T R O L t r e a t e d
2 1 1 . 7 1 5 , 0 1 . 2 4  . . N . S .
3 9 . 8 1 1 . 0 0 . 2 6 N . S .
3 9 . 7 .1 0 : 0 0 . 0 0  . N . S .
I N D U C E D  
M U T A N T S  
P E R  W E L L
0.0982
0.0319
0.0086
COMPOUND 31
STRAIN TA100
NO ACTIVATION
INCEUtration EXPERIIUENT NUMBER
crogRAMS/ML 451 455 459 472 547 65
WELLS POSIT I V E
0, oooooo 26 29 27 16 26 9
0. oooooo 1c -- 23 16 34 12
10. oooooo 24 28 22 -- - -
1 no. oooooo 14 32 -- 12 -- 1?
5n Q,oooooo 20 38 19 -- 20 --
concentration
MICROGRAMS/ML
NUMBER AVERAGE NUMBER
of  of  w e l l s
e x p t s . POSITIVE
p r o b a b
I L I T Y
induced
MUTANTS 
PER WELL
1o . o o o o o o  
1 0 0 . 0 0 0 0 0 0  
500.OOOOOO
CONTROL treated
3 21.2 24 v7 1 .74 N.S,
4 17.4 17; 5 0,00 n. s;
4 26.3 24*. 2 0.80 n. s;
0.1385 
0,0041
COMPOUND 31 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION
micrograms/ ml
EXPERIMENT NUMBER 
537 69 71 471
WELLS POSITIVE
0,000000 36 29 26 32
0,000000 mm 32 34 34
1 0 . oooooo mm 26 34 34
100.000000 31 26 30 34
200.OOOOOO 23 mm -- --
500.000000 30 33 2a 24
CONCENTRATION number AVERAGE number 2 probab INDUCED
MICROGRAMS/ML OF of wells X ILITY MUTANTS
EXPTS. POSITIVE PER WELL
CONTROL treated
10,OOOOOO 3 31 .6 3 1 :3 0,00 n. s;
1 0 0 . oooooo 4 32.1 30; 2 0,78 n. s;
2 0 0 . oooooo 1 36.0 23 ;o 6.87 TOXIC
500,000000 4 32.1 2877 2.62 n. s;
compound 31
strain TA100
intact hepatocyte activation
CONCENTRATION
micrograms/ ml
experiment number 
73 89 105
WELLS POSITIVE
0 , 000000 13 6 17
o., ooonoo 13 16
10., OOOoOO 21 - - 19
1 oo., OOOoOO 16 6 mm
500., OOOOOO 18 11 12
CONCENTRATION 
MICROr,RAMS/Ml
10.OOOOOn 
1 0 0 . o o o o o n  
500.OOOOOO
number average number 2 probab
OF OF WELLS X ilityEXPTS. POSITIVE
control TREATED
2 15.5 2o;o 2.26 N.S.Tt. 10.7 11.0 0.00 N.S.3 13.5 13.7 0.00 N.S.
INDUCED 
MUTANTS 
PER WELL
0,1490
0.0090
0.0048
COMPOUND 31
STRAIN TA98
NO a c t i v a t i o n
c o n c e n t r a t i o n  e x p e r i m e n t  NUu r FR
MlCPOGRAMS/ML 456 546 82
WELLS POSITIVE
0 . 0 0 0 0 0 0 12 11 21
0 . 0 0 0 0 0 0 - - 9 11
1 . o oo o oo — — . 4
1 0 , oooooo 8 11 9
1 9 0 .  oooooo 4 14 12
5 9 0 . OOOOOO 7 20 - -
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED •
m i c r o g r a m s / ml OF of  w e l l s X I L I T Y MUTANTS
EXPTS. p o s i t i v e p e r  w e l l
CONTROL t r e a t e d
1 . oooooo 1 1 6 , 0 4 ',0 1 0 . 0 1 TOXIC
1 0 . oooooo 3 1 2 , 8 9 : 3 2 . 3 3 N . S ,
1 0 0 . oooooo 3 1 2 . 8 1 0 ‘. o 1 . 5 0 n . s ;
5 0 0 . oooooo 2 1 0 . 7  • 1 3 ;  5 0 . 9 3 N . s . Cr. 0 7 8 9
COMPOUND 31 
STRAIN TA98  
S9 A CTIVATION
c o n c e n t r a t i o n  EXPERIMENT n u m b e r  
MICROGRAMS/ML 54 0  543 68  70
WELLS P O S I T I V E
0 , 0 0 0 0 0 0 12 25 21 19
0 . oooooo 12 - - 9 16
1 o,  oooooo . . . 19 19
1 0 0 , 0 0 0 0 0 0  . 11 29 16 18
2 0 0 , OOOOOO - - 33 - - ....
5 9 0 , OOOOOO 14 33 17 18
CONCENTRATION NUMBER AVe RAGe n u m b e r 2 PROBAB i n d u c e d
m i c r o g r a m s / ml OF of  w e l l s X I L I T Y MUTANTS
EXPTS. p o s i t i v e PER WELL
CONTROL TREATED
1 0 . oooooo £. 1 6 . 2 1 9 : 0 0 , 9 0 N . s ; 0 . 0 9 2 2
1 0 0 . 0 0 0 0 0 0 4 1 6 . 2 1 8 1 5 1 , 1 3 N . S . 0 . 0 7 3 5
2 0 0 . 0 0 0 0 0 0 1 2 5 . 0 3 3 ;  0 2 . 4 5 n . s ; 0 . 4 2 7 4
5 0 0 . 0 0 0 0 0 0 4 1 6 .  -2 2 0 : 5 4 . 1 3 < 0 . 0 2 5 0 . 1 4 3 7
COMPOUND 31 
STRAIN TA98
i n t a c t  h e p a t o c y t e  a c t i v a t i o n
CONCENTRATION 
MlCROGRAMr /ML
o . O O O O O O
o , o o o o o o  
*o.000O00 
1 9 0 , 0 0 0 0 0 0  
5 n 0 , O O O o O O
e x p e r i m e n t  NUMBER 
64  72 10 4
WELLS P O S I T I V E
6 5 13
6 9 12
3 11 11
8 6 7
3 9 14
CONCENTRATION
m i c r o g r a m s / ml
1 0 . OOOOOO
1 0 0 . 0 0 0 0 0 0
5 0 0 . 0 0 0 0 0 0
n u m b e r  a v e r a g e  n u m b e r  
up  of  w e l l s
EXPTS.  P O S I T I V E
PROBAB
I L I T V
3
c o n t r o l
8 . 5
t r e a t e d  
8 ;  3 o . o o N.S3 8 . 5 7 . 0 0 . 5 7 N.S3 8 . 5 8 : 7 0 . 0 0 N.S
INDUCED 
MUTANTS 
PER WELL
0.0042
STRAIN t A10u
no ACTIVATION
CONCENTRATION EXPERIMENT n u m b e r
MICROGRAMS/ML 523 53 6  541 77
WELLS P O S I T I V E
0 . oooooo 11 25 18 Ft
o . o o o o o o 20 - - 13 14
'>0.  0 0 0 0 0 0 — - - 13
5 0 . OOOOOO 16 - - - - - -
Too.OOOOOO 12 34 32 13
2 0 0 . OOOOOO - - 26 23 - -
5 n 0 , 0 9 0 0 0 0 — 30 23 20
CONCENTRATION NUMBER a v e r a g e n u m b e r 2 p r o b a b INDUCED
m i c r o g r a m s /ml OF of wel l s X ility m u t a n t s
EXPTS. POSITIVE PER WELL
CONTROL t r e a t e d
1 0 . oooooo 1 11.0 13: o 0.20 n .s ; 0.0556
50.000000 1 15.5 1670 0 . 0 0 n .s ; 0.0155
1 0 0 . oooooo 4 15.6 22V 7 11 .30 < 0.0005 0,2502
2 0 0 . OOOOOO 2 1 8 . 7 24.5 3.21 n .s ; 0.2217
500.OOOOOO 3 15.6 24; 3 12,11 < 0.0005 0.3141
COMPOUND 32
STRAIN TA100
S9 A CT IV A TI ON
c o n c e n t r a t i o n
m i c r o g r a m s / ml
EXPERIMENT NUMBER 
52 5  53 4  538  
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 31 26 26
0 . 0 0 0 0 0 0 33 28 21
1 0 , oooooo 29
1 0 0 . 0 0 0 0 0 0 33 32 23
2 0 0 , OOOOOO *■ m 32 29
6 0 0 , 0 0 0 0 0 0 31 22 24
c o n c e n t r a t i o n
m i c r o g r a m s / ml
n u m b e r  AVERAGE n u m b e r  
of  of  w e l l s
EXPTS,  P O S I T I V E
c o n t r o l  t r e a t e d
p r o b a b  
i l i t y  ,
i n d u c e d  
m u t a n t s  
PER WELL
1 o , o o o o o o
1 0 3 . 0 0 0 0 0 0
200.000000 
5 0 0 . OOOOOO
3 2 . 0
2 7 . 5  
2 5 . 3
2 7 . 5
29-; 0 
2 9 . 3  
3 0 ;  5 
2 5 !. 7
COMpOuNp 32 
STRAIN TA10O
i n t a c t  h e p a t o c y t e  a c t i v a t i o n
CONCENTRATION
m i c r o g r a m s / ml
EXPERIMENT n u m b e r  
8 7  92  9 6  106
WELLS P O S I T I V E
0 . OOOOOO 7 20 10 1 8
0 . OOOOOO 14 12 1 2 1 0
1 0 . ooonoo M rm 13 22
1 0 0 , oooooo 10 14 1 5 1 3
5 0 0 . ooonoo 10 mm 9 11
0 . 4 2
0 . 5 0
2 . 8 0
0 . 4 9
N . S .
N . S ,
n . s ;
N . S ,
0 . 0 9 3 7
0 . 2 6 2 4
CONCENTRATION
m i c r o g r a m s / ml
1 o . o o o o o n  
1 0 0 . OOOOOn 
5 0 0 . ooooon
n u m b e r  a v e r a g e  n u m b e r  
of  of  w e l l s
EXPTS.  P O S I T I V E
c o n t r o l  t r e a t e d
2 1 5 . 0 2 0 ; 0 2 . 8 44 1 2 . 9 1 3 . 0 0 . 0 03 1 1 . 8 1 0 . 0 0 . 6 8
p r o b a b
i l i t y
n . s .
N . S .
N . S .
i n d u c e d  
m u t a n t s  
p e r  w e l l
0.1643
0.0036
COMPOUND 32
STRAIN t A98
HO ACTIVATION
CONCEMTRATION 
MICPOGRAMS/Mi
EXPERIMENT MUh b F.R
533 <31 74
WELLS POSITIVE
o . o n o n o o  
o . o o o o o o  
i o . o o o o o o  
1 0 0 , 0 0 0 0 0 0  
<200, OOOOOO
5* 0 . o o o o o o
16
11
7
11
CONCENTRATION number AVERAGE number 2 PROBAB INDUCED
MICROGRAMS/ML OF of wells X I lity MUTANTS
EXPTS. positive PER WELL
CONTROL TREATED
10 . o o o o o o 1 4 . 7 4 ;  o 0.02 N.s;
100,000000 1 4.7 8 : o 1 .39 N.s. 0.0800
200.000000 •>(. 10.0 6v5 2.03 N.s.
500,000000 3 7 . 7 7*. 0 0.12 N.s.
COMPOUND 32
STRAIN TA98
S9 ACTIVATION •
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 526 532 543
WELLS POSITIVE
o . o o o o o o 19 26 25
0 . 0 0 0 0 0 0 17 - -
1 o , o o o o o o 15 m m m m
1 0 0 , 0 0 0 0 0 0 15 m m m m
* 0 0 , oooooo - ~ 19 33
5 0 0 , OOOOOO 19 20 27
CONCENTRATION
micrograms/ ml
NUMBER AVERAGE number 
of of wells
EXPTS. POSITIVE
CONTROL treated
PROBAB
ility
INDUCED
mutants
PER WELL
10.OOOOOO 1 18.0 15:0
1 0 0 . o o o o o o 1 18,0 1 5 ' . 0
200,000000 2 25.5 26'. 0
500.o o o o o o 3 21 .7 22'. 0
COMPOUND 32
strain TA98
intact hepatocyte ACTIVATION
CONCENTRATION experiment number
MICROGRAMS/ML 78 83 84 93 98
WELLS POSITIVE
o . o o o n o o 8 20 8 13 11
o . o o o o o o 1 1 1 1  6 7 - -
l o o . o o o n o o 12 13 — 8
200,OOOoOO 8 — 15
5^0.o o o n o o 19 21 7 m
0 , 4 2
0 . 4 2
0 . 01
0 . 0 0
■N.S.
n. s;
N.s.
N.s.
0 . 0 2 2 5
0 . 0 0 9 6
CONCENTRATION
MICROGRAMS/ML
NUMrER 
OF 
• EXPTS.
average number
OF WELLS
positive
PROBAB
ILITY
INDUCED 
MUTANTS 
PER WELL
CONTROL TREATED
100 . o o o o o n  
2 0 0 , o o o o o n  
5 0 0 , 0 0 0 0 0 0
11.7
1 2 . 7
10.7
11.0
11.5
14.2
0.07
0.16
3.34
N.S.
N.S.
N.S. 0, 0996
c o n c e n t r a t i o n  EXPERIMENT NUMBER
I I I  Cp.OGR AMS/ML 5 2 8  63 6  539 77
UELLS p o s i t i v e
0 . 0 0 0 0 0 0 10 8 2 8
0 , 0 0 0 0 0 0 13 — 5 14
1 0 , oooooo - - 12
1 0 0 , oooooo 16 7 9 16
2 0 0 . 0 0 0 0 0 0 15 0 2
5 0 0 . oooooo 12 8 2
c o n c e n t r a t i o n
MICROGRAHS/ML
n u m b e r  AVERAGE NUMBER 
of of  w e u l s
EXPTS,  P O S I T I V E
CONTROL TREATED
PROBAB 
I L I  T Y
1 0 . oooooo 1 1 1 . 0 1 2;  0 0 . 0 3 N;S
1 o u . o o o o o o 4 8 . 6 1 2 . 0 3 . 6 1 N.S
2 0 0 . OOOOOO 3 7 . 6 a : ? 0 , 2 5 N. S
5 0 0 . OOOOOO 3 7 . 6 7V3 0 . 0 1 N.S
INDUCED 
MUTANTS 
PER WELL
0 , 0 2 7 4  
0,091 0 
0 . 0 2 6 8
COMPOUND 33  
STRAIN T A 100 
S9 A CTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 5 2 4  529 5 3 7
WELLS P O S I T I V E
0 , 0 0 0 0 0 0 30 28 36
0 , 0 0 0 0 0 0 26 24
1 0 , 0 0 0 0 0 0 36 ... --
1 0 0 , 0 0 0 0 0 0 35 30 29
2 0 0 , 0 0 0 0 0 0 -- 27 24
5 0 0 , 0 0 0 0 0 0 32 21 35
CONCENTRATION NUMBER a v e r a g e n u m b e r 2 PROBAB INDUCED
MICROGRAMS/ML OF o f  w e l l s X I L I T Y  . MUTANTS
EXPTS. p o s i t i v e PER WELL
CONTROL t r e a t e d
1o . o o o o o o 1 2 8 , 0 36 ; o 3 . 5 0 N . S , 0 . 5 1 0 8
1 0 0 . 0 0 0 0 0 0 3 2 8 . 8 31 ' . 3 0 . 9 5 N . S . 0 , 1 4 1 5
2 0 0 . OOOOOO 2 2 9 . 3 2 5 ’. 5 1 . 3 5 n . s ;
5 0 0 , OOOOOO 3 2 8 . 8 2 9 r. 3 0 , 0 3 n . s ; 0 . 0 2 8 2
COMPOUND 33  
STRAIN TA100
I NTA Ct h e p a t o c y t e  a c t i v a t i o n
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 9 5  09 105 1 0 7
WELLS P O S I T I V E
0 . OOQoOO 11 6 17 12
o . o o o o o o 10 13 16 14
7 0 . 0 0 0 0 0 0 - - m m 4
5 0 . 0 0 0 0 0 0 6 6 ...
1 0 0 . OOOOOO 10 4 7
5 0 0 OOQoOO 7 1 6
CONCENTRATION
u i c r o g r a m s / ml
2 0 , o o o o o n
5 0 . 00000O
100 . o o o n o n  
5 0 0 . OOOQOo
n u m b e r AVERAGE n u m b e r 2 PROBAf
OF of  we l l s X i l i t y
EXPTS. p o s i t i v e
CONTROL t r e a t e d
1 1 2 . 7 4 . 0 6 , 3 5 TOXIC
2 1 3 . 5 6 : o 8 . 4 1 TOXIC
3 1 1 . 1 7 . 0 4 , 3 3 TOXIC
3 1 2 . 2 4 .7 1 4 . 0 9 TOXIC
INDUCED 
MUTANTS 
PER WELL
STRAIN TA98
NO ACTIVATION
CONCENTRATION 
(II CROGRAMS/ML.
tXPERIflENT NUMBER
527 546 81 74 82
WELLS POSITIVE
0.OOOOOO 11 21
0,000000 8 9 5 6 11
1 . oooooo —- - -  - - 2
' 0 , OOOOOO 2 —
1 no, OOOOOO 7 -  - - 1 5
2^0, OOOOOO 5 0 2
POO.oooooo 5 — 5
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
micrograms/ ml OF of wells X ility MUTANTS
EXPTS. POSITIVE PER WELL
CONTROL TREATED
1 . oooooo 1 5.0 2 : 0 1 .25 n. s. ,
10.OOOOOO 1 5.0 2.0 1 .25 N.S.
1 0 0 , oooooo 3 9.0 4.3 6.56 TOXIC
200.oooooo 3 7.5 2.3 10.00 TOXIC •
‘500. oooooo 2 6.2 5:0 0.29 n. s;
COMPOUND 33 
STRAIN TAP8 
S9 ACTIVATION
concentration experiment number
MICROGRAMS/ML 521 531 542
WELLS POSITIVE
0,000000 25 30 18
0,000000 11 28 19
10.000000 15 .... mm**
100,000000 17 24 12
200,OOOOOO -r. 21 20
500.OOOOOO 11 23 3
PROBAB INDUCED
il ity mutants
PER WELL
n. s;
n. s;
n. s;
TOXIC
CONCENTRATION • EXPERIMENT NUMBER 
MICROGRAMS/ML 78 33 93 98 104
WELLS POSITIVE
0..000000 8 20 13 11 13
0.OOOoOO 11 11 7 - - 12
1 00 ,'OOOftOO 17 -- p
200.OOOOOO -m 10 10 3 2
5no.OOOOOO 6 nt 7 --
CONCENTRATION NUMBER average number 2
MICROGRAMS/ML OF of wells X
EXPTS, positive
CONTROL treated
1 0 . o o o o o o 1 18. 0 1 5; 0 0.42
100,000000 3 21 .8 1717 2.78
200.000000 2 23.7 2015 1.05
500.OOOOOO 3 21.8 12f.3 15.41
compound 33
.strain TA98
INTACT hepatocyte activation
CONCENTRATION
MICROGRAMS/ML
100 . o o o o o n
200.OOODOn 
500.OOOOOO
number average number 2 PROBAf
of of Wells X ilityEXPTS. positive
control treated
2 1 0 . 0  1 3 ;o 1 . 09 N.S.4 12.5 6.2 12.39 TOXIC3 11.7 6.7 6.00 TOXIC
INDUCED 
MUTANTS 
PER WELL
0.0822
CONCENTRATION EXPERIMENT n u m b e r
MICPOGRAMS/ML 52 3  52 8  539 77
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 11 10 2 8
0 . 0 0 0 0 0 0 20 13 5 14
1 0 . oooooo 23 — 13
5 0 . OOOOOO 35 --
1 0 0 . oooooo 3<? 26 18 ?L
2 0 0 . oooooo -- -- 22 --
5n0.OOOOOO 40 32 45
c o n c e n t r a t i o n
MICROGRAMS/ML
13.000000
5 0 . 0 0 0 0 0 0
100.000000
2 0 0 . 0 0 0 0 0 0
5 0 0 . 0 0 0 0 0 0  
COMPOUND 
STRAIN
NUMBER
OE
EXPTS.
34
TA1 00
AVERAGE NUMBER
of  w e l l s  
p o s i t i v e
c o n t r o l  t r e a t e d
11.8
1 5 . 5
10.8
3 . 5
9 . 4
18; 0 
3 5 , 0  
2 6 . 3  
22:0 
3 9 ’. 0
5 . 3 3
2 0 . 4 6
6 6 , 1 3
2 8 . 3 7
PROBAB
I L I T Y
0 . 0 2 5
0 . 0 0 0 5
0 . 0 0 0 5
0 . 0 0 0 5
1 6 0 . 8 8  < 0 . 0 0 0 5
INDUCED 
MUTANTS 
PER WELL
0 . 1 3 7 9  
0 . 9 1 6 3  
0 . 5 6 0 5  
0 . 5 3 7 4  
1 . 4 5 5 3
S9 A CT IV A TI ON
c o n c e n t r a t i o n
MI CROGRAMS/ML
e x p e r i m e n t  n u m b e r  
5 2 4  529 5 3 7  
WELLS P O S I T I V E
0 , OOOOOO 30 28 36 '
0 , 0 0 0 0 0 0 26 24 - -
1o . o o o o o o 35 - - 44
1 0 0 , 0 0 0 0 0 0 39 42 tm m
2 0 0 , 0 0 0 0 0 0 47 mm
5 0 0 . 0 0 0 0 0 0 48 48 48
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF UE I L s  X I L I T Y  MUTANTS
EXPTS.  p o s i t i v e  p e r  WELL
CONTROL TREATED
10. oooooo 2 3 0 . 7 3 9 . 5 9 , 0 8 < 0 . 0 0 5 0 , 7 1 2 6
1 0 0 . OOOOOO 2 2 7 . 0 4 0 . 5 21 . 8 2 < 0 . 0 0 0 5 1 . 0 2 9 6
2 0 0 . OOOOOO 1 2 6 . 0 47'. 0 2 7 , 5 0 < 0 . 0 0 0 5 3 . 0 9 1 0
5 0 0 . OOOOOO 3 2 8 . 8 4 8 . 0 7 5 . 7 4 < 0 . 0 0 0 5 ? ? ? ? ? ? ?
COMPOUND 34
STRAIN TA100
INTACT HEPATOCYTE A C TI V A TI O N
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs / M L  87  92  95  10 6
WELLS P O S I T I V E
0 . ooonoo 7 20 11 18
0 , oooooo 14 12 10 10
1 . OOOnOO — 16 18
1 0 . OOOnOO — 14 40
5 0 . OOOoOO mm 48 43 42
1 no.OOOoOO 43 48 - - --
5 ^ 0 . OOOnOO 40 - - - - - -
CON Cr NTR AT t ON 
MICROGRAMS/ML
1.OOOOOO
10.000000
5 0 . 0 0 0 0 0 0
1 0 0 . ooooon  
5 0 0 . ooooon
n u m b e r
OF
EXPTS.
AVERAGE NUMBER 
of  w e l l s
P O S I T I V F
c o n t r o l  t r e a t e d
1 2 . 2
12.2
1 3 . 5  
1 3 . 2
1 0 . 5
1 7 . 0  
2 7 . 0  
4 4 . 3  
4 5 . 5  
4 0 .  0
2 . 8 2
2 5 . 6 4
1 5 7 . 1 8
1 1 4 . 2 2
4 8 . 2 5
PROBAB
I L I T Y
N . S .
0 . 0 0 0 5  
0 . 0 0 0 5  
0 . 0 0 0 5  
0 . 0 0 0 5
INDUCED 
MUTANTS 
PER WELL
0 . 1 4 2 6  
0 . 5 3 2 0  
2 . 2 4 1 7  
2 . 6 3 1 9  
1 . 5 4 4 9
STRAIN TA93 
NO activation
concentration
MI CPOGRAHS/ ML
0.000000 
0.000000 
1o . o o o o o o  
1 00 . o o o o o o  
d O O . o o o o o o
500.000000
EXPERIMENT n u m b e r
527 31 74
WELLS POSITIVE
4 3 4
3 5 6
—  —  2
— 2 
10 11 —
0 6 7
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB
MICROGRAMS/ML OF OF WELLS X il ity
EXPTS. POSITIVE
CONTROL TREATED
1 3 . 0 0 0 0 0 0 1 4 . 7 2 : 0 1 . 11 n. s;
1 0 3 .  0 0 0 0 0 0 1 4 . 7 2 . 0 1 . 1 1 N . s ,
2 0 3 . 0 0 0 0 0 0 2 6 . 2 1 0 . 5 3 . 4 2 N . s . 0 , 1 0 7 4
5 0 3 . 0 0 0 0 0 0 3 5 . 6 5.7 0.00 N.S. 0 . 0 0 2 2
COMPOUND 34 
STRAIN TA98 
S9 ACTIVATION •
concentration experiment number 
MICROGRAMS/ML 521 531 540
WELLS POSITIVE
0 . o o o o o o 2 5 3 0 12
0 . o o o o o o 11 2 8 12
10.000000 1 5 mm --
1 0 0 , 0 0 0 0 0 0 1 7 mm- mm
2 0 0 . OOOOOO 2 6 13
5 0 0 , OOOOOO 15 3 4 10
INDUCED
MUTANTS
per well
CONCENTRATION NUMrER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML Op OF WEUS X UlTY. MUTANTS
EXPTS, POSITIVE PER WELL
control TREATED
10 . o o o o o o 1 1 8 , 0 1 5 . 0 0 . 4 2 N.S,
1 0 3 . 0 0 0 0 0 0 1 1 8 , 0 1 7 VO 0 . 0 2 n. s;
2 0 3 . OOOOOO 2 2 0 . 5 1 9 7 5 0 . 0 8 N.s,
5 0 3 , 0 0 0 0 0 0 3 1 9 . 7 1 9 V 7 0 . 0 0 n. s;
COMPOUND 34 
strain tA98
intact HEPATOCYTE ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 78 83 93 104
WELLS POSITIVE
0 . o o o n o o 3 2 0 11 13
0 . o o o n o o 11. 11 - - 12
5 0 . OQOdOO — m — 1 4 1 3
100. o o o n o o 1 4 10 - -
290.OOOnOO -~ — 12
5 0 0 . OOOOOO 1 2 6 — 15
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB induced
MICROGRAMS/ML OF OF WpLLS X ility MUTANTS
EXPTS. POSITIVE PER WELL
control TREATED
50.o o o o o n tm 12.2 16,0 1 .74 N.S. 0.1108
1 0 0 . o o o o o n 2 12.5 12.0 0. 01 N.S.
200.o o o o o n 1 12.7 12'.0 0.01 N.S.
5 0 0 . o o o n o o 3 12.6 11.0 0.49 N.S.
STRAIN TA100
NO ACTIVATION
concentration 
MICroGRAMS/ML
0.000000 
0.000000 
10.000000
100.000000
290.000000
590.000000
EXPERIMENT n u m b e r
636 539 77
UELLS POSITIVE
1 4 
15
8
14
12
13
1 5
CONCENTRATION NUMBER AVERAGE number 2 probai
MICROGRAMS/ML OF of Wells X ILITY
EXPTS. positive
CONTROL treated
10.000000 1 11.0 1 2', 0 0.03 N.S,
100.OOOOOO 1 11.0 1370 0.20 N.S.
200.OOOOOO 2 5.0 9.5 3.79 N.S.
500.OOOOOO 3 7.4 11.7 4.38 < 0.025
COMPOUND 35 
STRAIN TA100 
S9 ACTIVATION
concentration experiment number
MICROGRAMS/ML 524 529
WELLS POSITIVE
o;oooooo 30 28
0.000000 26 24
10,000000 35 m m
1O0 .oooooo 24
290.OOOOOO •• P" 32
500,000000 36 30
concentration number average NUMBER 2 PROBAB
micrograms/ ml of of wells x ility
EXPTS, POSITIVE
CONTROL TREATED
1 0 . o o o o o o 1 2 8 . 0 3 5 7 0 2 , 6 2 N.S,
1 0 0 . 0 0 0 0 0 0 1 2 8 . 0 2 4 7 0 0 . 7 4 N.S.
2 0 0 . OOOOOO 1 2 6 . 0 3 2 . 0 1 . 8 1 N.S,
5 0 0 . OOOOOO 2 2 7 . 0 3 3 . 0 3 , 9 2  < 0 . 0 2 5
COMPOUND 35
STRAIv TA1 00
intact hepatocyte ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMs/ML 95 105 107
WElLS POSITIVE
0.OOOoOO 11 17 12
0,OOOoOO 10 16 14
100.OOOnOO 11 11 5
290.OOOOOO -- 15
500.OOOOOO 13 14 1 4
CONCENTRATION number average number 2 probai
MICROGRAMS/ML. OF of wells X ILITY
EXPTS. positive
control treated
100.o o o o o n 3 13,3 9.0 3.96 , TOXIC200.000009 1 16.5 15.0 0.03 N.S.
500, OOOOOn 3 13.3 13.7 0.01 N.S.
INDUCED 
MUTANTS 
PER WELL
0.0274
0.0556
0.1105
o . m o
induced 
mutants 
PER WELL
0.4308
0.3185
0.3365
induced
MUTANTS 
PER WELL
0. 0097
S T R A I M T A 9 <3
NO ACTIVATION
concentration 
mi crograms/ ml
o . o o o n o o
0 . OOOOOO
1o . o o o o o o
TOO.OOOOOO
£00 , o o o o o o  
s ^ o . o o o o o o
EXPERIMENT n u m b e r
327 74. 82
WELLS POSITIVE
4 4 21
8 6 11
3 —
11 — 4
8 2 5
CONCENTRATION NUMBER AVERAGE number 2 PROBAB
MICROGRAMS/ML OF of wElls X ILITY
EXPTS. . POSITIVE
CONTROL treated
1o . o o o o o o 1 4 . 7 3T 0 0 . 3 4 N. S,
1 0 0 . o o o o o o 1 4 . 7 3 0 0 . 3 4 n . s ;
2 0 0 . o o o o o o nu 1 1 . 0 7V5 1 . 87 n . s ;
5 0 0 . OOOOOO 3 8 . 3 5 . 0 3 . 4 0 N. S,
COMPOUND 35 
STRAIN TA98 
S9 ACTIVATION
concentrati on  e xp eri ment  number
MICROGRAMS/ML 521 522 531 545 
WELLS POSITIVE
0 , o o o o o o 25 18 30 28
0 . o o o o o o 11 17 28 25
1 0 , 00 00 00 -- 20 - - - -
m o , o o o o o o •» p* 19 »-
200 , 0 00 00 0 -- 26 20
5 0 0 , OOOOOO 13 24 8
CONCENTRATION NUMBER AVERAGE NUmBER 2 PROBAB
MICROGRAMS/ML OF OF We LLS X ILITY
EXPTS. POSITIVE
CONTROL TREATED
1 0 , o o o o o o 1 1 7 . 5 2 0 : 0 0 , 2 7 n . s ;
1 0 0 . o o o o o o 1 17 . 5 1 9 . 0 0 . 0 7 n . s ;
2 0 0 . OOOOOO 2 2 7 . 7 2 3 ‘.0 2 . 3 3 n . s ;
5 0 0 . OOOOOO 3 2 4 . 5 1 5'. 0 14 , 8 3 toxi c
compound 35
s trai n TA98
INTACT HEPATOCYTE ACTIVATION
CONCENTRATION e xp e ri me nt  number
MICROGRAMS/Ml 81 84 98 104
WELLS POSITIVE
o . o o o o o o • 28 8 11 13
o . o o o n o o - - 6 - - 12
5 0 . OOOoOO •»- 11 17
m o ,  o o o n o o 1 14 - - 15
5 * 0 . o o o n o o 25 u 11
concentrati on . •number AVERAGE NUMBER 2 pkqbab
mi crograms / ml of of wells X ILITY
EXPTS. p o s i t i v e
CONTROL TREATED
5 0 . 000000 2 1 2 . 0 1 4 , 0 0 . 4 7 N. S.
1 0 0 . OOOOOn 3 13 . 2 1 0 . 0 2.  04 N.S.
5 0 0 . o o o o o n 3 13 . 2 1 2 . 7 0 . 03 N. S.
i nduced 
mutants 
per WEIL
i n d u c e d  
MUTANTS 
PER WEtl
0 , 0 8 5 5
0 . 0 5 0 4
INDUCED 
MUTANTS 
PER WELL
0.0572
COMPOUND 36
STRAIN TA10O
NO ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 523 528 539
HELLS POSITIVE
0.000000 11 10 2
0.000000 20 13 5
. ” 0 , o o o o o o 11 - - - -
m o . o o o o o o 10 5 2
200.000000 - - 6 5
5 0 0 . 0 0 0 0 0 0 •I 4 7 9
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
m i c r o g r a m s / m l  o f  o f  w e l l s  x i l i t y  m u t a n t s
EXPTS.  P O S I T I V E  PER WELL
CONTROL TREATED
10 . o o o o o o 1 1 5 . 5 11.0 1 . 1 4 N . S ,
100 . o o o o o o 3 1 0 . 2 5 . 7 5 . 3 9 TOXIC
2 0 0 . OOOOOO 2 7 . 5 7 ;  0 0 , 0 2 n . s ;
5 0 0 . OOOOOO 3 1 0 . 2 1 0 ;  0 0 . 0 0 N . s ,
COMPOUND 36 
STRAIN TA100  
S9 A C TI VA TI ON
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r  
MICROGRAMS/ML 5 2 4  529 5 3 8  548  
WELLS P O S I T I V E
0.000000 3 0 2 8 2 6 2 0
0,000000 2 6 2 4 21 2 8
10.000000 45 -~ --
100, o o o o o o 4 3 4 4 3 6 30
200 , o o o o o o -- 3 6 21 29
5 0 0 , 0 0 0 0 0 0 3 8 3 6 1 9 26
CONCENTRATION NUMBER a v e r a g e n u m b e r 2 PROBAB i n d u c e d
MICROGRAMS/ML OF of  w e l l s X I L I T Y m u t a n t s
EXPTS. p o s i t i v e p e r  w e l l
CONTROL t r e a t e d
10 . o o o o o o 1 2 8 , 0 4 5 . 0 1 8 , 3 3 < 0 , 0 0 0 5 1 . 8 9 7 1
100.000000 4 2 5 . 4 3 8 ; 2 3 8 . 4 5 < 0 . 0 0 0 5 0 . 8 4 1 8
2 0 0 . OOOOOO 3 2 4 . 5 2 8 . 7 2 . 7 4 N . S . 0 , 1 9 5 2
5 0 0 . OOOOOO 4 2 5 . 4 29  ; 8 4 , 1 3 < 0 . 0 2 5 0 . 2 1 4 9
COMpOijND 36 
STRAIN TA100
i n t a c t  h e p a t o c y t e  a c t i v a t i o n
CONCENTRATION
MICROGRAMS/ML
e x p e r i m e n t  n u m b e r  
87  92  96  10 6
WELLS P O S I T I V E
0 . o o o n o o 7 2 0 1 0 1 8
0 . 0 0 0 O 0 0 14 12 12 10
100 , o o o o o o 2 1 7 1 6 21
2 a O;OOOoOO - - P* •• 6 5
5 0 0 . o o o n o o 8 1 3 10 - -
CONCENTRATION n u m b e r AVERAGE n u m b e r 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WELLS X I L I T Y MUTANTS
EXPTS. P O S I T I V E PER WELL
CONTROL TREATED
100 . o o o o o n 4 1 2 . 9  1 4 . 0 0 . 3 0 N . S . 0 . 0 3 2 6
2 0 0 .  OOOOOn 2 1 2 . 5  5 . 5 7 . 7  2 TOXIC
5 0 0 . o o o o o n 3 1 2 . 5  ' 1 0 . 3 0 , 9 4 N . S . •
COMPOUND 36
STRAIN TA98
NO ACTIVATION
concentration 
micrograms/ ml
o.oooooo 
o.oooooo 
'0 .oooooo 
1 0 0 . 0 0 0 0 0 0  
£00.oooooo 
mo.oooooo
EXPERIMENT NUMBER
520 527 82
WELLS POSITIVE
7 4 21
4 8 11
fl —  —
3 “ - —■
6 13
7 5 14
CONCENTRATION NUMBER average NUMBER 2 PROBAB induced
MICROGRAMS/ML OF of wElls X HITY MUTANTS
EXPTS. positive per well
CONTROL treated
1 I), oooooo 1 5.5 810 0.55 N.S. 0.0606
100.000000 1 5.5 310 0,71 N.S.
200 ,000000 2 11 .0 915 0.28 n. s;
500.OOOOOO 3 9.2 8 '.7 0.04 N.S.
COMPOUND 3o 
STRAIN • TA98 
S9 ACTIVATION
concentration experiment number 
MICROGRAMS/Ml  522 531 542
WELLS POSITIVE
0.000000 18 30 18
0,000000 17 28 19
10,000000 18 --
100,000000 13 mm 17
200,000000 0.- 21 19
500,000000 22 19 19
CONCENTRATION
micrograms/ ml
10.OOOOOO 
100. OOOOOO 
200.000000 
500.000000
NUMBER AVERAGE NUMBER
of of wells
EXPTS. POSITIVE
CONTROL TREATED
COMPOUND 36 
STRAIN TA98
intact hepatocyte ACTIVATION
PROBAB
ILITY
INDUCED
mutants 
PER WELL
1 17.5 1810 0.00 n. s; 0,0165
2 18.0 15.0 0,96 N.S.
2 23.7 2010 1.42 n. s;
3 21.7 20.0 0,40 n. s;
CONCENTRATION
MICROGRAMS/ML
experiment number 
78 84 94 99
WELLS POSITIVE
o.ooonoo R 8 4 15
o,ooonoo 11' 6 ....
50,OOOnOO mm 11
1 0 0 . ooonoo 11 18 3
500.OOOnOO 12 6 . 6 ..
CONCENTRATION
MICROGRAMS/ML
50.OOOoOn 
100.OOOOOn 
500.OOOOOO
NUMRER average number 
of of w^ lls
EXPTS. POSITIVE
CONTROL TREATED
PROBAB
ILITY
INDUCED
mutants 
PER well
1 15.0 11.0 0,65 N.S.
3 7.4 1 o; 7 2.60 N.S. 0.0839
3 7.4 8.0 0.06 N.S. 0.0149
L u 1 P U U N n s ti
STRAIN TA1no
NO ACTIVATION
c o n c e n t r a t i o n  
n i  c r o g r a m s / h l
0 . o o o n o o  
o . o o o o o n  
m . o o o o o o  
1 no,OOOOOO 
200. OOOOOO 
5 " o . o o o o o o
EXPERIMENT NUMBER 
52 3  52 8  536 541 
u e l l s  p o s i t i v e
11 
20 
14 
17
1?
10
13
25
28
24
18
13
17.
o
14
CONCENTRATION
MICROGRAMS/ML
NUMBER AVERAGE NUMBER
of of w ells
EXPTS,  P O S I T I V E
PR0BA8
ILITY
i n d u c e d
m u t a n t s
PER WELL
CONTROL t r e a t e d
10.000000 1 1 5 . 5 1 4 . 0 0 . 0 8 n . s ;
100 . o o o o o o 2 1 5 . 5 17; 0 0.22 N . s ,
200.000000 2 1 3 . 7 18 r 5 o .  no n . s ;
5 0 0 . OOOOOO 4 1 5 . 7 1 4 . 5 0 . 3 0 N . s .
0 . 0 4 7 3
COMPOUND 38  
STRAIN TA10U  
S9 a c t i v a t i o n
CONCENTRATION 
MICROGRAMS/ML
o . o o o o o o  
o . o o o o o o  
• 1o , o o o o o o  
1 0 0 . 0 0 0 0 0 0  
200,000000 
* 00 , o o o o o o
EXPERIMENT NUMBER 
525 5 2 °  5 3 4  54 8  
WELLS P O S I T I V E
31 28  26 20
33 24  28 28
3 1 ...........................
26 26  - -  17
—  22 27  26
31 - -  23 28
CONCENTRATION n u m b e r a v e r a g e NUMBER 2 pROBAf
MICROGRAMS/ML Of of  w e l l s X I L I T Y
EXPTS. P O S I T I V E
c o n t r o l t r e a t e d
1o . o o o o o o 1 3 2 . 0 3 1 . 0 0,02 N . s ;
100 . o o o o o o 3 2 7 . 3 2 3 ;  0 2 . 9 7 n . s ;
200 . o o o o o o 3 2 5 . 7 2 5 ’. 0 0 . 0 5 n . s ;
5 0 0 . 0 0 0 0 0 0 3 2 7 . 7 2 7 7 3 0.01 n . s ;
COMPOUND 38
STRAIN TA100
INDUCED 
MUTANTS 
PER WELL
I N TA C t h e p a t o c y t e  a c t i v a t i o n
CONCENTRATION e x p e r i m e n t  NUMBER
MICROGRAM^/ML 95  89 105 10 7
WELLS P O S I T I V E
o . o o o n o o 11 6 17 12
0,0OOnOO 10 13 16 14
100 . o o o n o o 11 11 - - ....
2 0 0 . OOOoOO a 15
5 n 0 , OOOnOO 8 14 12 0
CONCENTRATION n u m b e r a v e r a g e n u m b e r 2 PROBAB i n d u c e d
MICROGRAMS/ML OF OF WELLS X i l i t y MUTANTS
EXPTS. P O S I T I V E p e r  w e l l
CONTROL t r e a t e d
1 0 0 . o o o o o o 2 1 0 . 0 1 1 . 0 0 . 1 1 N . S . 0 . 0 2 6 7
2 0 0 . OOOOOn U 1 3 . 5 1 1 . 5 0 . 4 7 N . S .
5 0 0 . OOOOOO 4 1 2 . 3 1 0 . 7 0 . 6 9 N . S .
NO ACTIVATION
CONCENTRATION 
MI CROGRAMS/ML
0 . oooooo  
0,000000 
TO.OOOOOO
1 o n , o o o o o o  
2 * 0 . oooooo  
5*0. OOOOOO
EXPERIMENT NUMBER
520 527 533
WELLS POSITIVE
7 4 16
4 3 11
4 — —■
7 11
6 7 5
CONCENTRATION number AVERAGE number 2 PROBAB
MICROGRAMS/Mt QF of wells X ility
EXPTS. positive
CONTROL TREATED
10,OOOOOO 1 5.5 4 ; o 0.19 N.S.
1 0 0 , oooooo 1 5.5 6 *. 0 0.00 N.S.
200,000000 T>U 9.7 9.0 0,06 M.S.
500.OOOOOO 3 8.3 6 : o 1 .53 N.S.
INDUCED 
MUTANTS 
PER WELL
0.0118
COMPOUND 38 
STRAIN TA98 
59 ACTIVATION
concentration experiment number
MICROGRAMS/ML 522 531 542 545 
WELLS POSITIVE
0 . oooooo 18 30 18 28
0.000000 17 28 19 25
1 o , o o o o o o 21 ■»- - - - -
1 0 0 , oooooo 20 24 - -
200.000000 - - 22 20 27
500,000000 17 48 19 19
concentration NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF of wells X il ity MUTANTS
EXPTS. POSITIVE per WELL
CONTROL treated
1 0 . oooooo 1 17.5 21‘.0 0.57 N.S, 0.1219
10 0 . oooooo 2 23.2 22.0 0,13 n. s;
200.000000 3 24.7 23C0 0.40 N.s,
500.OOOOOO 4 22.9 25:7 1 .72 N.s," 0.1215
COMPOUND 38
strain TA98
intact hepatocyte activation
CONCENTRATION
MICROGRAMs/m.
0 . oooooo  
0 . ooonoo-
50,OOOOOO 
1 0 0 . ooonoo  
5*0;OOOnOO
EXPERIMENT NUMBER
81 93 99
WELLS POSITIVE
28 13 15
-- 7 •»-
- - 6 11
25 13 9
31 6 17
concentration
miCROGRAMS/ML
5 0. 0 0 0 0 0 0
100.00000O
500.OOOOOn
NUMBER AVERAGE NUMBER 
OF OF WELLS
EXPTS. POSITIVE
CONTROL TREATED
PROBAB
ility
2 11.7 8.5 1 .29 N.S.3 15.8 15.7 0.00 N. S.
3 15.8 » 18.0 1 .67 N. S.
induced
mutants
PER WELL
COMPOUND 1°
STRAIN T A1 0 u
NO ACTIVATION
CONCENTRATION experiment number
Ml Crograms/ml 528 53? 541 7?
WELLS POSITIVE
n. oooooo 10 2 13 8
o.oooooo 13 5 13 14
1.OOOOOO . . -- - - 1 0
1o,oooooo 2? 1 22 1 1
1 0 0. 0 00 0 00 37 7 25 26
CONCENTRATION HUMBER average number 2 PROBAB INDUCED
MICROGRAMS/ML OF of wells X ILITY mutants
EXPTS. POSITIVE per well
CONTROL treated
1.oooooo 1 1 2 . 0 10'.0 0.24 n.s;
1J.oooooo 4 io.a 14.0 3.06 N.S. 0,0?05
1 0 0. 0 0 0 0 0 0 4 1 0 . 8 22*. 5 37.19 < 0.0005 0.378?
COMPOUND .T9 
STRAIN TA100 
S9 ACTIVATION
CONCENTRATION EXPERIMENT number
MI CPOGRAMS/ML 524 529 53? 7-5
WELLS POSITIVE
o.oooooo 30 23 36 11
0.000000 26 24 -- 13
1.oooooo 28 -- 11
1 0,oooooo 31 33 14 0
100,000000 37 33 35 17
concentration NUMBER average number 2 PROBAB induced
MICROGRAMS/ML OF of wElls X I.LITY MUTANTS
EXPTS. POSITIVE PER WELL
CONTROL treated
1.oooooo 2 20.0 1 9; 5' 0.01 n.s;
10. 0 00 0 00 4 24,0 21 .7 0.98 N.s.
100.000000 4 24.0 30 V 5 8.78 < 0.005 0.3159
COMPOUND 39
STRAIN TA100
INTACT HEPATOCYTE ACTIVATION
concentration experiment number
MICROGRAMR/ml 37 92 95 96 106 107
WELLS POSITIVE
0 . OOOOOO 7 20 11 10 18 1?
0 , OOOnOO • 14 12 10 12 10 14
1 .OOOnOO - - - - 8 18 - -
’ 0 , OOOnOO 17 11 9 - - - - - -
5 0 . OOOOOO — — - - - - 26 - -
1 no-, OOOnOO 23 14 10 - - - - ••••
?no.OOOnOO — — - - - - - - 12
CONCENTRATION
MICROGRAMS/Ml
1 . OOOCOd 
10.OOOOOd
50 . 00000-', 
100.OOOOOO 
200.OOOOOn
number average number 
of of wells
EXPTS, POSITIVE
CONTROL treated
12. 5 
’2.3
14.0 
12.3
13.0
13.0 
1 2.3
26.0 
15.7 
’2.0
PROBAB
ILITY
0.01 N.S.
0.00 N,S,
a.01 < 0.005
2.13 N.S.
0.03 N.S.
INDUCED
MUTANTS
per well
0.0142
0.4353
0.0981
COMPOUND 30
s t r a i n TA93
NO a c t i v a t i o n
CONCENTRATION EXPERIMENT NUMfcFR
MICPOGRAMS/ML 52? 5 46 74 «2
WELLS POSITIVE
o.ooonoo /* 11 4 21
o.oooooo 8 9 6 11
•1 . OOQCOO -- - - 4
‘'0.000000 19 17 5 11
1 0 0 . 0 0 0 0 0 0 31 41 44 16
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
HI CROGRAf1S/ML OF of wells X ility MUTANTS
EXPTS. positive PER WELL
CONTROL TREATED
1 . oooooo 1 5 . 0 4 . 0 0 . 0 6 N.S.
13.OOOOOO 4 1 0 . 6 1 3 :0 1 . 78 N.S. 0 . 0 6 7 5
103.OOOOOO 4 10 . 6 33.0 1 2 4 . 5 6 < 0 . 0 00 5 0 . 9 1 4 8
COMPOUND 39 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
M!CrOGRAMS/ml 521 531 542 545 
WELLS POSITIVE
0,OOOOOO 25 30 13 28
0.000000 11 28 19 25
0.100000 - - 27 -- - -
1.oooooo 27 -- 19 21
10,000000 31 34 20 18
mo.oooooo 47 m m 21 29
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
MICROGRAMS/ML OF OF WeLLS X UlTY MUTANTS
EXPTS. POSITIVE PER WELL
CONTROL TREATED
0.1ooooo 1 29.0 2770 0.15 n.s;
1.oooooo 21 .0 2273 0.25 N.S. 0.0506
13.000000 4 23.0 2577 1 .57 n.s; 0.1165
103.000000 3 21 .0 3273 20.96 < 0.0005 0,5443
COMPOUND 3°
STRAIN TA98
intact hepatocyte activation
CONCENTRATION EXPERIMENT NUMBER
HICROGRAMS/ML 78 33 84 98 104
WELLS POSITIVE
o.ooonoo 8 20 8 11 13
0. OOOnOO 11 11 6 - - 12
0.1OOnOO -- 15 11 18 - -
1, OOO.nOO 25 - - - - 25
* 0.OOOnOO 40 47 31 - - - -
1 no.OOOnOO 48
CONCENTRATION
MICROGRAMS/ML
NUMBER AVERAGE NUMBER
of of Wells
EXPTS. POSITIVE
PHOBAB
ILITY
INDUCED
mutants 
PER WELL
CONTROL treated
0 . 1 0 0 n 0 n 3 1 1 . 2 1 4 . 7 2 . 2 5 N . S . 0 , 0 9 8 9
1 . 0 0 0 0  0 n 2 1 3 , 8 2 5 . 0 1 5 . 3 2 < 0 . 0 0 0 5 0 . 3 9 6 7
13 . ooo o o n 3 1 0 . 7 3 9 . 3 139 . 2 2 < 0 . 0 0 0 5 1 . 4 6 0 4
100. ooo o o n 1 9 . 5 4 3 . 0 81 . 1 4 < 0 . 0 0 0 5 ? ? ? ? ? “>?
NO ACTIVATION
COMrENTRATION EXPERIMENT NUMBER
HICROGRAMS/ml 523 520 536 541
WELLS POSITIVE
o.  oooooo 11 10 25 18
o.  oooooo 20 13 - - 1 3
1 0 . 0 0 0 0 0 0 14 - -
5 0 . 0 0 0 0 0 0 - - 17 30 31
1 0 0 . OOOOOO 30 19 19 10
2 0 0 . OOOOOO . — 1 17 1
c o n c e n t r a t i o n  n u m b e r  a v e r a g e  n u m b e r  2 p r o b a b  i n d u c e d
MICROGRAMS/ML OF OF U e LLS X U I T Y  MUTANTS
EXPTS.  P O S I T I V E  PER WELL
CONTROL TREATED
1 o . o o o o o o ■ 1 1 5 . 5 1 4 , 0 0 , 0 3 n . s ;
5 0 . o o o o o o 3 1 5 . S 2 6 v 0 1 6 . 3 3 < 0 . 0 0 0 5 0 . 3 8 0 9
1 0 0 . 0 0 0 0 0 0 4 1 5 . 7 21- .7 7 . 9 9 < 0 . 0 0 5 0 , 2 0 7 0
2 0 0 . 0 0 0 0 0 0 3 1 5 . 8 67 3 1 7 , 9 0 TOXIC
COMPOUND 40 
STRAIN TA100  
S9 AC TI VA TI ON
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 525 529  53 8
WELLS P O S I T I V E
0 . o o o o o o 31 28 26
0 . 0 0 0 0 0 0 33 24 21
1 0 . 0 0 0 0 0 0 25 - - —  ~
5 0 . 0 0 0 0 0 0 '. — - - 20
1 0 0 . 0 0 0 0 0 0 28 29 22
2 0 0 , 0 0 0 0 0 0 23 36 28
CONCENTRATION NUflBER AVERAGE NUMBER 2 PROBAB INDUCED
m i c r o g r a m s / ml  of  of  w e l l s  x i l i t y  m u t a n t s
EXPTS.  p o s i t i v e  p e r  w e l l
CONTROL TREATED
1 o . OOOOOO 1 3 2 . 0 2 5 ;  0 2 . 5 8 N . S .
5 J.OOOOOO 1 2 3 . 5 2 0 .  0 0 . 5 5 N . S ,
1 0 0 . o o o o o o 3 2 7 . 2 2 6 ;  3 0 . 0 3 N . S ,
2 0 0 . o o o o o o 3 2 7 . 2 3 0 ‘. 7 1 . 9 6 N . S , 0 . 1 8 3 9
COMPOUND 40
STRAIN TA100
INTACT h e p a t o c y t e  A C TI V A TI O N
CONCENTRATION e x p e r i m e n t  NUMBER
MICROGRAMs/ML 87  92  9 6  106
WELLS P O S I T I V E
0.OOOoOO 7 20 10 18
0.OOOnOO 14 12 12 10
50.OOOnOO - - - - 11
100.OOOnOO 14 18 - -
2n0.OPOnOO - - m 6 1 0
590.OOOnOO 11 17 9 - -
CONCCNTRATt ON n u m b e r AVERAGE n u m b e r 2 PROBAB INDUCED
MICROGRAMS/ML OF of  We l l s X I L I T Y MUTANTS
EXPTS. P O S I T I V E PER WELL
CONTROL t r e a t e d
5 0 .  vOOOOOO 1 1 1 . 0 1 1 ; o 0 . 0 0 N . S .
1 0 0 . ooooon 2 1 3 . 2 1 6 . 0 0 . 8 8 N . S . 0 . 0 8 2 4
2 0 0 . oooooo 2 1 3 . 6 8 . 0 4 . 6 7 TOXIC
500 . o o oo o n 3 1 2 . 5 1 2 . 3 0 . 0 0 N . S .
NO ACTIVATION
CONCENTRATION EXPERIMENT NUfiQPH
MICPOGRAMS/ML 520 527 533 81
WELLS POSITIVE
0.000000 7 4 16 8
0.000000 4 8 11 5
* o. oooooo 2 — -- - -
50,000000 -- 8 9 ■ 1
m o . o o o o o o 4 6 9 5
2nfj .  oooooo -- 5 9
500.000000 0 -- - - - -
CONCENTRATION
micrograms/ ml
NUMBER AVERAGE NUMBER 
OF OF UElLS
EXPTS. POSITIVE
PROBAB
ility
INDUCED 
MUTANTS 
PER WELL
control treated
1 o. oooooo 1 5 . 5 2, 0 1 . 65 N.S,
5 0 . 0 0 0 0 0 0 3 8,7 6 . 0 1.98 N.S.
1 0 0 . 0 0 0 0 0 0 4 7.9 6 ; 0 1 . 37 N.S.
200.OOOOOO 3 8.7 5 *.3 3 . 2 3 N.S.
5 0 0 . OOOOOO 1 5.5 O', o 5 . 1 7 TOXIC
COMPOUND 40 
STRAIN TA98 
S9 ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 522 526 531 542 
WELLS POSITIVE
0.000000 13 19 30 18
0.000000 17 17 28 19
10.000000 17 - - - - - -
50.000000 -- - - 18
1 0 0 . oooooo 23 17 24 23
200.000000 23 24 22
500,OOOOOO 13 -- — --
CONCENTRATION
micrograms/ ml
number average number 
of of wells
EXPTS. POSITIVE
probab
ILITY
INDUCED 
MUTANTS 
PER WELL
CONTROL TREATED
1 o. oooooo 1 1 7 . 5 17;  0 0 . 0 0 n. s;
50.OOOOOO 1 13.5 18; o 0 , 0 0 N.s,
100.OOOOOO 4 2 0 . 7 23;  0 1.04 N.S. 0,0862
200,  OOOOOO 3 21 .8 23'. 0 0 . 1 8 N.S. 0.0456
500.OOOOOO 1 17.5 1370 1 .06 N.S, .
COMpOijNd 40 
STRAIN TA98
INTACT hepatocyte ACTIVATION
CONCENTRATION EXPERIMENT NUMBER
HICROGRAMs/ML 78 84 99 104
WELLS POSITIVE
0,000O00 8 8 15 13
0 . ooonoo 11 6 ... 12
50,OOOoOO -- MM -- 14
mo. ooonoo 20 5 -- --
500.OOOOOO 17 14 27 19
CONCENTRATION
micrograms/ ml
50 .OOOOOC
1 0 0 . 000000
500.000000
number
OF
EXPTS,
average number 
of wells 
positive
control treated
12.7
8,2
10.5
14.0
12.5
19.2
0.08
2.85
18.09
PROBAB
ILITY
N.S.
N.S.
0,0005
induced
MUTANTS 
PER WELL
0.0385
0.1131
0.2657
NO ACTIVATION
CONCENTRATION
h i  c r o g r a m s / ml
o. oooooo  
o. oooooo  
10.000000 
ino,OOOOOO
doo. oooooo  
*0 0 . 0 0 0 0 0 0
EXPERIMENT NUMBER 
52 3  53 6  541
wells positive
11
20
11
12
11
25
25
23
18
13
16 
11
CONCENTRATION NUMBER a v e r a g e n u m b e r 2 p r o b a b INDUCED
m i c r o g r a m s / ml OF of  w e l l s X I L I T Y MUTANTS '
EXPTS. p o s i t i v e PER WELL
CONTROL t r e a t e d
1 0 . oooooo 1 1 5 . 5 11 *. 0 1 . 1 4 N . S ,
1 0 0 . 0 0 0 0 0 0 1 1 5 . 5 1 2 . 0 0 . 6 5 N . S .
2 0 0 , oooooo 2 1 8 . 5 2 0 . 5 0 . 3 8 n . s ; 0 . 0 7 0 2
5 0 0 . 0 0 0 0 0 0 3 1 7 . 5 1 5 . 0 1 . 0 4 N.s.
COMPOUND 41 
STRAIN T A 1 00 
S9 A C TI VA TI ON
C O N C E N T R A T I O N  E X P E R I M E N T  n u m b e r  
MICPOGRAMS/ML 525 529 53 3
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 31 28 26
0 . 0 0 0 0 0 0 33 24 21
1 o. oooooo 29 - - - -
1 0 0 . 0 0 0 0 0 0 42 - - 30
2 0 0 . 0 0 0 0 0 0 31 . 3 0
* 00 . oooooo 31 29 20
CONCENTRATION NUMBER AVERAGE NUMBER 2 PROBAB INDUCED
m i c r o g r a m s / m l  of  of w e l l s  x  i l i t y  m u t a n t s
EXPTS.  P O S I T I V E  PER WELL
CONTROL TREATED
1 o.oooooo 1 32.0 29:0 0.42 n . s :
100.oooooo 2 27.7 36;o 7.79 < 0.005 0.5232
200.000000 2 24.7 30.5 3.48 N . S , .0,2841
5 0 0 . OOOOOO 27.2 26 V 7 0.02 N . S .
COMPOUND' 41 
STRAIN T A 1 00
INTACT HEPATOCYTE A C TI V A TI O N •
CONCENTRATION EXPERIMENT NUMBER
MICROGRAMS/ML 37  92  9 6  106
WELLS P O S I T I V E
o. ooonoo 7 20 10 18
0.OOOoOO 14 12 12 10
50.OOOoOO - - 16
m o . o o o o o o 7 15 - -
290.000000 -- 8 14
500.OOOoOO 6 12 •5 —
CONCENTRATt ON NUMBER AVERAGE n u m b e r 2 p r o b a b INDUCED
m i CROGRAMS/ML OF OF Ue LLS X I L I T Y m u t a n t s
EXPTS. p o s i t i v f p e r  w e l l
CONTROL t r e a t e d
50.ooooon 1 11 . o' 16.0 1 .53 N . S . 0.1452
100,OOOOOn **t* 13.2 11.0 0.61 N . S .
200.OOOOOn nr. 13.6 11.0 0.89 N . S .
500.OOOOOn 3 12.5 7.7 5.27 TOXIC
COMPOUND 41
STRAIN T A9 8
NO a c t i v a t i o n
c o n c e n t r a t i o n
MICPOGRAMS/Ml
o .  o o o o o o  
0 . o o o o o o  
1o . o o o o o o
100.000000
4 0 0 . 0 0 0 0 0 0
* 9 0 . o o o o o o
EXPERIMENT NUMBFk
520 527 533 «1
WELLS POSITIVE
17 
11
16
11
c o n c e n t r a t i o n
MICROGRAMS/ML
n u m b e r  a v e r a g e  n u m b e r  
of  of  We l l s
EXPTS.  P O S I T I V E
PROBAB
I L I T Y
INDUCED 
MUTANTS 
PER WELL
1 o .  o o o o o o 1
CONTROL
5 . 5
TREATED
6 . 0 0 . 0 0 N . S .
1 0 0 . o o o o o o 3 8 . 5 7 . 3 0 . 3 2 N . S .
2 0 0 . oooooo 2 6 . 2 11' .  0 4 . 2 3 < 0 . 0 2 5
5 0 0 . oooooo 3 6 . 0 6 . 0 s 0 , 0 0 n . s :
0 . 0 1 1 8
0 . 1 2 0 8
COMPOUND 41 
STRAIN TA98 
S9 A C TI V A TI O N
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r  
m i c r o g r a m s / m l  5 2 2  531 542
WELLS P O S I T I V E
o . o o o o o o 18 30 18
0 , 0 0 0 0 0 0 17 28 19
1 0 , 0 0 0 0 0 0 13- - - - -
1 0 0 . 0 0 0 0 0 0 12 - - 20
4 0 0 . 0 0 0 0 0 0  “ 22 - -
5 0 0 . OOOOOO 13 25 21
CONCENTRATION NUMBER a v e r a g e NUMBER 2 PROBAB INDUCED
.MICROGRAMS/ML OF of  w e l l s X I L I T Y MUTANTS
EXPTS, P O S I T I V E PER WELL
CONTROL t r e a t e d
1 0 . OOOOOO 1 1 7 . 5 18' .  0 0 , 0 0 N . S . 0 . 0 1 6 5
1 0 0 . 0 0 0 0 0 0 2 1 8 . 0 1 6 ’. 0 0 . 4 0 N . S ,
2 0 0 . 0 0 0 0 0 0 1 2 9 . 0 22*. 0 2 . 4 7 N . S ,
5 0 0 . OOOOOO 3 21 . 7 1 9 ' . 7 0 . 6 0 N . S ,
COMPOUND 41 
•STRAIN TA98  
I N T A C t HEPATOCYTE A C TI V A TI O N
CONCENTRATION
MICROGRAMr / ml
EXPERIMENT NUMBER 
78 93  99
WELLS P O S I T I V E
o . o o o n o o 8 13 15
0 . 0 0 0 0 0 0 11 7
5 0 . OOOnOO -- 17 18
10 0 . OOOnOO 7 1
5n o . o o o n o o !■■ U 15 11
CONCENTRATION
MICROGRAMS/ML
5 0 . o o o o o n  
100. o o o o o n  
5 0 0 . 0 0 0 0 0 n
NUMBER AVERAGE NUMBER
of  of  We l l s
EXPTS.  P O S I T I V E
c o n t r o l  t r e a t e d
1 1 . 7  
9 . 7
10.8
1 7 . 5
4 . 0
1 3 7 3
3 . 8 3  
6 .  29 
1 . 2 2
p r o b a b
i l i t y
N . S .
TOXIC
N . S .
INDUCED 
MUTANTS 
PER WELL
0.1750
0.0705
STRAIN T A10 0
NO a c t i v a t i o n
CONCENTRATION EXPERIMENT NUMBER
HICpOORAMS/ML 523 536 541 547
WELLS P O S I T I V E
o. oooooo 11 25 13 26
o. oooooo 20 13 34
1 0 , 0 0 0 0 0 0 13 - - 25 23
2 0 , 0 0 0 0 0 0 - - 24 15 25
5 0 , OOOOOO 10 24 26 0
1 0 0 . 0 0 0 0 0 0 7 - - - - - -
CONCENTRATION NUMBER AVERAGE n u m b e r 2 p r o b a b I  n d u c e d
m i c r o g r a m s / ml OF of  we l l s X I L I T Y m u t a n t s
EXPTS. p o s i t i v e PER WELL
CONTROL TREATED
1o . oooooo 3 2 0 . 3 20' .  3 0 . 0 0 N . S .
2 0 , OOOOOO 'y•J 2 3 . 2 21 . 3 0 , 4 7 N . S .
5 0 , OOOOOO 4 21 . 0 1 7 ;  2 2 . 9 3 N . S .
1 0 0 . 0 0 0 0 0 0 1 1 5 . 5 7 , 0 4 , 7 2 TOXIC
COMPOUND 42 
STRAIN TA100  
S9 A C TI VA TI ON
c o n c e n t r a t i o n  e x p e r i m e n t  n u m b e r  
MICROGRAMS/ML 52 5  53 4  533
WELLS P O S I T I V E
0. oooooo 31 26 26
o. oooooo 33 28 21
' o . oooooo 30 29 21
20. OOOOOO — 23 21
50.OOOOOO 9 13 7
100.000000 16
CONCENTRATION NUMBER a v e r a g e NUMBER 2 p r o b a b i n d u c e d
HICROGRAMS/ML OF of  we l l s X i l i t y m u t a n t s
EXPTS. P O S I T I V E PER WELL
CONTROL t r e a t e d
1 0 . OOOOOO 3 2 7 . 5 2 6 . 7 0 . 0 9 n . s ;
2 0 . OOOOOO ->4. 2 5 . 3 2 2 ;  0 1 . 0 4 n . s ;
5 0 , OOOOOO 3 2 7 . 5 9 V7 5 2 . 8 1 TOXIC
1 0 0 , OOOOOO 1 3 2 . 0 1 6 . 0 1 3 , 7 3 TOXIC
COMPOUND 42
STRAIN TA100
INTACT h e p a t o c y t e a c t i v a t i o n
CONCENTRATION e x p e r i m e n t  n u m b e r
MICROGRAMS/ML 37  92  95  10 6
WELLS P O S I T I V E
o. ooonoo • 7 20 11 18
O.'OOOoOO 14 12 10 10
10,OOOnOO 5 -- 7 3
50,OOOnOO -- -- 5 - -
m o .  ooonoo 3 2 - - 5
5 9 0 , ooonoo - - 7 6
concentration
MICROGRAMS/ML
NUMBER AVERAGE NUMBER 
OF OF WELLS
EXPTS,  P O S I T I V E
CONTROL t r e a t e d
p r o b a b
I L I T Y
INDUCED
m u t a n t s  
PER WELL
1 0 , OOOOOn 3 1 2 . 6 6 . 7 8 . 4 0 TOXIC
5 0 . OOOOOo 1 1 0 . 5 5 . 0 2 . 4 7 N . S .
100 . ooooon 3 1 4 . 1 31 3 2 8 . 4 9 TOXIC
5 0 0 . OOOOOn 2 1 3 . 2 6 . 5 6 . 7 7 TOXIC
COMPOUND 42
STRAIN TA98
NO ACTIVATION
CONrENTRATION 
HI CROGRAMS/ML
EXPF.KHtF.NT NUMBER
520 533 5 46 8<|.
UR L US POSITIVE
o. oooooo ■7 16 11 a
u . oooooo 4 11 9 5
■ 0 . oooooo 4 5 12 V
70.OOOOOO -- 10 10 6
5 0 . OOOOOO - - 3 4 3
I 0 0 . oooooo 0 - - — —
CONCENTRATION . n u m b e r AVERAGE n u m b e r 2 p r o b a b i n d u c e d
MICROGRAMS/ML OF of  w e l l s X I L I T Y MUTANTS
EXPTS. p o s i t i v e PER WELL
CONTROL T r e a t e d
1 0 . oooooo 4 8 . 9 6*. 0 3 . 1 2 N . S .
. 2 0 . 0 0 0 0 0 0 3 1 0 . 0 8 . 7 0 . 3 8 N.S, .
5 0 . OOOOOO 3 1 0 . 0 3V3 1 3 . 1 3 TOXIC
100 . oooooo 1 5 . 5 o . o 5 . 1 7 TOXIC
COMPOUND 42 
STRAIN T A93 
S9 AC TI VA TI ON
CONCENTRATION
MICrOGRAMS/ML
EXPERIMENT NUMBER 
5 2 6  53 2  5A3 
WELLS P O S I T I V E
0 . 0 0 0 0 0 0 10 26 25
0 . oooooo 17 - ~
1 0 . 0 0 0 0 0 0 19 22 34
7 0 . OOOOOO ... 27 34
5 0 . OOOOOO 23 21 38
1 0 0 . 0 0 0 0 0 0 2 -- - -
CONCENTRATION NUMBER AVERAGE n u m b e r 2 p r o b a b i n d u c e d
M I C rOGr AMS/ML OF OF We l l s X i l i t y MUTANTS
EXPTS. P O S I T I V E PER WELL
CONTROL t r e a t e d
1 3 . OOOOOO 3 21 . 7 2 5 : 0 1 . 3 8 N . S . 0 , 1 3 2 2
2 3 . OOOOOO 2 2 5 . 5 30 . 5 1 . 9 3 N . S . 0 , 2 5 1 3
5 0 . OOOOOO 3 2 1 . 7 2 7 :  3 4 . 2 2 < 0 . 0 2 5 0 , 2 3 9 1
1 0 3 . OOOOOO 1 1 8 . 0 2 : 0 1 7 . 4 6 TOXIC
COMPOUND 42 
STRAIN TA98
I N T A C t HEPATOCYTE A CT IV A TI ON
CONCENTRATION 
MI CROGRAMr /ML
0.OOOoOO 
0,OOOOOO 
10, 000*00. 
5 0 , 0 0 0 * 0 0  
1n0, 00 0 * 0 0
EXPERIMENT NUMBER 
78 84  9 8  1 0 4
WELLS P O S I T I V E
8 8 11 13
11 6 - - 12
- - - - ' 1 5 16
17 22 16 14
0 1 .. 7
CONCFNTRATrON
MICROGRAMS/ML
10.OOOOOo
50 . OOOOOO
100,OOOOOo
n u m b e r a v e r a g e NUMBER 2
OF of  w e l l s X
EXPTS. • ' P O S I T I V E
CONTROL t r e a t e d
2 1 2 . 2 i  5 ;  s 1 . 3 04 1 0 . 2 17 . 2 1 3 . 7 03 1 0 . 1 5 . 7 5 . 5 5
PROBAB
i l i t y
N . s .
0 . 0 0 0 5
TOXIC
INDUCED 
MUTANTS 
PER WELL
0.0953
0.2051
